---
document_datetime: 2023-09-21 17:09:11
document_pages: 181
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/xeljanz-h-c-4214-x-0005-epar-assessment-report-variation_en.pdf
document_name: xeljanz-h-c-4214-x-0005-epar-assessment-report-variation_en.pdf
version: success
processing_time: 264.2358944
conversion_datetime: 2025-12-28 18:56:03.04706
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

31 May 2018 EMA/414633/2018 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Xeljanz

International non-proprietary name: tofacitinib

Procedure No. EMEA/H/C/004214/X/0005/G

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Administrative information

| Name of the medicinal product:         | Xeljanz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| MAH:                                   | Pfizer Limited 821 Ramsgate Road Sandwich Kent CT13 9NJ UNITED KINGDOM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Active substance:                      | TOFACITINIB CITRATE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| International Non-proprietary Name:    | tofacitinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Pharmaco-therapeutic group (ATC Code): | immunosuppressants, selective immunosuppressants                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Therapeutic indication(s):             | (L04AA29) Rheumatoid arthritis Tofacitinib in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs. Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate. Ulcerative colitis Tofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5.1). |
| Pharmaceutical form(s):                | Film-coated tablet                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Strength(s):                           | 5 mg and 10 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Route(s) of administration:            | Oral use                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| Packaging:       | blister (alu/PVC/alu) and bottle (HDPE)                          |
|------------------|------------------------------------------------------------------|
| Package size(s): | 112 tablets, 182 tablets, 56 tablets, 180 tablets and 60 tablets |

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure............................................                                   | 11                                                                                                    |
|--------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier ...................................................................................       | 11                                                                                                    |
| 1.2. Steps taken for the assessment of the product                                                                       | ...................................................... 12                                             |
| 2. Scientific discussion..............................................................................                   | 13                                                                                                    |
| 2.1. Problem statement.............................................................................................      | 13                                                                                                    |
| 2.1.1. Disease or condition ........................................................................................     | 13                                                                                                    |
| 2.1.2. Epidemiology..................................................................................................    | 13                                                                                                    |
| 2.1.3. Aetiology and pathogenesis                                                                                        | .............................................................................. 13                     |
| 2.1.4. Clinical presentation, diagnosis and prognosis.....................................................               | 13                                                                                                    |
| 2.1.5. Management...................................................................................................     | 13                                                                                                    |
| 2.2. Quality aspects ..................................................................................................  | 14                                                                                                    |
| 2.2.1. Introduction....................................................................................................  | 14                                                                                                    |
| 2.2.2. Active Substance.............................................................................................     | 15                                                                                                    |
| 2.2.3. Finished Medicinal Product................................................................................        | 15                                                                                                    |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects..............................                       | 19                                                                                                    |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                | ...................... 19                                                                             |
| 2.2.6. Recommendation(s) for future quality development.............................................                     | 19                                                                                                    |
| 2.3. Non-clinical aspects............................................................................................    | 19                                                                                                    |
| 2.3.1. Introduction....................................................................................................  | 19                                                                                                    |
| 2.3.2. Pharmacology.................................................................................................     | 20                                                                                                    |
| 2.3.3. Pharmacokinetics                                                                                                  | ............................................................................................ 21       |
| 2.3.4. Toxicology......................................................................................................  | 21                                                                                                    |
| 2.3.5. Ecotoxicity/environmental risk assessment.........................................................                | 21                                                                                                    |
| 2.3.6. Discussion on non-clinical aspects .....................................................................          | 24                                                                                                    |
| 2.3.7. Conclusion on the non-clinical aspects                                                                            | ............................................................... 24                                    |
| 2.4. Clinical aspects .................................................................................................. | 24                                                                                                    |
| 2.4.1. Introduction....................................................................................................  | 24                                                                                                    |
| 2.4.2. Pharmacokinetics                                                                                                  | ............................................................................................ 25       |
| 2.4.3. Pharmacodynamics..........................................................................................        | 29                                                                                                    |
| 2.4.4. Discussion on clinical pharmacology...................................................................            | 30                                                                                                    |
| 2.4.5. Conclusions on clinical pharmacology.................................................................             | 30                                                                                                    |
| 2.5. Clinical efficacy                                                                                                   | .................................................................................................. 30 |
| 2.5.1. Dose response study........................................................................................       | 30                                                                                                    |
| 2.5.2. Main studies ...................................................................................................  | 31                                                                                                    |
| 2.5.3. Discussion on clinical efficacy..........................................................................         | 104                                                                                                   |
| 2.5.4. Conclusions on the clinical efficacy ..................................................................           | 109                                                                                                   |
| 2.6. Clinical safety ..................................................................................................  | 109                                                                                                   |
| 2.6.1. Discussion on clinical safety............................................................................         | 138                                                                                                   |
| 2.6.2. Conclusions on the clinical safety                                                                                | .................................................................... 139                              |

<div style=\"page-break-after: always\"></div>

| 2.7. Risk Management Plan......................................................................................        | 139                                                                                            |
|------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| 2.8. Pharmacovigilance ...........................................................................................     | 147                                                                                            |
| 2.9. Product information..........................................................................................     | 147                                                                                            |
| 2.9.1. User consultation                                                                                               | .......................................................................................... 148 |
| 2.9.2. Additional monitoring.....................................................................................      | 148                                                                                            |
| 3. Benefit-Risk Balance...........................................................................                     | 148                                                                                            |
| 3.1. Therapeutic Context .........................................................................................     | 148                                                                                            |
| 3.1.1. Disease or condition ......................................................................................     | 148                                                                                            |
| 3.1.2. Available therapies and unmet medical need.....................................................                 | 148                                                                                            |
| 3.1.3. Main clinical studies.......................................................................................    | 148                                                                                            |
| 3.2. Favourable effects............................................................................................    | 149                                                                                            |
| 3.3. Uncertainties and limitations about favourable effects...........................................                 | 150                                                                                            |
| 3.4. Unfavourable effects.........................................................................................     | 152                                                                                            |
| 3.5. Uncertainties and limitations about unfavourable effects .......................................                  | 153                                                                                            |
| 3.6. Effects Table.................................................................................................... | 154                                                                                            |
| 3.7. Benefit-risk assessment and discussion...............................................................             | 157                                                                                            |
| 3.7.1. Importance of favourable and unfavourable effects............................................                   | 157                                                                                            |
| 3.7.2. Balance of benefits and risks ..........................................................................        | 158                                                                                            |
| 3.8. Conclusions.....................................................................................................  | 158                                                                                            |
| 4. Recommendations...............................................................................                      | 158                                                                                            |
| Appendix.................................................................................................              | 161                                                                                            |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

5-ASA  5-aminosalicylic acid 6-MP 6-mercaptopurine AA Atomic Absorption spectroscopy ADR adverse drug reaction AE adverse event AEDC   adverse event leading to discontinuation ALC absolute lymphocyte count ALT alanine aminotransferase AML acute myeloid leukaemia ANC absolute neutrophil count AST aspartate aminotransferase AUC area under the concentration-time curve AUC24 area under the concentration-time curve from 0 to 24 hours AZA azathioprine BCC basal cell carcinoma BCS biopharmaceutics classification system BID twice a day BL baseline Cavg average plasma concentration CD Crohn's disease CE capillary electrophoresis CHMP   Committee for Medicinal Products for Human Use CI confidence interval CK creatine kinase CMV cytomegalovirus CP-690,550 tofacitinib CPP critical process parameter CQA critical quality attribute CSR clinical study report

<div style=\"page-break-after: always\"></div>

- CYP cytochrome P450 DB double-blind DDI drug-drug interaction DMARD disease-modifying antirheumatic drug EIM extraintestinal manifestation EMA European Medicines Agency Emax   a model parameter (maximum response possible due to drug) used to name a model that EOP2 end of Phase 2 EQ-5D/VAS Euro Quality of Life 5 Dimensions/Visual Analog Scale EU European Union FA focus area FAS full analysis set FDA Food and Drug Administration FMECA  Failure mode effects critical analysis GC Gas Chromatography GCP Good Clinical Practice GI gastrointestinal HDL-c   high-density lipoprotein cholesterol HDPE High Density Polyethylene HPLC High pressure liquid chromatography HR hazard ratio HZ herpes zoster IBD inflammatory bowel disease IBDQ inflammatory bowel disease questionnaire ICH International Conference on Harmonisation ICP-AE Inductively coupled plasma atomic emission spectroscopy IFN interferon IL interleukin ILD interstitial lung disease IndNR  induction non-responder
- IPAA ileal pouch-anal anastomoses

<div style=\"page-break-after: always\"></div>

IR Infrared absorption spectrophotometry IR immediate release or incidence rate (per context) IV intravenous JAK Janus kinase JIA juvenile idiopathic arthritis KF Karl Fischer determination of water KPP Key process parameter LC Liquid Chromatography LDL-c   low-density lipoprotein cholesterol LTE long-term extension MAA Marketing Authorisation Application MACE   major adverse cardiovascular event MC multicentre MedDRA Medical Dictionary for Regulatory Activities mFAS modified full analysis set MOA mechanism of action MS Mass spectrum MTX methotrexate NA not applicable NDA New Drug Application NF (United States) National Formulary NMSC Non-melanoma skin cancer NMT Not more than NNH number needed to harm NNT number needed to treat NRI non-responder imputation OI opportunistic infection OIRC Opportunistic Infection Review Committee OL open-label OTIS Organization of Teratology Information Specialists P2 Phase 2

<div style=\"page-break-after: always\"></div>

P2P3LTE Phase 2, Phase 3, long-term extension

P3 Phase 3 PD predominant dose PGA Physician's Global Assessment Ph. Eur. European Pharmacopoeia PK pharmacokinetic(s) PO oral PP Polypropylene Ppm parts per million (µg per g) PRO patient-reported outcome PsA psoriatic arthritis PsO psoriasis PSUR   periodic safety update report PT preferred term PV pharmacovigilance PY patient-year Q every QoL quality of life QbD quality by design QTPP quality target product profile RA rheumatoid arthritis RCT randomized controlled trial RMM risk minimization measure RMP risk management plan RPM revolutions per minute SAE serious adverse event SAP statistical analysis plan SAS safety analysis set SAWP   Scientific Advice Working Party SC subcutaneous

SCC squamous cell carcinoma

<div style=\"page-break-after: always\"></div>

SCE summary of clinical efficacy SCP summary of clinical pharmacology SCS summary of clinical safety SD standard deviation SF-36   Short Form-36 Health Survey SmPC   Summary of Product Characteristics sNDA   supplemental New Drug Application SOC system Organ Class STAT signal transducer and activator of transcription TAMC Total aerobic microbial count TB tuberculosis TDM therapeutic drug monitoring TEAE treatment-emergent adverse event TNF tumour necrosis factor TNFi tumour necrosis factor inhibitor TPMT thiopurine S-methyl transferase TSE Transmissible Spongiform Encephalopathy TYK2 tyrosine kinase 2 TYMC Total combined yeast/mould count UC ulcerative colitis ULN upper limit of normal US United States UV/VIS Ultraviolet/Visible spectrophotometry WPAI-UC Work Productivity and Activity Impairment - Ulcerative Colitis

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

Pfizer Limited submitted on 27 July 2017 a group of variations consisting of an extension of the marketing authorisation

-  a new strength (10 mg film coated tablets) indicated in the 'treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent'.

and the following variation:

| Variation requested   | Variation requested                                                                                                  | Type   |
|-----------------------|----------------------------------------------------------------------------------------------------------------------|--------|
| C.I.6.a               | Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | II     |

## The legal basis for this application refers to:

Article 7.2 of Commission Regulation (EC) No 1234/2008 - Group of variations

## Information on Paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0195/2014 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0195/2014 was not yet completed as some measures were deferred.

In addition, the PIP P/144/2010 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

<div style=\"page-break-after: always\"></div>

## Additional Data exclusivity/Marketing protection

The MAH requested consideration of one year marketing protection in regards of its application for a new indication in accordance with Article 14(11) of Regulation (EC) 726/2004.

## Scientific Advice

The MAH received Scientific Advice from the CHMP on 22 September 2011 and 26 January 2017. The Scientific Advice pertained to clinical aspects of the dossier.

## 1.2. Steps taken for the assessment of the product

The Rapporteur appointed by the CHMP was:

Rapporteur: Robert James Hemmings

| The application was received by the EMA on                                                                                                                                              | 27 July 2017     |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| The procedure started on                                                                                                                                                                | 17 August 2017   |
| The Rapporteur's first Assessment Report was circulated to all CHMP members on                                                                                                          | 3 November 2017  |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on                                                                                                     | 14 November 2017 |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                | 24 November 2017 |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                                                                                 | 14 December 2017 |
| The MAH submitted the responses to the CHMP consolidated List of Questions on                                                                                                           | 27 March 2018    |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Questions to all CHMP members on                                                                 | 30 April 2018    |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                | 17 May 2018      |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Xeljanz on | 31 May 2018      |
| The CHMP adopted a report on the novelty of the indication/significant clinical benefit for Xeljanz in comparison with existing therapies (see Appendix 1)                              | 31 May 2018      |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

The indication for the product which was proposed by the company was: Xeljanz is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

## 2.1.2. Epidemiology

UC is a chronic, relapsing, inflammatory disease of the colon characterized by alternating episodes of remission and spontaneous relapse. The prevalence has been estimated to range from 38 to 249 cases per 100,000 persons in North America and 5 to 505 cases per 100,000 persons in Europe. It is most commonly diagnosed in late adolescence and early adulthood, with the peak incidence occurring between 20 to 39 years of age.

## 2.1.3. Aetiology and pathogenesis

The precise pathogenesis of UC is presently unknown; however, the prevailing paradigm is dysregulation of the enteric immune response in genetically susceptible individuals.  This leads to upregulation of macrophages and type-2 T helper (Th2) lymphocytes in UC, as a result of inability to appropriately downregulate both innate and adaptive immune responses to endogenous luminal antigens. This produces an excess of cytokines, interleukins (ILs) and chemokines, all of which can lead to enhanced inflammation and tissue damage. Evidence has shown that upregulation of some of the common gamma chain cytokines may play a role in the pathogenesis of inflammatory bowel disease (IBD), of which the 2 main forms are UC and Crohn's disease.

## 2.1.4. Clinical presentation, diagnosis and prognosis

The hallmark clinical presentations for UC include diarrhoea, rectal bleeding, passage of mucus, tenesmus, urgency, and abdominal pain. Patients may also experience fatigue, fevers, weight loss, and dehydration, particularly in more severe cases. Mortality is not increased in UC in general, but the disease may present as life-threatening fulminant colitis. Most patients follow a chronic intermittent course with periods of increased disease activity separated by periods of disease remission. After the initial diagnosis, approximately half of patients will have active disease at any single point in time and approximately 90% will have a disease course characterized by intermittent flares.

## 2.1.5. Management

Current therapy for the treatment of UC includes 5-aminosalicylic acid (5-ASA), systemic and/or topical corticosteroids, immunosuppressants such as azathioprine/6-mercaptopurine (6-MP) and cyclosporine, and tumour necrosis factor-alpha inhibitors (TNFis), and recently approved α4β7 integrin antagonist vedolizumab.

<div style=\"page-break-after: always\"></div>

A significant proportion of UC patients still require colectomy for refractory or severe fulminant disease, or in some cases for cancer prevention. Although patients with UC are often considered to be cured by restorative proctocolectomy, the quality of life may be poor and the surgery can be associated with short term and longterm complications, including a decreased female fecundity and the development of pouchitis. At present, no current pharmacological therapy can provide a cure for UC. The primary treatment goal is to induce remission and then to maintain this state.

## About the product

Tofacitinib is a selective JAK inhibitor, with a high degree of selectivity against other kinases in the human genome. In kinase assays, tofacitinib inhibits JAK1, JAK2, JAK3, and to a lesser extent tyrosine kinase 2 (TYK2). In cellular settings where JAK kinases signal in pairs, tofacitinib preferentially inhibits signalling by heterodimeric receptors associated with JAK3 and/or JAK1 with functional selectivity over receptors that signal via pairs of JAK2. Accordingly, tofacitinib may result in modulation of the adaptive and innate immune response in IBD and may, therefore, be effective in interrupting the chronic cycle of GI inflammation.

## Type of Application and aspects on development

This is an application for a Grouped Type II Variation (new indication) / Line Extension (10 mg new tablet strength) for Xeljanz (tofacitinib) in the treatment of ulcerative colitis (UC).

No new clinical pharmacology studies or in vitro studies are included in this UC application. A population PK analysis and DER was performed of plasma tofacitinib concentration-time data from 1 Phase 2 and 2 identical Phase 3 induction studies, and 1 Phase 3 maintenance study in UC patients. Additionally, reference is made to population PK in RA and psoriasis (PsO) patients.

Clinical efficacy and safety data are derived from one Phase 2 and three Phase 3 studies, and the MAH has submitted an interim clinical study report from an ongoing open-label, long-term extension study of tofacitinib in patients with UC.

The applicant sought CHMP scientific advice in 2011 EMEA/H/SA/1219/4/2011/II. Follow-up advice regarding the UC program was sought in 2017 EMEA/H/SA/1219/4/FU/1/2016/II.

## 2.2. Quality aspects

## 2.2.1. Introduction

The finished product is presented as film coated tablets containing tofacitinib citrate, equivalent to 10 mg tofacitinib as active substance.

Other ingredients are:

Tablet core : microcrystalline cellulose, lactose monohydrate, croscarmellose sodium and magnesium stearate.

<div style=\"page-break-after: always\"></div>

Film coating : hypromellose 6cP  (E464), titanium dioxide (E171), lactose monohydrate, macrogol 3350, triacetin (E1518), FD&amp;C Blue #2/Indigo Carmine Aluminium Lake (E132),  and FD&amp;C Blue #1/Brilliant Blue FCF Aluminium Lake (E133).

The product is available in HDPE bottles with silica gel desiccant and child-resistant caps, and aluminium foil/PVC backed aluminium foil blisters as described in section 6.5 of the SmPC.

## 2.2.2. Active Substance

The active substance used in the manufacture of the new strength is the same as that used in the manufacture of the currently authorised Xeljanz 5 mg film-coated tablets (EU/1/17/1178/001-004).

## 2.2.3. Finished Medicinal Product

## Description of the product and Pharmaceutical development

The finished product is presented as blue, film coated, round tablet, debossed with ' Pfizer ' on one side and ' JKI 10 ' on the other.

Apart from the film coating, the composition of the proposed 10 mg tablet is qualitatively identical and quantitatively proportional to the approved 5 mg tablets.

Both 5 mg and 10 mg tablets come from a common blend and are manufactured by the same conventional dry granulation process.  The quality target product profile (QTPP) for the proposed 10 mg strength was defined as blue, round, immediate release film-coated tablets containing 10 mg of tofacitinib that meet compendial and other relevant quality standards, packaged in blisters and bottles,  suitable for oral administration, twice daily, to adult patients. The formulation and process development was based on the Quality Target Product Profile (QTPP) that is linked to the quality attributes.

The critical quality attributes (CQAs) identified were appearance, identification, assay, degradants, uniformity of dosage units, disintegration, microbial limits, and water content.

The active substance is classified as BCS Class III (high solubility and low permeability) compound. Due to the high-solubility, the particle size of the active substance is not restricted by dissolution considerations. The particle size distribution specification was established primarily based on the consideration of the finished product content uniformity. Mathematical modelling of content uniformity, small scale multivariate experiments and actual manufacturing experience were employed to establish the active substance particle size specification.

A formulation containing microcrystalline cellulose, lactose, croscarmellose sodium and magnesium stearate was selected. This was based on the results of an excipient compatibility study and desired mechanical properties. Chemical compatibility studies were performed with the active substance and excipients typically used for dry granulation formulations to identify a suitable formulation. The selection of the excipients was based on data from a 6-week open dish accelerated stability study using different blends of excipients and active substance.

All excipients are well known pharmaceutical ingredients and their quality is compliant with Ph. Eur. standards except the coating and printing ink which comply with in-house standards. There are no novel

<div style=\"page-break-after: always\"></div>

excipients used in the finished product formulation. The list of excipients is included in section 6.1 of the SmPC and in paragraph 2.1.1 of this report.

A material attributes risk assessment was conducted to identify which active substance and excipient properties could potentially impact the finished product quality or the manufacturing process. The active substance particle size, raw material water content, and excipient batch-to-batch variability were identified as potentially important formulation factors.

A three arm study was used to demonstrate the bioequivalence among 10 mg commercial tablet, 5 mg Phase 3 tablet, and 5 mg Phase 2 tablet. Since the 5 mg and 10 mg commercial tablets use a common blend and share the same manufacturing process, the equivalence between the 5 mg and 10 mg commercial tablets was demonstrated by the in vitro dissolution test. The results of the bioequivalence study demonstrated that the 10 mg commercial tablet, 5 mg Phase 3 tablet, and 5 mg Phase 2 tablet are bioequivalent.

The in vitro dissolution test demonstrated similar dissolution profiles between the 5 mg and 10 mg commercial tablets.

A  dissolution  method  is  performed  in  accordance  with  the  following  standard  dissolution  test  conditions: Apparatus I (baskets) at 100 RPM, 0.1N HCl, pH 4.5 acetate buffer and pH 6.8 phosphate buffer. In order to select the the optimum dissolution conditions standard media screening (0.1N HCl, pH 4.5 acetate buffer and pH 6.8 phosphate buffer) was performed using Apparatus I (basket) at 100 RPM and Apparatus II (paddles) at 50 and 75 RPM. The conclusions from the method screening study are: the dissolution profiles generated under  same  agitation  conditions  are  consistent  across  pH,  the  dissolution  profiles  using  50  RPM  paddle showed slower onset release, which is attributed to the coning effect, no coning effect was observed with 75 RPM paddles and 100 RPM basket, rapid dissolution was achieved for both conditions.

Further  evaluation  of  aberrations  in  the  formulation  was  performed,  including  changes  in  the  composition including the lubricant amount, disintegrant content and also an increase in tablet hardness. The results have been  presented.  Due  to  the  nature  of  Xeljanz  tablets,  appropriate  discrimination  using  dissolution  is  not feasible.  Although  Apparatus  I  at  100  rpm  in  0.1  N  HCl  showed  no  ability  to  discriminate  the  aberrant formulations, it was chosen as the most suitable dissolution method for comparison between the two tablet strengths (5 mg and 10 mg).

The rapid release characteristics of the proposed product has been demonstrated on the development and registration stability batches. For the 10 mg tablets, disintegration has shown to be able to detect differences in the high hardness tablets versus the control. Since disintegration offers slightly better discriminatory capability against the aberrant formulations, disintegration is considered a more suitable performance method for evaluating tablets than dissolution. The same approach had also been adopted for the approved 5 mg tablets.

The tablets are manufactured by a conventional dry granulation process that includes blending, milling, blend lubrication, roller compaction and milling, blend lubrication, compression, and aqueous based film coating.

A staged risk assessment was conducted to evaluate the quality attributes and process parameters associated with the manufacturing process. Initially, a failure-mode effect-criticality analysis (FMECA) was conducted to establish the critical and non-critical quality attributes of the finished product. This assessment considered the quality target product profile (QTPP), the biopharmaceutical properties of finished product, and prior manufacturing experience. Focus areas (FA) were then defined, and a cause-and-effect analysis was performed on each focus area to assess the potential impact of the process parameters and upstream material properties on the quality attributes listed in the QTPP. Following each risk assessment, a

<div style=\"page-break-after: always\"></div>

comprehensive experimental plan was developed to study selected process parameters in each of the focus areas utilizing multivariate and univariate experiments, as well as engineering models. The goal of these studies was to generate the knowledge space that could be used to establish the design space (see below in Manufacture of the product and process controls). A summary of the process parameters and quality attributes evaluated was presented and considered satisfactory.

Uniformity of dosage units and the level of degradants observed during stability studies were identified as the critical quality attributes (CQA) that could be impacted by the formulation or manufacturing process. A series of statistically designed studies sought the functional relationships between the process parameters and these two CQAs. The knowledge gained from these studies, in conjunction with prior experience, provided the basis for a 3-tier system for designating the criticality of all parameters as follows: 1) critical process parameters (CPP), 2) key process parameters (KPP), and 3) non-critical process parameters (non- CPP). The 3-tier system was later changed to a 2-tier system (CPPs /non-CPPs only) to be aligned with the terminology defined by ICH Q8.

Process knowledge and process design space were established through univariate, multivariate and modelling studies performed for initial blending, dry granulation and compression, film coating and packaging process steps. The manufacturing process design space described for the 10 mg strength is identical to that of the already authorised 5 mg tablets which has been evaluated and accepted. Overall, the knowledge space has been systematically investigated to identify the relationship of process parameters to the quality attributes. The proven acceptable range for each process parameter has been established and the target values are appropriately specified.

The primary packages are HDPE bottles with silica gel desiccant and child-resistant caps or aluminium foil/PVC backed aluminium foil unit dose blisters. The material complies with Ph.Eur. and EC requirements. The choice of the container closure system has been validated by stability data and is adequate for the intended use of the product.

## Manufacture of the product and process controls

The manufacturing process consists of 10 main steps. In summary, the excipients are blended, dry granulated and then compressed to form the tablet core.  The core is then film-coated with Opadry and packed into the proposed container closure system. The process is considered to be a standard manufacturing process.

Design spaces have been proposed for the following steps of the manufacturing process of the medicinal product: dry granulation and milling. The design space has been developed at commercial scale. The available development data, the proposed control strategy and batch analysis data from commercial scale batches fully support the proposed design space. The available development data, the proposed control strategy and batch analysis data from commercial scale batches fully support the proposed PARs. The manufacturing process design space described for the 10 mg strength is identical to that of the already authorised 5 mg strength which has been evaluated and accepted.

Major  steps  of  the  manufacturing  process  have  been  validated  by  a  number  of  studies.  It  has  been demonstrated that the manufacturing process is capable of producing the finished product of intended quality in a reproducible manner. The in-process controls are adequate for this pharmaceutical form.

<div style=\"page-break-after: always\"></div>

## Product specification

The  finished  product  release  specifications,  include  appropriate  tests  for  this  kind  of  dosage  form: appearance/identification  (visual),  identification  (UV,  HPLC),  assay  (HPLC),  uniformity  of  dosage  units (HPLC), degradation products (HPLC, disintegration (Ph Eur), water content (KF), microbial limits.

The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines. No additional reference standards or materials are used for the testing of the finished product other than those of the active substance.

The rationale for the performance of disintegration testing instead of dissolution has been adequately discussed and is accepted. The limit of disintegration time is set at 7 minutes which is supported by the batch data.

A risk assessment of the elemental impurities in the finished product has been conducted in line with the requirements of the ICH Q3D guideline (EMA/CHMP/ICH/353369/2013). The potential sources of EIs from the active substance, excipients, manufacturing equipment and utilities, and packaging components were evaluated and based on these evaluations as well as batch testing no additional control is deemed necessary.

Batch analysis results are provided for 7 commercial and pilot scale batches confirming the consistency of the manufacturing process and its ability to manufacture to the intended product specification.

The finished product is released on the market based on the above release specifications, through traditional final product release testing.

## Stability of the product

Stability data from 3 commercial scale batches of the finished product packaged in high density polyethylene (HDPE) bottles with desiccant and in foil/foil blisters stored for up to 36 months under long term conditions (25  ºC  /  60%  RH)  and  intermediate  conditions  (30 o C/75  %)  and  for  up  to  6  months  under  accelerated conditions (40 ºC / 75% RH) according to the ICH guidelines were provided. The batches are identical to those proposed for marketing and were packed in both types of primary packaging proposed for marketing.

The samples were tested for appearance, assay and degradation products, as well as water content, dissolution, chiral purity, disintegration and microbiological quality. The analytical procedures used are stability indicating. The data from the long term and accelerated stability studies demonstrated that there were no significant trends observed in any of the measured parameters.

In addition, one batch was exposed to light as defined in the ICH Guideline on Photostability Testing of New Drug Substances and Products. The exposed samples were tested for appearance, assay, degradation products, water content, dissolution, disintegration and hardness. No significant changes were observed in any of the parameters measured. It is therefore concluded that the tablets are stable to light and no precautionary packaging/labelling is required.

An open dish in use stability study was carried out. Samples were removed from the package and stored in an open dish at 30 o C/75 % RH and tested after 2 and 4 weeks for appearance, assay and degradation products, water content, dissolution and disintegration.  The results showed that the exposed tablets absorbed moisture; however, this did not impact the stability, quality and performance of the product as measured by the other test attributes.

<div style=\"page-break-after: always\"></div>

The foil/foil blister is actively tested for all lots. A bracketing design is applied to the testing for the HDPE bottle packages.

Based on available stability data, the proposed shelf-life of 36 months without special storage conditions as stated in the SmPC (section 6.3) are acceptable.

## Adventitious agents

It is confirmed that the lactose is produced from milk from healthy animals in the same condition as those used to collect milk for human consumption and that the lactose has been prepared without the use of ruminant material other than calf rennet according to the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents Via Human and veterinary medicinal products.

## 2.2.4. Discussion on chemical, pharmaceutical and biological aspects

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

The applicant has applied QbD principles in the development of the finished product and its manufacturing process. Design spaces have been proposed for several steps in the manufacture of the finished product. The design spaces have been adequately verified.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. Data has been presented to give reassurance on viral/TSE safety.

## 2.2.6. Recommendation(s) for future quality development

Not applicable

## 2.3. Non-clinical aspects

## 2.3.1. Introduction

Tofacitinib (compound number: CP-690,550-10 [citrate salt]) is an oral, potent, selective inhibitor of Janus kinase (JAK) family of kinases with a high degree of selectivity against other kinases in the human genome. In kinase assays, tofacitinib inhibits JAK1, JAK2, JAK3, and to a lesser extent tyrosine kinase 2 (TYK2). In cellular settings where JAK kinases signal in pairs, tofacitinib preferentially inhibits signalling by heterodimeric receptors associated with JAK3 and/or JAK1 with functional selectivity over receptors that signal via pairs of

<div style=\"page-break-after: always\"></div>

JAK2.  The modulatory effects of JAK inhibition on multiple cytokine pathways central to the pathogenesis of UC could provide a scientific rationale for developing tofacitinib in the treatment of UC.

No new non-clinical pharmacology, pharmacokinetics or toxicology data were generated since the original application for RA was completed.  All reports that support either 5 or 10 mg dosing were previously provided and are therefore have not been revisited.  The applicant has provided updated discussions in the non-clinical overview, and new information not previously submitted to the RA dossier.  An updated environmental risk assessment (ERA) is provided.

## 2.3.2. Pharmacology

The primary pharmacology, secondary pharmacology and safety pharmacology section have previously been reviewed in the submission for RA and so are not reviewed again here.  A brief summary to support the proof of concept of utilising tofacitinib in the treatment of OC is provided.

Multiple functions behind the cellular response in inflammatory bowel disease (IBD) are thought to be regulated by multiple cytokines, which in turn would signal to a variety of JAKs.  The γ-common cytokines, IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21, all signal through the activation of JAK1/JAK3 and are associated with modulation of the adaptive immune function, including B-cell maturation and Th1, Th2, and Th17 differentiation (Hofmann et al, 2002).  Tofacitinib is a potent inhibitor of the JAK kinase family, with a high degree of selectivity within the human kinome (Karaman et al, 2008).  As a result, tofacitinib will block the signalling pathways of the γ-common cytokines by inhibiting JAK1 and JAK3.

It is predicted that tofacitinib will modestly inhibit IL-12 and IL-23 signalling through the combination of JAK2 and TYK2 and regulate innate immune responses, differentiation of Th1 and Th17, and production of proinflammatory cytokines (Langrish et al, 2004).

IL-13 signals through JAK1 and either JAK2 or TYK2 and is an important effector cytokine associated with impaired barrier function in IBD (Heller et al, 2005).  As a result, JAK pathways are central to both innate and adaptive immune responses in IBD, playing critical roles in T-cell differentiation, B-cell development, and production of mucus and antibodies required to maintain anti-viral and anti-bacterial defenses at the mucosal surface (Heneghan et al, 2013).

Due to the combination of these factors, tofacitinib may result in modulation of the adaptive and innate immune responses found in IBD and therefore may be effective in interrupting the chronic cycle of gastrointestinal inflammation (Sandborn et al, 2012).

No nonclinical pharmacology models of IBD were conducted to evaluate tofacitinib since the overall clinical predictability of these models is low.

The applicant has presented a number of literature articles suggesting the contribution of the range of JAKs on the possible immune modulation involved in the pathogenesis of IBD.  Tofacitinib is an identified inhibitor of JAK1, JAK2, JAK3, and to a lesser extent tyrosine kinase 2 (TYK2), so it is plausible that it may have activity in treating conditions such as UC.  No new non-clinical pharmacology studies have been performed. The applicant has argued that animal models of UC are not predictive of the clinical disease, although this has not been elaborated to any extent.  Clinical efficacy studies have been completed and an overall judgement on its effectiveness to treat UC will be clinically determined.

<div style=\"page-break-after: always\"></div>

## 2.3.3. Pharmacokinetics

No new pharmacokinetic studies were provided in this submission.  Reference is made to the earlier submission and to studies completed during the assessment of RA application.  Although no new data is presented, new exposure margins based upon the increased dosage for UC patients has been supplied.  This is based upon exposures generated during the non-clinical development programme for tofacitinib, however using unbound free plasma concentrations determined in clinical study PMAR-00178.  Comparison is made between the 5 mg BID and10 mg BID, with exposure margins approximately halving in line with increasing exposure in humans.  Overall there is no distinct change in the non-clinical assessment of this data, conclusions on exposure margins are similar to that made for the original application for RA.

## 2.3.4. Toxicology

The applicant has not provided any new toxicological study data, reference is made to studies completed in support of the RA submission.  The scope and range of studies previously supplied are extensive and sufficient to support the change in indication and the subsequent change in posology, 5 mg BID to 10 mg BID.  Safety margins reveal no additional non-clinical concern.

Tofacitinib was teratogenic (visceral and skeletal abnormalities) in rats and rabbits, with evidence of decreased pregnancy rates, decreases in corpora lutea, implantation sites, and viable fetuses, and an increase in early resorptions.  There is also reduced pup survival and number in the peri/post-natal development study in rats.  Tofacitinib is contraindicated in use during pregnancy and breastfeeding, in line with other indications of use.  Sections 4.3, 4.6 and 5.3 are acceptable.

The drug substance, tofacitinib citrate has previously been assessed as part of the RA submission.  Seven drug substance impurities are specified and have been qualified from toxicity batches used in the non-clinical testing programme.  The applicant has supplied sufficient information regarding each of these impurities, all are non-genotoxic and each are sufficiently qualified.

## 2.3.5. Ecotoxicity/environmental risk assessment

The applicant has provided a full ERA in support of this line extension and change in treatment indication. Approval of the new strength and to a new treatment population would be expected to increase the overall exposure, hence this updated document is required in line with the CHMP guidance EMEA/CHMP/ SWP/4447/00 entitled; 'Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use'.

The study on transformation in water sediment system (OECD 308) shows that the active ingredient tofacitinib citrate is very persistent in sediment considering the DT50 values of 273 d and 350 d at 12°C (128 d and 164 d at 20°C) and persistent in water with DT50 of 65.7 d at 12°C (30.8 d at 20°C). These values are based on recalculations by DE-UBA using the degradation kinetic model Modelmaker 4.0.  This is included in the table below.

Tofacitinib is already used as an existing marketed product and although an increase in environmental exposure is anticipated with the added new treatment population, considering the above data, tofacitinib is not expected to pose a risk to the environment.  The compound is considered as P in water, and vP in sediment.

<div style=\"page-break-after: always\"></div>

## Summary of main study results

| Substance (INN/Invented Name): Tofacitinib (XELJANZ) CAS-number (if available): 540737-29-9   | Substance (INN/Invented Name): Tofacitinib (XELJANZ) CAS-number (if available): 540737-29-9   | Substance (INN/Invented Name): Tofacitinib (XELJANZ) CAS-number (if available): 540737-29-9                                                                                                                                                         | Substance (INN/Invented Name): Tofacitinib (XELJANZ) CAS-number (if available): 540737-29-9                                                                                                                                                         | Substance (INN/Invented Name): Tofacitinib (XELJANZ) CAS-number (if available): 540737-29-9   |
|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| PBT screening                                                                                 |                                                                                               | Result                                                                                                                                                                                                                                              | Result                                                                                                                                                                                                                                              | Conclusion                                                                                    |
| Bioaccumulation potential- log K ow                                                           | OECD107                                                                                       | Log D = 0.114 (pH 4) Log D = 1.19 (pH 7)                                                                                                                                                                                                            | Log D = 0.114 (pH 4) Log D = 1.19 (pH 7)                                                                                                                                                                                                            | Potential PBT (N)                                                                             |
| PBT-assessment                                                                                |                                                                                               | Log D = 1.18 (pH 9)                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                     |                                                                                               |
| Parameter                                                                                     | Result relevant for conclusion                                                                |                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                     | Conclusion                                                                                    |
| Bioaccumulation                                                                               | log K ow                                                                                      | Log D = 1.19 (pH 7)                                                                                                                                                                                                                                 | Log D = 1.19 (pH 7)                                                                                                                                                                                                                                 | not B                                                                                         |
| Persistence                                                                                   | BCF DT50 or ready biodegradability                                                            | Below calculations based on Modelmaker 4.0: Brandywine creek (freshwater) DT50, water, 12°C: 29.9 d DT 50, sediment, 12°C: 350 d DT 50 total system, 12°C: 70.2 d Choptank river (freshwater) DT50, water, 12°C: 65.7 d DT50, sediment, 12°C: 273 d | Below calculations based on Modelmaker 4.0: Brandywine creek (freshwater) DT50, water, 12°C: 29.9 d DT 50, sediment, 12°C: 350 d DT 50 total system, 12°C: 70.2 d Choptank river (freshwater) DT50, water, 12°C: 65.7 d DT50, sediment, 12°C: 273 d | not B P in water vP in sediment                                                               |
| Toxicity                                                                                      | NOEC or CMR                                                                                   | DT50 total system, 12°C: 135.7 d                                                                                                                                                                                                                    | DT50 total system, 12°C: 135.7 d                                                                                                                                                                                                                    | not T                                                                                         |
| PBT-statement:                                                                                | The compound is considered as P in water, and vP in sediment                                  | The compound is considered as P in water, and vP in sediment                                                                                                                                                                                        | The compound is considered as P in water, and vP in sediment                                                                                                                                                                                        | The compound is considered as P in water, and vP in sediment                                  |
| Phase I Calculation                                                                           | Value                                                                                         | Unit                                                                                                                                                                                                                                                | Unit                                                                                                                                                                                                                                                | Conclusion                                                                                    |
| PEC surfacewater , default or refined (e.g. prevalence, literature)                           | 0.10                                                                                          | µ g/L                                                                                                                                                                                                                                               | µ g/L                                                                                                                                                                                                                                               | > 0.01 threshold (Y)                                                                          |
| Other concerns                                                                                | Other concerns                                                                                |                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                     | None                                                                                          |
| Phase II Physical-chemical properties and fate                                                | Phase II Physical-chemical properties and fate                                                |                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                     |                                                                                               |
| Study type                                                                                    | Test protocol                                                                                 | Results                                                                                                                                                                                                                                             | Results                                                                                                                                                                                                                                             | Remarks                                                                                       |
| Adsorption-Desorption                                                                         | OECD 106 or …                                                                                 | Koc = 102 (0.01M CaCl2) 4266 (Clay Loam TB-PF soil) 977 (Sandy soil) 10000 (Silty loam sediment) 4786 (Sandy sediment)                                                                                                                              | Koc = 102 (0.01M CaCl2) 4266 (Clay Loam TB-PF soil) 977 (Sandy soil) 10000 (Silty loam sediment) 4786 (Sandy sediment)                                                                                                                              |                                                                                               |
| Ready Biodegradability Test                                                                   | OECD 301                                                                                      |                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                     |                                                                                               |
| Aerobic and Anaerobic Transformation in Aquatic Sediment systems                              | OECD 308                                                                                      | DT 50, water = DT 50, sediment = DT 50, whole system = % shifting to sediment =                                                                                                                                                                     | DT 50, water = DT 50, sediment = DT 50, whole system = % shifting to sediment =                                                                                                                                                                     |                                                                                               |
| Phase IIa Effect studies                                                                      | Phase IIa Effect studies                                                                      | Phase IIa Effect studies                                                                                                                                                                                                                            | Phase IIa Effect studies                                                                                                                                                                                                                            | Phase IIa Effect studies                                                                      |
| Study type                                                                                    | Test protocol                                                                                 | Endpoin t                                                                                                                                                                                                                                           | value Unit                                                                                                                                                                                                                                          | Remarks                                                                                       |
| Algae, Growth Inhibition Test/ Species                                                        | OECD 201                                                                                      | NOEC                                                                                                                                                                                                                                                | 11 µg/L                                                                                                                                                                                                                                             | Pseudokirchinell a subcapitata                                                                |
| Daphnia sp . Reproduction Test                                                                | OECD 211                                                                                      | NOEC                                                                                                                                                                                                                                                | 4.8 µg/L                                                                                                                                                                                                                                            | Daphnia sp                                                                                    |
| Fish, Early Life Stage Toxicity Test/ Species                                                 | OECD 210                                                                                      | NOEC                                                                                                                                                                                                                                                | 2.9 µg/L                                                                                                                                                                                                                                            | Pimephales promelas                                                                           |
| Activated Sludge, Respiration Inhibition Test                                                 | OECD 209                                                                                      | EC50 NOEC (EC10)                                                                                                                                                                                                                                    | >1000 µg/L                                                                                                                                                                                                                                          |                                                                                               |
| Phase IIb Studies                                                                             |                                                                                               | 1000                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                     |                                                                                               |
| Bioaccumulation                                                                               | OECD 305                                                                                      | BCF                                                                                                                                                                                                                                                 | ND L/kg                                                                                                                                                                                                                                             | %lipids:                                                                                      |
| Aerobic and anaerobic transformation in soil                                                  | OECD 307                                                                                      | DT50 %CO 2                                                                                                                                                                                                                                          | ND                                                                                                                                                                                                                                                  | for all 4 soils                                                                               |
| Soil Micro organisms: Nitrogen Transformation Test                                            | OECD 216                                                                                      | %effect                                                                                                                                                                                                                                             | ND mg/kg                                                                                                                                                                                                                                            |                                                                                               |
| Terrestrial Plants, Growth Test/ Species                                                      | OECD 208                                                                                      | NOEC                                                                                                                                                                                                                                                | ND mg/kg                                                                                                                                                                                                                                            |                                                                                               |
| Earthworm, Acute Toxicity Tests                                                               | OECD 207                                                                                      | NOEC                                                                                                                                                                                                                                                | ND mg/kg                                                                                                                                                                                                                                            |                                                                                               |

<div style=\"page-break-after: always\"></div>

| Collembola, Reproduction Test   | ISO 11267   | NOEC   |   ND | mg/kg   |                     |
|---------------------------------|-------------|--------|------|---------|---------------------|
| Sediment dwelling organism      |             | NOEC   |   46 | mg/kg   | Chironomus riparius |

## 2.3.6. Discussion on non-clinical aspects

Tofacitinib is potent, selective JAK inhibitor, with a high degree of selectivity against other kinases in the human genome.  It is already orally administered to treat RA, and given its novel mechanism of action in inhibiting of the JAK family of kinases it has potential to have effect on immune modulatory effects linked with the pathogenesis of UC.  The applicant has not provided any new non-clinical data to support this application, reference is made to completed studies submitted in support of XELJANZ 5 mg tablets to treat RA.

The applicant's position for providing no new non-clinical data to support the 10 mg tablet and change in treatment population (ulcerative colitis) in this grouped line extension and Type II variation is acceptable.

Impurities in the drug substance have been adequately qualified.

An environmental risk assessment has been provided for tofacitinib, this does not highlight any significant risk posed to the environment, although shows evidence of persistence in water and in sediment.

## 2.3.7. Conclusion on the non-clinical aspects

From a non-clinical perspective, the marketing authorisation of XELJANZ 10 mg tablets to treat ulcerative colitis is supported.

## 2.4. Clinical aspects

## 2.4.1. Introduction

The applicant has conducted 1 Phase 2 and 3 Phase 3 studies, and has submitted an interim clinical study report from an ongoing open-label, long-term extension study of tofacitinib in patients with UC.

The phase 2 dose finding study evaluated a 30-fold dose range (0.5, 3, 10, and 15 mg BID) in moderately to severely active UC patients.

The pivotal phase 3 studies consisted of two identically conducted studies to investigate efficacy in induction of remission (studies A3921094 and A3921095) and one examining efficacy in maintenance of remission study A3921096).

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant

The applicant has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

<div style=\"page-break-after: always\"></div>

## · Tabular overview of clinical studies

| Study Study status                      | Study design Treatmentduration                                                                                                                            | Patientpopulation                                                                                                                                                                                                                  | Treatment arms                                                                                                              | Number of subjects                                                   |
|-----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|
| Phase 2 dose-ranging (induction) study  | Phase 2 dose-ranging (induction) study                                                                                                                    | Phase 2 dose-ranging (induction) study                                                                                                                                                                                             | Phase 2 dose-ranging (induction) study                                                                                      | Phase 2 dose-ranging (induction) study                               |
| A3921063 Completed                      | Randomised, MC, DB, placebo-controlled, parallel-group study to investigate the safety and efficacyin subjects with moderate tosevereUC 8 weeks           | Adult subjects with moderatelytoseverely active UC who had previously been or were currently being pharmacologically treated for UC                                                                                                | Randomisation 2:2:2:3:3 Tofacitinib 0.5 mg BID Tofacitinib 3 mg BID Tofacitinib 10 mg BID Tofacitinib 15 mg BID Placebo BID | 31 33 33 49 48                                                       |
| Phase3inductionstudies                  | Phase3inductionstudies                                                                                                                                    | Phase3inductionstudies                                                                                                                                                                                                             | Phase3inductionstudies                                                                                                      | Phase3inductionstudies                                               |
| A3921094 and A3921095 Completed         | Randomised,MC,DB, placebo-controlled, parallel-group study of tofacitinibasaninduction therapy in subjects with moderately to severely active UC 8 weeksa | Adultsubjectswith moderatelytoseverely activeUC withhistory of failure or intolerance, as assessed by the investigator, to at least 1 of the following UC treatments:oralorIV corticosteroids; azathioprine or6-MP;or TNFi therapy | Randomisation 4:1b Tofacitinib 10 mg BID Placebo                                                                            | A3921094:476 A3921095:429 A3921094:122 A3921095:112                  |
| Phase3maintenancestudy                  | Phase3maintenancestudy                                                                                                                                    | Phase3maintenancestudy                                                                                                                                                                                                             | Phase3maintenancestudy                                                                                                      | Phase3maintenancestudy                                               |
| A3921096 Completed                      | Randomised, MC, DB, placebo-controlled, parallel-group study of tofacitinibasmaintenance therapyinsubjectswithUc 52 weeksc                                | Subjects achieving clinical responsed after 8 weeks of induction treatment (ie, responders from StudiesA3921094or A3921095)                                                                                                        | Randomisation 1:1:1 Tofacitinib5mgBID Tofacitinib 10 mg BID Placebo                                                         | 198 197 198                                                          |
| Phase3open-labellong-termextensionstudy | Phase3open-labellong-termextensionstudy                                                                                                                   | Phase3open-labellong-termextensionstudy                                                                                                                                                                                            | Phase3open-labellong-termextensionstudy                                                                                     | Phase3open-labellong-termextensionstudy                              |
| A3921139 Ongoing                        | MC, OL study of tofacitinib insubjectswithmoderately to severely active UC Up to first global marketing authorisation                                     | Adult subjects with UC who were non-responders after completing Study A3921094 or Study A3921095 or who completed or demonstrated treatment failure in Study A3921096                                                              | Tofacitinib 5 mg BID (subjects entering in remission)e Tofacitinib 10 mg (all other subjects) e                             | Included in interim snapshot: 156f 758f Total enrolled in study: 944 |

Source:A3921063CSR,A3921094CSR;A3921095CSR;A3921096CSR;A3921139interimdata. 6-MP = 6-mercaptopurine; BID = twice daily; CSR = clinical study report; DB = double-blind; IV = intravenous; MC=multicentre;OL=open-label;TNFi=tumour necrosisfactor inhibitor;UC=ulcerative colitis.

b. A total of 22 patients were randomised to tofacitinib 15 mg (16 patients for Study A3921094 and 6 patients for Study A3921095)prior to the dose group being removed from the protocol.

d. Clinical response was defined by a decrease from the induction study baseline (Study A3921094 or Study A3921095) in Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the rectal bleeding subscore of at least

c. The final efficacy assessment was at Week 52 and the end of treatment was at Week 53.

1pointoranabsoluterectalbleedingsubscoreofoor1.

f. Number of subjects to be included in the interim CSR based on data snapshot on 08 July 2016.

e. Based on initial treatment assignment in Study A3921139.

## 2.4.2. Pharmacokinetics

The following Phase 1 and in vitro studies were previously submitted as part of the Marketing Authorization Application (MAA) for rheumatoid arthritis (RA): Nineteen in vitro studies with human biomaterials relevant to PK processes and Twenty-Five Phase 1 studies comprising 20 clinical pharmacology and 5 biopharmaceutics studies. No new clinical pharmacology studies or in vitro studies are included in this UC application. A

<div style=\"page-break-after: always\"></div>

population analysis and DER was performed of plasma tofacitinib concentration-time data from 1 Phase 2 and 2 identical Phase 3 induction studies, and 1 Phase 3 maintenance study in UC patients.

A summary of the ADME properties is provided:

- Following oral administration, systemic exposure of tofacitinib increases in an approximately dose proportional manner in healthy subjects
- The apparent terminal half-life (t½) of tofacitinib is approximately 3 hours
- Steady-state PK is predictable from single dose data. Upon multiple dosing, steady-state is achieved within 24-48 hours with negligible accumulation
- Tofacitinib is rapidly absorbed and has an absolute bioavailability of 74% after oral administration
- Approximately 39% of circulating tofacitinib is bound to plasma proteins
- Clearance mechanisms for tofacitinib are approximately 70% hepatic metabolism and 30% renal excretion of the parent drug
- The metabolism of tofacitinib is primarily mediated by CYP3A4 with minor contribution from CYP2C19
- All human circulating and excreted metabolites have been observed at &lt;8% of total radioactivity and have been observed in animal species and are predicted to have ≤10% of the potency of tofacitinib for Janus Kinase (JAK) 1/3 inhibition

For the POPPK model, a 1-compartment model parameterised in terms of apparent oral clearance (CL/F), apparent volume of distribution (V/F), and first-order absorption adequately described the plasma concentration-time profile of tofacitinib in UC patients.  Plasma clearance (23.7 L/h) is slightly higher than that estimated for RA patients and similar to that in PsO patient, however the exposures are expected to be similar and within 20% of the exposure in RA patients. Inter-subject variability (percent coefficient of variation [%CV]) in AUC24 was generally similar across UC, RA and PsO patients (23%, 27% and 28%, respectively). Based on the demonstrated lack of time-dependence of tofacitinib clearance, plasma tofacitinib exposure at a given dose in individual UC patients is expected to be stable (ie, not change significantly) during the course of induction and maintenance treatment. Dose modification or restrictions for age, body weight, sex, race, ethnicity, or baseline disease severity (eg, baseline Mayo score and baseline albumin), to account for differences in exposure, are not required. There was &lt;20% estimated difference in AUC or maximum concentration (Cmax) between a reference patient with a typical value and those with values at the tails of the distributions of patient-specific factors that were statistically significant in the PK model.

Based on the overall comparability of tofacitinib PK profile between UC and RA patients, the proposed dosing adjustment recommendations derived for RA patients, primarily based on Phase 1 clinical pharmacology studies, are also applicable in patients with UC. Consistent with the current Summary of Product Characteristics (SmPC) for RA, it is recommended that: In UC patients with severe renal impairment or moderate hepatic impairment:

- the recommended dose is XELJANZ 5 mg BID when the indicated dose in the presence of normal renal and hepatic function is XELJANZ 10 mg BID,

<div style=\"page-break-after: always\"></div>

- the recommended dose is XELJANZ 5 mg QD when the indicated dose in the presence of normal renal and hepatic function is XELJANZ 5 mg BID
- In UC patients receiving potent inhibitors of Cytochrome P450 3A4 (CYP3A4 (eg, ketoconazole) or one (1) or more concomitant medications that result in both moderate inhibition of CYP3A4 and exhibit potent inhibition of CYP2C19 (eg, fluconazole): the recommended dose is half the daily dose indicated for patients not receiving these CYP inhibitors, ie, in patients already taking:
- XELJANZ 10 mg BID, reduce the dose to XELJANZ 5 mg BID or
- XELJANZ 5 mg BID, reduce the dose to XELJANZ 5 mg QD.

Tofacitinib has not been studied in subjects with severe hepatic impairment as defined by the Child-Pugh classification system. Tofacitinib is contraindicated in UC patients with severe hepatic impairment. Co-administration of tofacitinib to UC patients with potent inducers of CYP3A4, such as rifampin, may result in loss of or reduced clinical response.

Phase 1 drug-drug interaction studies and in vitro studies indicate the potential for tofacitinib to affect the PK of other drugs, including those metabolized by CYP450 isoforms, is low. The drugs evaluated for interactions included midazolam, oral contraceptives, methotrexate and metformin.

In vitro data indicated that tofacitinib does not inhibit or induce the CYP450 system, which was confirmed in a Phase 1 drug interaction study with midazolam, a highly sensitive CYP3A substrate. There was no effect of tofacitinib on the PK of oral contraceptives (ethinyl estradiol and levonorgestrel) or metformin (an organic cation transporter [OCT] substrate).

In vitro studies also indicate: There is low potential for tofacitinib to influence the metabolism of coadministered drugs that are metabolized by uridine diphosphate-glucuronosyltransferase enzymes. The potential for tofacitinib to inhibit transporters such as P-glycoprotein, organic anion transporting polypeptide (OATP) 1B1 or 1B3 (OATP1B1 or OATP1B3), or OCT-2 is low. Tofacitinib is not a substrate for breast cancer resistance protein, OCT1 or OCT2, or OATP1B1 or OATP1B3.

## Exposure-Response Relationships for Efficacy

Using pooled data from Phase 3 induction studies (A3921094 and A3921095), predicted placebo-adjusted probability of remission (primary endpoint) and mucosal healing (key secondary endpoint) were 12.7% and 17.8%, respectively, at 10 mg BID.

Comparison of predicted probability of remission and mucosal healing in the induction studies at the expected Cavg values for 5 mg and 10 mg BID indicated lower efficacy at 5 mg BID. The predicted placebo-adjusted probability of remission of 6.36% at 5 mg BID is not likely to be clinically meaningful. Although 15 mg BID was initially included in the induction studies, this dose was discontinued soon after study initiation as it was not considered an optimal induction dose. Therefore, E-R characterization of efficacy in the induction studies supports 10 mg BID as the induction dose for moderate to severe UC patients.  Covariate evaluation indicated that baseline Mayo score and prior tumor necrosis factor inhibitor (TNFi) failure status were significant predictors of response, in addition to tofacitinib exposure, in the E-R models for remission and

<div style=\"page-break-after: always\"></div>

mucosal healing. Predicted placebo-adjusted probability for remission and mucosal healing at Week 8 were inversely related to baseline Mayo score. Predicted placebo adjusted probability for remission and mucosal healing were generally similar between subjects who had previously failed TNFi and those who had not failed TNFi previously. Longitudinal E-R analysis of partial Mayo scores at Week 2, 4, and 8 indicated that onset of efficacy was rapid, with 68% of Week 8 effect achieved by Week 2.

Relative increase in model predicted efficacy response at Week 52 between 5 mg and 10 mg BID was 27% for remission among patients in remission at the maintenance baseline (ie, those who achieved remission during induction), and 30% for remission among non-remitters at baseline; 41% and 44%, respectively, for mucosal healing among patients in mucosal healing, and those who were not in mucosal healing, at baseline; and 34% for sustained steroid free remission among remitters at baseline. Therefore, predicted response at the 10 mg BID maintenance dose was 27% to 44% higher relative to 5 mg BID in the overall population, across the primary and key secondary endpoints. Estimated EC50 from base Markov models for remission, mucosal healing, and steroid free remission were 16.2, 40.3, and 14.3 ng/mL, respectively. The EC50 for remission was similar to the geometric mean Cavg at 5 mg BID (16.8 ng/mL), indicating that 5 mg BID is the approximate ED50 for remission. The geometric mean Cavg at 10 mg BID (33.6 ng/mL) corresponds to ED68 on the E-R curve for remission. In the subgroup of patients who previously failed TNFi, the relative increase in predicted probability of remission at Week 52 between 5 mg and 10 mg BID was 41%. Among those who had not failed TNFi previously, the increase was 19%, indicating that these patients were more likely to derive greater benefit from the 10 mg BID maintenance dose than patients who had not previously failed TNFi. Placebo-adjusted probability of remission at Week 52 was 29% and 41% among baseline remitters at Cavg values corresponding to 5 mg and 10 mg BID, respectively. Among baseline non-remitters, the Week 52 placebo-adjusted probability of remission from the Markov E-R model was 18% and 26% at 5 mg and 10 mg BID, respectively. This indicates higher maintenance efficacy among patients more responsive (ie, achieving remission) to induction treatment. Based on the longitudinal logistic regression model that included the effect of prior TNFi failure, predicted placebo-adjusted probability of remission at Week 52 among prior TNFi failures was 14% and 24% at 5 mg and 10 mg BID, respectively. Among patients who had not failed TNFi previously, predicted placebo-adjusted remission probability was 29% and 36% at 5 mg and 10 mg BID, respectively, indicating higher efficacy at both doses in this less refractory population.

Covariate evaluation using a multivariate analysis approach indicated that baseline Mayo score, age, and oral steroid use at baseline of maintenance were significant predictors in the final models for remission and mucosal healing. Prior TNFi failure status was not a significant covariate in the final models possibly due to correlation with other predictors. Probability of remission and mucosal healing was inversely correlated with baseline Mayo score. Oral steroid use at maintenance baseline was associated with lower probability of remission and mucosal healing at Week 52. There was a small positive correlation between probability of remission and age.

<div style=\"page-break-after: always\"></div>

## Exposure-Response Relationships for Safety

Overall, there was a trend for increase in estimated incidence rates (IR) of AEs with increasing tofacitinib exposure. However, except for HZ, the estimated IR at 10 mg and 5 mg BID were not significantly different, based on the ratio of IR (risk ratio) and 95% confidence interval (CI): The estimated risk ratio of 10 mg BID versus (vs) 5 mg BID doses of tofacitinib and 95% CI, from models using mean Cavg (MCAV) as predictor, were 1.12 (95% CI: 0.642, 1.95) for SI, 1.85 (95% CI: 0.857, 3.98) for OI, 1.84 (95% CI: 1.21, 2.79) for HZ, and 2.33 (95% CI: 0.863, 6.28) for NMSC.

E-R for ALT and AST indicated a small increase in enzyme concentration with tofacitinib exposure. The estimated mean (95% CI) difference from placebo for ALT was 1.86 (0.84, 2.88) IU/L and 3.72 (1.68, 5.76) IU/L at the geometric mean Cavg values in the 5 mg and 10 mg BID dose groups, respectively. Similarly, estimated mean (95% CI) difference from placebo for AST was 1.98 (1.21, 2.75) IU/L and 3.96 (2.41, 5.50) IU/L at the geometric mean Cavg values in the 5 mg and 10 mg BID dose groups, respectively. There was a trend for a small decrease in Hgb with increasing tofacitinib exposure, which was not statistically significant in maintenance. There was no significant change in NEU as a function of tofacitinib exposure during induction or maintenance. There was no statistically significant change in ALC with time or tofacitinib exposure during induction, and a trend for a decrease in ALC over time was observed during the maintenance phase, consistent with such decreases observed in the RA and PsO programs following long term treatment.

## 2.4.3. Pharmacodynamics

## Mechanism of action

The scientific rationale behind the use of Xeljanz in UC is based on its ability to block the signalling pathways of the γ -common cytokines by inhibiting JAK1 and JAK3. Cellular functions associated with the immune response in IBD are believed to be regulated by multiple different cytokines, which, in turn, signal through different combinations of JAKs. The primary and secondary pharmacology of tofacitinib has been well described and reviewed in the initial application.

## Primary and Secondary pharmacology

No specific drug interaction studies have been submitted in this variation application. Co-administration with the more commonly used UC drugs (e.g., 5-ASA and corticosteroids) was not studied. In clinical practice coadministration with these drugs is likely. The MAH considered that the routes of elimination of 5-ASA and corticosteroids render the likelihood of interaction to be low. Tofacitinib is not expected to impact on the PK of 5-ASA, based on the lack of overlap in elimination pathways. No CYP-mediated metabolism by 5-ASA or its metabolite is reported, and no effect of 5-ASA co-administration on tofacitinib exposure is expected. For corticosteroids, no clinically relevant inhibition or induction of CYP enzymes have been reported, and the lack of effect of tofacitinib on the pharmacokinetics of midazolam, a probe CYP3A4 substrate, was demonstrated. Therefore, concomitant administration of these corticosteroids is not expected to impact the PK of tofacitinib, and no impact of tofacitinib on the PK of corticosteroids is expected.  Evaluation of concomitant corticosteroid

<div style=\"page-break-after: always\"></div>

use as a covariate in the population PK analysis of tofacitinib in UC patients, using pooled data from Phase 2 and Phase 3 studies, indicated that there was no effect of corticosteroid co-administration on the PK of tofacitinib.  Concomitant corticosteroid use at baseline of Phase 3 induction studies in UC patients was evaluated as a covariate in exposure-response models for efficacy and safety (adverse events [AEs] of special interest).  Concomitant corticosteroid use was not found to be a significant predictor of AEs such as serious infections, opportunistic infections, or herpes zoster in UC patients. However, in other indications such as RA, increase incidence of AEs have been observed with concomitant corticosteroid use as may be expected based on the immunosuppressant effects of steroids.  Corticosteroid use was also not a significant predictor in the exposure response model for the primary induction efficacy endpoint of remission, but was significant for some secondary efficacy endpoints, as may be expected based on the pharmacodynamic (PD) activity of corticosteroids.

It is reported that genetic polymorphisms in the JAK/STAT pathway have been associated with UC in humans. The MAH provided details of a number of single nucleotide polymorphisms (SNPs) and genes associated with inflammatory bowel disease that may be considered candidate loci to query when looking for differential effects of tofacitinib in UC.  In study A3921063 samples were taken for pharmacogenomic studies to examine the genetic basis of drug response,  and the MAH has confirmed that DNA samples from patients collected in the UC trial programme are currently being genotyped via SNP arrays, and data derived may be useful for future identification of differential efficacy/safety effects of tofacitinib.

Extensive DER modelling has been performed and this supports the dose of 10 mg for efficacy for induction and the 5mg for maintenance of remission. There is an increased risk of some of the safety parameters studied e.g. HZ and opportunistic infections at the higher dose however this is not statistically significant.

## 2.4.4. Discussion on clinical pharmacology

The pharmacokinetics have been well described in previous applications.  Phase 3 data was used to further investigate important covariates on the PK and these were found to be consistent with other findings.  The primary and secondary pharmacology of tofacitinib has been well described and reviewed in the initial application.

## 2.4.5. Conclusions on clinical pharmacology

From a pharmacological perspective, the application for marketing authorisation of XELJANZ 10 mg tablets to treat ulcerative colitis is supported.

## 2.5. Clinical efficacy

## 2.5.1. Dose response study

Study A3921063 was a randomised, placebo controlled study conducted to evaluate a 30-fold dose range (0.5, 3, 10, and 15 mg BID) in moderately to severely active UC patients. The study was subject-, investigator-, and sponsor-blinded.

The primary objective was to demonstrate efficacy of CP-690,550 in inducing a clinical response in subjects with moderate-to-severe ulcerative colitis (UC). The primary efficacy endpoint was the proportion of clinical

<div style=\"page-break-after: always\"></div>

responders at Week 8. Clinical response was defined as a decrease from baseline in Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the subscore for rectal bleeding of at least 1 point or an absolute sub-score for rectal bleeding of 0 or 1.

The study design and length of the study of 8 weeks, which although is at the lower end of the acceptable length, is acceptable. Randomisation was stratified according to disease activity which was appropriate.

The primary efficacy point utilised did not include a separate evaluation on endoscopic subscore and this limits clinical interpretation of the results as both clinical symptom improvement and mucosal healing are imperative in assessing clinical response. This was not considered to be a significant concern as this was an exploratory phase 2 dose finding study.

For the primary efficacy endpoint, which was clinical response 47.5%, 29.6%, 51.6%, 63.3%, and 80% of subjects (FAS) in the placebo and CP-690,550 0.5 mg, 3 mg, 10 mg, and 15 mg treatment groups, respectively, achieved a clinical response at Week 8. The lower doses of 0.5mg and 3mg were substantially less efficacious than the 10mg and 15mg doses.

The secondary efficacy endpoint of clinical remission was defined as a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and as such did encompass both aspects of symptomatic and endoscopic remission. For the secondary efficacy endpoints, 12.2%, 7.4%, 35.5%, 50%, and 42.2% of subjects (FAS) in the placebo and CP-690,550 0.5 mg, 3 mg, 10 mg, and 15 mg treatment groups, respectively, were in clinical remission at Week 8. Based on the primary and secondary endpoints there was evidence of statistically significant effect for the 10mg and 15 mg but not the 0.5 and 3mg.

Based on the linear mixed-effects model analysis of the partial Mayo scores, a statistically significant difference from placebo was observed at Week 2 in the tofacitinib 10 mg and 15 mg BID treatment groups. The tofacitinib doses evaluated in the Phase 3 induction studies (A3921094 and A3921095) were selected based on dose-response modelling of efficacy data from the Phase 2, study A3921063.

## 2.5.2. Main studies

The main studies were from the phase 3 program, which consisted of  2 completed, identically designed 8week induction studies (A3921094 and A3921095) with tofacitinib 10 mg BID or placebo, 1 separate completed 52-week maintenance study (A3921096) with tofacitinib 5 mg BID, tofacitinib 10 mg BID or placebo, and 1 ongoing open-label LTE study (A3921139) with tofacitinib 5 mg BID and tofacitinib 10 mg BID.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## STUDIES A3921094 and A3921095

<!-- image -->

Abbreviations:BID= twice a day;DB=double-blind.

## Methods

## Study Participants

Subjects were selected based on a diagnosis (endoscopic or radiographic and histological) of UC &gt;4 months prior to entry into the study, with a histological confirmation. Moderately to severely active disease was defined by a total Mayo score of &gt;6, with a rectal bleeding score of &gt;1, and an endoscopic subscore of &gt;2 on the Mayo score determined within 10 days of baseline visit. Appropriate measures of diagnosis and disease severity were utilised for subject selection.

Subjects had failed or been intolerant of at least 1 of the oral or intravenous (IV) corticosteroids; Azathioprine, 6-MP; or TNFi therapy: infliximab or adalimumab.

The enrolled population is representative of the anticipated UC treatment population for tofacitinib in the proposed indication.

## Treatments

Subjects were randomized to either tofacitinib 10 mg BID or placebo BID, with a treatment allocation ratio of 4:1. Subjects were stratified by previous treatment with TNFi therapy, oral corticosteroid use at baseline, and geographic region. Active treatment in the study continued for 8 weeks which was an acceptable length of time.

At entry into the induction studies, subjects were permitted to continue oral corticosteroids or 5-ASA for UC. The continuation of background therapy was acceptable, considering the proposed indication and is consistent with CHMP guidance CHMP/EWP/18463/2006 Guideline on the development of new medicinal products for the treatment of Ulcerative Colitis. Chronic treatment for UC with antibiotics was permitted, it would be expected that antibiotic use would be excluded, per the Guideline on the development of new medicinal products for

<div style=\"page-break-after: always\"></div>

the treatment of ulcerative colitis, which states that 'Antibiotics should normally be excluded and in severe disease, anti-cholinergic, anti-diarrhoeal, NSAID and opioid drugs should not be allowed as they may contribute to worsening of the relapse.' The MAH has clarified that the number of patients who received concomitant antibiotics for UC treatment was 6/905 (0.7%) of the patients receiving tofacitinib 10mg BID in the induction studies and has provided adequate justification for the inclusion of these few patients. It is accepted that these few subjects are unlikely to have had a significant effect on the overall results of the studies.The enrolled population is representative of the anticipated UC treatment population for tofacitinib in the proposed indication.

Patients were stratified depending on their previous treatment and efficacy sub-analysis for each subpopulation was evaluated separately.

## Objectives

Primary Objective:

- To demonstrate the efficacy of tofacitinib in inducing remission in subjects with moderately to severely active UC.

Secondary Objectives

- To evaluate the safety and tolerability of tofacitinib in subjects with moderately to severely active UC
- To evaluate the efficacy of tofacitinib in achieving mucosal healing in subjects with moderately to severely active UC
- To evaluate the effect of tofacitinib induction therapy on other clinical outcomes in subjects with moderately to severely active UC
- To evaluate tofacitinib pharmacokinetic (PK) exposure during induction therapy in subjects with moderately to severely active UC
- To evaluate the effect of induction treatment of tofacitinib on quality-of-life in subjects with moderately to severely active UC.

## Outcomes/endpoints

Primary Efficacy Endpoint:

- Remission at Week 8. Remission was defined by a total Mayo score of 2 points or lower, with no individual sub score exceeding 1 point and a rectal bleeding sub score of 0.

Key Secondary Efficacy Endpoint:

- Mucosal healing at Week 8. Mucosal healing was defined by a Mayo endoscopic sub score of 0 or 1.

Other Secondary Efficacy endpoints:

- Clinical response at Week 8. Clinical response was defined by a decrease from baseline in Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the sub score for rectal bleeding of at least 1 point or absolute sub score for rectal bleeding of 0 or 1;

<div style=\"page-break-after: always\"></div>

- Endoscopic remission at Week 8. Endoscopic remission was defined by a Mayo  endoscopic sub score of 0;
- Clinical remission at Week 8. Clinical remission was defined by a total Mayo score of 2 points or lower, with no individual sub score exceeding 1 point;
- Symptomatic remission at Week 8. Symptomatic remission was defined by a total Mayo score of 2 points or lower, with no individual sub score exceeding 1 point, and both rectal bleeding and stool frequency sub score of 0;
- Deep remission at Week 8. Deep remission was defined by a total Mayo score of 2 points or lower, with no individual sub score exceeding 1 point and a 0 on both endoscopic and rectal bleeding subscores;
- Partial Mayo scores and change from baseline over time;
- Change from baseline at Week 8 in total Mayo score

## Exploratory Efficacy endpoints

- The partial Mayo score remission, defined as a partial Mayo score of ≤ 2 with no individual sub score &gt;1 over time;
- The partial Mayo score response, defined as a reduction of ≤ 2 points from baseline in partial Mayo score over time;
- The endoscopic response at Week 8. Endoscopic response was defined by a decrease from baseline in the endoscopic sub score of 1 point or more;
- Mayo subscores over time: stool frequency, rectal bleeding, findings of flexible sigmoidoscopy, PGA;
- The proportion of subjects with a reduction of ≥ 1 point from baseline in stool frequency;
- The proportion of subjects with a reduction of ≥ 1 point from baseline in rectal bleeding;
- The proportion of subjects with a reduction of ≥ 1 point from baseline in PGA
- Absolute counts and change from baseline in the following lymphocyte subsets: CD4+T cells, CD8+ T cells, B cells, and natural killer (NK) cells (UK only).

Health outcomes Endpoints:

- The scores and change from baseline in IBDQ total score and domains (Bowel Symptoms, Systemic Symptoms, Emotional Function and Social Function) over time;
- The IBDQ-170 remission, defined as IBDQ total score ≥ 170 at Week 4 and Week 8;
- The IBDQ-16 point change response, defined as ≥ 16 point increase in IBDQ total score from baseline at Week 4 and Week 8;
- Improvement in IBDQ Bowel Symptoms domain at Week 4, Week 8, and both Weeks 4 and 8. The improvement was defined as an increase of at least 1.2 points from baseline in average score among IBDQ Bowel Symptoms domain (item 1, 5, 9, 13, 17,

<div style=\"page-break-after: always\"></div>

20, 22, 24, 26, 29);

- The PGIC scores at Week 8;
- The scores for the PRTI at Week 8;
- The scores and change from baseline in SF-36, Version 2, acute (physical and mental component summary scores, and 8 domain scores) at Week 8;
- The scores and change from baseline in EQ-5D/VAS over time;
- The scores and change from baseline in the 4 WPAI-UC questionnaire domains

(Absenteeism, Presenteeism, Work Productivity Loss, Activity Impairment) at Week 8;

- Summary of subjects who utilize the healthcare services and the frequency of utilization of such services specified in the UC-HCRU-All at Week 4, and Week 8;
- Summary of incidences and duration of UC-related hospitalizations;
- Summary of subjects requiring colectomy for UC or UC-related complications.

Biomarker Evaluations:

- Serum high sensitivity C-reactive protein (hsCRP) and change from baseline in hsCRP over time.

## Sample size

The sample size, planned to be enrolled into the study and randomized in a 4:1 ratio to either tofacitinib 10 mg BID or placebo, was estimated based on the primary endpoint of remission at Week 8 and the key secondary endpoint of mucosal healing at Week 8. This sample size was proposed to give at least 90% power to detect a treatment difference assuming a difference of 17.5% between treatment groups in the proportion of subjects in remission at Week 8 using Chi-square test at the significant level of 5% (2-sided) under the assumption of a placebo rate of 15%. The sample size also provided at least 90% power to detect a treatment difference assuming a difference of 17.5% between treatment groups in the proportion of subjects achieving mucosal healing at Week 8 using Chi-square test at the significant level of 5% under the assumption of a placebo rate of 35%.

## Randomisation

Subjects who met the inclusion and exclusion criteria at the baseline visit were randomly assigned to receive either tofacitinib 10 mg BID or matching placebo BID at a 4:1 allocation ratio. This reflected a change resulting from a protocol amendment which discontinued further enrolment into the tofacitinib 15 mg group. Subjects were stratified based on the status of prior treatment with TNFi therapy, corticosteroid use at baseline, and geographic region.

Subjects enrolled prior to Protocol Amendment 3 were randomized into 1 of the 3 treatment groups of tofacitinib 10 mg or 15 mg BID, or placebo BID with an allocation ratio of 2:2:1.

<div style=\"page-break-after: always\"></div>

The subject was randomized to trial medication via the tele-randomization system, according to a computer generated pseudo random code using the method of permutated blocks balanced within each randomization strata.

## Blinding (masking)

The study was subject-, investigator-, and sponsor-blinded.  Blinding was achieved by the use of placebo tablets matching tofacitinib 5mg tablets.

## Statistical methods

## Analysis Populations

The primary analysis population for efficacy endpoints was the FAS, defined as all subjects randomly assigned to either tofacitinib 10 mg BID or placebo. Additional analyses were performed for the PPAS, defined as a subset of subjects from the FAS population who had no major protocol violations that could have potentially had a significant impact on efficacy analyses, as determined by the sponsor prior to database lock. The safety analysis set included all randomised subjects who received at least one dose of study medication.

## Multiple Testing Procedure

The family-wise Type I error rate was controlled at the level of 0.05 across the primary endpoint remission at Week 8, and the key secondary endpoint mucosal healing status at week 8, using a fixed sequence testing procedure: the superiority of tofacitinib 10 mg BID over placebo for the primary endpoint at Week 8 was tested first, and if the test p-value was less than 0.05, then the superiority of tofacitinib 10 mg BID over placebo for the key secondary endpoint was tested. Statistical significance could be claimed for the key secondary endpoint only if the treatment effect for the primary efficacy endpoint was also significant. All other efficacy endpoints were evaluated at the 0.05 level of significance, without adjustments for multiple comparisons.

## Analysis of Binary Efficacy Endpoints

For all binary endpoints including the primary efficacy endpoint remission at Week 8 and the key secondary efficacy endpoint mucosal healing at Week 8, the Cochran-Mantel Haenszel (CMH) chi-square test stratified by prior TNFi exposure, corticosteroid use at baseline and geographic region was pre-specified for the comparisons of tofacitinib 10 mg BID versus the placebo group. The number of subjects and the proportion of responders are presented for each treatment group. The difference between treatment groups is presented along with the 95% CI using the normal approximation for the difference in binomial proportions. Subjects with missing data were treated as non-responders (referred to as the non-responder imputation [NRI] method).

## Analysis of Continuous Efficacy Endpoints

For continuous endpoints that were measured repeatedly over time, such as partial Mayo score, the change from baseline was analysed using a linear mixed-effects model with baseline, treatment group, prior TNFi exposure, corticosteroid use at baseline, geographic region, visit, and treatment group-by-visit interaction as fixed effects, and subject as a random effect. The adjusted estimates of the differences and associated 95% CIs for the comparison of tofacitinib 10 mg BID to placebo were computed at each visit. For continuous endpoints that were only measured at baseline and Week 8, such as Mayo score, the change from baseline at

<div style=\"page-break-after: always\"></div>

Week 8 was analysed using an ANCOVA model with treatment group, prior TNFi exposure, corticosteroid use at baseline, and geographic region as factors, and baseline as a covariate.  No imputation was performed for missing data and analyses were performed on observed-case databased. Estimates of the differences and associated 95% CIs for the comparison of tofacitinib 10 mg BID to placebo were computed.

## Subgroup Analyses in the Individual Studies

Subgroup analyses were performed for the primary efficacy endpoint and the key secondary efficacy endpoint. Results are presented for the subgroups defined by prior TNFi status, corticosteroid use at baseline, and geographic region. Prior failure or intolerance to TNFi agents, as assessed by the investigator, included the following reasons: (1) adverse event (AE), (2) lack of efficacy with failure to achieve a response, (3) lack of efficacy with failure to maintain a response, (4) lack of efficacy with failure to achieve a response and AE, and (5) lack of efficacy with failure to maintain a response and AE. TNFi failure was further analysed by primary non-response, defined as categories 2 or 4, and secondary non-response, defined as categories 3 or 5.

## Pooled Analyses

The data from the 2 pivotal induction studies, A3921094 and A3921095, were pooled to obtain the estimates of the treatment effects in the pooled FAS population. The purpose of the pooled analyses was to provide more precise estimates of the treatment effects overall and within subgroups. The same analysis methods as described above for the individual studies were used for the pooled analyses of binary and continuous endpoints except that study was also included as a stratum or factor. Analyses were also performed for various subgroups based on the pooled data, including demography, geographic region, baseline clinical characteristics, prior UC treatments, and corticosteroid use at baseline.

## Results induction study A3921094

## Participant flow

A total of 614 subjects were randomized to study treatment. Of these, 598 subjects were randomized to tofacitinib 10 mg BID (476) or placebo (122), and comprised the FAS. All randomized subjects received at least 1 dose of study drug.

There were 16 subjects who were randomized to and received tofacitinib 15 mg BID prior to Protocol Amendment 3; subjects who were assigned to the tofacitinib 15 mg BID dose group were not included in the analysis sets.

## Subject Disposition by Treatment Group:

<div style=\"page-break-after: always\"></div>

|                                           | Tofacitinib 10 mg BID n (%)   | Placebo n (%)   | Total n (%)   |
|-------------------------------------------|-------------------------------|-----------------|---------------|
| Screened                                  |                               |                 | 990           |
| Randomized                                | 476                           | 122             | 614 (62.0)a,b |
| Prior to Protocol Amendment 3             | 14                            | 8               | 38b           |
| After Protocol Amendment 3c               | 462                           | 114             | 576           |
| Full Analysis Set                         | 476 (100.0)                   | 122 (100.0)     | 598 (100.0)   |
| Per Protocol Analysis Set                 | 443 (93.1)                    | 117 (95.9)      | 560 (93.6)    |
| Safety Analysis Set                       | 476 (100.0)                   | 122 (100.0)     | 598 (100.0)   |
| Adverse eventsd                           | 476 (100.0)                   | 122 (100.0)     | 598 (100.0)   |
| Laboratory data?                          | 474 (99.6)                    | 122 (100.0)     | 596 (99.7)    |
| Treated                                   | 476                           | 122             | 598           |
| Completed                                 | 445 (93.5)                    | 118 (96.7)      | 563 (94.1)    |
| Discontinuedf                             | 31 (6.5)                      | 4 (3.3)         | 35 (5.9)      |
| Primary Reason for Discontinuation        |                               |                 |               |
| Subject died                              | 1 (0.2)                       | 0               | 1 (0.2)       |
| Related to study diug                     | 19 (4.0)                      | 2 (1.6)         | 21 (3.5)      |
| Adverse event                             | 8 (1.7)                       | 1 (0.8)         | 9 (1.5)       |
| Insufficient clinical response?           | 11 (2.3)                      | 1 (0.8)         | 12 (2.0)      |
| Not related to study drug                 | 11 (2.3)                      | 2 (1.6)         | 13 (2.2)      |
| Adverse event                             | 1 (0.2)                       | 0               | 1 (0.2)       |
| No longer willing to participate in study | 4 (0.8)                       | 1 (0.8)         | 5 (0.8)       |
| Protocol violation                        | 4 (0.8)                       | 1 (0.8)         | 5 (0.8)       |
| Other                                     | 2 (0.4)                       | 0               | 2 (0.3)       |

Source: Table 14.1.1.1.1, Table 14.1.1.1.3, Table 14.1.1.2.1,Table 14.1.1.2.3, Table 14.2.2.2. Table 16.1.7.2.

BID = twice a day, n = number of subjects meeting prespecified criteria.

a Percentage for randomized was calculated using the number screened as the denominator

(Table 14.1.1.1.3). All other percentages were calculated using the total number randomized (598) to tofacitinib 10 mg BID and placebo as the denominator.

b. Sixteen subjects were randomized to tofacitinib 15 mg BID prior to removal of this dose from the study (Table 14.1.1.1.2).

° Number of subjects in each treatment group is from Table 14.2.2.2, and total number of subjects is from Table 14.1.1.1.3.

d. Adverse events (AEs) - all randomized subjects for which the Adverse Event case report form (CRF) was completed in the database.

e Laboratory data - all randomized subjects that had lab data collected at both baseline and 1 of the post-baseline visits. As Subjects 10261004 and 12321003 only had baseline laboratory values, they were not included in the laboratory data analysis set (Table 16.2.1.1).

Subject 13561001 (tofacitinib 10 mg BID treatment group) completed the Week 8 visit and was then withdrawn for an AE. This subject was counted as discontinued instead of completed (Table 16.2.1.1).

AEs of worsening of ulcerative colitis leading to discontinuation were designated as insufficient clinical response.

## Rollover Status of Completed Subjects into Follow-On Studies:

<div style=\"page-break-after: always\"></div>

|                                                  | Tofacitinib 10 mg BID (N = 476) n (%)   | Placebo (N =122) n (%)   | Total (N = 598) n (%)   |
|--------------------------------------------------|-----------------------------------------|--------------------------|-------------------------|
| Entered maintenance study (A3921096)             | 277 (58.2)                              | 37 (30.3)                | 314 (52.5)              |
| Entered open-label study (A3921139)              | 155 (32.6)                              | 77 (63.1)                | 232 (38.8)              |
| Did not enter maintenance or open-label studya,b | 14 (2.9)                                | 4 (3.3)                  | 18 (3.0)                |
| Investigator decision                            | 2 (0.4)                                 | 0                        | 2 (0.3)                 |
| Lost to follow-up                                | 0                                       | 0                        | 0                       |
| Subject refused participation                    | 3 (0.6)                                 | 1 (0.8)                  | 4 (0.7)                 |
| Not eligible                                     | 7 (1.5)                                 | 1 (0.8)                  | 8 (1.3)                 |
| Other                                            | 2 (0.4)                                 | 2 (1.6)                  | 4 (0.7)                 |

Source: Table 14.1.1.3.1.

Early termination subjects were not required to provide the Study Continuation - Extension Rollover information. They are not summarized in this table.

BID = twice a day, N = number of randomized subjects, n = number of subjects meeting prespecified criteria.

0. Subject 13561001 (tofacitinib 10 mg BID treatment group) completed the Week 8 visit and was then withdrawn for an adverse event. This subject was counted as discontinued.

a Subjects who completed Week 8 visit and did not advance to Study A3921096 or A3921139.

## Recruitment

First Subject First Visit (FSFV): 18 April 2012

Last Subject Last Visit (LSLV): 22 May 2015

## Conduct of the study

There were a number of amendments and the most significant was Protocol Amendment 3 (Dated 30 November 2012); this amendment removed the tofacitinib 15 mg BID arm from the study.

The most frequent cause for a protocol deviation was that the subject did not have screening endoscopy performed within the protocol specified window (11.9%), which occurred in 12.8% of the tofacitinib 10 mg BID group, and in 8.2% of placebo group.

## Baseline data

Overall, demographic characteristics were similar between treatment groups. For all subjects included in the FAS, there were more male (354/598, 59.2%) than female subjects (244/598, 40.8%), and the majority were white (82.4%). For the subjects who indicated their race as Asian (11.4%), Other (3.0%) or Unspecified (2.2%), the most frequent racial designation was Japanese (10.4%). Overall, the mean age of subjects was 41.6 years (range: 18 to 81 years); the mean weight of subjects was 72.8 kg (range: 37.0 to 156.5 kg), and the mean body mass index (BMI) was 24.6 kg/m2 (range: 15.6 to 48.1 kg/m2

Overall, enrolment within geographical areas was similar across treatment groups. The majority of subjects were enrolled at sites in Europe (59.7%) and North America (22.1%).

## Demographic and Baseline Characteristics by Treatment Group (FAS )

<div style=\"page-break-after: always\"></div>

|                            | Tofacitinib 10 mg BID   | Tofacitinib 10 mg BID   | Tofacitinib 10 mg BID   | Placebo       | Placebo         | Placebo         |
|----------------------------|-------------------------|-------------------------|-------------------------|---------------|-----------------|-----------------|
|                            | Male (N = 277)          | Female (N = 199)        | Total (N = 476)         | Male (N = 77) | Female (N = 45) | Total (N = 122) |
| Age (years)                |                         |                         |                         |               |                 |                 |
| Mean (SD)                  | 41.9 (14.7)             | 40.5 (13.3)             | 41.3 (14.1)             | 41.2 (15.2)   | 42.9 (15.6)     | 41.8 (15.3)     |
| Range                      | 18,77                   | 18,74                   | 18,77                   | 19,81         | 19,76           | 19, 81          |
| <18, n (%)                 | 0                       | 0                       | 0                       | 0             | 0               | 0               |
| 18 to 44, n (%)            | 165 (59.6)              | 130 (65.3)              | 295 (62.0)              | 47 (61.0)     | 25 (55.6)       | 72 (59.0)       |
| 45 to 64, n (%)            | 86 (31.0)               | 59 (29.6)               | 145 (30.5)              | 24 (31.2)     | 15 (33.3)       | 39 (32.0)       |
| ≥65, n (%)                 | 26 (9.4)                | 10 (5.0)                | 36 (7.6)                | 6 (7.8)       | 5 (11.1)        | 11 (9.0)        |
| Race, n (%)a               |                         |                         |                         |               |                 |                 |
| White                      | 230 (83.0)              | 165 (82.9)              | 395 (83.0)              | 62 (80.5)     | 36 (80.0)       | 98 (80.3)       |
| Black                      | 2 (0.7)                 | 1 (0.5)                 | 3 (0.6)                 | 1 (1.3)       | 2 (4.4)         | 3 (2.5)         |
| Asian                      | 32 (11.6)               | 22 (11.1)               | 54 (11.3)               | 11 (14.3)     | 3 (6.7)         | 14 (11.5)       |
| Other                      | 6 (2.2)                 | 9 (4.5)                 | 15 (3.2)                | 1 (1.3)       | 2 (4.4)         | 3 (2.5)         |
| Unspecified                | 7 (2.5)                 | 2 (1.0)                 | 9 (1.9)                 | 2 (2.6)       | 2 (4.4)         | 4 (3.3)         |
| Racial designation, n (%)a |                         |                         |                         |               |                 |                 |
| Indian Subcontinent        | 2 (0.7)                 | 2 (1.0)                 | 4 (0.8)                 | 0             | 0               | 0               |
| Asian                      |                         |                         |                         |               |                 |                 |
| Southeast Asian            | 0                       | 0                       | 0                       | 1(1.3)        | 0               | 1 (0.8)         |
| North American             | 0                       | 1 (0.5)                 | 1 (0.2)                 | 0             | 1 (2.2)         | 1 (0.8)         |
| Indian                     |                         |                         |                         |               |                 |                 |
| Japanese                   | 29 (10.5)               | 20 (10.1)               | 49 (10.3)               | 10 (13.0)     | 3 (6.7)         | 13 (10.7)       |
| Other                      | 7 (2.5)                 | 8 (4.0)                 | 15 (3.2)                | 1 (1.3)       | 1 (2.2)         | 2 (1.6)         |
| Unspecified                | 7 (2.5)                 | 2 (1.0)                 | 9 (1.9)                 | 2 (2.6)       | 2 (4.4)         | 4 (3.3)         |
| Ethnicity, n (%)           |                         |                         |                         |               |                 |                 |
| Hispanic/Latino            | 9 (3.2)                 | 14 (7.0)                | 23 (4.8)                | 3 (3.9)       | 2 (4.4)         | 5 (4.1)         |
| Not Hispanic/Latino        | 261 (94.2)              | 183 (92.0)              | 444 (93.3)              | 72 (93.5)     | 41 (91.1)       | 113 (92.6)      |
| Unspecified                | 7 (2.5)                 | 2 (1.0)                 | 9 (1.9)                 | 2 (2.6)       | 2 (4.4)         | 4 (3.3)         |
| Geographic region, n (%)   |                         |                         |                         |               |                 |                 |
| Europe                     | 171 (61.7)              | 114 (57.3)              | 285 (59.9)              | 47 (61.0)     | 25 (55.6)       | 72 (59.0)       |
| North America              | 55 (19.9)               | 47 (23.6)               | 102 (21.4)              | 17 (22.1)     | 13 (28.9)       | 30 (24.6)       |
| Other                      | 51 (18.4)               | 38 (19.1)               | 89 (18.7)               | 13 (16.9)     | 7 (15.6)        | 20 (16.4)       |
| Weight (kg)                |                         |                         |                         |               |                 |                 |
| Mean (SD)                  | 77.9 (15.6)             | 65.9 (15.8)             | 72.9 (16.8)             | 77.9 (17.1)   | 63.8 (11.6)     | 72.7 (16.7)     |
| Range                      | 49.6, 156.5             | 37.0,123                | 37.0, 156.5             | 46.7, 130     | 37.4, 82.7      | 37.4, 130       |
| Height (cm)                |                         |                         |                         |               |                 |                 |
| Mean (SD)                  | 176.6 (7.5)             | 164.3 (7.2)             | 171.4 (9.6)             | 178.1 (7.1)   | 162.6 (7.4)     | 172.4 (10.4)    |
| Range                      | 152.0,                  | 145.5,                  | 145.5,                  | 156.7,        | 143.0,          | 143.0,          |
| Body mass index (kg/m?)    |                         |                         |                         |               |                 |                 |
|                            | 196.0 24.9              | 186.0 24.4              | 24.7                    |               |                 | 199.0           |
| Range                      |                         |                         | 196.0                   | 199.0         | 179.0           |                 |
| Mean (SD)                  |                         |                         |                         | 24.5          | 24.2            | 24.4            |
|                            | 16.9, 48.1              | 15.8, 45.6              | 15.8, 48.1              | 15.6, 41.4    | 15.6, 35.1      | 15.6, 41.4      |

Source: Table 14.1.2.1, Table 14.1.2.1.3.

BMI was defined as weight/(height x 0.01)?, with weight in kg, and height in cm.

Race/Ethnicity was not collected for French subjects.

BID = twice a day, BMI = body mass index, FAS = full analysis set, N = number of subjects randomized, n =

number of subjects meeting prespecified criteria, SD = standard deviation.

Racial designation was collected for those subjects whose race was marked as Asian, Other, or Unspecified.

Overall, the median duration of disease was 6.3 years (range: 0.3 to 42.5). The median time since start of the most recent UC flare was 3.1 months (range: 0.0 to 154.4).

For all subjects, the mean total Mayo score at baseline was 9.0 (SD: 1.4), with similar scores observed across treatment groups. The overall mean partial Mayo score at baseline was 6.4 (SD: 1.2), with similar scores across treatment groups. The extent of disease at baseline was similar across treatment groups. Overall, 53.3% of subjects had extensive colitis or pancolitis, including 53.1% in the tofacitinib 10 mg BID group and 54.1% in the placebo group. Extra-intestinal manifestations at baseline were reported in 23.7% of subjects overall.

<div style=\"page-break-after: always\"></div>

## Baseline Clinical Characteristics by Treatment Group:

|                                                             | Tofacitinib 10 mg BID (N = 476)   | Placebo (N =122)   | Total (N = 598)   |
|-------------------------------------------------------------|-----------------------------------|--------------------|-------------------|
| Duration of disease (years)                                 |                                   |                    |                   |
| Mean (SD)                                                   | 8.3 (7.1)                         | 8.4 (7.6)          | 8.3 (7.2)         |
| Median                                                      | 6.5                               | 6.0                | 6.3               |
| Range                                                       | 0.3,42.5                          | 0.5, 36.2          | 0.3,42.5          |
| Time since start of most recent UC flare                    |                                   |                    |                   |
| (months)                                                    |                                   |                    |                   |
| Mean (SD)                                                   | 6.9 (13.5)                        | 7.8 (12.8)         | 7.1 (13.3)        |
| Median                                                      | 2.9                               | 3.4                | 3.1               |
| Range                                                       | 0.0, 154.4                        | 0.0, 86.9          | 0.0, 154.4        |
| Number of UC flares in the last 12 months                   |                                   |                    |                   |
| Mean (SD)                                                   | 1.9 (1.4)                         | 1.8 (1.1)          | 1.9 (1.3)         |
| Median                                                      | 2.0                               | 1.5                | 2.0               |
| Range                                                       | 0.0, 12.0                         | 0.0, 9.0           | 0.0, 12.0         |
| 0 flares, n (%)                                             | 2 (0.4)                           | 2 (1.6)            | 4 (0.7)           |
| 1-2 flares, n (%)                                           | 373 (78.4)                        | 95 (77.9)          | 468 (78.3)        |
| 3-4 flares, n (%)                                           | 81 (17.0)                         | 23 (18.9)          | 104 (17.4)        |
| 5+ flares, n (%)                                            | 20 (4.2)                          | 2 (1.6)            | 22(3.7)           |
| Subjects with a prior hospitalization for UC, n (%)         |                                   |                    |                   |
| N1                                                          | 473                               | 122                | 595               |
| Yes                                                         | 280 (58.8)                        | 72 (59.0)          | 352 (58.9)        |
| No                                                          | 189 (39.7)                        | 48 (39.3)          | 237 (39.6)        |
| Unknown                                                     | 4 (0.8)                           | 2 (1.6)            | 6 (1.0)           |
| Number of hospitalizations in the past                      |                                   |                    |                   |
| 12 monthsa                                                  |                                   |                    |                   |
| Mean (SD)                                                   | 0.5 (0.9)                         | 0.4 (0.7)          | 0.5 (0.9)         |
| Median                                                      | 0                                 | 0                  | 0                 |
| Range                                                       | 0.0, 6.0                          | 0.0, 3.0           | 0.0, 6.0          |
| Total Mayo scoreb                                           |                                   |                    |                   |
| N1                                                          | 475                               | 121                | 596               |
| Mean (SD)                                                   | 9.0 (1.4)                         | 9.1 (1.4)          | 9.0 (1.4)         |
| Median                                                      | 9.0                               | 9.0                | 9.0               |
| Range                                                       | 5.0, 12.0                         | 6.0, 12.0          | 5.0, 12.0         |
| Partial Mayo scoreb                                         |                                   |                    |                   |
| N1                                                          | 475                               | 121                | 596               |
| Mean (SD)                                                   | 6.3 (1.2)                         | 6.5 (1.2)          | 6.4 (1.2)         |
| Median                                                      | 6.0                               | 7.0                | 6.0               |
| Range                                                       | 3.0, 9.0                          | 4.0, 9.0           | 3.0, 9.0          |
| Baseline high sensitivity C-reactive protein (hsCRP) (mg/L) |                                   |                    |                   |
| N1                                                          | 469                               | 121                | N/A               |
| Mean (SD)                                                   | 11.0 (18.6)                       | 10.6 (14.7)        | N/A               |
| Median                                                      | 4.4                               | 4.7                | N/A               |
| Range                                                       | 0.1, 208.4                        | 0.1, 82.5          | N/A               |
| Extent of disease, n (%)*                                   |                                   |                    |                   |
| N1                                                          | 475                               | 122                | 597               |
| Proctosigmoiditis                                           | 65 (13.7)                         | 19 (15.6)          | 84 (14.1)         |
| Left-sided colitis                                          | 158 (33.3)                        | 37 (30.3)          | 195 (32.7)        |
| Extensive colitis/pancolitis                                | 252 (53.1)                        | 66 (54.1)          | 318 (53.3)        |
| Any extra-intestinal manifestations, n (%)d                 |                                   |                    |                   |
| Yes                                                         | 119 (25.0)                        | 23 (18.9)          | 142 (23.7)        |
| No                                                          | 357 (75.0)                        | 99 (81.1)          | 456 (76.3)        |
| Alcohol use, n (%)                                          |                                   |                    |                   |
| Yes                                                         | 148 (31.1)                        | 23 (18.9)          | 171 (28.6)        |

<div style=\"page-break-after: always\"></div>

|                                                         | Tofacitinib10mgBID (N= 476)   | Placebo (N = 122)   | Total (N = 598)   |
|---------------------------------------------------------|-------------------------------|---------------------|-------------------|
| No                                                      | 328 (68.9)                    | 99 (81.1)           | 427 (71.4)        |
| Smoking status, n (%)                                   |                               |                     |                   |
| Never smoked                                            | 301 (63.2)                    | 80 (65.6)           | 381 (63.7)        |
| Current smoker                                          | 22 (4.6)                      | 4 (3.3)             | 26 (4.3)          |
| Ex-smoker                                               | 153 (32.1)                    | 38 (31.1)           | 191 (31.9)        |
| If a current smoker, time since started smoking (years) |                               |                     |                   |
| N1                                                      | 22                            | 4                   | 26                |
| Mean (SD)                                               | 15.9 (9.3)                    | 22.3 (18.8)         | 16.8 (11.0)       |
| Median                                                  | 14.5                          | 15.5                | 15.0              |
| Range                                                   | 4.0, 35.0                     | 8.0, 50.0           | 4.0, 50.0         |
| If an ex-smoker, time since stopping smoking (years)    |                               |                     |                   |
| N1                                                      | 153                           | 38                  | 191               |
| Mean (SD)                                               | 13.4 (10.6)                   | 16 (12.1)           | 13.9 (10.9)       |
| Median                                                  | 10.0                          | 10.5                | 10.0              |
| Range                                                   | 1.0, 46.0                     | 2.0, 48.0           | 1.0, 48.0         |

Source:Table 14.1.2.1.3,Table 14.1.2.2,Table14.3.4.1.8.

BID = twice a day, N = number of randomized subjects in the total population, n = number of subjects meeting prespecified criteria, N1 = Number of subjects with non-missing data, N/A = not available,

SD= standard deviation, UC = ulcerative colitis.

a Mean, median, and range were based on subjects with a prior hospitalization for UC.

Hence, partial and total Mayo scores were not derived.

b. Subjects 12641001 and 12041011 had missing stool frequency and rectal bleeding scores at baseline.

° Extent of Disease: The maximal area of involvement was summarized in case of more than 1 area.

Proctitis:Involvement limited to the rectum;Proctosigmoiditis:Involvement limited to rectum/sigmoid; Left-sided colitis: Involvement limited to portion of colon distal to splenic flexure; Extensive colitis:

Involvement that extends proximal to the splenic flexure; Pancolitis: Involvement of the entire colon.

d Included past or curently active extra-intestinal manifestations.

<div style=\"page-break-after: always\"></div>

## Classification of Prior Drug Treatments for Ulcerative Colitis by Treatment Group:

|                                 | Tofacitinib 10 mg BID (N=476) n (%)   | Placebo (N = 122) n (%)   | Total (N =598) n (%)   |
|---------------------------------|---------------------------------------|---------------------------|------------------------|
| Previous diug treatments for UC |                                       |                           |                        |
| Aminosalicylates                | 446 (93.7)                            | 113 (92.6)                | 559 (93.5)             |
| Antibiotics                     | 49 (10.3)                             | 17 (13.9)                 | 66 (11.0)              |
| Biologics - non-TNFi            | 12 (2.5)                              | 5 (4.1)                   | 17 (2.8)               |
| Biologics - TNFi                | 254 (53.4)                            | 65 (53.3)                 | 319 (53.3)             |
| Corticosteroidsa                | 427 (89.7)                            | 115 (94.3)                | 542 (90.6)             |
| Immunosuppressants              | 371 (77.9)                            | 84 (68.9)                 | 455 (76.1)             |
| Failed drug treatments for UC   |                                       |                           |                        |
| Aminosalicylates                | 383 (80.5)                            | 99 (81.1)                 | 482 (80.6)             |
| Antibiotics                     | 27 (5.7)                              | 11 (9.0)                  | 38 (6.4)               |
| Biologics - non-TNFi            | 11 (2.3)                              | 5 (4.1)                   | 16 (2.7)               |
| Biologics - TNFi                | 243 (51.1)                            | 64 (52.5)                 | 307 (51.3)             |
| Corticosteroidsb                | 350 (73.5)                            | 98 (80.3)                 | 448 (74.9)             |
| Immunosuppressants              | 360 (75.6)                            | 83 (68.0)                 | 443 (74.1)             |

Source:Table 14.1.2.1.3, Table 14.4.2.2.2,Table 14.4.2.2.3.

WHO-Drug (vJun2014) coding dictionary applied.

Analysis is based on data collected on the case report form (CRF) of Previous Drug Treatment for Primary Diagnosis, along with Response to medication as Inadequate Response. The diug classes for each medication were classified by the clinical team and do not reflect the Anatomic Therapeutic Chemical Classification (ATC2) coded teims.

BID = twice a day, IV = intravenous, N = number of randomized subjects, n = number of subjects meeting prespecified criteria, TNFi = tumor necrosis factor-alpha inhibitor, UC = ulcerative colitis, WHO = World Health Organization.

a Refers to corticosteroids administered via any route for UC.

b From Table 14.1.2.1.3. Refers only to oral or IV corticosteroids for UC.

## Numbers analysed

For the 8-week double-blind treatment period, 100.0%, 93.6%, and 100.0% of randomized subjects met the criteria for FAS, PPAS, and safety analysis set, respectively.  The percentages of subjects excluded from the PPAS were similar for both the tofacitinib 10 mg BID and placebo treatment groups.

Exclusions From the Per Protocol Analysis Set by Reason for Exclusion (FAS):

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                                                          | Tofacitinib 10 mgBID (N=476) n (%)   | Placebo (N =122) n (%)   | Total (N = 598) n (%)   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|--------------------------|-------------------------|
| Full Analysis Set (FAS)                                                                                                                                                                  | 476 (100)                            | 122 (100)                | 598 (100)               |
| Per Protocol Analysis Set (PPAS)                                                                                                                                                         | 443 (93.1)                           | 117 (95.9)               | 560 (93.6)              |
| Subjects excluded from the PPAS?                                                                                                                                                         | 33 (6.9)                             | 5 (4.1)                  | 38 (6.4)                |
| Reason for Exclusiona                                                                                                                                                                    |                                      |                          |                         |
| Subject did not have a screening Clostridium difficile (C. difficile) stool test and was then found to have a positive post-baseline stool examination for C. difficile toxin            | 0                                    | 1 (20.0)                 | 1 (2.6)                 |
| Duration between screening endoscopy and baseline visit >17 days                                                                                                                         | 13 (39.4)                            | 1 (20.0)                 | 14 (36.8)               |
| Subject had a change in background corticosteroid dose outside of protocol-permitted dose changes which was deemed to have a potentially significant impact on final efficacy assessment | 4 (12.1)                             | 2 (40.0)                 | 6 (15.8)                |
| MissingbaselinebowelmovementdiarydatainICOPhone                                                                                                                                          | 1 (3.0)                              | 0                        | 1 (2.6)                 |
| MissingBaselineTotal MayoScore                                                                                                                                                           | 1 (3.0)                              | 1 (20.0)                 | 2 (5.3)                 |
| Overall study medication compliance <80% or >120%                                                                                                                                        | 2 (6.1)                              | 0                        | 2 (5.3)                 |
| Prednisone dose >25 mg during study treatment                                                                                                                                            | 2 (6.1)                              | 0                        | 2 (5.3)                 |
| Subject did not have a history of treatment with oral or IV corticosteroids, azathioprine or6-MP,orTNFi                                                                                  | 1 (3.0)                              | 0                        | 1 (2.6)                 |
| Withdrawal for administrative reason with treatment duration <8 weeks (eg, protocol deviation, withdrawal of consent, site closure)                                                      | 7 (21.2)                             | 1 (20.0)                 | 8 (21.1)                |
| Withdrawal within 7 days of baseline for non-administrative reasons (eg, adverse event, insufficient clinical response)                                                                  | 3 (9.1)                              | 0                        | 3 (7.9)                 |

Source: Table 14.2.1.2.

Percentages for reasons for exclusion are based on the number of subjects excluded from the PPAS; all other percentages are based on randomized subjects. BID = twice a day, IV = intravenous, 6-MP = 6-mercaptopurine, N = number of randomized subjects, n = number of subjects meeting prespecified criteria,

Subjects may be counted in more than 1 exclusion criteria.

TNFi = tumor necrosis factor-alpha inhibitor.

## Outcomes and estimation

## Primary Efficacy Endpoint:

A statistically significantly higher proportion of subjects in the tofacitinib 10 mg BID group achieved the primary endpoint of remission p = 0.0070.

## Summary of Study A3921094 Efficacy Results at Week 8 (FAS, NRI, Central Read):

|                      | Tofacitinib 10 mg BID (N=476)   | Placebo (N=122)   | DifferenceFromPlacebo   | DifferenceFromPlacebo   |
|----------------------|---------------------------------|-------------------|-------------------------|-------------------------|
| Endpoint             | n (%)                           | n (%)             | Difference (95% CI)     | P-valueb                |
| Remission,           | 88 (18.5)                       | 10 (8.2)          | 10.3 (4.3, 16.3)        | 0.0070                  |
| Mucosal Healing      | 149 (31.3)                      | 19 (15.6)         | 15.7 (8.1, 23.4)        | 0.0005                  |
| Clinical Remission   | 88 (18.5)                       | 10 (8.2)          | 10.3 (4.3, 16.3)        | 0.0070                  |
| Clinical Response,   | 285 (59.9)                      | 40 (32.8)         | 27.1 (17.7,36.5)        | <0.0001                 |
| Endoscopic Remission | 32 (6.7)                        | 2 (1.6)           | 5.1 (1.9, 8.3)          | 0.0345                  |

Sources: 5.3.5.1 A3921094-report-body Table 14.2.2.1; Table 14.2.3.1; Table 14.2.4.1.

Abbreviations: BID = twice a day, CI = confidence interval, FAS = full analysis set, NRI = non-responder imputation, N = number of subjects in the analysis set, n = number of subjects meeting specific criteria; TNFi = tumor necrosis factor inhibitor.

a. The 95% CI is based on the normal approximation for the difference.

b. The p-value is based on Cochran-Mantel-Haenzel (CMH) Chi-squared test stratified by prior treatment with TNFi, corticosteroid use at baseline, and geographical region.

## Key Secondary Endpoints:

<div style=\"page-break-after: always\"></div>

- Statistically significantly higher proportions of subjects in the tofacitinib 10 mg BID group achieved mucosal healing (p = 0.0005) at Week 8 compared with placebo based on both the centrally and locally read endoscopy data.

Other secondary endpoints:

- clinical remission and clinical response at Week 8, tofacitinib 10 mg BID had significantly higher proportions of subjects with clinical remission and clinical response at Week 8 compared with placebo, based on both the centrally read (p = 0.0070 and p &lt;0.0001, respectively) and locally read (p = 0.0017 and p &lt;0.0001, respectively) endoscopic findings.
- Tofacitinib 10 mg BID had significantly higher proportions of subjects with endoscopic remission, deep remission, and endoscopic response at Week 8 compared with placebo for both the centrally and locally read endoscopic scores.
- Tofacitinib 10 mg BID showed significantly greater improvement from baseline of partial Mayo score compared with placebo by Week 2 which was the first post-baseline timepoint assessed, (mean difference -0.9, p &lt;0.0001), and these improvements continued to increase at Week 4 and Week 8 (differences from placebo: -1.1 and -1.5, respectively, p &lt;0.0001 for both Week 4 and Week 8).
- Tofacitinib 10 mg BID showed significantly greater improvement from baseline of total Mayo score compared with placebo at Week 8.

Binary exploratory endpoints:

- Tofacitinib 10 mg BID had significantly greater improvement on PRO questionnaire scores compared with placebo, including IBDQ (total and all individual domains) and SF-36 (all component and domain scores), and significantly more favourable responses to treatment were seen with tofacitinib 10 mg BID compared with placebo on the PRTI.
- Tofacitinib 10 mg BID showed significantly greater improvement from baseline compared with placebo for EQ-5D Utility Index and VAS score at both Week 2 and Week 8.
- Subject ratings of 'very much improved' and 'much improved' were more frequently reported by subjects in the tofacitinib 10 mg BID treatment group compared with subjects in the placebo group on the PGIC.
- Tofacitinib 10 mg BID had a greater reduction in hsCRP levels compared with placebo at Week 4 and Week 8.

## Summary of Other Secondary Binary Efficacy Endpoints at Week 8 (FAS, NRI):

<div style=\"page-break-after: always\"></div>

|                      | Tofacitinib 10 mg BID (N = 476)   | Placebo (N =122)   | Difference From Placebo   | Difference From Placebo   |
|----------------------|-----------------------------------|--------------------|---------------------------|---------------------------|
|                      | n (%)                             | n (%)              | Difference (95%C1)\"       | P-Valueb                  |
| Clinicalremission    |                                   |                    |                           |                           |
| Central read         | 88 (18.5)                         | 10 (8.2)           | 10.3 (4.3, 16.3)          | 0.0070                    |
| Local read           | 118 (24.8)                        | 14 (11.5)          | 13.3 (6.5, 20.2)          | 0.0017                    |
| Clinical response    |                                   |                    |                           |                           |
| Central read         | 285 (59.9)                        | 40 (32.8)          | 27.1 (17.7, 36.5)         | <0.0001                   |
| Localread            | 289 (60.7)                        | 42 (34.4)          | 26.3 (16.8, 35.8)         | <0.0001                   |
| Endoscopic remission |                                   |                    |                           |                           |
| Centralread          | 32 (6.7)                          | 2 (1.6)            | 5.1 (1.9, 8.3)            | 0.0345                    |
| Local read           | 52 (10.9)                         | 3 (2.5)            | 8.5 (4.5, 12.4)           | 0.0039                    |
| Symptomaticremission |                                   |                    |                           |                           |
| Central read         | 56 (11.8)                         | 7 (5.7)            | 6.0 (1.0, 11.1)           | 0.0601                    |
| Local read           | 74 (15.5)                         | 9 (7.4)            | 8.2 (2.5, 13.8)           | 0.0217                    |
| Deep remission       |                                   |                    |                           |                           |
| Centralread          | 31 (6.5)                          | (0)                | 6.5 (4.3, 8.7)            | 0.0043                    |
| Local read           | 49 (10.3)                         | 3 (2.5)            | 7.8 (4.0, 11.7)           | 0.0064                    |

Source:Table14.2.4.1,Table14.2.4.2.

BID = twice a day, CI = confidence interval, FAS = full analysis set, NRI = non-responder imputation,

? 95% CI was based on the normal approximation for the difference.

N = number of subjects in the analysis set, n = number of subjects meeting specific criteria, TNFi = tumor necrosisfactor-alphainhibitor.

b P-value was based on Cochran-Mantel-Haenszel (CMH) Chi-squared test stratified by prior treatment with

TNFi, corticosteroid use at baseline, and geographical region; p-value from Fisher's exact test was also provided in the source table.

Treatment effects for remission at Week 8 (FAS, NRI) were observed across all subgroups defined by prior TNFi treatment, prior TNFi failure, baseline corticosteroid use, and geographic region.

## Proportion of Subjects in Clinical Remission at Week 8 by Subgroup (FAS, NRI, Central Read):

|                             | Tofacitinib 10mg BID (N = 476)   | Tofacitinib 10mg BID (N = 476)   | Placebo (N = 122)   | Placebo (N = 122)   | DifferenceFromPlacebo   | DifferenceFromPlacebo   |
|-----------------------------|----------------------------------|----------------------------------|---------------------|---------------------|-------------------------|-------------------------|
|                             | N1                               | n (%)                            | N1                  | n (%)               | Difference              | (95% C1)*               |
| Prior TNFi treatment        |                                  |                                  |                     |                     |                         |                         |
| Yes                         | 254                              | 32 (12.6)                        | 65                  | 1 (1.5)             | 11.1                    | (6.0, 16.1)             |
| No                          | 222                              | 56 (25.2)                        | 57                  | 9 (15.8)            | 9.4                     | (-1.6, 20.5)            |
| Prior TNFi failure          |                                  |                                  |                     |                     |                         |                         |
| Yes                         | 243                              | 27 (11.1)                        | 64                  | 1 (1.6)             | 9.5                     | (4.6, 14.5)             |
| No                          | 233                              | 61 (26.2)                        | 58                  | 9 (15.5)            | 10.7                    | (-0.2, 21.6)            |
| Baseline corticosteroid use |                                  |                                  |                     |                     |                         |                         |
| Yes                         | 214                              | 37 (17.3)                        | 58                  | 5 (8.6)             | 8.7                     | (-0.2, 17.5)            |
| No                          | 262                              | 51 (19.5)                        | 64                  | 5 (7.8)             | 11.7                    | (3.5, 19.8)             |
| Geographic region           |                                  |                                  |                     |                     |                         |                         |
| Europe                      | 285                              | 49 (17.2)                        | 72                  | 7 (9.7)             | 7.5                     | (-0.7, 15.6)            |
| North America               | 102                              | 17 (16.7)                        | 30                  | 1 (3.3)             | 13.3                    | (3.7, 23.0)             |
| Other                       | 89                               | 22 (24.7)                        | 20                  | 2 (10.0)            | 14.7                    | (-1.2, 30.6)            |

Source: Table 14.2.3.4

Clinical remission was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point.

? 95% CI based on the normal approximation for the difference.

BID = twice a day, CI = confidence interval, FAS = full analysis set, NRI = non-responder imputation, N = number of subjects in the analysis set, n = number of subjects meeting specific criteria, N1 = number of subjects in each group at Week 8, and was used as the denominator in the percentage calculation, TNFi= tumor necrosis factor-alpha inhibitor.

<div style=\"page-break-after: always\"></div>

## Proportion of Subjects with Clinical Response at Week 8 by Subgroup (FAS, NRI, Central Read):

|                            | Tofacitinib10mgBID (N=476)   | Tofacitinib10mgBID (N=476)   | Placebo (N = 122)   | Placebo (N = 122)   | DifferenceFromPlacebo   | DifferenceFromPlacebo   |
|----------------------------|------------------------------|------------------------------|---------------------|---------------------|-------------------------|-------------------------|
|                            | N1                           | n (%)                        | N1                  | n (%)               | Difference              | (95% C1)                |
| Prior TNFi treatment       |                              |                              |                     |                     |                         |                         |
| Yes                        | 254                          | 138 (54.3)                   | 65                  | 12 (18.5)           | 35.9                    | (24.6, 47.1)            |
| No                         | 222                          | 147 (66.2)                   | 57                  | 28 (49.1)           | 17.1                    | (2.7,31.5)              |
| Prior TNFi failure         |                              |                              |                     |                     |                         |                         |
| Yes                        | 243                          | 128 (52.7)                   | 64                  | 12 (18.8)           | 33.9                    | (22.5, 45.4)            |
| No                         | 233                          | 157 (67.4)                   | 58                  | 28 (48.3)           | 19.1                    | (4.9, 33.3)             |
| Baselinecorticosteroid use |                              |                              |                     |                     |                         |                         |
| Yes                        | 214                          | 139 (65.0)                   | 58                  | 20 (34.5)           | 30.5                    | (16.7, 44.3)            |
| No                         | 262                          | 146 (55.7)                   | 64                  | 20 (31.3)           | 24.5                    | (11.6, 37.3)            |
| Geographic region          |                              |                              |                     |                     |                         |                         |
| Europe                     | 285                          | 179 (62.8)                   | 72                  | 25 (34.7)           | 28.1                    | (15.7, 40.4)            |
| North America              | 102                          | 52 (51.0)                    | 30                  | 7(23.3)             | 27.6                    | (9.7, 45.6)             |
| Other                      | 89                           | 54 (60.7)                    | 20                  | 8 (40.0)            | 20.7                    | (-3.1, 44.4)            |

Source:Table 14.2.3.5.

Clinical response was defined by a decrease from baseline in Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1.

BID = twice a day, CI = confidence interval, FAS = full analysis set, NRI = non-responder imputation,

² 95% CI based on the normal approximation for the difference.

N = number of subjects in the analysis set, N1=number of subjects in each group at Week 8, and used as denominator in percentage calculation, TNFi = tumor necrosis factor-alpha inhibitor.

Tofacitinib 10 mg BID showed significantly greater improvement from baseline in partial Mayo score compared with placebo by Week 2, which was the first post-baseline timepoint assessed (mean difference 0.9, p &lt;0.0001) and these improvements continued to increase at Week 4 and Week 8 (differences from placebo: -1.1 and -1.5, respectively, p &lt;0.0001 for both Week 4 and Week 8).

For all other binary exploratory endpoints (partial Mayo score remission, partial Mayo score response, improvement based on individual Mayo subscores), statistically significant differences compared with placebo were observed as early as Week 2, and were sustained or increased at Week 8.

Summary of Exploratory Binary Efficacy Endpoints by Study Visit (FAS, NRI):

<div style=\"page-break-after: always\"></div>

|                                                                                          | Tofacitinib 10 mg BID (N =476)                                                           | Placebo (N = 122)                                                                        | DifferenceFromPlacebo                                                                    | DifferenceFromPlacebo                                                                    |
|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
|                                                                                          | n (%)                                                                                    | n (%)                                                                                    | Difference (95% C1)aP-Valueb                                                             |                                                                                          |
| Partial Mayo score of <2 with no individual subscore >1 (partial Mayo score remission)   | Partial Mayo score of <2 with no individual subscore >1 (partial Mayo score remission)   | Partial Mayo score of <2 with no individual subscore >1 (partial Mayo score remission)   | Partial Mayo score of <2 with no individual subscore >1 (partial Mayo score remission)   | Partial Mayo score of <2 with no individual subscore >1 (partial Mayo score remission)   |
| Week 2                                                                                   | 105 (22.1)                                                                               | 15 (12.3)                                                                                | 9.8 (2.8, 16.7)                                                                          | 0.0171                                                                                   |
| Week 4                                                                                   | 168 (35.3)                                                                               | 24 (19.7)                                                                                | 15.6 (7.4, 23.9)                                                                         | 0.0010                                                                                   |
| Week 8                                                                                   | 216 (45.4)                                                                               | 29 (23.8)                                                                                | 21.6 (12.8, 30.4)                                                                        | <0.0001                                                                                  |
| Reduction of ≥2 points from baseline in partial Mayo score (partial Mayo score response) | Reduction of ≥2 points from baseline in partial Mayo score (partial Mayo score response) | Reduction of ≥2 points from baseline in partial Mayo score (partial Mayo score response) | Reduction of ≥2 points from baseline in partial Mayo score (partial Mayo score response) | Reduction of ≥2 points from baseline in partial Mayo score (partial Mayo score response) |
| Week 2                                                                                   | 260 (54.6)                                                                               | 44 (36.1)                                                                                | 18.6 (8.9, 28.2)                                                                         | 0.0002                                                                                   |
| Week 4                                                                                   | 326 (68.5)                                                                               | 54 (44.3)                                                                                | 24.2 (14.5, 34.0)                                                                        | <0.0001                                                                                  |
| Week 8                                                                                   | 334 (70.2)                                                                               | 53 (43.4)                                                                                | 26.7 (17.0, 36.4)                                                                        | <0.0001                                                                                  |
| Reduction of≥1 point from baseline in stool frequency                                    | Reduction of≥1 point from baseline in stool frequency                                    | Reduction of≥1 point from baseline in stool frequency                                    | Reduction of≥1 point from baseline in stool frequency                                    | Reduction of≥1 point from baseline in stool frequency                                    |
| Week 2                                                                                   | 249 (52.3)                                                                               | 35 (28.7)                                                                                | 23.6 (14.4, 32.8)                                                                        | <0.0001                                                                                  |
| Week 4                                                                                   | 285 (59.9)                                                                               | 47 (38.5)                                                                                | 21.3 (11.7, 31.0)                                                                        | <0.0001                                                                                  |
| Week 8                                                                                   | 306 (64.3)                                                                               | 44 (36.1)                                                                                | 28.2 (18.7, 37.8)                                                                        | <0.0001                                                                                  |
| Reduction of ≥1 point from baseline in rectal bleeding                                   | Reduction of ≥1 point from baseline in rectal bleeding                                   | Reduction of ≥1 point from baseline in rectal bleeding                                   | Reduction of ≥1 point from baseline in rectal bleeding                                   | Reduction of ≥1 point from baseline in rectal bleeding                                   |
| Week 2                                                                                   | 282 (59.2)                                                                               | 45 (36.9)                                                                                | 22.4 (12.7, 32.0)                                                                        | <0.0001                                                                                  |
| Week 4                                                                                   | 332 (69.7)                                                                               | 58 (47.5)                                                                                | 22.2 (12.4, 32.0)                                                                        | <0.0001                                                                                  |
| Week 8                                                                                   | 348 (73.1)                                                                               | 66 (54.1)                                                                                | 19.0 (9.3, 28.7)                                                                         | <0.0001                                                                                  |
| Reduction of ≥1 point from baseline in PGA                                               | Reduction of ≥1 point from baseline in PGA                                               | Reduction of ≥1 point from baseline in PGA                                               | Reduction of ≥1 point from baseline in PGA                                               | Reduction of ≥1 point from baseline in PGA                                               |
| Week 2                                                                                   | 259 (54.4)                                                                               | 52 (42.6)                                                                                | 11.8 (1.9, 21.6)                                                                         | 0.0167                                                                                   |
| Week 4                                                                                   | 327 (68.7)                                                                               | 66 (54.1)                                                                                | 14.6 (4.8, 24.4)                                                                         | 0.0024                                                                                   |
| Week 8                                                                                   | 308 (64.7)                                                                               | 50 (41.0)                                                                                | 23.7 (14.0, 33.4)                                                                        | <0.0001                                                                                  |
| Endoscopic response at Week 8                                                            | Endoscopic response at Week 8                                                            | Endoscopic response at Week 8                                                            | Endoscopic response at Week 8                                                            | Endoscopic response at Week 8                                                            |
| Central read                                                                             | 220 (46.2)                                                                               | 30 (24.6)                                                                                | 21.6 (12.8, 30.5)                                                                        | <0.0001                                                                                  |
| Local read                                                                               | 253 (53.2)                                                                               | 36 (29.5)                                                                                | 23.6 (14.4, 32.9)                                                                        | <0.0001                                                                                  |

Source: Table 14.2.6.1.

Endoscopic response was defined by a decrease from baseline in the endoscopic subscore of 1 point or more.

BID = twice a day, CI = confidence interval, FAS = full analysis set, NRI = non-responder imputation,

N = number of subjects randomized, n = number of subjects in the analysis set, PGA = Physician's Global

Assessment,TNFi=tumornecrosisfactor-alphaimhibitor.

b. P-value was based on Cochran-Mantel-Haenszel (CMH) Chi-squared test stratified by prior treatment with

? 95% CI was based on the normal approximation for the difference.

TNFi, corticosteroid use at baseline and geographic region.

Mean endoscopic findings Mayo sub score using centrally read findings (0 to 3) at baseline was 2.6 for both treatment groups Mean endoscopic sub score at Week 8 was 2.0 for the tofacitinib 10 mg BID group and 2.4 for the placebo group. The mean change from baseline at Week 8 was -0.6 for the tofacitinib 10 mg BID group and -0.2 for the placebo group.  Endoscopic sub score of 0 at Week 8 occurred in 7.2% of subjects in the tofacitinib 10 mg BID group, and in 1.7% of subjects in the placebo group.

Frequency Distribution of Mayo Subscore - Endoscopic Findings - by Visit (FAS, Observed Cases):

<div style=\"page-break-after: always\"></div>

| EndoscopicFindings             | Tofacitinib10mgBID (N = 476) n (%)   | Placebo (N = 122) n (%)   |
|--------------------------------|--------------------------------------|---------------------------|
| Baseline                       |                                      |                           |
| N1                             | 476                                  | 122                       |
| Normal or inactive disease (O) | 0                                    | 0                         |
| Mild disease (1)               | 0                                    | 0                         |
| Moderate disease (2)           | 181 (38.0)                           | 48 (39.3)                 |
| Severe disease (3)             | 295 (62.0)                           | 74 (60.7)                 |
| Week 8                         |                                      |                           |
| N1                             | 447                                  | 118                       |
| Normal or inactive disease (O) | 32 (7.2)                             | 2 (1.7)                   |
| Mild disease (1)               | 117 (26.2)                           | 17 (14.4)                 |
| Moderate disease (2)           | 126 (28.2)                           | 29 (24.6)                 |
| Severe disease (3)             | 172 (38.5)                           | 70 (59.3)                 |

Source:Table14.2.6.2

BID = twice a day, FAS = full analysis set, N = number of subjects in the analysis set, n = number of subjects in the specified category with non-missing values, N1 = number of subjects with non-missing values.

Mean rectal bleeding Mayo sub score (0 to 3) at baseline was 1.6 for both treatment groups. Mean rectal bleeding sub score at Week 8 was 0.5 for the tofacitinib 10 mg BID group and 0.9 for the placebo group. The mean change from baseline at Week 8 was -1.1 for the tofacitinib 10 mg BID group and -0.7 for the placebo group. The majority of subjects in both treatment groups had a rectal bleeding sub score of 2 at baseline. Rectal bleeding sub score of 0 at Weeks 2, 4, and 8 occurred in 39.6%, 54.0%, and 64.0%, respectively, of subjects in the tofacitinib 10 mg BID group, and in 21.3%, 28.0%, and 37.0% respectively, of subjects in the placebo group.

## Frequency Distribution of Mayo Subscore - Rectal Bleeding - by Visit (FAS, Observed Cases):

<div style=\"page-break-after: always\"></div>

| Rectal Bleeding                                         | Tofacitinib10mgBID (N =476) n (%)   | Placebo (N =122) n (%)   |
|---------------------------------------------------------|-------------------------------------|--------------------------|
| Baseline                                                |                                     |                          |
| N1                                                      | 475                                 | 121                      |
| No blood seen (0)                                       | 8(1.7)                              | 2 (1.7)                  |
| Streaks of blood with stool less than half the time (1) | 192 (40.4)                          | 47 (38.8)                |
| Obvious blood with stool most of the time (2)           | 256 (53.9)                          | 66 (54.5)                |
| Blood alone passed (3)                                  | 19 (4.0)                            | 6 (5.0)                  |
| Week 2                                                  |                                     |                          |
| N1                                                      | 467                                 | 122                      |
| No blood seen (0)                                       | 185 (39.6)                          | 26 (21.3)                |
| Streaks of blood with stool less than half the time (1) | 181 (38.8)                          | 51 (41.8)                |
| Obvious blood with stool most of the time (2)           | 88 (18.8)                           | 44 (36.1)                |
| Blood alone passed (3)                                  | 13 (2.8)                            | 1 (0.8)                  |
| Week 4                                                  |                                     |                          |
| N1                                                      | 461                                 | 118                      |
| No blood seen (0)                                       | 249 (54.0)                          | 33 (28.0)                |
| Streaks of blood with stool less than half the time (1) | 142 (30.8)                          | 51 (43.2)                |
| Obvious blood with stool most of the time (2)           | 64 (13.9)                           | 31 (26.3)                |
| Blood alone passed (3)                                  | 6 (1.3)                             | 3 (2.5)                  |
| Week8                                                   |                                     |                          |
| N1                                                      | 450                                 | 119                      |
| No blood seen (0)                                       | 288 (64.0)                          | 44 (37.0)                |
| Streaks of blood with stool less than half the time (1) | 102 (22.7)                          | 46 (38.7)                |
| Obvious blood with stool most of the time (2)           | 51 (11.3)                           | 27 (22.7)                |
| Blood alone passed (3)                                  | 9 (2.0)                             | 2 (1.7)                  |

Source:Table14.2.6.2.

BID = twice a day, FAS = full analysis set, N = number of subjects in the analysis set, n = number of subjects in the specified category with non-missing values, N1 = number of subjects with non-missing values.

## Results induction study A3921095

## Participant flow

Of 914 subjects screened for entry into the study, 547 subjects were randomized to study treatment. Of these, 541 subjects were randomized to tofacitinib 10 mg BID or placebo (FAS): 429 subjects were randomized to tofacitinib 10 mg BID group, and 112 subjects were randomized to placebo. All randomized subjects received at least 1 dose of study drug (safety analysis set). There were 6 subjects who were randomized to and received tofacitinib 15 mg BID prior to Protocol Amendment 2; subjects who were assigned to the tofacitinib 15 mg BID dose group were not included in the analysis sets. Across all treatment groups there were 18 subjects randomized prior to Protocol Amendment 2 and 529 subjects randomized after Protocol Amendment 2.

## Subject Disposition by Treatment Group:

<div style=\"page-break-after: always\"></div>

|                                           | Tofacitinib10mgBID n (%)   | Placebo n (%)   | Total n (%)   |
|-------------------------------------------|----------------------------|-----------------|---------------|
| Screened                                  |                            |                 | 914           |
| Randomized                                | 429                        | 112             | 547 (59.8)a.b |
| Prior to Protocol Amendment 2             | 8                          | 4               | 18b           |
| After Protocol Amendment 2c               | 421                        | 108             | 529           |
| Full Analysis Set                         | 429 (100.0)                | 112 (100.0)     | 541 (100.0)   |
| Per Protocol Analysis Set                 | 406 (94.6)                 | 102 (91.1)      | 508 (93.9)    |
| Safety Analysis Set                       | 429 (100.0)                | 112 (100.0)     | 541 (100.0)   |
| Adverse eventsd                           | 429 (100.0)                | 112 (100.0)     | 541 (100.0)   |
| Laboratory data?                          | 426 (99.3)                 | 112 (100.0)     | 538 (99.4)    |
| Treated                                   | 429                        | 112             | 541           |
| Completed                                 | 397 (92.5)                 | 97 (86.6)       | 494 (91.3)    |
| Discontinued                              | 32 (7.5)                   | 15 (13.4)       | 47 (8.7)      |
| Primary Reason for Discontinuation        |                            |                 |               |
| Related to study drug                     | 21 (4.9)                   | 12 (10.7)       | 33 (6.1)      |
| Adverse event                             | 4 (0.9)                    | 1 (0.9)         | 5 (0.9)       |
| Insufficient clinical response            | 17 (4.0)                   | 11 (9.8)        | 28 (5.2)      |
| Not related to study drug                 | 11 (2.6)                   | 3 (2.7)         | 14 (2.6)      |
| Adverse event                             | 3 (0.7)                    | 1 (0.9)         | 4 (0.7)       |
| No longer willing to participate in study | 2 (0.5)                    | 2 (1.8)         | 4 (0.7)       |
| Protocol violation                        | 5 (1.2)                    | 0               | 5 (0.9)       |
| Other                                     | 1 (0.2)                    | 0               | 1 (0.2)       |

Source: Table 14.1.1.1.1, Table 14.1.1.1.3, Table 14.1.1.2.1, Table 14.1.1.2.3, Table 14.2.2.2, Table 16.1.7.2.

BID = twice a day, n = number of subjects meeting prespecified criteria.

a. Percentage for randomized was calculated using the number screened as the denominator

(Table 14.1.1.1.3). All other percentages were calculated using the total number randomized (541) to tofacitinib 10 mg BID and placebo as the denominator.

c Number of subjects in each treatment group is from Table 14.2.2.2, and total number of subjects is from Table 14.1.1.1.3.

b. Six subjects were randomized to tofacitinib 15 mg BID prior to removal of this dose from the study (Table 14.1.1.1.2).

d. Adverse events (AEs) - all randomized subjects for whom the Adverse Event case report form (CRF) was completed in the database.

e Laboratory data - all randomized subjects who had their lab data collected at both baseline and 1 of the post-baseline visits. As Subjects 11961003, 13331006, and 11731005 only had baseline laboratory values, they were not included in the laboratory data analysis set (Table 16.2.1.1).

f. AEs of worsening of ulcerative colitis leading to discontinuation were designated as insufficient clinical response.

## Rollover Status of Completed Subjects into Follow-On Studies:

<div style=\"page-break-after: always\"></div>

|                                                | Tofacitinib 10 mg BID (N = 429) n (%)   | Placebo (N = 112) n (%)   | Total (N = 541) n (%)   |
|------------------------------------------------|-----------------------------------------|---------------------------|-------------------------|
| Entered maintenance study (A3921096)           | 228 (53.1)                              | 33 (29.5)                 | 261 (48.2)              |
| Entered open-label study (A3921139)            | 152 (35.4)                              | 61 (54.5)                 | 213 (39.4)              |
| Did not enter maintenance or open-label studya | 17 (4.0)                                | 3 (2.7)                   | 20 (3.7)                |
| Investigator decision                          | 2 (0.5)                                 | 0                         | 2 (0.4)                 |
| Lost to follow-up                              | 0                                       | 0                         | 0                       |
| Subject refused participation                  | 4 (0.9)                                 | 2 (1.8)                   | 6 (1.1)                 |
| Not eligible                                   | 7 (1.6)                                 | 1 (0.9)                   | 8 (1.5)                 |
| Other                                          | 4 (0.9)                                 | 0                         | 4 (0.7)                 |

Source: Table 14.1.1.3.1.

Early termination subjects were not required to provide the Study Continuation - Extension Rollover information. They are not summarized in this table.

BID = twice a day, N = number of randomized subjects, n = number of subjects meeting prespecified criteria.

a. Subjects who completed Week 8 visit and did not advance to Study A3921096 or A3921139.

## Recruitment

First Subject First Visit (FSFV): 21 June 2012

Last Subject Last Visit (LSLV): 09 June 2015

## Conduct of the study

The original protocol (dated 30 September 2011) was amended on 28 September 2012. This amendment updated standard Pfizer protocol text, including safety language in various sections, including Administration, Reproductive Status of Female Subjects, and Adverse Event Reporting.

Protocol Amendment 2 (dated 30 November 2012) This amendment removed the tofacitinib 15 mg BID arm from the study, and accordingly updated the Statistical Methods section and Rationale for Dose Selection section. This amendment also revised the country-specific upper age limit for subject eligibility in India, although no sites were initiated in India.

Protocol Amendment 3 (Country-Specific, dated 09 July 2013) This was a country-specific amendment applicable to the UK, incorporating lymphocyte subset monitoring for exploratory purposes, modification of exclusion criterion related to ALC, and addition of a discontinuation criterion for opportunistic infection.

Protocol Amendment 4 (Country-Specific, dated 06 February 2015) This was a country-specific amendment applicable to Canada, specifying that subjects in Canada who were women of childbearing potential and sexually active were required to use 2 methods of contraception at the same time, 1 highly effective contraceptive method and 1 additional effective contraceptive method.

The original SAP (27 September 2011, Version 1) was amended on 23 June 2015, (Version 2). All changes to the SAP were finalized and approved prior to database lock and unblinding of the study.

<div style=\"page-break-after: always\"></div>

## Baseline data

## Demographic and Baseline Characteristics by Treatment Group (FAS)

|                            | Tofacitinib10mgBID      | Tofacitinib10mgBID   | Tofacitinib10mgBID   | Placebo       | Placebo         | Placebo         |
|----------------------------|-------------------------|----------------------|----------------------|---------------|-----------------|-----------------|
|                            | Male (N = 259)          | Female (N =170)      | Total (N = 429)      | Male (N = 55) | Female (N = 57) | Total (N = 112) |
| Age (years)                |                         |                      |                      |               |                 |                 |
| Mean (SD)                  | 41 (13.2)               | 41.1 (14)            | 41.1 (13.5)          | 40.6 (13.5)   | 40.1 (13.1)     | 40.4 (13.2)     |
| Range                      | 18, 76 0                | 18, 80 0             | 18, 80 0             | 21, 70 0      | 18,64 0         | 18, 70 0        |
| <18, n (%) 18 to 44, n (%) | 159 (61.4)              | 106 (62.4)           | 265 (61.8)           | 37 (67.3)     | 35 (61.4)       | 72 (64.3)       |
| 45 to 64, n (%)            | 84 (32.4)               | 55 (32.4)            | 139 (32.4)           | 13 (23.6)     | 22 (38.6)       | 35 (31.3)       |
| ≥65, n (%)                 | 16 (6.2)                | 9 (5.3)              | 25 (5.8)             | 5 (9.1)       | 0               | 5 (4.5)         |
| Race, n (%)                |                         |                      |                      |               |                 |                 |
| White                      | 201 (77.6)              | 130 (76.5)           | 331 (77.2)           | 47 (85.5)     | 41 (71.9)       | 88 (78.6)       |
| Black                      | 3 (1.2)                 | 0                    | 3 (0.7)              | 0             | 0               | 0               |
| Asian                      | 40 (15.4)               | 20 (11.8)            | 60 (14.0)            | 6 (10.9)      | 8 (14.0)        | 14 (12.5)       |
| Other                      | 9 (3.5)                 | 9 (5.3)              | 18 (4.2)             | 1 (1.8)       | 3 (5.3)         | 4 (3.6)         |
| Unspecified                | 6 (2.3)                 | 11 (6.5)             | 17 (4.0)             | 1 (1.8)       | 5 (8.8)         | 6 (5.4)         |
| Racial designation, n (%)a |                         |                      |                      |               |                 |                 |
| Indian                     | 6 (2.3)                 | 1 (0.6)              | 7 (1.6)              | 1 (1.8)       | 0               | 1 (0.9)         |
| Subcontinent Asian         |                         |                      |                      |               |                 |                 |
| Southeast Asian            | 3 (1.2)                 | 4 (2.4)              | 7 (1.6)              | 0             | 0               | 0               |
| Far East Asian             | 30 (11.6)               | 16 (9.4)             | 46 (10.7)            | 5 (9.1)       | 8 (14.0)        | 13 (11.6)       |
| Other                      | 10 (3.9)                | 8 (4.7)              | 18 (4.2)             | 1 (1.8)       | 3 (5.3)         | 4 (3.6)         |
| Unspecified                | 6 (2.3)                 | 11 (6.5)             | 17 (4.0)             | 1 (1.8)       | 5 (8.8)         | 6 (5.4)         |
| Ethnicity, n (%)           |                         |                      |                      |               |                 |                 |
| Hispanic/Latino            | 6 (2.3)                 | 5 (2.9)              | 11 (2.6)             | 2 (3.6)       | 1 (1.8)         | 3 (2.7)         |
| Not                        | 247 (95.4)              | 154 (90.6)           | 401 (93.5)           | 52 (94.5)     | 51 (89.5)       | 103 (92.0)      |
| Hispanic/Latino            |                         |                      |                      |               |                 |                 |
| Unspecified                | 6 (2.3)                 | 11 (6.5)             | 17 (4.0)             | 1 (1.8)       | 5 (8.8)         | 6 (5.4)         |
| Geographic region, n (%)   |                         |                      |                      |               |                 |                 |
| Europe                     | 148 (57.1)              | 101 (59.4)           | 249 (58.0)           | 29 (52.7)     | 34 (59.6)       | 63 (56.3)       |
| North America              | 54 (20.8)               | 31 (18.2)            | 85 (19.8)            | 15 (27.3)     | 8 (14.0)        | 23 (20.5)       |
| Other                      | 57 (22.0)               | 38 (22.4)            | 95 (22.1)            | 11 (20.0)     | 15 (26.3)       | 26 (23.2)       |
| Weight (kg)                |                         |                      |                      |               |                 |                 |
| Mean (SD)                  | 78.9 (14.9)             | 67.6 (17.3)          | 74.4 (16.8)          | 81 (15.4)     | 65.6 (13.3)     | 73.2 (16.2)     |
| Range                      | 48.0, 134.3             | 42.1, 135.5          | 42.1, 135.5          | 57.6, 126     | 42.5, 104.8     | 42.5,126        |
| Height (cm)                |                         |                      |                      |               |                 |                 |
| Mean (SD)                  | 176.9 (7.4)             | 164.5 (7.3)          | 172.0 (9.5)          | 177.7 (7.3)   | 164.7 (7.4)     | 171.1 (9.8)     |
| Range                      | 154.9, 199.0            | 149.0,               | 149.0,               | 160.0,        | 145.5,          | 145.5,          |
|                            |                         | 184.0                | 199.0                | 195.6         | 180.0           | 195.6           |
| Body mass index (kg/m?)    | Body mass index (kg/m?) |                      |                      |               |                 |                 |
| Mean (SD)                  | 25.2 (4.2)              | 24.9 (6.0)           | 25.1 (5.0)           | 25.6 (4.4)    | 24.2 (4.8)      | 24.9 (4.7)      |
| Range                      | 16.1, 44.2              | 15.9, 55.0           | 15.9, 55.0           | 18.1, 39.7    | 17.6, 37.6      | 17.6, 39.7      |

Source: Table 14.1.2.1, Table 14.1.2.1.3.

BMI was defined as weight/(height x 0.01)?, with weight in kg, and height in cm.

Race/Ethnicity was not collected for French subjects.

BID = twice a day, BMI = body mass index, FAS = full analysis set, N = number of subjects randomized,

n = number of subjects meeting prespecified criteria, SD = standard deviation.

a Racial designation was collected for those subjects whose race was marked as Asian, Other.

<div style=\"page-break-after: always\"></div>

## Baseline Clinical Characteristics by Treatment Group:

|                                                             | Tofacitinib10mgBID (N = 429)   | Placebo (N =112)   | Total (N = 541)   |
|-------------------------------------------------------------|--------------------------------|--------------------|-------------------|
| Duration of disease (years)                                 |                                |                    |                   |
| Mean (SD)                                                   | 8.0 (6.9)                      | 7.7 (6.3)          | 7.9 (6.8)         |
| Median                                                      | 6.0                            | 6.2                | 6.1               |
| Range                                                       | 0.4, 39.4                      | 0.4, 27.9          | 0.4, 39.4         |
| Time since start of most recent UC flare                    |                                |                    |                   |
| (months)                                                    |                                |                    |                   |
| Mean (SD)                                                   | 6.9 (13.9)                     | 5.8 (9.9)          | 6.7 (13.2)        |
| Median                                                      | 3.3                            | 2.9                | 3.2               |
| Range                                                       | 0.0, 143.1                     | 0.0, 88.7          | 0.0, 143.1        |
| Number of UC flares in the last 12 months                   |                                |                    |                   |
| Mean (SD)                                                   | 2.0 (2.3)                      | 1.7 (1.3)          | 1.9 (2.1)         |
| Median                                                      | 1.0                            | 1.0                | 1.0               |
| Range                                                       | 0.0, 36.0                      | 1.0, 12.0          | 0.0, 36.0         |
| 0 flares, n (%)                                             | 1 (0.2)                        | 0                  | 1 (0.2)           |
| 1-2 flares, n (%)                                           | 343 (80.0)                     | 99 (88.4)          | 442 (81.7)        |
| 3-4 flares, n (%)                                           | 69 (16.1)                      | 10 (8.9)           | 79 (14.6)         |
| 5+ flares, n (%)                                            | 16 (3.7)                       | 3 (2.7)            | 19 (3.5)          |
| Subjects with a prior hospitalization for UC, n (%)         |                                |                    |                   |
| N1                                                          | 428                            | 112                | 540               |
| Yes                                                         | 226 (52.7)                     | 65 (58.0)          | 291 (53.8)        |
| No                                                          | 194 (45.2)                     | 45 (40.2)          | 239 (44.2)        |
| Unknown                                                     | 8 (1.9)                        | 2 (1.8)            | 10 (1.8)          |
| Number of hospitalizations in the past                      |                                |                    |                   |
| 12 monthsa                                                  |                                |                    |                   |
| Mean (SD)                                                   | 0.4 (0.8)                      | 0.3 (0.7)          | 0.4 (0.8)         |
| Median                                                      | 0.0                            | 0.0                | 0.0               |
| Range                                                       | 0.0, 6.0                       | 0.0, 5.0           | 0.0, 6.0          |
| Total Mayo scoreb                                           |                                |                    |                   |
| N1                                                          | 428                            | 112                | 540               |
| Mean (SD)                                                   | 9.0 (1.5)                      | 8.9 (1.5)          | 9.0 (1.5)         |
| Median                                                      | 9.0                            | 9.0                | 9.0               |
| Range                                                       | 6.0, 12.0                      | 5.0, 12.0          | 5.0,12.0          |
| Partial Mayo scoreb                                         |                                |                    |                   |
| N1                                                          | 428                            | 112                | 540               |
| Mean (SD)                                                   | 6.4 (1.3)                      | 6.4 (1.2)          | 6.4 (1.3)         |
| Median                                                      | 6.5                            | 6.0                | 6.0               |
| Range                                                       | 3.0, 9.0                       | 3.0, 9.0           | 3.0,9.0           |
| Baseline high sensitivity C-reactive protein (hsCRP) (mg/L) |                                |                    |                   |
| N1                                                          | 422                            | 112                | N/A               |
| Mean (SD)                                                   | 11.5 (18.7)                    | 13.5 (23.8)        | N/A               |
| Median                                                      | 4.6                            | 5.0                | N/A               |
| Range                                                       | 0.2, 156.0                     | 0.2, 205.1         | N/A               |
| Extent of disease, n (%)c                                   |                                |                    |                   |
| N1                                                          | 428                            | 111                | 539               |
| Proctitis                                                   | 1 (0.2)                        | 0                  | 1 (0.2)           |
| Proctosigmoiditis                                           | 67 (15.7)                      | 16 (14.4)          | 83 (15.4)         |
| Left-sided colitis                                          | 149 (34.8)                     | 39 (35.1)          | 188 (34.9)        |
| Extensive colitis/pancolitis                                | 211 (49.3)                     | 56 (50.4)          | 267 (49.5)        |
| Any extra-intestinal manifestations, n (%)*                 |                                |                    |                   |
| N1                                                          | 426                            | 111                | 537               |
| Yes                                                         | 130 (30.5)                     | 35 (31.5)          | 165 (30.7)        |
| No                                                          | 296 (69.5)                     | 76 (68.5)          | 372 (69.3)        |

<div style=\"page-break-after: always\"></div>

|                                                         | Tofacitinib10mgBID (N = 429)   | Placebo (N = 112)   | Total (N = 541)   |
|---------------------------------------------------------|--------------------------------|---------------------|-------------------|
| Alcohol use, n (%)                                      |                                |                     |                   |
| Yes                                                     | 134 (31.2)                     | 36 (32.1)           | 170 (31.4)        |
| No                                                      | 295 (68.8)                     | 76 (67.9)           | 371 (68.6)        |
| Smoking status, n (%)                                   |                                |                     |                   |
| Never smoked                                            | 268 (62.5)                     | 81 (72.3)           | 349 (64.5)        |
| Current smoker                                          | 25 (5.8)                       | 5 (4.5)             | 30 (5.5)          |
| Ex-smoker                                               | 136 (31.7)                     | 26 (23.2)           | 162 (29.9)        |
| If a cuurent smoker, time since started smoking (years) |                                |                     |                   |
| N1                                                      | 25                             | 5                   | 30                |
| Mean (SD)                                               | 15.2 (9.6)                     | 8.8 (6.8)           | 14.2 (9.4)        |
| Median                                                  | 13.0                           | 6.0                 | 10.0              |
| Range                                                   | 3.0, 35.0                      | 3.0, 20.0           | 3.0, 35.0         |
| If an ex-smoker, time since stopped smoking (years)     |                                |                     |                   |
| N1                                                      | 136                            | 26                  | 162               |
| Mean (SD)                                               | 11.6 (9.6)                     | 10.6 (6.1)          | 11.4 (9.1)        |
| Median                                                  | 8.5                            | 9.5                 | 9.0               |
| Range                                                   | 0.0, 47.0                      | 2.0, 20.0           | 0.0, 47.0         |

Source: Table 14.1.2.1.3, Table 14.1.2.2, Table 14.3.4.1.8.

BID = twice a day, N = number of randomized subjects in the total population, n = number of subjects meeting prespecified criteria, N1 = Number of subjects with non-missing data, N/A = not available,

SD = standard deviation, UC = ulcerative colitis.

b. Subject 13471001 had missing Stool Frequency and Rectal Bleeding scores at baseline. Hence, partial and total Mayo scores were not derived.

a Mean, median, and range were based on subjects with a prior hospitalization for UC.

° Extent of Disease: The maximal area of involvement was summarized in case of &gt;1 area; Proctitis:

Involvement limited to the rectum. Proctosigmoiditis: Involvement limited to rectum/sigmoid. Left-sided colitis: Involvement limited to portion of colon distal to splenic flexure; Extensive colitis: Involvement that extends proximal to the splenic flexure; Pancolitis: Involvement of the entire colon.

d Included past or curently active extra-intestinal manifestations.

Previous treatment with TNFi agents was reported in 55.3% of enrolled subjects, with 54.5% reported in the tofacitinib 10 mg BID treatment group and 58% in the placebo group. Prior failure to TNFi treatment for UC was reported in 52.1%, with similar proportions across treatment groups.

Prior treatment with corticosteroids was reported in 90.0% of enrolled subjects, with similar proportions across treatment groups. Prior failure to corticosteroid treatment for UC was reported in 71.3% of enrolled subjects, with similar proportions across treatment groups

Prior treatment with immunosuppressants was reported in 71.7% of enrolled subjects, with similar proportions across treatment groups. Prior failure to corticosteroid treatment for UC was reported in 69.5% of enrolled subjects, with similar proportions across treatment groups.

<div style=\"page-break-after: always\"></div>

## Classification of Prior Drug Treatments for Ulcerative Colitis by Treatment Group

|                                 | Tofacitinib 10 mg BID (N = 429) n (%)   | Placebo (N =112) n (%)   | Total (N = 541) n (%)   |
|---------------------------------|-----------------------------------------|--------------------------|-------------------------|
| Previous drug treatments for UC |                                         |                          |                         |
| Aminosalicylates                | 396 (92.3)                              | 102 (91.1)               | 498 (92.1)              |
| Antibiotics                     | 34 (7.9)                                | 10 (8.9)                 | 44 (8.1)                |
| Biologics - non-TNFi            | 12 (2.8)                                | 1 (0.9)                  | 13 (2.4)                |
| Biologics - TNFi                | 234 (54.5)                              | 65 (58.0)                | 299 (55.3)              |
| Corticosteroidsa                | 385 (89.7)                              | 102 (91.1)               | 487 (90.0)              |
| Immunosuppressants              | 312 (72.7)                              | 76 (67.9)                | 388 (71.7)              |
| Failed drug treatments for UC   |                                         |                          |                         |
| Aminosalicylates                | 305 (71.1)                              | 84 (75.0)                | 389 (71.9)              |
| Antibiotics                     | 17 (4.0)                                | 7 (6.3)                  | 24 (4.4)                |
| Biologics - non-TNFi            | 12 (2.8)                                | 1 (0.9)                  | 13 (2.4)                |
| Biologics - TNFi                | 222 (51.7)                              | 60 (53.6)                | 282 (52.1)              |
| Corticosteroidsb                | 303 (70.6)                              | 83 (74.1)                | 386 (71.3)              |
| Immunosuppressants              | 301 (70.2)                              | 75 (67.0)                | 376 (69.5)              |

Source: Table 14.1.2.1.3, Table 14.4.2.2.2, Table 14.4.2.2.3.

WHO-Drug (vJun2014) coding dictionary applied.

Analysis is based on data collected on the case report form (CRF) of Previous Drug Treatment for Primary Diagnosis, along with Response to medication as Inadequate Response.

The diug classes for each medication were classified by the clinical team and do not reflect the Anatomic Therapeutic Chemical Classification (ATC2) coded terms.

BID = twice a day, N = number of randomized subjects, n = number of subjects meeting prespecified criteria, TNFi = tumor necrosis factor-alpha inhibitor, UC = ulcerative colitis, WHO = World Health

Organization.

From Table 14.1.2.1.3. Refers only to oral or IV corticosteroids for UC.

a Refers to corticosteroids administered via any route for UC.

The most frequent concomitant drug treatments for UC were aminosalicylates (tofacitinib 10 mg BID: 72.7%; placebo: 67.9%) and corticosteroids (tofacitinib 10 mg BID: 47.1%; placebo: 50.0%). The mean dose of corticosteroids at baseline was 16.4 mg/day for the tofacitinib 10 mg BID group, and 16.2 mg/day for the placebo group.

## Concomitant Drug Treatments for Ulcerative Colitis

<div style=\"page-break-after: always\"></div>

|                    | Tofacitinib 10 mg BID (N = 429) n (%)   | Placebo (N = 112) n (%)   | Total (N = 541) n (%)   |
|--------------------|-----------------------------------------|---------------------------|-------------------------|
| Aminosalicylates   | 312 (72.7)                              | 76 (67.9)                 | 388 (71.7)              |
| Antibiotics        | 5 (1.2)                                 | 0                         | 5 (0.9)                 |
| Corticosteroids    | 202 (47.1)                              | 56 (50.0)                 | 258 (47.7)              |
| Immunosuppressants | 5 (1.2)                                 | 0                         | 5 (0.9)                 |

Source: Table 14.4.2.5.2.

WHO-Drug (vJun2014) coding dictionary applied.

Analysis was based on data collected on the Case Report Form (CRF) for Concomitant Corticosteroid and Concomitant UC Medication.

The diug classes for each medication were classified by the clinical team and do not reflect the Anatomic Therapeutic Chemical Classification (ATC2) coded terms.

Subjects that started medication on or after the last dose of study drug are excluded from summary. BID = twice a day, N = number of subjects, n = number of subjects meeting prespecified criteria

WHO = World Health Organization, UC = ulcerative colitis.

## Numbers analysed

6.1% of subjects were excluded from the PPAS, including 5.4% from the tofacitinib 10 mg BID group and 8.9% from the placebo group. Of the subjects excluded from the PPAS, the most frequent reason for exclusion was duration between screening endoscopy and baseline visit &gt;17 days (tofacitinib 10 mg BID: 39.1%; placebo: 10.0%).

|                                                                                                                                                                                          | Tofacitinib 10 mg BID (N = 429) n (%)   | Placebo (N =112) n (%)   | Total (N = 541) n (%)   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|--------------------------|-------------------------|
| Full Analysis Set (FAS)                                                                                                                                                                  | 429 (100)                               | 112 (100)                | 541 (100)               |
| Per Protocol Analysis Set (PPAS)                                                                                                                                                         | 406 (94.6)                              | 102 (91.1)               | 508 (93.9)              |
| Subjects excluded from the PPASa                                                                                                                                                         | 23 (5.4)                                | 10 (8.9)                 | 33 (6.1)                |
| ReasonforExclusiona                                                                                                                                                                      |                                         |                          |                         |
| Baseline total Mayoscore of 5withrectal bleeding subscore of 0                                                                                                                           | 0                                       | 1 (10.0)                 | 1 (3.0)                 |
| Diagnosis of Crohn's disease                                                                                                                                                             | 2 (8.7)                                 | 0                        | 2 (6.1)                 |
| Duration between screening endoscopy and baseline visit >17 days                                                                                                                         | 9 (39.1)                                | 1 (10.0)                 | 10 (30.3)               |
| Missingbaseline total Mayoscore                                                                                                                                                          | 1 (4.3)                                 | 0                        | 1 (3.0)                 |
| Overall study medication compliance <80% or >120%                                                                                                                                        | 1 (4.3)                                 | 1 (10.0)                 | 2 (6.1)                 |
| Subject had a change in background corticosteroid dose outside of protocol-permitted dose changes which was deemed to have a potentially significant impact on final efficacy assessment | 0                                       | 3 (30.0)                 | 3 (9.1)                 |
| Subject received a prohibited medication which was deemed to have a potentially significant impact on final efficacy assessment                                                          | 2 (8.7)                                 | 1 (10.0)                 | 3 (9.1)                 |
| Withdrawal for administrative reason with treatment duration <8 weeks (eg, protocol deviation,withdrawal of consent, site closure)                                                       | 6 (26.1)                                | 2 (20.0)                 | 8 (24.2)                |
| Withdrawal within 7 days of baseline for non-administrative reasons (eg, adverse event, insufficient clinical response)                                                                  | 2 (8.7)                                 | 1 (10.0)                 | 3 (9.1)                 |

Percentages for reasons for exclusion are based on the number of subjects excluded from the PPAS; all other percentages are based on randomized subjects.

a. Subjects may be counted in &gt;1 exclusion criteria.

BID = twice a day, N = number of randomized subjects, n = number of subjects meeting prespecified criteria.

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

Primary Efficacy endpoint:

- Remission: a statistically significant treatment effects for tofacitinib 10 mg BID, compared to placebo p = 0.0005) was seen for remission.

## Key secondary endpoints:

- Mucosal healing was statistically higher (p = 0.0002) at Week 8 compared with placebo based on both the centrally and locally read endoscopy data.

## Other secondary endpoints

- Clinical remission and clinical response at Week 8, tofacitinib 10 mg BID had significantly higher proportions of subjects with clinical remission and clinical response at Week 8 compared with placebo based on both the centrally read (p = 0.0004 and p &lt;0.0001, respectively) and locally read (p = 0.0002 and p &lt;0.0001, respectively) endoscopic findings.
- Endoscopic remission and symptomatic remission, as well as the tofacitinib 10 mg BID had significantly higher proportions of subjects with endoscopic remission, symptomatic remission, at Week 8 compared with placebo for both the centrally and locally read endoscopic scores.
- Partial Mayo score: tofacitinib 10 mg BID showed significantly greater improvement from baseline compared with placebo by Week 2, which was the first post-baseline timepoint assessed, (mean difference -1.0, p &lt;0.0001), and these improvements continued to increase at Week 4 and Week 8 (differences from placebo: -1.2 and -1.3, respectively, p &lt;0.0001 for both Week 4 and Week 8).
- Total Mayo score: tofacitinib 10 mg BID showed significantly greater improvement from baseline of total Mayo score compared with placebo at Week 8.

## Binary exploratory endpoints

- Partial Mayo score remission, partial Mayo score response, improvement based on individual Mayo subscores), statistically significant differences compared with placebo were observed with tofacitinib 10 mg BID as early as Week 2, and were sustained or increased at Week 8.
- Endoscopic response, tofacitinib 10 mg BID had significantly higher proportions of subjects with endoscopic response at Week 8 compared with placebo for both the centrally and locally read endoscopic scores.
- Tofacitinib 10 mg BID had significantly greater improvement on PRO questionnaire scores than placebo, including IBDQ (total and all individual domains) and SF-36 (all component and domain scores), and significantly more favourable responses to treatment were seen with tofacitinib 10 mg BID compared with placebo on most items of the PRTI.
- Tofacitinib 10 mg BID showed significantly greater improvement from baseline compared with placebo at Week 2 for Utility Index score and at both Week 2 and Week 8 for VAS score, on the EQ5D.
- Subject ratings of 'very much improved' and 'much improved' were more frequently reported by subjects in the tofacitinib 10 mg BID treatment group compared with subjects in the placebo group on the PGIC.

<div style=\"page-break-after: always\"></div>

- Tofacitinib 10 mg BID had a greater reduction in hsCRP levels compared with placebo at Week 4 and Week 8.

The primary efficacy endpoint was the remission at Week 8. The proportion of subjects achieving remission at Week 8 (FAS, NRI) was statistically significantly (p = 0.0005) greater in the tofacitinib 10 mg BID group (16.6%) compared with the placebo group (3.6%).

## Proportion of Subjects in Remission at Week 8 (FAS, NRI)

|              | Tofacitinib 10 mg BID (N = 429)   | Placebo (N = 112)   | DifferenceFromPlacebo   | DifferenceFromPlacebo   |
|--------------|-----------------------------------|---------------------|-------------------------|-------------------------|
|              | n (%)                             | n (%)               | Difference(95%C1)       | P-Value                 |
| Remission    |                                   |                     |                         |                         |
| Central read | 71 (16.6)                         | 4 (3.6)             | 13.0 (8.1, 17.9)        | 0.0005                  |
| Localread    | 89 (20.7)                         | 6 (5.4)             | 15.4 (9.7, 21.1)        | 0.0002                  |

Source: Table 14.2.2.1,Table 14.2.2.2

BID = twice a day, CI = confidence interval, FAS = full analysis set, NRI = non-responder imputation,

N = number of subjects in the analysis set, n = number of subjects meeting prespecified criteria, TNFi = tumor necrosisfactor-alphainhibitor.

a. 95% CI was based on the normal approximation for the difference.

b. P-value was based on Cochran-Mantel-Haenszel (CMH) Chi-squared test stratified by prior treatment with TNFi, corticosteroid use at baseline, and geographical region.

Treatment effects for remission at Week 8 (FAS, NRI) were observed across all subgroups defined by prior TNFi treatment, prior TNFi failure, baseline corticosteroid use, and geographic region. The overall treatment effect was not driven by a single subgroup.

## Proportion of Subjects in Remission at Week 8 by Subgroup (FAS, NRI, Central Read)

|                             | Tofacitinib 10 mg BID (N = 429)   | Tofacitinib 10 mg BID (N = 429)   | Placebo (N = 112)   | Placebo (N = 112)   | Difference From Placebo   | Difference From Placebo   |
|-----------------------------|-----------------------------------|-----------------------------------|---------------------|---------------------|---------------------------|---------------------------|
|                             | N1                                | n (%)                             | N1                  | n (%)               | Difference                | (95% CI)a                 |
| Prior TNFi treatment        |                                   |                                   |                     |                     |                           |                           |
| Yes                         | 234                               | 28 (12.0)                         | 65                  | 0 (0.0)             | 12.0                      | (7.8, 16.1)               |
| No                          | 195                               | 43 (22.1)                         | 47                  | 4 (8.5)             | 13.5                      | (3.7, 23.4)               |
| Prior TNFi failure          |                                   |                                   |                     |                     |                           |                           |
| Yes                         | 222                               | 26 (11.7)                         | 60                  | 0 (0.0)             | 11.7                      | (7.5, 15.9)               |
| No                          | 207                               | 45 (21.7)                         | 52                  | 4 (7.7)             | 14.0                      | (4.9, 23.2)               |
| Baseline corticosteroid use |                                   |                                   |                     |                     |                           |                           |
| Yes                         | 198                               | 33 (16.7)                         | 55                  | 3 (5.5)             | 11.2                      | (3.3, 19.1)               |
| No                          | 231                               | 38 (16.5)                         | 57                  | 1 (1.8)             | 14.7                      | (8.8, 20.6)               |
| Geographic region           |                                   |                                   |                     |                     |                           |                           |
| Europe                      | 249                               | 48 (19.3)                         | 63                  | 2 (3.2)             | 16.1                      | (9.6, 22.6)               |
| North America               | 85                                | 11 (12.9)                         | 23                  | 2 (8.7)             | 4.2                       | (-9.3, 17.8)              |
| Other                       | 95                                | 12 (12.6)                         | 26                  | 0 (0.0)             | 12.6                      | (6.0, 19.3)               |

Source: Table 14.2.2.3.

BID = twice a day, CI = confidence interval, FAS = full analysis set, NRI = non-responder imputation, N = number of subjects in the analysis set, n = number of subjects meeting specific criteria, N1 = number of subjects in each group at Week 8, and was used as the denominator in the percentage calculation,

TNFi = tumor necrosis factor-alpha inhibitor.

a. 95% CI was based on the normal approximation for the difference.

<div style=\"page-break-after: always\"></div>

The key secondary efficacy endpoint was the mucosal healing at Week 8. Mucosal healing was defined by a Mayo endoscopic sub score of 0 or 1. The key secondary endpoint analysis was based on the centrally read endoscopic score. The proportion of subjects achieving mucosal healing at Week 8 (FAS, NRI) was statistically significantly (p = 0.0002) greater in the tofacitinib 10 mg BID group (28.4%) compared with the placebo group (11.6%).

## Proportion of Subjects With Mucosal Healing at Week 8 (FAS, NRI):

|                 | Tofacitinib10mgBID (N = 429)   | Placebo (N = 112)   | DifferenceFromPlacebo   | DifferenceFromPlacebo   |
|-----------------|--------------------------------|---------------------|-------------------------|-------------------------|
|                 | n (%)                          | n (%)               | Difference (95% CI)*    | P-Valueb                |
| Mucosal Healing |                                |                     |                         |                         |
| Central read    | 122 (28.4)                     | 13 (11.6)           | 16.8 (9.5, 24.1)        | 0.0002                  |
| Local read      | 156 (36.4)                     | 17 (15.2)           | 21.2 (13.1, 29.2)       | <0.0001                 |

Source: Table 14.2.3.1, Table 14.2.3.2.

Mucosal healing was defined by Mayo endoscopic subscore of O or 1.

BID = twice a day, CI = confidence interval, FAS = full analysis set, NRI = non-responder imputation,

N = number of subjects in the analysis set, n = number of subjects meeting specific criteria, TNFi = tumor necrosis factor-alpha inhibitor.

a. 95% CI was based on the normal approximation for the difference.

b P-value was based on Cochran-Mantel-Haenszel (CMH) Chi-squared test stratified by prior treatment with TNFi, corticosteroid use at baseline, and geographical region.

There were some differences for mucosal healing in the observed magnitude of treatment effect between certain subgroups as defined by prior TNFi treatment, prior TNFi failure, baseline corticosteroid use, and geographic region, however there was evidence of a treatment effect in all subgroups and the overall treatment effect was not driven by a single subgroup.

## Proportion of Subjects with Mucosal Healing at Week 8 by Subgroup (FAS, NRI, Central Read):

<div style=\"page-break-after: always\"></div>

|                             | Tofacitinib10mgBID (N = 429)   | Tofacitinib10mgBID (N = 429)   | Placebo (N = 112)   | Placebo (N = 112)   | DifferenceFromPlacebo   | DifferenceFromPlacebo   |
|-----------------------------|--------------------------------|--------------------------------|---------------------|---------------------|-------------------------|-------------------------|
|                             | N1                             | n (%)                          | N1                  | n (%)               | Difference              | (95% CI)                |
| Prior TNFi treatment        |                                |                                |                     |                     |                         |                         |
| Yes                         | 234                            | 51 (21.8)                      | 65                  | 4 (6.2)             | 15.6                    | (7.8, 23.5)             |
| No                          | 195                            | 71 (36.4)                      | 47                  | 9 (19.1)            | 17.3                    | (4.1, 30.4)             |
| Prior TNFi failure          |                                |                                |                     |                     |                         |                         |
| Yes                         | 222                            | 48 (21.6)                      | 60                  | 4 (6.7)             | 15.0                    | (6.6, 23.3)             |
| No                          | 207                            | 74 (35.7)                      | 52                  | 9 (17.3)            | 18.4                    | (6.3, 30.6)             |
| Baseline corticosteroid use |                                |                                |                     |                     |                         |                         |
| Yes                         | 198                            | 65 (32.8)                      | 55                  | 11 (20.0)           | 12.8                    | (0.4, 25.3)             |
| No                          | 231                            | 57 (24.7)                      | 57                  | 2 (3.5)             | 21.2                    | (13.8, 28.5)            |
| Geographic region           |                                |                                |                     |                     |                         |                         |
| Europe                      | 249                            | 81 (32.5)                      | 63                  | 9 (14.3)            | 18.2                    | (7.8, 28.7)             |
| North America               | 85                             | 21 (24.7)                      | 23                  | 3 (13.0)            | 11.7                    | (-4.9, 28.2)            |
| Other                       | 95                             | 20 (21.1)                      | 26                  | 1 (3.8)             | 17.2                    | (6.2, 28.2)             |

Source: Table 14.2.3.3.

Mucosal healing was defined by Mayo endoscopic subscore of O or 1.

BID = twice a day, CI = confidence interval, FAS = full analysis set, NRI = non-responder imputation,

N = number of subjects in the analysis set, n = number of subjects meeting specific criteria, N1 = number of subjects in each group at Week 8, and used as denominator in percentage calculation, TNFi = tumor necrosis factor-alpha inhibitor.

a 95% CI based on the normal approximation for the difference.

## Summary of Other Secondary Binary Efficacy Endpoints at Week 8 (FAS, NRI):

|                       | Tofacitinib 10 mg BID (N = 429)   | Placebo (N = 112)   | Difference From Placebo   | Difference From Placebo   |
|-----------------------|-----------------------------------|---------------------|---------------------------|---------------------------|
|                       | n (%)                             | n (%)               | Difference (95%C1)a       | P-Valueb                  |
| Clinical remission    |                                   |                     |                           |                           |
| Central read          | 72 (16.8)                         | 4 (3.6)             | 13.2 (8.3, 18.1)          | 0.0004                    |
| Local read            | 90 (21.0)                         | 6 (5.4)             | 15.6 (9.9, 21.3)          | 0.0002                    |
| Clinical response     |                                   |                     |                           |                           |
| Central read          | 236 (55.0)                        | 32 (28.6)           | 26.4 (16.8, 36.0)         | <0.0001                   |
| Local read            | 249 (58.0)                        | 33 (29.5)           | 28.6 (18.9, 38.2)         | <0.0001                   |
| Endoscopic remission  |                                   |                     |                           |                           |
| Central read          | 30 (7.0)                          | 2 (1.8)             | 5.2 (1.8, 8.6)            | 0.0425                    |
| Local read            | 39 (9.1)                          | 0 (0.0)             | 9.1 (6.4, 11.8)           | 0.0011                    |
| Symptomatic remission |                                   |                     |                           |                           |
| Central read          | 46 (10.7)                         | 3 (2.7)             | 8.0 (3.9, 12.2)           | 0.0090                    |
| Local read            | 60 (14.0)                         | 6 (5.4)             | 8.6 (3.3, 13.9)           | 0.0144                    |
| Deep remission        |                                   |                     |                           |                           |
| Central read          | 22 (5.1)                          | 2 (1.8)             | 3.3 (0.1, 6.6)            | 0.1408                    |
| Local read            | 33 (7.7)                          | 0 (0.0)             | 7.7 (5.2, 10.2)           | 0.0028                    |

Source: Table 14.2.4.1, Table 14.2.4.2

BID = twice a day, CI = confidence interval, FAS = full analysis set, NRI = non-responder imputation,

N = number of subjects in the analysis set, n = number of subjects meeting specific criteria, TNFi = tumor

necrosis factor-alpha inhibitor.

b P-value was based on Cochran-Mantel-Haenszel (CMH) Chi-squared test stratified by prior treatment with TNFi, corticosteroid use at baseline, and geographical region; p-value from Fisher's exact test was also provided in the source table.

a. 95% CI was based on the normal approximation for the difference.

<div style=\"page-break-after: always\"></div>

## Proportion of Subjects With Clinical Remission at Week 8 by Subgroup (FAS, NRI, Central Read)

|                             | Tofacitinib 10 mg BID (N = 429)   | Tofacitinib 10 mg BID (N = 429)   | Placebo (N = 112)   | Placebo (N = 112)   | Difference From Placebo   | Difference From Placebo   |
|-----------------------------|-----------------------------------|-----------------------------------|---------------------|---------------------|---------------------------|---------------------------|
|                             | N1                                | n (%)                             | N1                  | n (%)               | Difference                | (95% CI)a                 |
| Prior TNFi treatment        |                                   |                                   |                     |                     |                           |                           |
| Yes                         | 234                               | 28 (12.0)                         | 65                  | 0 (0.0)             | 12.0                      | (7.8, 16.1)               |
| No                          | 195                               | 44 (22.6)                         | 47                  | 4 (8.5)             | 14.1                      | (4.2, 24.0)               |
| Prior TNFi failure          |                                   |                                   |                     |                     |                           |                           |
| Yes                         | 222                               | 26 (11.7)                         | 60                  | 0 (0.0)             | 11.7                      | (7.5, 15.9)               |
| No                          | 207                               | 46 (22.2)                         | 52                  | 4 (7.7)             | 14.5                      | (5.3, 23.7)               |
| Baseline corticosteroid use |                                   |                                   |                     |                     |                           |                           |
| Yes                         | 198                               | 33 (16.7)                         | 55                  | 3 (5.5)             | 11.2                      | (3.3, 19.1)               |
| No                          | 231                               | 39 (16.9)                         | 57                  | 1 (1.8)             | 15.1                      | (9.2, 21.0)               |
| Geographic region           |                                   |                                   |                     |                     |                           |                           |
| Europe                      | 249                               | 49 (19.7)                         | 63                  | 2 (3.2)             | 16.5                      | (9.9, 23.1)               |
| North America               | 85                                | 11 (12.9)                         | 23                  | 2 (8.7)             | 4.2                       | (-9.3, 17.8)              |
| Other                       | 95                                | 12 (12.6)                         | 26                  | 0 (0.0)             | 12.6                      | (6.0, 19.3)               |

Source: Table 14.2.3.4.

Clinical remission was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point.

BID = twice a day, CI = confidence interval, FAS = Full Analysis Set, NRI = non-responder imputation, N = number of subjects in the analysis set, n = number of subjects meeting specific criteria, N1 = number of subjects in each group at Week 8, and used as denominator in percentage calculation, TNFi = tumor necrosis factor-alpha inhibitor.

a. 95% CI based on the normal approximation for the difference.

## Proportion of Subjects With Clinical Response at Week 8 by Subgroup (FAS, NRI, Central Read):

|                             | Tofacitinib10mgBID (N = 429)   | Tofacitinib10mgBID (N = 429)   | Placebo (N =112)   | Placebo (N =112)   | Difference From Placebo   | Difference From Placebo   |
|-----------------------------|--------------------------------|--------------------------------|--------------------|--------------------|---------------------------|---------------------------|
|                             | N1                             | n (%)                          | N1                 | n (%)              | Difference                | (95% CI)a                 |
| Prior TNFi treatment        |                                |                                |                    |                    |                           |                           |
| Yes                         | 234                            | 116 (49.6)                     | 65                 | 17 (26.2)          | 23.4                      | (11.0, 35.9)              |
| No                          | 195                            | 120 (61.5)                     | 47                 | 15 (31.9)          | 29.6                      | (14.6, 44.6)              |
| Prior TNFi failure          |                                |                                |                    |                    |                           |                           |
| Yes                         | 222                            | 109 (49.1)                     | 60                 | 17 (28.3)          | 20.8                      | (7.6, 33.9)               |
| No                          | 207                            | 127 (61.4)                     | 52                 | 15 (28.8)          | 32.5                      | (18.5, 46.5)              |
| Baseline corticosteroid use |                                |                                |                    |                    |                           |                           |
| Yes                         | 198                            | 116 (58.6)                     | 55                 | 20 (36.4)          | 22.2                      | (7.8, 36.7)               |
| No                          | 231                            | 120 (51.9)                     | 57                 | 12 (21.1)          | 30.9                      | (18.5, 43.3)              |
| Geographic region           |                                |                                |                    |                    |                           |                           |
| Europe                      | 249                            | 136 (54.6)                     | 63                 | 18 (28.6)          | 26.0                      | (13.3, 38.8)              |
| North America               | 85                             | 51 (60.0)                      | 23                 | 9 (39.1)           | 20.9                      | (-1.6, 43.4)              |
| Other                       | 95                             | 49 (51.6)                      | 26                 | 5 (19.2)           | 32.3                      | (14.2, 50.5)              |

Source: Table 14.2.3.5.

Clinical response was defined by a decrease from baseline in Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1.

BID = twice a day, CI = confidence interval, FAS = full analysis set, NRI = non-responder imputation, N = number of subjects in the analysis set, n = number of subjects meeting specific criteria, N1=number of subjects in each group at Week 8, and used as denominator in percentage calculation, TNFi = tumor necrosis factor-alpha inhibitor.

a 95% CI based on the normal approximation for the difference.

<div style=\"page-break-after: always\"></div>

Exploratory binary efficacy endpoints, were based on individual components of the Mayo score. Statistically significant differences compared with placebo were observed for endoscopic response at Week 8 and for all other exploratory endpoints over time, as early as Week 2, and sustained or increased at Week 8.

## Summary of Exploratory Binary Efficacy Endpoints by Study Visit (FAS, NRI)

|                                                                                          | Tofacitinib 10 mg BID (N = 429)                                                          | Placebo (N = 112)                                                                        | Difference From Placebo                                                                  | Difference From Placebo                                                                  |
|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
|                                                                                          | n (%)                                                                                    | n (%)                                                                                    | Difference (95% C1)*                                                                     | P-Valueb                                                                                 |
| Partial Mayo score of ≤2 with no individual subscore >1 (partial Mayo score remission)   | Partial Mayo score of ≤2 with no individual subscore >1 (partial Mayo score remission)   | Partial Mayo score of ≤2 with no individual subscore >1 (partial Mayo score remission)   | Partial Mayo score of ≤2 with no individual subscore >1 (partial Mayo score remission)   | Partial Mayo score of ≤2 with no individual subscore >1 (partial Mayo score remission)   |
| Week 2                                                                                   | 88 (20.5)                                                                                | 8 (7.1)                                                                                  | 13.4 (7.3, 19.5)                                                                         | 0.0010                                                                                   |
| Week 4                                                                                   | 140 (32.6)                                                                               | 14 (12.5)                                                                                | 20.1 (12.6, 27.7)                                                                        | <0.0001                                                                                  |
| Week 8                                                                                   | 175 (40.8)                                                                               | 17 (15.2)                                                                                | 25.6 (17.5, 33.7)                                                                        | <0.0001                                                                                  |
| Reduction of ≥2 points from baseline in partial Mayo score (partial Mayo score response) | Reduction of ≥2 points from baseline in partial Mayo score (partial Mayo score response) | Reduction of ≥2 points from baseline in partial Mayo score (partial Mayo score response) | Reduction of ≥2 points from baseline in partial Mayo score (partial Mayo score response) | Reduction of ≥2 points from baseline in partial Mayo score (partial Mayo score response) |
| Week 2                                                                                   | 228 (53.1)                                                                               | 30 (26.8)                                                                                | 26.4 (16.9, 35.8)                                                                        | <0.0001                                                                                  |
| Week 4                                                                                   | 277 (64.6)                                                                               | 44 (39.3)                                                                                | 25.3 (15.2, 35.4)                                                                        | <0.0001                                                                                  |
| Week 8                                                                                   | 291 (67.8)                                                                               | 49 (43.8)                                                                                | 24.1 (13.9, 34.3)                                                                        | <0.0001                                                                                  |
| Reduction of ≥1 point from baseline in stool frequency                                   | Reduction of ≥1 point from baseline in stool frequency                                   | Reduction of ≥1 point from baseline in stool frequency                                   | Reduction of ≥1 point from baseline in stool frequency                                   | Reduction of ≥1 point from baseline in stool frequency                                   |
| Week 2                                                                                   | 187 (43.6)                                                                               | 28 (25.0)                                                                                | 18.6 (9.3, 27.9)                                                                         | 0.0004                                                                                   |
| Week 4                                                                                   | 243 (56.6)                                                                               | 34 (30.4)                                                                                | 26.3 (16.6, 36.0)                                                                        | <0.0001                                                                                  |
| Week 8                                                                                   | 256 (59.7)                                                                               | 49 (43.8)                                                                                | 15.9 (5.6, 26.2)                                                                         | 0.0025                                                                                   |
| Reduction of≥l point from baseline in rectal bleeding                                    | Reduction of≥l point from baseline in rectal bleeding                                    | Reduction of≥l point from baseline in rectal bleeding                                    | Reduction of≥l point from baseline in rectal bleeding                                    | Reduction of≥l point from baseline in rectal bleeding                                    |
| Week 2                                                                                   | 254 (59.2)                                                                               | 38 (33.9)                                                                                | 25.3 (15.4, 35.2)                                                                        | <0.0001                                                                                  |
| Week 4                                                                                   | 280 (65.3)                                                                               | 44 (39.3)                                                                                | 26.0 (15.9, 36.1)                                                                        | <0.0001                                                                                  |
| Week 8                                                                                   | 299 (69.7)                                                                               | 56 (50.0)                                                                                | 19.7 (9.5, 29.9)                                                                         | 0.0001                                                                                   |
| Reduction of ≥l point from baseline in PGA                                               | Reduction of ≥l point from baseline in PGA                                               | Reduction of ≥l point from baseline in PGA                                               | Reduction of ≥l point from baseline in PGA                                               | Reduction of ≥l point from baseline in PGA                                               |
| Week 2                                                                                   | 212 (49.4)                                                                               | 36 (32.1)                                                                                | 17.3 (7.4, 27.1)                                                                         | 0.0008                                                                                   |
| Week 4                                                                                   | 288 (67.1)                                                                               | 55 (49.1)                                                                                | 18.0 (7.8, 28.3)                                                                         | 0.0004                                                                                   |
| Week 8                                                                                   | 267 (62.2)                                                                               | 45 (40.2)                                                                                | 22.1 (11.9, 32.2)                                                                        | <0.0001                                                                                  |
| Endoscopic response at Week 8                                                            | Endoscopic response at Week 8                                                            | Endoscopic response at Week 8                                                            | Endoscopic response at Week 8                                                            | Endoscopic response at Week 8                                                            |
| Central read                                                                             | 179 (41.7)                                                                               | 25 (22.3)                                                                                | 19.4 (10.4, 28.4)                                                                        | 0.0001                                                                                   |
| Local read                                                                               | 233 (54.3)                                                                               | 28 (25.0)                                                                                | 29.3 (20.0, 38.6)                                                                        | <0.0001                                                                                  |

Source: Table 14.2.6.1.

Endoscopic response was defined by a decrease from baseline in the endoscopic subscore of 1 point or more.

BID = twice a day, CI = confidence interval, FAS = full analysis set, NRI = non-responder imputation,

N = number of subjects randomized, n = number of subjects in the analysis set, PGA = Physician's Global Assessment, TNFi = tumor necrosis factor-alpha inhibitor.

a. 95% CI was based on the normal approximation for the difference.

b P-value was based on Cochran-Mantel-Haenszel (CMH) Chi-squared test stratified by prior treatment with TNFi, corticosteroid use at baseline and geographic region.

## Patient Reported Outcomes for Health Outcomes Assessment

Inflammatory Bowel Disease Questionnaire:

Mean observed IBDQ total scores in Studies A3921094 and A3921095 were similar between the treatment groups at baseline of each study: 123.2 for the tofacitinib 10 mg BID group and 124.9 for the placebo group in Study A3921094, and 120.0 for the tofacitinib 10 mg BID group and 117.5 for the placebo group in Study A3921095. At the last visit, mean IBDQ total score was 164.3 for the tofacitinib 10 mg BID group and 146.7

<div style=\"page-break-after: always\"></div>

for the placebo group in Study A3921094, and 163.1 for the tofacitinib 10 mg BID group and 141.3 for the placebo group in Study A3921095.

The tofacitinib 10 mg BID group showed statistically significantly greater improvements than placebo in IBDQ total score at both Week 4 and Week 8 of Studies A3921094 and A3921095. A similar result was seen for the 4 domain scores at Weeks 4 and 8 of both studies. Statistically significantly more subjects in the tofacitinib 10 mg BID group had IBDQ scores ≥ 170 (IBDQ remission) and ≥ 16 point increase from baseline in IBDQ total score (IBDQ response) in Studies A3921094 and A3921095. A similar result was seen for improvement in IBDQ Bowel Symptom domain (defined as an increase from baseline of at least 1.2 points in average score among IBDQ Bowel Symptom domain items 1, 5, 9, 13, 17, 20, 22, 24, 26, and 29) at Weeks 4 and 8.

Short Form-36:

Statistically significant improvement at Week 8 was demonstrated for tofacitinib 10 mg BID relative to the placebo group for the SF-36 components in Studies A3921094 and A3921095.  A similar result was seen for all SF-36 domains at Week 8

Work Productivity and Activity Impairment -Ulcerative Colitis:

In Study A3921094, the tofacitinib 10 mg BID treatment group demonstrated statistically significantly greater improvements than placebo in presenteeism, work productivity loss, and non-work activity impairment. In Study A3921095, the tofacitinib 10 mg BID treatment group demonstrated statistically significantly greater improvements compared with placebo in non-work activity impairment.

Euro Quality of Life 5 Dimensions/Visual Analog Scale:

EQ-5D Utility Index observed mean scores in Studies A3921094 and A3921095 were similar between the treatment groups at baseline of each study: 0.65 for both the tofacitinib 10 mg BID group and the placebo group in Study A3921094, and 0.65 for the tofacitinib 10 mg BID group and 0.64 for the placebo group in Study A3921095. Similarly, EQ-5D VAS observed mean scores at baseline were 50.75 for the tofacitinib 10 mg BID group and 51.65 for the placebo group in Study A3921094, and 50.61 for the tofacitinib 10 mg BID group and 53.85 for the placebo group in Study A3921095.

At Week 2, tofacitinib 10 mg BID showed statistically significantly greater improvement from baseline compared with placebo for Utility Index score and VAS score in Studies A3921094 and A3921095 (Table 50). These differences doubled by Week 8 of Study A3921094; whereas in Study A3921095, the difference in Utility Index score was lower at Week 8 (p = 0.2201), while the statistically significant difference in VAS score was maintained at Week 8.

## Study A3921096

This was a Phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicentre study in subjects with UC who had completed 1 of the induction studies (A3921094 or A3921095) and demonstrated clinical response. The study was conducted as a 53week double-blind treatment period followed by a 4week safety follow-up for subjects who did not participate in the open-label study (A3921139). The study was conducted at 196 study centres in 31 countries.

Study Design for A3921096:

<div style=\"page-break-after: always\"></div>

Abbreviations: BID =twice a day; DB = double-blind; OLE = open-label extension.

<!-- image -->

## Methods

## Study Participants

The study participants were subjects who had met study entry criteria and completed a 9-week induction treatment from Study A3921094 or Study A3921095. These subjects had achieved a clinical response in Study A3921094 or Study A3921095.

Subjects were ineligible to participate in this study if any of the following criteria were met:

1. Subjects who had a major protocol violation (as determined by the sponsor) in Study A3921094 or Study A3921095.
2. Presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, or clinical findings suggestive of Crohn ' s disease.
3. Subjects who had surgery for UC or who, in the opinion of the investigator, were likely to require surgery for UC during the study period.
4. Subjects who were expected to receive any prohibited concomitant medications, including medications that were either moderate to potent cytochrome P450, Family 3, subfamily A (CYP3A) inducers or inhibitors, during the study period
5. Subjects who were expected to receive live or attenuated virus vaccination during the study period and for 6 weeks after the last dose of study drug.
6. Women who were pregnant or breastfeeding, or planning to become pregnant during the study period.
7. Baseline 12-lead electrocardiogram (ECG) that demonstrated clinically relevant abnormalities which may have affected subject safety or interpretation of study results

<div style=\"page-break-after: always\"></div>

8. Subjects who, in the opinion of the investigator or Pfizer, were uncooperative or unable to comply with study procedures.
9. Subjects who were investigational site staff members or relatives of those site staff members or subjects who were Pfizer employees directly involved in the conduct of the study.

10. Any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may have increased the risk associated with study participation or investigational product administration or may have interfered with the interpretation of study results and in the judgment of the investigator, would have made the subject inappropriate for entry into this study.

11. Subjects who were participating in or interested in participating in other investigational studies during Study A3921096.

## Treatments

Subjects were randomly assigned to receive 1 of 3 treatments: tofacitinib 10 mg twice a day (BID), tofacitinib 5 mg BID, or the matching placebo BID, with an allocation ratio of 1:1:1. for up to 53 weeks, the study drug was taken orally BID (approximately every 12 hours).

Subjects were dispensed 2 bottles; either both containing 5 mg tofacitinib tablets; one containing 5mg tablets and one containing placebo; or both containing matching placebo tablets. Subjects took one tablet from each bottle for each treatment administration.

Subjects were required to remain on stable doses of their concomitant medications for UC during the study treatment period, with the exception of corticosteroids. For subjects taking corticosteroids at the baseline visit of this study, tapering of the corticosteroids was to commence from Week 0.

## Objectives

## Primary Objective:

The primary objective was to demonstrate the efficacy of tofacitinib as maintenance therapy in subjects with UC.

## Secondary Objectives

Secondary objectives were to evaluate the safety and tolerability of tofacitinib as maintenance therapy in subjects with UC; to evaluate the efficacy of tofacitinib maintenance therapy in achieving mucosal healing in subjects with UC; to evaluate the tofacitinib pharmacokinetic (PK) exposure during maintenance therapy in subjects with UC; and to evaluate the effect of tofacitinib as maintenance therapy on quality-of-life in subjects with UC.

## Outcomes/endpoints

Primary efficacy endpoint

- Remission at Week 52, defined by a Mayo score of 2 points or lower, with no individual sub score exceeding 1 point and a rectal bleeding sub score of 0.

<div style=\"page-break-after: always\"></div>

The key secondary endpoints were as follows:

- Mucosal healing at Week 52, defined by a Mayo endoscopic sub score of 0 or 1;
- Sustained corticosteroid-free remission among subjects in remission at baseline of this study, (i.e., remission and corticosteroid-free at both Weeks 24 and 52), defined by a Mayo score of 2 points or lower, with no individual sub score exceeding 1 point and a rectal bleeding sub score of 0, in addition to not requiring any treatment with corticosteroids for at least 4 weeks prior to the visit.

Other secondary endpoints were as follows:

- Remission at Week 24 and sustained remission (i.e., remission at both Weeks 24 and 52);
- Remission at Week 24 and Week 52 and sustained remission, among subjects with remission at baseline of this study;
- Mucosal healing at Week 24, and sustained mucosal healing (i.e., mucosal healing at both Weeks 24 and 52);
- Mucosal healing at Week 24 and Week 52 and sustained mucosal healing, among subjects with mucosal healing at baseline of this study;
- Corticosteroid-free remission at Week 24 and Week 52 among subjects in remission at baseline;
- Clinical response at Week 24 and Week 52 and sustained clinical response (i.e., clinical response at both Weeks 24 and 52), defined by a decrease from induction study (A3921094 or A3921095) baseline Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the rectal bleeding sub score of at least 1 point or absolute sub score for rectal bleeding of 0 or 1;
- Clinical remission at Week 24 and Week 52 and sustained clinical remission (i.e., clinical remission at both Weeks 24 and 52), defined by a Mayo score of 2 points or lower, with no individual sub score exceeding 1 point;
- Deep remission at Week 24 and Week 52 and sustained deep remission (i.e., deep remission at both Weeks 24 and 52), defined by a Mayo score of 2 points or lower, with no individual sub score exceeding 1 point and both absolute endoscopic and rectal bleeding subscores of 0;

## Exploratory Efficacy Endpoints

- Partial Mayo score and change from baseline in partial Mayo score over time;
- Partial Mayo score remission, defined as the proportion of subjects having partial Mayo score of ≤ 2 with no individual sub score &gt;1 over time;
- Partial Mayo score response, defined as the proportion of subjects having a reduction in partial Mayo score by ≤ 2 points from baseline value of induction Study A3921094 or Study A3921095 over time;
- Endoscopic response at Week 24, Week 52, and sustained endoscopic response. Endoscopic response was defined by a decrease from the induction study (A3921094 or A3921095) baseline in the endoscopic sub score of 1 point or more;
- Time to treatment failure, defined by an increase in Mayo score of at least 3 points from the baseline of the maintenance study, accompanied by an increase in rectal bleeding sub score by at least 1

<div style=\"page-break-after: always\"></div>

point, and an increase of endoscopic sub score of at least 1 point yielding an absolute endoscopic sub score of at least 2 after a minimum treatment of 8 weeks in the study;

- Subjects who dropped out or completed the study without meeting the treatment failure criteria were treated as censored at the last visit with Mayo score assessment. Subjects who did not meet the treatment failure criteria, but dropped out due to lack of efficacy (i.e., insufficient clinical response) were treated as treatment failures at the time of drop out.
- Time to loss of response, defined by an increase in partial Mayo score of at least 2 points from baseline in the maintenance study (A3921096) for 2 consecutive visits (at least 2 weeks apart), with an increase of rectal bleeding sub score of at least 1 from baseline of this study;

Time to loss of response was the first instance among 2 consecutive visits when the criteria for loss of response was met. Subjects who dropped out or completed the study without meeting the loss of response criteria were treated as censored at the last visit with partial Mayo score assessment. Subjects who did not meet the loss of response criteria, but dropped out due to lack of efficacy (i.e., insufficient clinical response), were treated a meeting loss of response at the time of drop out. Subjects who did not meet the loss of response criteria at the previous visit, but met the criteria (i.e., an increase in partial Mayo score of at least 2 points from baseline in the maintenance study at the last visit with partial Mayo score assessment), were analysed using 2 different methods: A) as loss of response at the time of the last visit with partial Mayo score assessment, and B) censored at the time of the last visit with partial Mayo score assessment.

- The 4 subcomponents of the Mayo score over time: stool frequency, rectal bleeding, findings of flexible sigmoidoscopy, and PGA;Corticosteroid doses among subjects receiving corticosteroids at baseline;
- Proportion of subjects who were off corticosteroids at Week 24 and Week 52 among subjects receiving corticosteroids at baseline;
- Proportion of subjects who were without corticosteroids at Week 24 and Week 52;
- Corticosteroid-free remission at Week 24, Week 52, and sustained corticosteroid-free remission.
- Absolute counts and change from baseline in the following lymphocyte subsets: cluster of differentiation (CD) 4+ T cells, CD8+ T cells, B cells, and natural killer (NK) cells (UK only).

Patient reported health outcomes endpoints:

- Scores and change from baseline in IBDQ total score and domains (Bowel Symptoms, Systemic Symptoms, Emotional Function and Social Function) over time;
- IBDQ remission, defined as IBDQ total score ≥ 170 over time;
- IBDQ response over time, defined as ≥ 16-point increase in IBDQ total score from the induction study (A3921094 or A3921095) baseline;
- PGIC scores at Week 52;
- PRTI scores at Week 52;
- SF-36 scores and change from baseline (PCS and MCS scores, and 8 domain scores) over time;

<div style=\"page-break-after: always\"></div>

- EQ-5D/VAS scores and change from baseline over time;
- WPAI-UC scores and change from baseline in the 4 WPAI-UC questionnaire domains
- (Absenteeism, Presenteeism, Work Productivity Loss, Activity Impairment) over time;
- Summary of subjects who utilized the healthcare services and the frequency of utilization of such services specified in the UC-HCRU-All and post-treatment Healthcare Resource Utilization (HCRU) questionnaires;
- Summary of incidences and duration of UC-related hospitalizations;
- Summary of subjects requiring colectomy for UC or UC-related complications;
- The time to deterioration in IBDQ Bowel Symptom domain. The deterioration was defined as a decrease of 1.2 points from baseline of this study (A3921096) in average score of the IBDQ Bowel Symptom domain (Items 1, 5, 9, 13, 17, 20, 22, 24, 26, and 29). Subjects who dropped out or completed the study without meeting the deterioration criteria were treated as censored at the last visit in which they completed the IBDQ. Subjects who did not meet the deterioration criteria but dropped out due to lack of efficacy were treated as deterioration.

Biomarker endpoint

- Serum high sensitivity C-reactive protein (hsCRP) and change from baseline in hsCRP over time.

## Sample size

Sample size estimations were based on the assumptions regarding clinical response and remission rates in subjects receiving tofacitinib or placebo induction treatment in Study A3921094 and Study A3921095. These assumptions led to an estimate of 654 subjects eligible and 315 subjects in remission at baseline of Study A3921096. This sample size would have provided at least 90% power to detect a treatment difference between tofacitinib and placebo in the primary endpoint and the first key secondary endpoint and approximately 72% power to detect a treatment difference in the second key secondary endpoint assuming a difference of 17.5% between a tofacitinib dose and placebo using the Chi-square test at the significant level of 5%. Placebo rates were assumed to be 30% (primary endpoint), 50% (first key secondary endpoint), and 40% (second key secondary endpoint).

Once induction studies (A3921094 and A3921095) were completed, power calculations based on actual sample size were possible. There were approximately 594 subjects (198 per group) actually randomized to Study A3921096, including approximately 180 subjects (60 per group) in remission at baseline of Study A3921096. Based on the actual sample size and the same initial assumptions on placebo rates, there was at least 90% power to detect a treatment difference in the primary or first key secondary endpoint at the significant level of 5% or 2.5%. There was also an approximately 49% power to detect a treatment difference for the second key secondary endpoint. With the same assumptions but at the significance level of 2.5%, the estimated power was 38%.

In addition, the original placebo assumptions were based on limited historical data. However emerging data from other UC studies over the years and the assumption of lower rates with central reading compared local reading for endoscopic scoring resulted in revised assumptions for the placebo rates. The assumptions for the placebo rates were updated to 10% to 15% for remission at Week 52, 15% to 20% for mucosal healing at

<div style=\"page-break-after: always\"></div>

Week 52, 15% to 20% for sustained steroid-free remission among subjects in remission at baseline of the maintenance study.

Taking into account actual sample size from the induction studies and the revised assumptions for placebo rates, the actual sample size provided more than 90% power to detect a treatment difference between tofacitinib and placebo in the primary endpoint and the first key secondary endpoint. There was approximately 57% to 63% power to detect a treatment difference in the second key secondary endpoint. With the same assumptions but at the significance level of 2.5%, the estimated power was 46% to 51%.

## Randomisation

Subjects were prospectively stratified according to their prior treatment assignments in Study A3921094 and Study A3921095 and whether they were in remission, and then randomized according to a computer generated pseudo random code using the method of permutated blocks balanced within each randomization strata. Subjects were randomized into 1 of the 3 treatment groups: tofacitinib 10 mg BID, tofacitinib 5 mg BID, or placebo BID with an allocation ratio of 1:1:1.

## Blinding (masking)

The study was subject, investigator and sponsor-blinded. Blinding was achieved by the use of placebo tablets matching tofacitinib 5mg tablets.

## Statistical methods

Analysis Populations

The primary analysis population for efficacy endpoints was the FAS, defined as all subjects randomised.

The modified full analysis set (mFAS) is a subset of the FAS including only subjects who received tofacitinib in the induction studies.

The PPAS, defined as a subset of subjects from the FAS population who had no major protocol violations. as determined by the sponsor prior to the study being unblinded.

The safety analysis set included all randomised subjects who received at least one dose of study medication.

A sequentially rejective Bonferroni-based iterative multiple test procedure was prespecified to control the family-wise Type I error rate for the 6 comparisons of tofacitinib 10 mg BID or tofacitinib 5 mg BID versus placebo for the primary endpoint of remission and the 2 key secondary endpoints of mucosal healing and sustained corticosteroid-free remission among subjects in remission at baseline.

The primary endpoint of remission at Week 52 was analysed in the FAS population using a stratified CochranMantel Haenszel (CMH) Chi-square test. The primary analysis was stratified by treatment received in the induction study and status of remission (remission or not) at Study A3921096 baseline.

Non-responder imputation (NRI) was used to handle missing values. The difference in the proportion of responders and associated 95% confidence intervals (CIs) were presented for active versus placebo groups using the normal approximation for the difference in binomial proportions.

<div style=\"page-break-after: always\"></div>

The continuous secondary efficacy endpoints of Mayo score (measured at baseline, Week 24, and Week 52) and partial Mayo score (measured repeatedly over time) were analysed using a longitudinal linear mixedeffects model assuming the mechanism of the missing data were missing at random. The 4 Mayo sub-scores were treated as ordered-categorical data. Missing data were not imputed, and descriptive statistics were based upon the observed-case data.

Missing values for the PRO endpoints of WPAI, PRTI, PGIC, and UC-HCRU were not imputed. Analyses of these endpoints were based on the observed-case data. For the PRO endpoints of IBDQ, EQ 5D/VAS, and SF36, rules suggested by the developers of the questionnaires were followed in calculating the endpoints with any missing items. If these rules were not sufficient to impute the missing values, then the missing values were handled as following

-For IBDQ binary endpoints, missing data were treated as non-responder data.

-For IBDQ, EQ-5D/VAS, and SF-36 continuous endpoints, analyses were performed using a linear mixedeffects model with repeated measures, where the missing values were assumed to be missing at random.

Serum hsCRP concentrations were summarized as continuous data. For data analysis, assayed values below the limit of quantification (BLQ) were set to 10% less than the given assay lower limit for the specific biomarker. In listings, BLQ values were reported as &lt; lower limit of quantification (LLQ) and replaced with the LLQ value. Assay values were set to missing if a value was indicated to be not done (ND) or no sample (NS). Otherwise, missing data were not imputed.

## Results

## Participant flow

Overall, 593 subjects were randomized to study treatment (FAS). This included 198 subjects randomized to the tofacitinib 5 mg BID group, 197 subjects to the tofacitinib 10 mg BID group, and 198 subjects randomized to the placebo group. Of the 593 randomized subjects, 592 subjects received at least 1 dose of study drug (safety analysis set).

Subject 10611004 was randomized but withdrew consent without commencing study drug. Subject 10061001 was randomized into Study A3921096 in the tofacitinib 5 mg BID group in error (the subject did not achieve clinical response at Week 8 of the induction study) instead of being enrolled into the open-label extension Study A3921139. Based on incorrect information that the subject was not dosed after randomization, the subject was permitted to be removed (i.e., de-randomized) from Study A3921096 and enrolled in Study A3921139. It was later realized that the subject had taken 6 (out of 8) tablets of tofacitinib 5 mg in Study A3921096 before de-randomization. This subject had no AEs reported while taking the Study A3921096 study drug. This subject was not included in any Study A3921096 analysis sets. Subject 10611004 was included in FAS, but Subject 10061001 was not included in FAS.

## Subject Disposition by Treatment Group - FAS

<div style=\"page-break-after: always\"></div>

|                                           | Tofacitinib 5 mg BID n (%)   | Tofacitinib 10 mg BID n (%)   | Placebo n (%)   | Total n (%)   |
|-------------------------------------------|------------------------------|-------------------------------|-----------------|---------------|
| Randomizeda                               | 198 (100.0)                  | 197 (100.0)                   | 198 (100.0)     | 593 (100.0)   |
| Treatedb,c                                | 198                          | 196                           | 198             | 592           |
| Analyzed for efficacy                     |                              |                               |                 |               |
| FAS                                       | 198 (100.0)                  | 197 (100.0)                   | 198 (100.0)     | 593 (100.0)   |
| PPAS                                      | 183 (92.4)                   | 186 (94.4)                    | 188 (94.9)      | 557 (93.9)    |
| mFAS                                      | 176 (88.9)                   | 173 (87.8)                    | 174 (87.9)      | 523 (88.2)    |
| Analyzed for safety                       |                              |                               |                 |               |
| Safety analysis set                       | 198 (100.0)                  | 196 (99.5)                    | 198 (100.0)     | 592 (99.8)    |
| mFAS                                      | 176 (88.9)                   | 173 (87.8)                    | 174 (87.9)      | 523 (88.2)    |
| AEs                                       | 198 (100.0)                  | 196 (99.5)                    | 198 (100.0)     | 592 (99.8)    |
| Laboratory datad                          | 198 (100.0)                  | 195 (99.0)                    | 198 (100.0)     | 591 (99.7)    |
| Completedc                                | 111 (56.1)                   | 126 (64.3)                    | 53 (26.8)       | 290 (49.0)    |
| Discontinuede                             | 87 (43.9)                    | 70 (35.7)e                    | 145 (73.2)      | 302 (51.0)    |
| Primary reason for discontinuationc       |                              |                               |                 |               |
| Subject died                              | 0                            | 0                             | 0               | 0             |
| Related to study drug                     | 74 (37.4)                    | 61 (31.1)                     | 134 (67.7)      | 269 (45.4)    |
| AE                                        | 4 (2.0)                      | 8 (4.1)                       | 2 (1.0)         | 14 (2.4)      |
| Insufficient clinical response            | 70 (35.4)                    | 53 (27.0)                     | 132 (66.7)      | 255 (43.1)    |
| Not related to study drug                 | 13 (6.6)                     | 9 (4.6)                       | 11 (5.6)        | 33 (5.6)      |
| AE                                        | 1 (0.5)                      | 1 (0.5)                       | 5 (2.5)         | 7 (1.2)       |
| No longer willing to participate in study | 6 (3.0)                      | 3 (1.5)                       | 5 (2.5)         | 14 (2.4)      |
| Protocol violation                        | 0                            | 1 (0.5)                       | 0               | 1 (0.2)       |
| Lost to follow-up                         | 3 (1.5)                      | 2 (1.0)                       | 1 (0.5)         | 6 (1.0)       |
| Discontinued due to pregnancy             | 1 (0.5)                      | 1 (0.5)                       | 0               | 2 (0.3)       |
| Other                                     | 2 (1.0)                      | 1 (0.5)                       | 0               | 3 (0.5)       |

Source: Table 14.1.1.1.1, Table 14.1.1.1.2, Table 14.1.1.2.

AE = adverse event; BID = twice a day; FAS = full analysis set; PPAS = per protocol analysis set; mFAS = modified full analysis set; n = number of subjects meeting prespecified criteria; UC = ulcerative collitis.

- a. Subject 10061001 was misrandomized to tofacitinib 5 mg BID (did not achieve clinical response) and was de-randomized after receiving 2 days of study drug. This subject had no reported AEs and was not included in the analysis sets.
- b. Subject 10611004 was randomized to tofacitinib 10 mg BID but withdrew consent and did not receive any doses of study drug.
3. The percentages for completed, discontinued, and primary reason for discontinuation were based on the number of subjects treated (ie, the safety analysis set).
4. Laboratory data consisted of all randomized subjects that have lab data collected at both baseline and 1 of the post-baseline visits. Subject 12851001 with only baseline labs was not counted.
- e. Percentage for discontinued in the tofacitinib 10 mg BID group was based on the safety analysis set (the number of subjects treated), from Table 14.1.1.2.
- f. AEs of worsening of UC leading to discontinuation were designated as insufficient clinical response.

All randomized subjects in the mFAS received at least 1 dose of study drug and were analysed for efficacy. Of the 523 subjects in the mFAS, 272 (52.0%) discontinued, and 251 (48.0%) completed the study. Those who discontinued due to reasons related to study drug included 38.1% in the tofacitinib 5 mg group, 31.8% in the tofacitinib 10 mg group, and 70.7% in the placebo group; the greater percentage in the placebo group was due to more subjects with discontinuation due to insufficient clinical response (tofacitinib 5 mg BID: 35.8%, tofacitinib 10 mg BID: 27.2%, and placebo: 69.5%).

<div style=\"page-break-after: always\"></div>

Subject Disposition by Treatment Group - mFAS

|                                           | Tofacitinib 5 mg BID n (%)   | Tofacitinib 10 mg BID n (%)   | Placebo n (%)   | Total n (%)   |
|-------------------------------------------|------------------------------|-------------------------------|-----------------|---------------|
| Randomized (mFAS)                         | 176                          | 173                           | 174             | 523           |
| Treated                                   | 176                          | 173                           | 174             | 523           |
| Analyzed for safety                       |                              |                               |                 |               |
| AEs                                       | 176 (100.0)                  | 173 (100.0)                   | 174 (100.0)     | 523 (100.0)   |
| Laboratory data                           | 176 (100.0)                  | 172 (99.4)                    | 174 (100.0)     | 522 (99.8)    |
| Completed                                 | 97 (55.1)                    | 110 (63.6)                    | 44 (25.3)       | 251 (48.0)    |
| Discontinued                              | 79 (44.9)                    | 63 (36.4)                     | 130 (74.7)      | 272 (52.0)    |
| Primary reason for discontinuation        |                              |                               |                 |               |
| Subject died                              | 0                            | 0                             | 0               | 0             |
| Related to study drug                     | 67 (38.1)                    | 55 (31.8)                     | 123 (70.7)      | 245 (46.8)    |
| AE                                        | 4 (2.3)                      | 8 (4.6)                       | 2 (1.1)         | 14 (2.7)      |
| Insufficient clinical responsea           | 63 (35.8)                    | 47 (27.2)                     | 121 (69.5)      | 231 (44.2)    |
| Not related to study drug                 | 12 (6.8)                     | 8 (4.6)                       | 7 (4.0)         | 27 (5.2)      |
| AE                                        | 1 (0.6)                      | 1 (0.6)                       | 3 (1.7)         | 5 (1.0)       |
| No longer willing to participate in study | 6 (3.4)                      | 3 (1.7)                       | 4 (2.3)         | 13 (2.5)      |
| Lost to follow-up                         | 3 (1.7)                      | 2 (1.2)                       | 0               | 5 (1.0)       |
| Discontinued due to pregnancy             | 1 (0.6)                      | 1 (0.6)                       | 0               | 2 (0.4)       |
| Other                                     | 1 (0.6)                      | 1 (0.6)                       | 0               | 2 (0.4)       |

Source: Table 14.1.1.1.2,Table 14.1.1.3, Table 14.3.2.1.

AE = adverse event; BID = twice a day; mFAS = modified full analysis set; n = number of subjects meeting prespecified criteria; UC = ulcerative colitis.

a. AEs of worsening of UC leading to discontinuation were designated as insufficient clinical response.

## Recruitment

First Subject First Visit (FSFV): 20 July 2012

Last Subject Last Visit (LSLV): 27 May 2016

Study subjects were enrolled from 196 investigational sites in Asia, Australia, Europe, North America, and South America.

## Conduct of the study

The most frequent cause for a key protocol deviation was that the subject was randomized according to the wrong stratification factor of baseline remission status (34.1%). In this study, subjects were stratified by induction study (A3921094 or A3921095) treatment assignment and baseline remission status. Baseline remission status was to be determined by the investigator based on the subject's remission status at the Week 8 visit of the induction study. Reasons for this deviation included inaccurate assessment of subjects' status based on protocol-specified clinical response and investigator blinding to Study A3921096 stratification factors. In combination, these reasons contributed to delay in implementing corrective actions. This deviation occurred in similar proportions of subjects across treatment groups (32.8%, 35.5%, and 33.8%, in the tofacitinib 5 mg BID, tofacitinib 10 mg BID, and placebo groups, respectively) thereby mitigating the impact upon the analyses.

<div style=\"page-break-after: always\"></div>

## Summary of Key Protocol Deviations

| Protocol Deviation                                                                             | Tofacitinib 5 mg BID (N = 198) n (%)   | Tofacitinib 10 mg BID (N = 197) n (%)   | Placebo (N = 198) n (%)   | Total (N = 593) n (%)   |
|------------------------------------------------------------------------------------------------|----------------------------------------|-----------------------------------------|---------------------------|-------------------------|
| Concomitant medications                                                                        | 22 (11.1)                              | 32 (16.2)                               | 26 (13.1)                 | 80 (13.5)               |
| Subject did not taper oral corticosteroids during study treatment                              | 0                                      | 3 (1.5)                                 | 3 (1.5)                   | 6 (1.0)                 |
| Subject did not taper oral corticosteroids per protocol specifications                         | 14 (7.1)                               | 19 (9.6)                                | 9 (4.5)                   | 42 (7.1)                |
| Subject discontinued a permitted medication for treatment of UC during study treatment         | 1 (0.5)                                | 0                                       | 0                         | 1 (0.2)                 |
| Subject initiated or changed a permitted medication for treatment of UC during study treatment | 2 (1.0)                                | 7 (3.6)                                 | 2 (1.0)                   | 11 (1.9)                |
| Subject re-initiated oral corticosteroids after achieving steroid-free status                  | 0                                      | 2 (1.0)                                 | 2 (1.0)                   | 4 (0.7)                 |
| Subject received other prohibited medications during study treatment                           | 5 (2.5)                                | 5 (2.5)                                 | 11 (5.6)                  | 21 (3.5)                |
| Subject received prohibited UC medications during study treatment                              | 0                                      | 1 (0.5)                                 | 2 (1.0)                   | 3 (0.5)                 |
| ICF issues                                                                                     | 28 (14.1)                              | 36 (18.3)                               | 20 (10.1)                 | 84 (14.2)               |
| ICD not dated, timed, or initialed where applicable by subject (but subject signed ICF)        | 8 (4.0)                                | 7 (3.6)                                 | 9 (4.5)                   | 24 (4.0)                |
| Obsolete ICD version signed                                                                    | 2 (1.0)                                | 7 (3.6)                                 | 0                         | 9 (1.5)                 |
| Study procedure prior to consent                                                               | 3 (1.5)                                | 3 (1.5)                                 | 2 (1.0)                   | 8 (1.3)                 |
| Updated consent not signed at subject visit                                                    | 17 (8.6)                               | 20 (10.2)                               | 9 (4.5)                   | 46 (7.8)                |
| Inclusion/exclusion                                                                            | 6 (3.0)                                | 2 (1.0)                                 | 3 (1.5)                   | 11 (1.9)                |
| Eligibility was not confirmed prior to randomization                                           | 1 (0.5)                                | 0                                       | 0                         | 1 (0.2)                 |
| Subject did not achieve clinical response in Study A3921094 or Study A3921095                  | 5 (2.5)                                | 2 (1.0)                                 | 3 (1.5)                   | 10 (1.7)                |
| Laboratory                                                                                     | 14 (7.1)                               | 16 (8.1)                                | 17 (8.6)                  | 47 (7.9)                |
| Safety laboratory samples not collected                                                        | 5 (2.5)                                | 6 (3.0)                                 | 11 (5.6)                  | 22 (3.7)                |
| Safety monitoring for abnormal laboratory values not done per protocol                         | 4 (2.0)                                | 7 (3.6)                                 | 3 (1.5)                   | 14 (2.4)                |

<div style=\"page-break-after: always\"></div>

| Protocol Deviation                                                                                            | Tofacitinib 5 mg BID (N =198) n (%)   | Tofacitinib 10 mg BID (N = 197) n (%)   | Placebo (N = 198) n (%)   | Total (N = 593) n (%)   |
|---------------------------------------------------------------------------------------------------------------|---------------------------------------|-----------------------------------------|---------------------------|-------------------------|
| Urine pregnancy test not performed in a woman of childbearing potential                                       | 6 (3.0)                               | 4 (2.0)                                 | 5 (2.5)                   | 15 (2.5)                |
| Other - safety                                                                                                | 2 (1.0)                               | 2 (1.0)                                 | 5 (2.5)                   | 9 (1.5)                 |
| Safety reporting - SAE reported late                                                                          | 2 (1.0)                               | 1 (0.5)                                 | 4 (2.0)                   | 7 (1.2)                 |
| Safety reporting - unreported SAE                                                                             | 0                                     | 1 (0.5)                                 | 1 (0.5)                   | 2 (0.3)                 |
| Other - protocol-specific discontinuation criteria                                                            | 1 (0.5)                               | 2 (1.0)                                 | 1 (0.5)                   | 4 (0.7)                 |
| Subject was not discontinued per discontinuation criteria for UC rescue                                       | 0                                     | 2 (1.0)                                 | 1 (0.5)                   | 3 (0.5)                 |
| therapy Subject was not discontinued per discontinuation criteria for serious infection                       | 1 (0.5)                               | 0                                       | 0                         | 1 (0.2)                 |
| Procedures/tests                                                                                              | 49 (24.7)                             | 53 (26.9)                               | 67 (33.8)                 | 169 (28.5)              |
| An alternate data source was used to calculate rectal bleeding and stool frequency subscores as data were not | 8 (4.0)                               | 9 (4.6)                                 | 6 (3.0)                   | 23 (3.9)                |
| entered in the ediary Endoscopy not done or not centrally-read                                                | 19 (9.6)                              | 21 (10.7)                               | 26 (13.1)                 | 66 (11.1)               |
| Partial Mayo not done or not complete                                                                         | 16 (8.1)                              | 17 (8.6)                                | 11 (5.6)                  | 44 (7.4)                |
| Procedures to confirm treatment failure not done per-protocol                                                 | 14 (7.1)                              | 13 (6.6)                                | 38 (19.2)                 | 65 (11.0)               |
| Study drug                                                                                                    | 65 (32.8)                             | 71 (36.0)                               | 67 (33.8)                 | 203 (34.2)              |
| Incorrectbottleswere dispensed to the subject                                                                 | 1 (0.5)                               | 0                                       | 0                         | 1 (0.2)                 |
| Compliance with study drug was <80% or >120% during the entire double-blind treatment period                  | 0                                     | 1 (0.5)                                 | 0                         | 1 (0.2)                 |
| Subject was randomized according to the wrong stratification                                                  | 65 (32.8)                             | 70 (35.5)                               | 67 (33.8)                 | 202 (34.1)              |
| Visit schedule                                                                                                | 4 (2.0)                               | 6 (3.0)                                 | 8 (4.0)                   | 18 (3.0)                |
| Visit not done                                                                                                | 4 (2.0)                               | 6 (3.0)                                 | 8 (4.0)                   | 18 (3.0)                |

Source: Table 14.2.1.3.1.

Subjects may be included in more than 1 deviation category.

BID = twice a day; ICD = informed consent document; ICF = informed consent form; N = number of randomized subjects; n = number of subjects meeting prespecified criteria; SAE = serious adverse event;

UC = ulcerative colitis.

## Baseline data

## Baseline Demographic Characteristics in Study A3921096 (FAS):

<div style=\"page-break-after: always\"></div>

|                          | Tofacitinib 5 mg BID (N=198)   | Tofacitinib 10 mg BID (N=197)   | Placebo (N=198)   | Total (N=593)   |
|--------------------------|--------------------------------|---------------------------------|-------------------|-----------------|
| Age (years)              |                                |                                 |                   |                 |
| Mean (SD)                | 41.9 (13.7)                    | 42.9 (14.4)                     | 43.4 (14.0)       | 42.7 (14.0)     |
| Median                   | 41.0                           | 40.0                            | 42.0              | 41.0            |
| Range                    | 18 -79                         | 18-79                           | 19 -80            | 18-80           |
| Sex, n (%)               |                                |                                 |                   |                 |
| Male                     | 103 (52.0)                     | 110 (55.8)                      | 116 (58.6)        | 329 (55.5)      |
| Female                   | 95 (48.0)                      | 87 (44.2)                       | 82 (41.4)         | 264 (44.5)      |
| Race, n (%)              |                                |                                 |                   |                 |
| White                    | 164 (82.8)                     | 153 (77.7)                      | 155 (78.3)        | 472 (79.6)      |
| Black                    | 2 (1.0)                        | 0                               | 3 (1.5)           | 5 (0.8)         |
| Asian                    | 23 (11.6)                      | 25 (12.7)                       | 26 (13.1)         | 74 (12.5)       |
| Other                    | 5 (2.5)                        | 9 (4.6)                         | 9 (4.5)           | 23 (3.9)        |
| Body mass index (kg/m?)  |                                |                                 |                   |                 |
| Mean (SD)                | 25.1 (5.1)                     | 25.5 (4.8)                      | 25.8 (4.9)        | 25.5 (4.9)      |
| Median                   | 24.5                           | 24.9                            | 24.9              | 24.7            |
| Range                    | 11.8 -49.1                     | 17.0-55.6                       | 17.4 - 43.5       | 11.8 -55.6      |
| Geographic region, n (%) |                                |                                 |                   |                 |
| Europe                   | 113 (57.1)                     | 121 (61.4)                      | 112 (56.6)        | 346 (58.3)      |
| North America            | 39 (19.7)                      | 44 (22.3)                       | 45 (22.7)         | 128 (21.6)      |
| Other                    | 46 (23.2)                      | 32 (16.2)                       | 41 (20.7)         | 119 (20.1)      |

Sources: 5.3.5.1 A3921096-rep0rt-body Table 14.1.2.1.1; Table 14.1.2.1.3.1.

Abbreviations: BID = twice a day; BMI = body mass index; FAS = full analysis set; N = number of subjects in the total population, n = number of subjects meeting criteria; SD = standard deviation.

BMI is defined as weight/(height x 0.01)?, with weight in kilograms and height in centimeters. Weight is from Week 8 of induction study and height and age are from screening of induction study.

Clinical characteristics for the FAS population were generally similar among the 3 treatment groups, similar proportions of subjects across the treatment groups were in remission at the baseline of Study A3921096. The mean Mayo score at baseline of Study A3921096 was 3.3 (SD: 1.8), with similar scores observed across treatment groups. The overall mean partial Mayo score at baseline was 1.8 (SD: 1.3), with similar scores across treatment groups.

<div style=\"page-break-after: always\"></div>

## Baseline Clinical Characteristics in Study A3921096 (FAS)

|                                                | Tofacitinib 5 mg BID (N=198)   | Tofacitinib 10 mg BID (N=197)   | Placebo (N=198)   | Total      |
|------------------------------------------------|--------------------------------|---------------------------------|-------------------|------------|
| Treatment assignment in induction study, n (%) |                                |                                 |                   | (N=593)    |
| N1                                             | 198                            | 197                             | 198               | 593        |
| Tofacitinib 10 mg and 15 mg                    | 176 (88.9)                     | 173 (87.8)                      | 174 (87.9)        | 523 (88.2) |
| Placebo                                        | 22 (11.1)                      | 24 (12.2)                       | 24 (12.1)         | 70 (11.8)  |
| Tofacitinib 10 mg                              | 170 (85.9)                     | 167 (84.8)                      | 167 (84.3)        | 504 (85.0) |
| Remission at baseline, n (%)                   |                                |                                 |                   |            |
| N1                                             | 198                            | 197                             | 198               | 593        |
| Yes                                            | 65 (32.8)                      | 55 (27.9)                       | 59 (29.8)         | 179 (30.2) |
| No                                             | 133 (67.2)                     | 142 (72.1)                      | 139 (70.2)        | 414 (69.8) |
| Mucosal healing at baseline, n (%)             |                                |                                 |                   |            |
| N1                                             | 198                            | 197                             | 198               | 593        |
| Yes                                            | 105 (53.0)                     | 89 (45.2)                       | 101 (51.0)        | 295 (49.7) |
| No                                             | 93 (47.0)                      | 108 (54.8)                      | 97 (49.0)         | 298 (50.3) |
| Mayo score                                     |                                |                                 |                   |            |
| N1                                             | 198                            | 197                             | 198               | 593        |
| Mean (SD)                                      | 3.3 (1.8)                      | 3.4 (1.8)                       | 3.3 (1.8)         | 3.3 (1.8)  |
| Partial Mayo score                             |                                |                                 |                   |            |
| N1                                             | 198                            | 197                             | 198               | 593        |
| Mean (SD)                                      | 1.8 (1.3)                      | 1.8 (1.3)                       | 1.8 (1.4)         | 1.8 (1.3)  |
| Baseline high sensitivity                      |                                |                                 |                   |            |
| C-reactive protein (mg/L)                      |                                |                                 |                   |            |
| N1                                             | 198                            | 196                             | 198               | N/A        |
| Mean (SD)                                      | 2.2 (3.8)                      | 4.0 (9.3)                       | 3.3 (6.1)         | N/A        |
| Median                                         | 0.69                           | 0.89                            | 1.00              | N/A        |
| Range                                          | 0.1 -33.7                      | 0.1-74.3                        | 0.1 - 45.0        | N/A        |
| Disease duration? (years)                      |                                |                                 |                   |            |
| N1                                             | 198                            | 197                             | 198               | 593        |
| Mean (SD)                                      | 8.3 (7.2)                      | 8.6 (7.0)                       | 8.8 (7.5)         | 8.6 (7.2)  |
| Median                                         | 6.5                            | 6.8                             | 7.2               | 6.8        |
| Range                                          | 0.6 -40.3                      | 0.6 - 35.7                      | 0.6 -42.7         | 0.6 -42.7  |
| Extent of disease, n (%)                       |                                |                                 |                   |            |
| N1                                             | 196                            | 196                             | 198               | 590        |
| Proctosigmoiditis                              | 28 (14.3)                      | 33 (16.8)                       | 21 (10.6)         | 82 (13.9)  |
| Left-sided colitis                             | 66 (33.7)                      | 60 (30.6)                       | 68 (34.3)         | 194 (32.9) |
| Extensive colitis or Pancolitis                | 102 (52.0)                     | 103 (52.6)                      | 108 (54.5)        | 313 (53.1) |
| Smoking, n (%)                                 |                                |                                 |                   |            |
| N1                                             | 198                            | 197                             | 198               | 593        |
| Never smoked                                   | 142 (71.7)                     | 128 (65.0)                      | 113 (57.1)        | 383 (64.6) |
| Curent smoker                                  | 7 (3.5)                        | 6 (3.0)                         | 12 (6.1)          | 25 (4.2)   |
| Ex-smoker                                      | 49 (24.7)                      | 63 (32.0)                       | 73 (36.9)         | 185 (31.2) |

Sources: 5.3.5.1 A3921096-report-body Table 14.1.2.1.3.2; Table 14.1.2.1.3.1; Table 14.1.2.2.

Abbreviations: BID = twice a day, FAS = full analysis set; N = number of randomized subjects in the total population; N1 = number of subjects in the specified category with non-missing values; n = number of subjects with the specified response within the given category, N/A = not available; % = n/N1; SD = standard deviation.

a.Disease duration is computed per Study A3921096 randomization date.

<div style=\"page-break-after: always\"></div>

Overall, previous treatment with TNFi agents was reported in 47.6% of enrolled subjects in Study A3921096, prior to entry in the induction studies, and the proportions of subjects were similar across the 3 treatment groups. Overall, corticosteroid use at baseline (48.7%) was comparable across treatment groups and the mean

## Prior drug treatment for UC in Study A3921096

| Treatment                                 | Tofacitinib 5 mg BID (N=198) n (%)   | Tofacitinib 10 mg BID (N=196) n (%)   | Placebo (N=198) n (%)   | Total (N=592) n (%)   |
|-------------------------------------------|--------------------------------------|---------------------------------------|-------------------------|-----------------------|
| Previous drug treatments for Uc?          |                                      |                                       |                         |                       |
| Biologics - TNFi                          | 90 (45.5)                            | 100 (51.0)                            | 92 (46.5)               | 282 (47.6)            |
| Failed drug treatments for UCb            |                                      |                                       |                         |                       |
| Biologics -- TNFi                         | 83 (41.9)                            | 92 (46.9)                             | 89 (44.9)               | 264 (44.6)            |
| Corticosteroids                           | 153 (77.3)                           | 158 (80.6)                            | 160 (80.8)              | 471 (79.6)            |
| Immunosuppressants                        | 143 (72.2)                           | 141 (71.9)                            | 129 (65.2)              | 413 (69.8)            |
| Oralcorticosteroid use at baseline, n (%) |                                      |                                       |                         |                       |
| N1                                        | 198                                  | 197                                   | 198                     | 593                   |
| Yes                                       | 101 (51.0)                           | 87 (44.2)                             | 101 (51.0)              | 289 (48.7)            |
| No                                        | 97 (49.0)                            | 110 (55.8)                            | 97 (49.0)               | 304 (51.3)            |

- Abbreviations: BID = twice a day; N = number of randomized subjects in the total population; N1 = number of subjects in the specified category with non-missing values; n = number of subjects with the specified response within the given category;, TNFi = tumor necrosis factor imhibitor; UC = ulcerative colitis.
- a. Analysis is based on data collected on Case Report Forms of induction studies for prior drug treatment for UC.
- b. Analysis is based on data collected in induction studies on Case Report Form of previous drug treatment for primary diagnosis, along with response to medication as inadequate response.

## Numbers analysed

The list of subjects to be excluded from the PPAS was defined prior to database lock based on a clinical review of the protocol deviations log. The categories of protocol deviations resulting in exclusion from the PPAS were consistent with those described in the SAP. All decisions regarding excluding subjects from evaluable populations because of protocol violations were made prior to unblinding.

36 (6.1%) subjects were excluded from the PPAS, including 15 (7.6%) from the tofacitinib 5 mg BID group, 11 (5.6%) from the tofacitinib 10 mg BID group, and 10 (5.1%) from the placebo group.

The most common reason for excluding subjects from the PPAS was: subject was discontinued from the study for an administrative reason. This occurred in 11 (73.3%) subjects in the tofacitinib 5 mg BID group; 7 (63.9%) subjects in the, tofacitinib 10 mg BID group; and 6 (60.0%) subjects in the placebo group.

Ten (10) subjects excluded from the PPAS were randomized although they did not demonstrate at least clinical response during the induction studies, including 5 (33.3%) subjects in the tofacitinib 5 mg BID group, 2 (18.2%) subjects in the tofacitinib 10 mg BID group, and 3 (30.0%) subjects in the placebo group.

<div style=\"page-break-after: always\"></div>

## Exclusions From the Per Protocol Population by Reason for Exclusion -FAS

|                                                                                                      | Tofacitinib5mgBID (N =198) n (%)   | Tofacitinib10mgBID (N =197) n (%)   | Placebo (N=198) n (%)   | (N=593) n (%)   |
|------------------------------------------------------------------------------------------------------|------------------------------------|-------------------------------------|-------------------------|-----------------|
| FAS                                                                                                  | 198 (100)                          | 197 (100)                           | 198 (100)               | 593 (100)       |
| Per PPAS                                                                                             | 183 (92.4)                         | 186 (94.4)                          | 188 (94.9)              | 557 (93.9)      |
| Subjectsexcludedfrom thePPAsa                                                                        | 15 (7.6)                           | 11 (5.6)                            | 10 (5.1)                | 36 (6.1)        |
| Reasonsforexclusiona                                                                                 |                                    |                                     |                         |                 |
| MissingWeek52Mayoscore                                                                               | 0                                  | 0                                   | 1 (10.0)                | 1 (2.8)         |
| Subject didnot achieve at least clinical responsein induction StudyA3921094orStudyA3921095           | 5 (33.3)                           | 2 (18.2)                            | 3 (30.0)                | 10 (27.8)       |
| Subjectdidnothaveahistoryof treatmentwithoral orIV corticosteroids,azathioprine or 6-MP,orTNFi agent | 0                                  | 1 (9.1)                             | 0                       | 1 (2.8)         |
| SubjectwasrandomizedbutdidnottakeanydoseofA3921096 studydrug                                         | 0                                  | 1 (9.1)                             | 0                       | 1 (2.8)         |
| Subject was discontinued from the studyfor an administrative reason                                  | 11 (73.3)                          | 7 (63.6)                            | 6 (60.0)                | 24 (66.7)       |

Source:Table14.2.1.2

Percentages forreasons for exclusion are based on the number of subjects excluded from PPAS.All other percentages are based on randomized subjects. BID=twice a day;FAS =full analysis set;IV=intravenous; 6-MP=6-mercaptopurine;N=number ofrandomized subjects; n =number of subjects meeting prespecified criteria;PPAS=per protocol analysis set;TNFi = tumor necrosis factor-alpha inhibitor.

a.Subjects may be counted in more than 1 exclusion criteria.

## Outcomes and estimation

Study A3921096 showed statistically significantly greater treatment effects for both treatment groups tofacitinib 5 mg BID and 10 mg BID versus placebo for remission at Week 52 (primary endpoint), mucosal healing at Week 52, and sustained corticosteroid free remission among subjects in remission at baseline (key secondary endpoints). Tofacitinib 5 mg BID and 10 mg BID also demonstrated statistically significantly higher proportions of subjects with clinical remission and clinical response compared with placebo. The 6 hypotheses of no difference from placebo for the primary endpoint and the 2 key secondary endpoints in both dose groups are all rejected based on the pre-specified multiple testing procedure.

<div style=\"page-break-after: always\"></div>

## Summary of Study A3921096 Efficacy Results at Week 52 (FAS, NRI, Central Read):

|                                                                              |            | DifferenceFromPlacebo   | DifferenceFromPlacebo   |
|------------------------------------------------------------------------------|------------|-------------------------|-------------------------|
| Endpoint Treatment                                                           | n (%)      | Difference (95% CI)     | P-valueb                |
| Remission                                                                    |            |                         |                         |
| Tofacitinib 5 mg BID (N=198)                                                 | 68 (34.3)  | 23.2 (15.3, 31.2)       | <0.0001                 |
| Tofacitinib 10 mg BID (N=197)                                                | 80 (40.6)  | 29.5 (21.4, 37.6)       | <0.0001                 |
| Placebo (N=198)                                                              | 22 (11.1)  |                         |                         |
| Mucosal Healing                                                              |            |                         |                         |
| Tofacitinib 5 mg BID (N=198)                                                 | 74 (37.4)  | 24.2 (16.0, 32.5)       | <0.0001                 |
| Tofacitinib 10 mg BID (N=197)                                                | 90 (45.7)  | 32.6 (24.2, 41.0)       | <0.0001                 |
| Placebo (N=198)                                                              | 26 (13.1)  |                         |                         |
| SustainedCorticosteroid-FreeRemission among Subjects inRemission at Baseline |            |                         |                         |
| Tofacitinib 5 mg BID (N=198)                                                 | 23 (35.4)  | 30.3 (17.4, 43.2)       | <0.0001                 |
| Tofacitinib 10 mg BID (N=197)                                                | 26 (47.3)  | 42.2 (27.9, 56.5)       | <0.0001                 |
| Placebo (N=198)                                                              | 3 (5.1)    |                         |                         |
| Clinical Remission                                                           |            |                         |                         |
| Tofacitinib 5 mg BID (N=198)                                                 | 68 (34.3)  | 23.2 (15.3, 31.2)       | <0.0001                 |
| Tofacitinib 10 mg BID (N=197)                                                | 81 (41.1)  | 30.0 (21.9, 38.2)       | <0.0001                 |
| Placebo (N=198)                                                              | 22 (11.1)  |                         |                         |
| Clinical Response                                                            |            |                         |                         |
| Tofacitinib 5 mg BID (N=198)                                                 | 102 (51.5) | 31.3 (22.4, 40.2)       | <0.0001                 |
| Tofacitinib 10 mg BID (N=197)                                                | 122 (61.9) | 41.7 (32.9, 50.5)       | <0.0001                 |
| Placebo (N=198)                                                              | 40 (20.2)  |                         |                         |
| Endoscopic Remission                                                         |            |                         |                         |
| Tofacitinib 5 mg BID (N=198)                                                 | 29 (14.6)  | 10.6 (5.0, 16.2)        | 0.0004                  |
| Tofacitinib 10 mg BID (N=197)                                                | 33 (16.8)  | 12.7 (6.8, 18.6)        | <0.0001                 |
| Placebo (N=198)                                                              | 8 (4.0)    |                         |                         |

Sources: 5.3.5.1 A3921096-report-body Table 14.2.2.1; Table 14.2.3.1; Table 14.2.4.1; Table 14.2.5.1.

Abbreviations: BID = twice a day; CI = confidence interval; FAS = full analysis set; N = number of subjects in the analysis set; n = number of subjects meeting the endpoint criteria; NRI = non-responder imputation.

Remission is defined as a Mayo score of 2 points or lower, with no individual subscores exceeding 1 point and a rectal bleeding subscore of 0.

Week 52 is defined as Day ≥337.

- a.The 95% CI is based on the normal approximation for the difference in binomial proportions.
- b. The p-value is based on Cochran-Mantel-Haenszel (CMH) chi-squared test stratified by treatment assignment in the induction study and remission at baseline.

## Dose response

The observed treatment effect was higher in the tofacitinib 10 mg BID group than the tofacitinib 5 mg BID group in the overall population for primary and key secondary endpoints.

## Proportion of subjects in remission at week 52 (primary endpoint)

<div style=\"page-break-after: always\"></div>

Table 21.Proportion of Subjects in Remission at Week 52 -FAS (NRI)

|                          | Placebo (N=198)   | Placebo (N=198)   | Tofacitinib5mgBID (N=198)   | Tofacitinib5mgBID (N=198)   | Tofacitinib5mgBID (N=198)   | Tofacitinib5mgBID (N=198)   | Tofacitinib10mgBID (N = 197)   | Tofacitinib10mgBID (N = 197)   | Tofacitinib10mgBID (N = 197)   | Tofacitinib10mgBID (N = 197)   |
|--------------------------|-------------------|-------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
|                          |                   |                   |                             |                             | DifferenceFromPlacebo       | DifferenceFromPlacebo       |                                |                                | DifferenceFromPlacebo          | DifferenceFromPlacebo          |
|                          | N1                | n (%)             | N1                          | n (%)                       | Diff (95% C1)               | p-value                     | N1                             | n (%)                          | Diff (95% C1)a                 | p-value                        |
| Remission Centrally-read | 198               | 22 (11.1)         | 198                         | 68 (34.3)                   | 23.2 (15.3,31.2)            | <0.0001                     | 197                            | 80 (40.6)                      | 29.5 (21.4, 37.6)              | <0.0001                        |
| Locally-read             | 198               | 26 (13.1)         | 198                         | 78 (39.4)                   | 26.3 (18.0,34.5)            | <0.0001                     | 197                            | 94 (47.7)                      | 34.6(26.2,43.0)                | <0.0001                        |

CnrcTk1141Th114511

There were statistically significantly more patients in remission at week 52 in both tofacitinib groups compared to placebo.

Table 23.Sunmary of Proportion of Subjects inRemission atWeek52by Subgroup-FAS (NRI, Centrally-Read)

|                                          | Placebo                                  | Placebo                                  | Tofacitinib5mgBID (N=198) (N=198)        | Tofacitinib5mgBID (N=198) (N=198)        | Tofacitinib5mgBID (N=198) (N=198)        | Tofacitinib5mgBID (N=198) (N=198)        | Tofacitinib10mgBID (N = 197)             | Tofacitinib10mgBID (N = 197)             | Tofacitinib10mgBID (N = 197)             | Tofacitinib10mgBID (N = 197)             |
|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|
|                                          |                                          |                                          |                                          |                                          | DifferenceFromPlacebo                    | DifferenceFromPlacebo                    |                                          |                                          | DifferenceFromPlacebo                    | DifferenceFromPlacebo                    |
|                                          | N1                                       | n (%)                                    | N1                                       | n (%)                                    | Diff (95% C1)                            | p-valuea                                 | N1                                       | n (%)                                    | Diff (95% CI)                            | p-valuea                                 |
| CharacteristicsatBaselineofStudyA392l096 | CharacteristicsatBaselineofStudyA392l096 | CharacteristicsatBaselineofStudyA392l096 | CharacteristicsatBaselineofStudyA392l096 | CharacteristicsatBaselineofStudyA392l096 | CharacteristicsatBaselineofStudyA392l096 | CharacteristicsatBaselineofStudyA392l096 | CharacteristicsatBaselineofStudyA392l096 | CharacteristicsatBaselineofStudyA392l096 | CharacteristicsatBaselineofStudyA392l096 | CharacteristicsatBaselineofStudyA392l096 |
| Treatment assignmentintheinductionstudy  | Treatment assignmentintheinductionstudy  | Treatment assignmentintheinductionstudy  | Treatment assignmentintheinductionstudy  | Treatment assignmentintheinductionstudy  | Treatment assignmentintheinductionstudy  | Treatment assignmentintheinductionstudy  | Treatment assignmentintheinductionstudy  | Treatment assignmentintheinductionstudy  | Treatment assignmentintheinductionstudy  | Treatment assignmentintheinductionstudy  |
| Tofacitinib10mgBID                       | 167                                      | 17 (10.2)                                | 170                                      | 55 (32.4)                                | 22.2 (13.8,30.6)                         | <0.0001                                  | 167                                      | 69 (41.3)                                | 31.1 (22.4,39.9)                         | <0.0001                                  |
| Tofacitinib10mgand 15 mg BID             | 174                                      | 18 (10.3)                                | 176                                      | 57 (32.4)                                | 22.0 (13.8, 30.3)                        | <0.0001                                  | 173                                      | 71 (41.0)                                | 30.7 (22.1,39.3)                         | <0.0001                                  |
| Placebo                                  | 24                                       | 4 (16.7)                                 | 22                                       | 11 (50.0)                                | 33.3 (7.7, 59.0)                         | 0.0160                                   | 24                                       | 9 (37.5)                                 | 20.8 (-3.6, 45.3)                        | 0.1044                                   |
| Inremissionatbaseline                    | Inremissionatbaseline                    | Inremissionatbaseline                    | Inremissionatbaseline                    | Inremissionatbaseline                    | Inremissionatbaseline                    | Inremissionatbaseline                    | Inremissionatbaseline                    | Inremissionatbaseline                    | Inremissionatbaseline                    | Inremissionatbaseline                    |
| Yes                                      | 59                                       | 6 (10.2)                                 | 65                                       | 30 (46.2)                                | 36.0 (21.6, 50.3)                        | <0.0001                                  | 55                                       | 31 (56.4)                                | 46.2 (31.0, 61.4)                        | <0.0001                                  |
| No                                       | 139                                      | 16 (11.5)                                | 133                                      | 38 (28.6)                                | 17.1 (7.7, 26.4)                         | 0.0004                                   | 142                                      | 49 (34.5)                                | 23.0 (13.5, 32.4)                        | <0.0001                                  |

The benefit was also seen when looking only at patients in remission at baseline, which is important for a maintenance of remission indications.

Benefit was also seen for those not in remission at baseline, showing that continued treatment of responders with tofacitinib can eventually lead to remission.

## Proportion of subjects in sustained corticosteroid-free remission among subjects in remission at baseline (key secondary endpoint and guideline recommended primary endpoint)

This is the primary endpoint recommended in the draft CHMP guideline when assessing a claim for maintenance of remission. The results in table 27 show that for patients who achieved remission in the induction trials, they are more likely to maintain that remission for 12 months without the use of steroids if treated with tofacitinib (either 5mg or 10mg) (p&lt;0.0001).

Table 27.Proportion ofSubjectsinSustainedCorticosteroid-FreeRemissionAmongSubjectsinRemission at Baseline -FAS (NRI)

|                | Placebo (N=198)   | Placebo (N=198)   | Tofacitinib5mgBID (N=198)   | Tofacitinib5mgBID (N=198)   | Tofacitinib5mgBID (N=198)   | Tofacitinib5mgBID (N=198)   | Tofacitinib10mgBID (N =197)   | Tofacitinib10mgBID (N =197)   | Tofacitinib10mgBID (N =197)   | Tofacitinib10mgBID (N =197)   |
|----------------|-------------------|-------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|
|                |                   | n (%)             |                             |                             | DifferenceFromPlacebo       | DifferenceFromPlacebo       |                               |                               | DifferenceFromPlacebo         | DifferenceFromPlacebo         |
|                | N1                |                   | N1                          | n (%)                       | %Diff (95% C1)              | p-valueb                    | N1                            | n (%)                         | Diff (95% C1)a                | p-valueb                      |
| Centrally-read | 59                | 3 (5.1)           | 65                          | 23 (35.4)                   | 30.3 (17.4, 43.2)           | <0.0001                     | 55                            | 26 (47.3)                     | 42.2(27.9,56.5)               | <0.0001                       |
| Locally-read   | 59                | 7 (11.9)          | 65                          | 31 (47.7)                   | 35.8 (21.1,50.5)            | <0.0001                     | 55                            | 32 (58.2)                     | 46.3 (30.9, 61.7)             | <0.0001                       |

## Proportion of subject with mucosal healing at week 52 (key secondary endpoint)

Table24. Proportion of Subjects With Mucosal Healing at Week 52 -FAS (NRI)

|                | Placebo (N=198)   | Placebo (N=198)   | Tofacitinib5mgBID (N =198)   | Tofacitinib5mgBID (N =198)   | Tofacitinib5mgBID (N =198)   | Tofacitinib5mgBID (N =198)   | Tofacitinib10mgBID (N = 197)   | Tofacitinib10mgBID (N = 197)   | Tofacitinib10mgBID (N = 197)   | Tofacitinib10mgBID (N = 197)   |
|----------------|-------------------|-------------------|------------------------------|------------------------------|------------------------------|------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
|                |                   |                   |                              |                              | DifferenceFromPlacebo        | DifferenceFromPlacebo        |                                |                                | DifferenceFromPlacebo          | DifferenceFromPlacebo          |
|                | N1                | n (%)             | N1                           | n (%)                        | Diff (95% CI)                | p-value                      | N1                             | n (%)                          | Diff (95% C1)                  | p-value                        |
| MucosalHealing |                   |                   |                              |                              |                              |                              |                                |                                |                                |                                |
| Centrally-read | 198               | 26 (13.1)         | 198                          | 74 (37.4)                    | 24.2 (16.0, 32.5)            | <0.0001                      | 197                            | 90 (45.7)                      | 32.6 (24.2, 41.0)              | <0.0001                        |
| Locally-read   | 198               | 31 (15.7)         | 198                          | 89 (44.9)                    | 29.3 (20.7, 37.9)            | <0.0001                      | 197                            | 106 (53.8)                     | 38.2 (29.5, 46.8)              | <0.0001                        |

Cmrc.T1141Tk11A511

<div style=\"page-break-after: always\"></div>

There were statistically significantly more patients with mucosal healing at week 52 in both tofacitinib groups compared to placebo.

Table26.Summaryof Proportionof SubjectsWithMucosalHealingatWeek52bySubgroup-FAS(NRI,Centrally-Read)

|                                          | Placebo                                  | Placebo                                  | Tofacitinib5mgBID (N = 198) (N=198)      | Tofacitinib5mgBID (N = 198) (N=198)      | Tofacitinib5mgBID (N = 198) (N=198)      | Tofacitinib5mgBID (N = 198) (N=198)      | Tofacitinib10mgBID (N = 197)             | Tofacitinib10mgBID (N = 197)             | Tofacitinib10mgBID (N = 197)             | Tofacitinib10mgBID (N = 197)             |
|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|
|                                          |                                          |                                          |                                          |                                          | DifferenceFromPlacebo                    | DifferenceFromPlacebo                    |                                          |                                          | DifferenceFromPlacebo                    | DifferenceFromPlacebo                    |
|                                          | N1                                       | n (%)                                    | N1                                       | n (%)                                    | Diff (95% CI)                            | p-valuea                                 | N1                                       | n (%)                                    | Diff(95%CI)                              | p-valuea                                 |
| CharacteristicsatBaselineofStudyA392l096 | CharacteristicsatBaselineofStudyA392l096 | CharacteristicsatBaselineofStudyA392l096 | CharacteristicsatBaselineofStudyA392l096 | CharacteristicsatBaselineofStudyA392l096 | CharacteristicsatBaselineofStudyA392l096 | CharacteristicsatBaselineofStudyA392l096 | CharacteristicsatBaselineofStudyA392l096 | CharacteristicsatBaselineofStudyA392l096 | CharacteristicsatBaselineofStudyA392l096 | CharacteristicsatBaselineofStudyA392l096 |
| Treatmentassignmentintheinductionstudy   | Treatmentassignmentintheinductionstudy   | Treatmentassignmentintheinductionstudy   | Treatmentassignmentintheinductionstudy   | Treatmentassignmentintheinductionstudy   | Treatmentassignmentintheinductionstudy   | Treatmentassignmentintheinductionstudy   | Treatmentassignmentintheinductionstudy   | Treatmentassignmentintheinductionstudy   | Treatmentassignmentintheinductionstudy   | Treatmentassignmentintheinductionstudy   |
| Tofacitinib10mgBID                       | 167                                      | 21 (12.6)                                | 170                                      | 61 (35.9)                                | 23.3 (14.5, 32.1)                        | <0.0001                                  | 167                                      | 78 (46.7)                                | 34.1 (25.0, 43.2)                        | <0.0001                                  |
| Tofacitinib10mgand 15 mgBID              | 174                                      | 22 (12.6)                                | 176                                      | 63 (35.8)                                | 23.2 (14.5, 31.8)                        | <0.0001                                  | 173                                      | 80 (46.2)                                | 33.6 (24.7, 42.5)                        | <0.0001                                  |
| Placebo                                  | 24                                       | 4 (16.7)                                 | 22                                       | 11 (50.0)                                | 33.3 (7.7,59.0)                          | 0.0160                                   | 24                                       | 10 (41.7)                                | 25.0 (0.3, 49.7)                         | 0.0567                                   |
| Inremissionatbaseline                    | Inremissionatbaseline                    | Inremissionatbaseline                    | Inremissionatbaseline                    | Inremissionatbaseline                    | Inremissionatbaseline                    | Inremissionatbaseline                    | Inremissionatbaseline                    | Inremissionatbaseline                    | Inremissionatbaseline                    | Inremissionatbaseline                    |
| Yes                                      | 59                                       | 6 (10.2)                                 | 65                                       | 32 (49.2)                                | 39.1 (24.7, 53.5)                        | <0.0001                                  | 55                                       | 32 (58.2)                                | 48.0 (32.9, 63.2)                        | <0.0001                                  |
| No                                       | 139                                      | 20 (14.4)                                | 133                                      | 42 (31.6)                                | 17.2 (7.4,27.0)                          | 0.0007                                   | 142                                      | 58 (40.8)                                | 26.5 (16.5, 36.4)                        | <0.0001                                  |

The benefit was also seen when looking only at patients in remission at baseline, which is important for a maintenance of remission indications.

## Ancillary analyses

The efficacy of tofacitinib 5 mg BID and 10 mg BID as maintenance therapy was supported by all other secondary and exploratory efficacy endpoints, various analysis populations, sensitivity analyses, and locallyread endoscopic findings. For all efficacy endpoints, the efficacy results based on the mFAS, which excluded subjects who received placebo in the induction studies, were consistent with the results based on the FAS.

For remission, greater observed treatment effects were demonstrated for both tofacitinib 5 mg BID and 10 mg BID versus placebo at Week 52 in subjects with baseline remission than without baseline remission, with lower baseline Mayo or partial Mayo score than with higher baseline Mayo or partial Mayo score, with lower baseline C-reactive protein (CRP) than with higher baseline CRP, without baseline corticosteroid use than with baseline corticosteroid use, and without prior TNFi use or failure than with prior TNFi use or failure.

At Week 4, which was the first post-baseline timepoint assessed, partial Mayo score worsened in the placebo group when compared with both tofacitinib treatment groups.

Time to treatment failure was statistically significantly different in the tofacitinib 5 mg BID and 10 mg BID treatment groups compared with placebo, with earlier and more frequent events in the placebo group.

Study A3921096 demonstrated maintenance of statistically significant improvements in the IBDQ, SF-36, and WPAI scores for both treatment groups versus placebo from the first measured timepoint through Week 52.

The proportion of subjects who had treatment failure was lower in both tofacitinib groups compared to the proportion of subjects in the placebo group at each timepoint starting from Week 8, the first time point where treatment failure was assessed, through the entire 52-week study

Remission, Mucosal Healing, Sustained Corticosteroid-Free Remission Among Maintenance Baseline Remitters at Week 52 in Study A3921096 for Tofacitinib 5 mg BID or 10 mg BID Versus Placebo by Subgroup (Central Read):

<div style=\"page-break-after: always\"></div>

Sources: 5.3.5.1 A3921096-report-body Table 14.2.2.4; Table 14.2.2.5; Table 14.2.3.4; Table 14.2.3.5; Table 14.2.4.3; Table 14.2.4.4; additional analyses Table 3.1.1.b; Table 3.1.3.b; Table 3.2.1.b; Table 3.2.3.b.

<!-- image -->

Abbreviations: AE = adverse event; BID = twice a day; CI = confidence interval; FAS = full analysis set; LOE = lack of efficacy; N = number of subjects in each group and used as denominator in percentage calculation; NRI = non-responder imputation; TNFi = tumor necrosis factor inhibitor.

## FAS, NRI.

- a. The 95% CI is based on the normal approximation for the difference in binomial proportions.
- b. Primary non-response included subjects whose failure reason was LOE or both AE/LOE, failure to achieve a response. Secondary non-response included subjects whose failure reason was LOE or both AE/LOE, failure to maintain a sustained response.

Subgroup analyses by prior TNFi status demonstrated that a treatment effect was observed in those with prior TNFi failure and even in the most refractory TNFi subgroup, i.e., those with primary non-response to TNFi. The magnitude of observed treatment effects was similar for subjects treated with tofacitinib 5 mg BID and tofacitinib 10 mg BID in the subgroups of subjects without prior TNFi exposure or failure. In contrast, there was a clinically meaningful observed treatment difference between tofacitinib 10 mg BID and 5 mg BID in the subgroup of subjects with prior TNFi failure, with differences between the 2 tofacitinib groups ranging from 9.7 to 16.7 percentage points across the primary and key secondary endpoints.

<div style=\"page-break-after: always\"></div>

## Remission at Week 52 in Study A3921096 for Tofacitinib 5 mg BID or 10 mg BID Versus Placebo by TNFi Exposure/Failure Subgroup (FAS, NRI, Central Read)

|                            | Placebo (N=198)   | Placebo (N=198)   | Tofacitinib 5mg BID (N=198)   | Tofacitinib 5mg BID (N=198)   | Tofacitinib 5mg BID (N=198)     | Tofacitinib 10 mg BID (N=197)   | Tofacitinib 10 mg BID (N=197)   | Tofacitinib 10 mg BID (N=197)   |
|----------------------------|-------------------|-------------------|-------------------------------|-------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Subgroup                   | N1                | n (%)             | N1                            | n (%)                         | DifferenceFrom Placebo (95% C1) | N1                              | n (%)                           | DifferenceFrom Placebo (95% C1  |
| Prior TNFi exposure?       |                   |                   |                               |                               |                                 |                                 |                                 |                                 |
| No                         | 106               | 11 (10.4)         | 108                           | 44 (40.7)                     | 30.4 (19.4, 41.3)               | 96                              | 43 (44.8)                       | 34.4 (22.9, 45.9)               |
| Yes                        | 92                | 11 (12.0)         | 90                            | 24 (26.7)                     | 14.7 (3.4, 26.0)                | 101                             | 37 (36.6)                       | 24.7 (13.2, 36.2)               |
| Prior TNFi failure         |                   |                   |                               |                               |                                 |                                 |                                 |                                 |
| No                         | 109               | 12 (11.0)         | 115                           | 48 (41.7)                     | 30.7 (20.0, 41.5)               | 104                             | 46 (44.2)                       | 33.2 (22.0, 44.4)               |
| Yes                        | 89                | 10 (11.2)         | 83                            | 20 (24.1)                     | 12.9 (1.6, 24.2)                | 93                              | 34 (36.6)                       | 25.3 (13.5, 37.1)               |
| PriorTNFi failurebyreasona |                   |                   |                               |                               |                                 |                                 |                                 |                                 |
| Primarynon-responder       | 46                | 5 (10.9)          | 39                            | 9 (23.1)                      | 12.2 (-3.8, 28.2)               | 49                              | 15 (30.6)                       | 19.7 (4.0, 35.5)                |
| Secondarynon-responder     | 34                | 4 (11.8)          | 36                            | 9 (25.0)                      | 13.2 (-4.6, 31.0)               | 41                              | 17 (41.5)                       | 29.7 (11.1, 48.3)               |

Source:5.3.5.1 A3921096-report-body Table 14.2.2.4;Table 14.2.2.5;and 5.3.5.1 A3921096-additional-analysesTable 3.1.1.b;Tab1e 3.1.3.b.

The95%CIis based on the normalapproximationfor the difference inbinomialproportions.

Remission (n) is defined as a Mayo score of 2 points orlower,with no individual subscores exceeding 1 point and a rectal bleeding subscore of 0.

a.Datafrombaselineofinductionstudies.

## Mucosal Healing at Week 52 in Study A3921096 for Tofacitinib 5 mg BID or 10 mg BID Versus Placebo by TNFi Exposure/Failure Subgroup (FAS, NRI, Central Read)

|                               | Placebo (N=198)   | Placebo (N=198)   | Tofacitinib 5 mg BID (N=198)   | Tofacitinib 5 mg BID (N=198)   | Tofacitinib 5 mg BID (N=198)    | Tofacitinib 10 mg BID (N=197)   | Tofacitinib 10 mg BID (N=197)   | Tofacitinib 10 mg BID (N=197)   |
|-------------------------------|-------------------|-------------------|--------------------------------|--------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Subgroup                      | N1                | n (%)             | N1                             | n (%)                          | DifferenceFrom Placebo (95% C1) | N1                              | n (%)                           | DifferenceFrom Placebo (95% C1) |
| Prior TNFi exposure?          |                   |                   |                                |                                |                                 |                                 |                                 |                                 |
| No                            | 106               | 14 (13.2)         | 108                            | 45 (41.7)                      | 28.5 (17.1, 39.8)               | 96                              | 50 (52.1)                       | 38.9 (27.0, 50.8)               |
| Yes                           | 92                | 12 (13.0)         | 90                             | 29 (32.2)                      | 19.2 (7.3, 31.0)                | 101                             | 40 (39.6)                       | 26.6 (14.8,38.3)                |
| Prior TNFi failure?           |                   |                   |                                |                                |                                 |                                 |                                 |                                 |
| No                            | 109               | 15 (13.8)         | 115                            | 49 (42.6)                      | 28.8 (17.7, 40.0)               | 104                             | 53 (51.0)                       | 37.2 (25.6, 48.8)               |
| Yes                           | 89                | 11 (12.4)         | 83                             | 25 (30.1)                      | 17.8 (5.8, 29.8)                | 93                              | 37 (39.8)                       | 27.4 (15.4, 39.5)               |
| Prior TNFi failure by reasona |                   |                   |                                |                                |                                 |                                 |                                 |                                 |
| Primarynon-responder          | 46                | 5 (10.9)          | 39                             | 11 (28.2)                      | 17.3 (0.6, 34.1)                | 49                              | 18 (36.7)                       | 25.9 (9.6, 42.1)                |
| Secondarynon-responder        | 34                | 5 (14.7)          | 36                             | 12 (33.3)                      | 18.6 (-0.8,38.1)                | 41                              | 17 (41.5)                       | 26.8 (7.5, 46.0)                |

Source:5.3.5.1A3921096-report-body Table 14.2.3.4;Table14.2.3.5; and 5.3.5.1 A3921096-additional-analysesTable 3.2.1.b;Table 3.2.3.b.

Abbreviations: BID = twice a day; CI = confidence interval; FAS =full analysis set; N = number of subjects in the analysis set; n = number of subjects meeting criteria; N1 = number of subjects in each group and used as denominator in percentage calculation; NRI = non-responder imputation; TNFi= tumor necrosis factor inhibitor.

The 95% CI is based on the normal approximation for the difference in binomial proportions.

Mucosal healing(n)is defined by Mayo endoscopic subscore of0or 1.

a.Datafrombaselineofinductionstudies.

Sustained Corticosteroid-Free Remission at Both Weeks 24 and 52 in Study A3921096 Among Subjects in Remission at Baseline for Tofacitinib 5 mg BID or 10 mg BID Versus Placebo by TNFi Exposure/Failure Subgroup (FAS, NRI, Central Read)

<div style=\"page-break-after: always\"></div>

|                     | Placebo (N=198)   | Placebo (N=198)   | Tofacitinib5mgBID (N=198)   | Tofacitinib5mgBID (N=198)   | Tofacitinib5mgBID (N=198)      | Tofacitinib10mgBID (N=197)   | Tofacitinib10mgBID (N=197)   | Tofacitinib10mgBID (N=197)    |
|---------------------|-------------------|-------------------|-----------------------------|-----------------------------|--------------------------------|------------------------------|------------------------------|-------------------------------|
| Subgroup            | N1                | n (%)             | N1                          | n (%)                       | DifferenceFrom Placebo (95%CI) | N1                           | n (%)                        | DifferenceFrom Placebo(95%C1) |
| Prior TNFi exposure |                   |                   |                             |                             |                                |                              |                              |                               |
| No                  | 36                | 1 (2.8)           | 43                          | 17 (39.5)                   | 36.8 (21.2, 52.3)              | 34                           | 17 (50.0)                    | 47.2 (29.6, 64.9)             |
| Yes                 | 23                | 2 (8.7)           | 22                          | 6 (27.3)                    | 18.6 (-3.3, 40.5)              | 21                           | 9 (42.9)                     | 34.2 (10.1, 58.3)             |
| PriorTNFi failure   |                   |                   |                             |                             |                                |                              |                              |                               |
| No                  | 38                | 2 (5.3)           | 47                          | 19 (40.4)                   | 35.2 (19.4, 50.9)              | 37                           | 19 (51.4)                    | 46.1 (28.5, 63.7)             |
| Yes                 | 21                | 1 (4.8)           | 18                          | 4 (22.2)                    | 17.5(-3.8, 38.7)               | 18                           | 7 (38.9)                     | 34.1 (9.8, 58.4)              |

Source:5.3.5.1A3921096-report-body Table14.2.4.3;Table14.2.4.4

Abbreviations:BID=twice a day;CI=confidence interval;FAS=full analysis set;N=number of subjects in remission at baseline,regardless of steroid use at baseline;n=number of subjects meeting criteria;N1=number of subjects in each group and used as denominatorin percentage calculation;NRI =nonresponderimputation;TNFi=tumornecrosisfactorinhibitor.

The95%CIisbasedonthenormalapproximationforthedifferenceinbinomialproportions.

Sustained corticosteroid-free remission among subjects in remission at baseline (n) is defined by subjects in remission at Study A3921096baseline who are also in remissionwithnocorticosteroidsforat 1east 4weekspriortobothWeek24andWeek 52.

a.Datafrombaselineofinductionstudies.

A Kaplan-Meier plot of time to treatment failure (FAS) shows earlier and more frequent treatment failure in placebo subjects compared with both tofacitinib groups.

Analysis of time to treatment failure (FAS) as an estimated rate (number of treatment failure events/number of subjects at risk)  was performed.  By Week 8, there was a statistically significant difference in the rates of treatment failure between the placebo group and both of the tofacitinib treatment groups. At Week 8, the placebo group had a higher estimated treatment failure rate (23.6%) compared with the tofacitinib 5 mg BID and 10 mg BID groups (7.0% and 5.2%, respectively). At Week 52, the rates were 73.0%, 41.9%, and 31.2% in placebo, tofacitinib 5 mg BID, and 10 mg BID groups, respectively.

Kaplan-Meier Plot of Time to Treatment Failure - FAS

<!-- image -->

Source:Figure14.3.6.2

P-valuewasbased on thelog-rank teststratified by treatment assignment in theinduction study(tofacitinib,placebo)andremission at baseline(yes,no). Subjectsthatdiscontinued thestudyduetothereasonofinsufficientclinicalresponsequalifiedfortheeventoftreatmentfailure.

BID=twicedaily;FAS=full analysis sct;Vs=versus.

<div style=\"page-break-after: always\"></div>

## Summary of Study efficacy endpoints for tofacitinib 5 mg and 10 mg BID treatment groups (FAS, NRI):

|                                                                                                                 | Placebo (N=198)   | Tofacitinib5mgBID (N = 198)   | Tofacitinib5mgBID (N = 198)      | Tofacitinib5mgBID (N = 198)   | Tofacitinib10mgBID (N = 197)   | Tofacitinib10mgBID (N = 197)    | Tofacitinib10mgBID (N = 197)   |
|-----------------------------------------------------------------------------------------------------------------|-------------------|-------------------------------|----------------------------------|-------------------------------|--------------------------------|---------------------------------|--------------------------------|
|                                                                                                                 | n/N1 (%)          | n/N1 (%)                      | Difference from placebo (95% CI) | p-Value                       | n/N1 (%)                       | Difference fromplacebo (95% CI) | p-Value                        |
| Primary endpoint: remission at Week 52                                                                          |                   |                               |                                  |                               |                                |                                 |                                |
| Central read                                                                                                    | 22/198 (11.1)     | 68/198 (34.3)                 | 23.2 (15.3, 31.2)                | <0.0001                       | 80/197 (40.6)                  | 29.5 (21.4, 37.6)               | <0.0001                        |
| Local read                                                                                                      | 26/198 (13.1)     | 78/198 (39.4)                 | 26.3 (18.0, 34.5)                | <0.0001                       | 94/197 (47.7)                  | 34.6 (26.2, 43.0)               | <0.0001                        |
| Keysecondaryendpoint: MucosalhealingatWeek52                                                                    |                   |                               |                                  |                               |                                |                                 |                                |
| Central read                                                                                                    | 26/198 (13.1)     | 74/198 (37.4)                 | 24.2 (16.0, 32.5)                | <0.0001                       | 90/197 (45.7)                  | 32.6 (24.2, 41.0)               | <0.0001                        |
| Local read                                                                                                      | 31/198 (15.7)     | 89/198 (44.9)                 | 29.3 (20.7, 37.9)                | <0.0001                       | 106/197 (53.8)                 | 38.2 (29.5, 46.8)               | <0.0001                        |
| Keysecondaryendpoint: Sustainedcorticosteroid-freeremissionatbothWeeks24and52amongsubjectsinremissionatbaseline |                   |                               |                                  |                               |                                |                                 |                                |
| Central read                                                                                                    | 3/59 (5.1)        | 23/65 (35.4)                  | 30.3 (17.4, 43.2)                | <0.0001                       | 26/55 (47.3)                   | 42.2 (27.9, 56.5)               | <0.0001                        |
| Local read                                                                                                      | 7/59 (11.9)       | 31/65 (47.7)                  | 35.8 (21.1, 50.5)                | <0.0001                       | 32/55 (58.2)                   | 46.3 (30.9, 61.7)               | <0.0001                        |

95%CI based on the normal approximationfor the difference inbinomial proportions.

The p-value for remission and mucosal healing was based on CMH chi-squared test stratified by treatment assignment in the induction study (tofacitinib, placebo) and remission at baseline (Yes, No).

Cochran-Mantel-Haenszel(CMH) chi-squared test stratified by treatment assignment in theinduction study(tofacitinib, placebo).

BID=twice daily;CI=confidenceinterval;CMH=Cochran-Mantel-Haenzel;FAS=fullanalysisset;N=number of subjectsin the analysis set;N1 =number of subjects in remission at baseline,regardless of steroid use at baseline;n = number of subjects meeting the endpoint criteria; NRI = non-responder imputation.

## Patient Related Outcomes

Inflammatory Bowel Disease Questionnaire:

Mean observed IBDQ total scores in Study A3921096 were similar among the 3 treatment groups at baseline of the study. At the last visit, mean IBDQ total score was 167.8 for the tofacitinib 5 mg BID group, 171.6 for the tofacitinib 10 mg BID group, and 133.2 for the placebo group.

Both the tofacitinib 5 mg BID and 10 mg BID groups showed statistically significantly greater improvements than placebo in IBDQ total score at all timepoints analysed (Weeks 8, 16, 24, 32, 40, and 52) of Study A3921096 (Table 61). A similar result was seen for the 4 domain scores at the timepoints.

Statistically significantly more subjects in both the tofacitinib 5 mg BID and 10 mg BID groups had IBDQ scores ≥ 170 (IBDQ remission) compared with the placebo group at all timepoints analysed (Weeks 8, 16, 24, 32, 40, and 52). A similar result was seen for IBDQ response ( ≥ 16 point increase in IBDQ total score from induction baseline) at the timepoints analysed.

## Short Form-36:

<div style=\"page-break-after: always\"></div>

Statistically significant improvement was demonstrated at Weeks 24 and 52 for both the tofacitinib 5 mg BID and 10 mg BID groups relative to the placebo group for the SF-36 components in Study A3921096. A similar result was seen for all SF-36 domains at Weeks 24 and 52.

Work Productivity and Activity Impairment - Ulcerative Colitis:

There was a statistically significant difference between each of the tofacitinib treatment groups and placebo at Week 52 in presenteeism and non-work activity impairment. The tofacitinib treatment groups also showed greater effect on absenteeism and work productivity loss; however, the differences versus placebo were not statistically significant.

Euro Quality of Life 5 Dimensions/Visual Analog Scale:

EQ-5D Utility Index observed mean scores in Study A3921096 were similar between the treatment groups at baseline of each study: 0.87 for tofacitinib 5 mg BID, 0.86 for tofacitinib 10 mg BID, and 0.85 for placebo. Similarly, EQ-5D VAS observed mean scores at baseline were 76.19 for tofacitinib 5 mg BID, 76.19 for tofacitinib 10 mg BID, and 77.23 for placebo.

There was a statistically significant difference between each of the tofacitinib treatment groups and placebo in Utility Index score and VAS score at Weeks 24 and 52. Similar results were observed at other timepoints (Weeks 8, 16, 32, and 40).

## Summary of main studies

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

## Table Summary of efficacy for trial A3921094

| Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral CP-690,550 as an Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis   | Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral CP-690,550 as an Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis   | Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral CP-690,550 as an Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                             | Study A3921094                                                                                                                                                                               | Study A3921094                                                                                                                                                                               |
| Design                                                                                                                                                                                       | Phase 3 randomized, multicenter, double-blind DB, placebo controlled, parallel-group induction therapy study                                                                                 | Phase 3 randomized, multicenter, double-blind DB, placebo controlled, parallel-group induction therapy study                                                                                 |
|                                                                                                                                                                                              | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                               | 8weeks not applicable not applicable                                                                                                                                                         |
| Hypothesis                                                                                                                                                                                   | No treatment effect between the tofacitinib 10 mg BID and the placebo                                                                                                                        | No treatment effect between the tofacitinib 10 mg BID and the placebo                                                                                                                        |
| Treatments groups                                                                                                                                                                            | Tofacitinib 10 mg BID                                                                                                                                                                        | 476                                                                                                                                                                                          |
| Treatments groups                                                                                                                                                                            | Placebo BID                                                                                                                                                                                  | 122                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| Endpoints and definitions   | Primary       | Remission                                              | Remission was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0 at week 8                                                                                                     |
|-----------------------------|---------------|--------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Endpoints and definitions   | Key secondary | Mucosal healing                                        | Mucosal healing was defined by a Mayo endoscopic subscore of 0 or 1. The key secondary endpoint analysis was based on the centrally read endoscopic score at Week 8                                                                                               |
| Endpoints and definitions   | Secondary     | Clinical response                                      | Clinical response was defined by a decrease from baseline in Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the subscore for rectal bleeding of at least 1 point or absolute subscore for rectal bleeding of 0 or 1 at week 8 |
| Endpoints and definitions   | Secondary     | Endoscopic remission                                   | Endoscopic remission was defined by a Mayo endoscopic subscore of 0;at week 8                                                                                                                                                                                     |
|                             | Secondary     | Clinical remission                                     | Clinical remission was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point, at week 8                                                                                                                               |
|                             | Secondary     | Symptomatic remission                                  | Symptomatic remission was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point, and both rectal bleeding and stool frequency subscore of 0; Week 8.                                                                  |
|                             | Secondary     | Deep remission                                         | Deep remission was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a 0 on both endoscopic and rectal bleeding subscores;                                                                                    |
|                             | Secondary     | Partial Mayo scores and change from baseline over time | The Mayo score includes all 4 components and ranges from 0 to 12, whereas the partial Mayo score excludes the endoscopic subscore and ranges from 0 to 9.                                                                                                         |

<div style=\"page-break-after: always\"></div>

|                                                | Secondary                                                                                                                                                                | Change from baseline at Week 8 in total Mayo score                                                                                                                       | Mayo Scoring System consists of 4 subscores, each graded from 0 to 3, with higher scores indicating more severe disease activity: stool frequency (0-3), rectal bleeding (0-3), endoscopic assessment (0- 3), and physician global assessment (0-3). The Mayo score includes all 4 components and ranges from 0 to 12   | Mayo Scoring System consists of 4 subscores, each graded from 0 to 3, with higher scores indicating more severe disease activity: stool frequency (0-3), rectal bleeding (0-3), endoscopic assessment (0- 3), and physician global assessment (0-3). The Mayo score includes all 4 components and ranges from 0 to 12   |
|------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Database lock                                  | 25 th May Study report date                                                                                                                                              | 25 th May Study report date                                                                                                                                              | 25 th May Study report date                                                                                                                                                                                                                                                                                             | 25 th May Study report date                                                                                                                                                                                                                                                                                             |
| Results and Analysis                           | Results and Analysis                                                                                                                                                     | Results and Analysis                                                                                                                                                     | Results and Analysis                                                                                                                                                                                                                                                                                                    | Results and Analysis                                                                                                                                                                                                                                                                                                    |
| Analysis description                           | Primary Analysis                                                                                                                                                         | Primary Analysis                                                                                                                                                         | Primary Analysis                                                                                                                                                                                                                                                                                                        | Primary Analysis                                                                                                                                                                                                                                                                                                        |
| Analysis population and time point description | The primary analysis population for efficacy endpoints was the final analysis set, defined as all subjects randomly assigned to either tofacitinib 10 mg BID or placebo. | The primary analysis population for efficacy endpoints was the final analysis set, defined as all subjects randomly assigned to either tofacitinib 10 mg BID or placebo. | The primary analysis population for efficacy endpoints was the final analysis set, defined as all subjects randomly assigned to either tofacitinib 10 mg BID or placebo.                                                                                                                                                | The primary analysis population for efficacy endpoints was the final analysis set, defined as all subjects randomly assigned to either tofacitinib 10 mg BID or placebo.                                                                                                                                                |
| Number of subject                              | 476                                                                                                                                                                      | 122                                                                                                                                                                      | 122                                                                                                                                                                                                                                                                                                                     | Placebo                                                                                                                                                                                                                                                                                                                 |
| Number of subject                              | Number of subject                                                                                                                                                        | 476                                                                                                                                                                      | 476                                                                                                                                                                                                                                                                                                                     | 122                                                                                                                                                                                                                                                                                                                     |
| Number of subject                              | Remission%                                                                                                                                                               | 18.5                                                                                                                                                                     | 18.5                                                                                                                                                                                                                                                                                                                    | 8.2                                                                                                                                                                                                                                                                                                                     |
| Number of subject                              | Number of subject                                                                                                                                                        | 476                                                                                                                                                                      | 476                                                                                                                                                                                                                                                                                                                     | 122                                                                                                                                                                                                                                                                                                                     |
| Number of subject                              | Mucosal healing %                                                                                                                                                        | 31.3                                                                                                                                                                     | 31.3                                                                                                                                                                                                                                                                                                                    | 15.6                                                                                                                                                                                                                                                                                                                    |
| Number of subject                              | Number of subject                                                                                                                                                        | 476                                                                                                                                                                      | 476                                                                                                                                                                                                                                                                                                                     | 122                                                                                                                                                                                                                                                                                                                     |
| Number of subject                              | Clinical response %                                                                                                                                                      | 59.9                                                                                                                                                                     | 59.9                                                                                                                                                                                                                                                                                                                    | 32.8                                                                                                                                                                                                                                                                                                                    |
| Number of subject                              | Number of subject                                                                                                                                                        | 476                                                                                                                                                                      | 476                                                                                                                                                                                                                                                                                                                     | 122                                                                                                                                                                                                                                                                                                                     |
| Number of subject                              | Endoscopic remission%                                                                                                                                                    | 6.7                                                                                                                                                                      | 6.7                                                                                                                                                                                                                                                                                                                     | 1.6                                                                                                                                                                                                                                                                                                                     |
| Number of subject                              | Number of subject                                                                                                                                                        | 476                                                                                                                                                                      | 476                                                                                                                                                                                                                                                                                                                     | 122                                                                                                                                                                                                                                                                                                                     |
| Number of subject                              | Clinical remission                                                                                                                                                       | 18.5                                                                                                                                                                     | 18.5                                                                                                                                                                                                                                                                                                                    | 8.2                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|                                | Number of subject                                    | 476                                           | 122                                           | 122                              |                                  |
|--------------------------------|------------------------------------------------------|-----------------------------------------------|-----------------------------------------------|----------------------------------|----------------------------------|
|                                | Symptomatic remission                                | 11.8                                          | 5.7                                           | 5.7                              |                                  |
|                                | Number of subject                                    | 476                                           | 122                                           | 122                              |                                  |
|                                | Deep remission                                       | 10.3                                          | 2.5                                           | 2.5                              |                                  |
|                                | Number of subject                                    | 448                                           | 118                                           | 118                              |                                  |
|                                | Change from baseline at Week 8 in Partial Mayo score | -3.1                                          | -1.6                                          | -1.6                             |                                  |
|                                | Number of subject                                    | 446                                           | 117                                           | 117                              |                                  |
|                                | Change from baseline at Week 8 in total Mayo score   | -3.8                                          | -1.8                                          | -1.8                             |                                  |
| Effect estimate per comparison | Primary Remission Comparison groups                  | Primary Remission Comparison groups           | Primary Remission Comparison groups           | Tofacitinib 10 mg BID vs placebo | Tofacitinib 10 mg BID vs placebo |
| Effect estimate per comparison | Difference                                           | Difference                                    | Difference                                    | 10.3                             | 10.3                             |
| Effect estimate per comparison | 95% CI                                               | 95% CI                                        | 95% CI                                        | 4.3, 16.3                        | 4.3, 16.3                        |
| Effect estimate per comparison | P-value                                              | P-value                                       | P-value                                       | 0.0070                           | 0.0070                           |
| Effect estimate per comparison | Mucosal healing Comparison groups                    | Mucosal healing Comparison groups             | Mucosal healing Comparison groups             | Tofacitinib 10 mg BID vs placebo | Tofacitinib 10 mg BID vs placebo |
| Effect estimate per comparison | Difference                                           | Difference                                    | Difference                                    | 15.7                             | 15.7                             |
| Effect estimate per comparison | 95% CI                                               | 95% CI                                        | 95% CI                                        | 8.1, 23.4                        | 8.1, 23.4                        |
| Effect estimate per comparison | P-value                                              | P-value                                       | P-value                                       | 0.0005                           | 0.0005                           |
| Effect estimate per comparison | Secondary Clinical response Comparison groups        | Secondary Clinical response Comparison groups | Secondary Clinical response Comparison groups | Tofacitinib 10 mg BID vs placebo | Tofacitinib 10 mg BID vs placebo |
| Effect estimate per comparison | Difference                                           | Difference                                    | Difference                                    | 27.1                             | 27.1                             |
| Effect estimate per comparison | 95% CI                                               | 95% CI                                        | 95% CI                                        | 17.7, 36.5                       | 17.7, 36.5                       |

<div style=\"page-break-after: always\"></div>

|                                        | P-value           | <0.0001                          |
|----------------------------------------|-------------------|----------------------------------|
| Secondary Endoscopic remission         | Comparison groups | Tofacitinib 10 mg BID vs placebo |
|                                        | Difference        | 5.1                              |
|                                        | 95% CI            | 1.9, 8.3                         |
|                                        | P-value           | 0.0345                           |
| Secondary Clinical remission           | Comparison groups | Tofacitinib 10 mg BID vs placebo |
|                                        | Difference        | 10.3                             |
|                                        | 95% CI            | 4.3, 16.3                        |
|                                        | P-value           | <0.0070                          |
| Secondary Symptomatic remission        | Comparison groups | Tofacitinib 10 mg BID vs placebo |
|                                        | Difference        | 6.0                              |
|                                        | 95% CI            | 1.0, 11.1                        |
|                                        | P-value           | <0.0601                          |
| Secondary Deep remission               | Comparison groups | Tofacitinib 10 mg BID vs placebo |
|                                        | Difference        | 6.5                              |
|                                        | 95% CI            | 4.3, 8.7                         |
|                                        | P-value           | <0.0043                          |
| Secondary Change from                  | Comparison groups | Tofacitinib 10 mg BID vs placebo |
| baseline at Week                       | Difference        | -1.5                             |
| 8 in Partial Mayo score                | 95% CI            | -1.9. -1.1                       |
|                                        | P-value           | <0.0001                          |
| Secondary Change from baseline at Week | Comparison groups | Tofacitinib 10 mg BID vs placebo |
| 8 in total Mayo                        | Difference        | -1.9                             |

<div style=\"page-break-after: always\"></div>

| score   | 95% CI   | -2.5,-1.4   |
|---------|----------|-------------|
|         | P-value  | <0.0001     |

## Table Summary of efficacy for trial A3921095

| Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral CP-690,550 as an Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis   | Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral CP-690,550 as an Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis   | Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral CP-690,550 as an Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis   | Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral CP-690,550 as an Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis                                                                        |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                             | Study A3921095                                                                                                                                                                               | Study A3921095                                                                                                                                                                               | Study A3921095                                                                                                                                                                                                                                                    |
| Design                                                                                                                                                                                       | Phase 3 randomized, multicenter, double-blind DB, placebo controlled, parallel-group induction therapy study                                                                                 | Phase 3 randomized, multicenter, double-blind DB, placebo controlled, parallel-group induction therapy study                                                                                 | Phase 3 randomized, multicenter, double-blind DB, placebo controlled, parallel-group induction therapy study                                                                                                                                                      |
| Design                                                                                                                                                                                       | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                               | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                               | 8weeks not applicable not applicable                                                                                                                                                                                                                              |
| Hypothesis                                                                                                                                                                                   | No treatment effect between the tofacitinib 10 mg BID and the placebo                                                                                                                        | No treatment effect between the tofacitinib 10 mg BID and the placebo                                                                                                                        | No treatment effect between the tofacitinib 10 mg BID and the placebo                                                                                                                                                                                             |
| Treatments groups                                                                                                                                                                            | Tofacitinib 10 mg BID                                                                                                                                                                        | Tofacitinib 10 mg BID                                                                                                                                                                        | 429                                                                                                                                                                                                                                                               |
| Treatments groups                                                                                                                                                                            | Placebo BID                                                                                                                                                                                  | Placebo BID                                                                                                                                                                                  | 112                                                                                                                                                                                                                                                               |
| Endpoints and definitions                                                                                                                                                                    | Primary                                                                                                                                                                                      | Remission                                                                                                                                                                                    | Remission was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0 at week 8                                                                                                     |
| Endpoints and definitions                                                                                                                                                                    | Key secondary                                                                                                                                                                                | Mucosal healing                                                                                                                                                                              | Mucosal healing was defined by a Mayo endoscopic subscore of 0 or 1. The key secondary endpoint analysis was based on the centrally read endoscopic score at Week 8                                                                                               |
| Endpoints and definitions                                                                                                                                                                    | Secondary                                                                                                                                                                                    | Clinical response                                                                                                                                                                            | Clinical response was defined by a decrease from baseline in Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the subscore for rectal bleeding of at least 1 point or absolute subscore for rectal bleeding of 0 or 1 at week 8 |
| Endpoints and definitions                                                                                                                                                                    | Secondary                                                                                                                                                                                    | Endoscopic remission                                                                                                                                                                         | Endoscopic remission was defined by a Mayo endoscopic subscore of 0;at week 8                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|                                                 | Secondary                                                                                                                                                                          | Clinical remission                                                                                                                                                                 | Clinical remission was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point, at week 8                                                                                                                                                                                   | Clinical remission was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point, at week 8                                                                                                                                                                                   |
|-------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 | Secondary                                                                                                                                                                          | Symptomatic remission                                                                                                                                                              | Symptomatic remission was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point, and both rectal bleeding and stool frequency subscore of 0; Week 8.                                                                                                                      | Symptomatic remission was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point, and both rectal bleeding and stool frequency subscore of 0; Week 8.                                                                                                                      |
|                                                 | Secondary                                                                                                                                                                          | Deep remission                                                                                                                                                                     | Deep remission was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a 0 on both endoscopic and rectal bleeding subscores;                                                                                                                                        | Deep remission was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a 0 on both endoscopic and rectal bleeding subscores;                                                                                                                                        |
|                                                 | Secondary                                                                                                                                                                          | Partial Mayo scores and change from baseline over time                                                                                                                             | The Mayo score includes all 4 components and ranges from 0 to 12, whereas the partial Mayo score excludes the endoscopic subscore and ranges from 0 to 9.                                                                                                                                                             | The Mayo score includes all 4 components and ranges from 0 to 12, whereas the partial Mayo score excludes the endoscopic subscore and ranges from 0 to 9.                                                                                                                                                             |
|                                                 | Secondary                                                                                                                                                                          | Change from baseline at Week 8 in total Mayo score                                                                                                                                 | Mayo Scoring System consists of 4 subscores, each graded from 0 to 3, with higher scores indicating more severe disease activity: stool frequency (0-3), rectal bleeding (0-3), endoscopic assessment (0- 3), and physician global assessment (0-3). The Mayo score includes all 4 components and ranges from 0 to 12 | Mayo Scoring System consists of 4 subscores, each graded from 0 to 3, with higher scores indicating more severe disease activity: stool frequency (0-3), rectal bleeding (0-3), endoscopic assessment (0- 3), and physician global assessment (0-3). The Mayo score includes all 4 components and ranges from 0 to 12 |
| Database lock                                   | 06 May 2016 Study report date                                                                                                                                                      | 06 May 2016 Study report date                                                                                                                                                      | 06 May 2016 Study report date                                                                                                                                                                                                                                                                                         | 06 May 2016 Study report date                                                                                                                                                                                                                                                                                         |
| Results and Analysis                            | Results and Analysis                                                                                                                                                               | Results and Analysis                                                                                                                                                               | Results and Analysis                                                                                                                                                                                                                                                                                                  | Results and Analysis                                                                                                                                                                                                                                                                                                  |
| Analysis description                            | Primary Analysis                                                                                                                                                                   | Primary Analysis                                                                                                                                                                   | Primary Analysis                                                                                                                                                                                                                                                                                                      | Primary Analysis                                                                                                                                                                                                                                                                                                      |
| Analysis population and time point description  | The primary analysis population for efficacy endpoints was the final analysis set, defined as all subjects randomly assigned to either tofacitinib 10 mg BID or placebo at week 8. | The primary analysis population for efficacy endpoints was the final analysis set, defined as all subjects randomly assigned to either tofacitinib 10 mg BID or placebo at week 8. | The primary analysis population for efficacy endpoints was the final analysis set, defined as all subjects randomly assigned to either tofacitinib 10 mg BID or placebo at week 8.                                                                                                                                    | The primary analysis population for efficacy endpoints was the final analysis set, defined as all subjects randomly assigned to either tofacitinib 10 mg BID or placebo at week 8.                                                                                                                                    |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                    | Tofacitinib 10 mg BID                                                                                                                                                              | Tofacitinib 10 mg BID                                                                                                                                                                                                                                                                                                 | Placebo                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability | Number of subject                                                                                                                                                                  | 429                                                                                                                                                                                | 429                                                                                                                                                                                                                                                                                                                   | 112                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| Remission%                                           |   16.6 |   3.6 |
|------------------------------------------------------|--------|-------|
| Number of subject                                    |  429   | 112   |
| Mucosal healing %                                    |   28.4 |  11.6 |
| Number of subject                                    |  429   | 112   |
| Clinical response %                                  |   55   |  28.6 |
| Number of subject                                    |  429   | 112   |
| Endoscopic remission%                                |    7   |   1.8 |
| Number of subject                                    |  429   | 112   |
| Clinical remission                                   |   16.8 |   3.6 |
| Number of subject                                    |  429   | 112   |
| Symptomatic remission                                |   10.7 |   2.7 |
| Number of subject                                    |  429   | 112   |
| Deep remission                                       |    5.1 |   1.8 |
| Number of subject                                    |  400   |  98   |
| Change from baseline at Week 8 in Partial Mayo score |   -3   |  -1.7 |
| Number of subject                                    |  396   |  98   |
| Change from baseline at Week 8 in total Mayo score   |   -3.7 |  -2.1 |

<div style=\"page-break-after: always\"></div>

| Effect estimate per comparison   | Primary Remission               | Comparison groups   | Tofacitinib 10 mg BID vs placebo   |
|----------------------------------|---------------------------------|---------------------|------------------------------------|
|                                  | Primary Remission               | Difference          | 13.0                               |
|                                  | Primary Remission               | 95% CI              | 8.1, 19.7                          |
|                                  | Primary Remission               | P-value             | 0.0005                             |
|                                  | Mucosal healing                 | Comparison groups   | Tofacitinib 10 mg BID vs placebo   |
|                                  | Mucosal healing                 | Difference          | 16.8                               |
|                                  | Mucosal healing                 | 95% CI              | 9.5. 24.1                          |
|                                  | Secondary Clinical response     | P-value             | 0.0002                             |
|                                  | Secondary Clinical response     | Difference          | 26.4                               |
|                                  | Secondary Clinical response     | 95% CI              | 16.8, 36                           |
|                                  | Secondary Clinical response     | P-value             | <0.0001                            |
|                                  | Secondary Endoscopic remission  | Comparison groups   | Tofacitinib 10 mg BID vs placebo   |
|                                  | Secondary Endoscopic remission  | Difference          | 5.2                                |
|                                  | Secondary Endoscopic remission  | 95% CI              | 1.8, 8.6                           |
|                                  | Secondary Endoscopic remission  | P-value             | 0.0425                             |
|                                  | Secondary Clinical remission    | Comparison groups   | Tofacitinib 10 mg BID vs placebo   |
|                                  | Secondary Clinical remission    | Difference          | 13.2                               |
|                                  | Secondary Clinical remission    | 95% CI              | 8.3, 18.1                          |
|                                  | Secondary Clinical remission    | P-value             | <0.0004                            |
|                                  | Secondary Symptomatic remission | Comparison groups   | Tofacitinib 10 mg BID vs placebo   |
|                                  |                                 | Difference          | 8.0                                |
|                                  |                                 | 95% CI              | 3.9, 12.2                          |
|                                  |                                 | P-value             | 0.009                              |
|                                  | Secondary Deep remission        | Comparison groups   | Tofacitinib 10 mg BID vs placebo   |
|                                  | Secondary Deep remission        | Difference          | 3.3                                |
|                                  | Secondary Deep remission        | 95% CI              | 0.1, 6.6                           |

<div style=\"page-break-after: always\"></div>

|                                                                | P-value           | 0.1408                           |
|----------------------------------------------------------------|-------------------|----------------------------------|
| Secondary Change from baseline at Week 8 in Partial Mayo score | Comparison groups | Tofacitinib 10 mg BID vs placebo |
| Secondary Change from baseline at Week 8 in Partial Mayo score | Difference        | -1.3                             |
| Secondary Change from baseline at Week 8 in Partial Mayo score | 95% CI            | -7.7, -0.9                       |
|                                                                | P-value           | <0.0001                          |
| Secondary Change from baseline at Week 8 in total Mayo score   | Comparison groups | Tofacitinib 10 mg BID vs placebo |
| Secondary Change from baseline at Week 8 in total Mayo score   | Difference        | -1.6                             |
| Secondary Change from baseline at Week 8 in total Mayo score   | 95% CI            | -2.2, -1.0                       |
| Secondary Change from baseline at Week 8 in total Mayo score   | P-value           | <0.0001                          |

## Table Summary of efficacy for trial A3921096

| Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral CP-690,550 as a Maintenance Therapy in Subjects With Ulcerative Colitis   | Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral CP-690,550 as a Maintenance Therapy in Subjects With Ulcerative Colitis     | Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral CP-690,550 as a Maintenance Therapy in Subjects With Ulcerative Colitis     | Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral CP-690,550 as a Maintenance Therapy in Subjects With Ulcerative Colitis     |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                           | Study A3921096                                                                                                                                                               | Study A3921096                                                                                                                                                               | Study A3921096                                                                                                                                                               |
| Design                                                                                                                                                                     | Phase 3 randomized, multicenter, double-blind DB, placebo controlled, parallel-group maintenance therapy study                                                               | Phase 3 randomized, multicenter, double-blind DB, placebo controlled, parallel-group maintenance therapy study                                                               | Phase 3 randomized, multicenter, double-blind DB, placebo controlled, parallel-group maintenance therapy study                                                               |
|                                                                                                                                                                            | Duration of main phase: Duration of Run-in phase: Duration                                                                                                                   | Extension phase:                                                                                                                                                             | 52weeks not applicable not applicable                                                                                                                                        |
| Hypothesis                                                                                                                                                                 | No difference in the remission at Week 52 for tofacitinib 10 mg BID versus placebo; and for tofacitinib 10 mg BID versus placebo for the primary and key secondary endpoints | No difference in the remission at Week 52 for tofacitinib 10 mg BID versus placebo; and for tofacitinib 10 mg BID versus placebo for the primary and key secondary endpoints | No difference in the remission at Week 52 for tofacitinib 10 mg BID versus placebo; and for tofacitinib 10 mg BID versus placebo for the primary and key secondary endpoints |
| Treatments groups                                                                                                                                                          | Tofacitinib 5mg BID                                                                                                                                                          | Tofacitinib 5mg BID                                                                                                                                                          | 198                                                                                                                                                                          |
|                                                                                                                                                                            | Tofacitinib 10mg BID                                                                                                                                                         | Tofacitinib 10mg BID                                                                                                                                                         | 197                                                                                                                                                                          |
|                                                                                                                                                                            | Placebo BID                                                                                                                                                                  | Placebo BID                                                                                                                                                                  | 198                                                                                                                                                                          |
| Endpoints and definitions                                                                                                                                                  | Primary                                                                                                                                                                      | Remission                                                                                                                                                                    | Remission was defined by a Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0 at week 52                     |

<div style=\"page-break-after: always\"></div>

|                                                 | Key secondary                                                                                                                                                                              | Mucosal healing                                                                                                                                                                            | Mucosal healing was defined by a Mayo endoscopic subscore of 0 or 1. The key secondary endpoint analysis was based on the centrally read endoscopic score at Week 52                                                                                                                                                                                                                                       | Mucosal healing was defined by a Mayo endoscopic subscore of 0 or 1. The key secondary endpoint analysis was based on the centrally read endoscopic score at Week 52                                                                                                                                                                                                                                       |
|-------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 | Key Secondary                                                                                                                                                                              | Sustained corticosteroid- free remission                                                                                                                                                   | Sustained corticosteroid-free remission among subjects in remission at baseline of this study, (i.e., remission and corticosteroid-free at both Weeks 24 and 52), defined by a Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0, in addition to not requiring any treatment with corticosteroids for at least 4 weeks prior to the visit | Sustained corticosteroid-free remission among subjects in remission at baseline of this study, (i.e., remission and corticosteroid-free at both Weeks 24 and 52), defined by a Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0, in addition to not requiring any treatment with corticosteroids for at least 4 weeks prior to the visit |
| Database lock                                   | 16 th Dec 2016 Study ate                                                                                                                                                                   | 16 th Dec 2016 Study ate                                                                                                                                                                   | 16 th Dec 2016 Study ate                                                                                                                                                                                                                                                                                                                                                                                   | 16 th Dec 2016 Study ate                                                                                                                                                                                                                                                                                                                                                                                   |
| Results and Analysis                            | Results and Analysis                                                                                                                                                                       | Results and Analysis                                                                                                                                                                       | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                       | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                       |
| Analysis description                            | Primary Analysis                                                                                                                                                                           | Primary Analysis                                                                                                                                                                           | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                           | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                           |
| Analysis population and time point description  | The primary analysis population for efficacy endpoints was the FAS defined as all subjects randomly assigned to either tofacitinib 10 mg BID, tofacitinib 5 mg BID, or placebo at week 52. | The primary analysis population for efficacy endpoints was the FAS defined as all subjects randomly assigned to either tofacitinib 10 mg BID, tofacitinib 5 mg BID, or placebo at week 52. | The primary analysis population for efficacy endpoints was the FAS defined as all subjects randomly assigned to either tofacitinib 10 mg BID, tofacitinib 5 mg BID, or placebo at week 52.                                                                                                                                                                                                                 | The primary analysis population for efficacy endpoints was the FAS defined as all subjects randomly assigned to either tofacitinib 10 mg BID, tofacitinib 5 mg BID, or placebo at week 52.                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                            | Tofacitinib 5 mg BID Tofacitinib BID                                                                                                                                                       | Tofacitinib 5 mg BID Tofacitinib BID                                                                                                                                                                                                                                                                                                                                                                       | Placebo                                                                                                                                                                                                                                                                                                                                                                                                    |
| Descriptive statistics and estimate variability | Number of subject                                                                                                                                                                          | 198 197                                                                                                                                                                                    | 198 197                                                                                                                                                                                                                                                                                                                                                                                                    | 198                                                                                                                                                                                                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability | Remission%                                                                                                                                                                                 | 34.3 40.6                                                                                                                                                                                  | 34.3 40.6                                                                                                                                                                                                                                                                                                                                                                                                  | 11.1                                                                                                                                                                                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | Number of subject                                                                                                                                                                          | 198 197                                                                                                                                                                                    | 198 197                                                                                                                                                                                                                                                                                                                                                                                                    | 198                                                                                                                                                                                                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability | Mucosal healing %                                                                                                                                                                          | 37.4 45.7                                                                                                                                                                                  | 37.4 45.7                                                                                                                                                                                                                                                                                                                                                                                                  | 13.1                                                                                                                                                                                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | Number of subject                                                                                                                                                                          | 198 197                                                                                                                                                                                    | 198 197                                                                                                                                                                                                                                                                                                                                                                                                    | 198                                                                                                                                                                                                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability | Sustained corticosteroid- free remission                                                                                                                                                   | 35.4 47.3                                                                                                                                                                                  | 35.4 47.3                                                                                                                                                                                                                                                                                                                                                                                                  | 5.1                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| Effect estimate per comparison   | Primary Remission                                     | Comparison groups   | Tofacitinib 5 mg BID vs placebo   | Tofacitinib 10 mg BID vs placebo   |
|----------------------------------|-------------------------------------------------------|---------------------|-----------------------------------|------------------------------------|
| Effect estimate per comparison   | Primary Remission                                     | Difference          | 23.2                              | 29.5                               |
| Effect estimate per comparison   | Primary Remission                                     | 95% CI              | 15.3, 31.2                        | 21.4, 37.6                         |
| Effect estimate per comparison   | Primary Remission                                     | P-value             | <0.0001                           | <0.0001                            |
| Effect estimate per comparison   | Key Secondary Mucosal healing                         | Comparison groups   | Tofacitinib 5 mg BID vs placebo   | Tofacitinib 10 mg BID vs placebo   |
| Effect estimate per comparison   | Key Secondary Mucosal healing                         | Difference          | 37.4                              | 45.7                               |
| Effect estimate per comparison   | Key Secondary Mucosal healing                         | 95% CI              | 16.0, 32.5                        | 24.2, 41.0                         |
| Effect estimate per comparison   | Key Secondary Mucosal healing                         | P-value             | <0.0001                           | <0.0001                            |
| Effect estimate per comparison   | Key Secondary Sustained corticosteroid-free remission | Comparison groups   | Tofacitinib 5 mg BID vs placebo   | Tofacitinib 10 mg BID vs placebo   |
| Effect estimate per comparison   | Key Secondary Sustained corticosteroid-free remission | Difference          | 30.3                              | 42.2                               |
| Effect estimate per comparison   | Key Secondary Sustained corticosteroid-free remission | 95% CI              | 17.4, 43.2                        | 27.9, 56.5                         |
| Effect estimate per comparison   | Key Secondary Sustained corticosteroid-free remission | P-value             | <0.0001                           | <0.0001                            |

## Analysis performed across trials (pooled analyses and meta-analysis)

The data from the 2 pivotal induction studies, A3921094 and A3921095, were pooled to obtain the estimates of the treatment effects in the pooled FAS population. The pooled FAS population, which includes the FAS from each study, consists of 1139 subjects (598 subjects in Study A3921094 and 541 subjects in Study A3921095). Subjects randomized to tofacitinib 15 mg BID prior to the Protocol Amendment 3 for Study A3921094 and Protocol Amendment 2 for Study A3921095 are not included in the FAS (16 subjects in Study A3921094 and 6 subjects in Study A3921095). In both Studies A3921094 and A3921095, the proportion of subjects who were in remission at Week 8 was significantly greater in the tofacitinib 10 mg BID group compared with the placebo group (p=0.0070 and p=0.0005, respectively) and the treatment effect was similar between studies.

<div style=\"page-break-after: always\"></div>

## Remission at Week 8 in Studies A3921094 and A3921095 (FAS, NRI)

|                     | Tofacitinib 10 mg BID N=476 (1094) N=429 (1095)   | Placebo N=122 (1094) N=112 (1095) N=234 (Po0ledl)   | DifferenceFromPlacebo   | DifferenceFromPlacebo   |
|---------------------|---------------------------------------------------|-----------------------------------------------------|-------------------------|-------------------------|
| Read                |                                                   |                                                     | Difference (95% CI)a    | P-valueb                |
| Central Read        | n (%)                                             |                                                     |                         |                         |
|                     |                                                   | n (%)                                               |                         |                         |
| Study               |                                                   |                                                     |                         |                         |
|                     | N=905 (Pooled)                                    |                                                     |                         |                         |
| A3921094            | 88 (18.5)                                         | 10 (8.2)                                            | 10.3 (4.3, 16.3)        | 0.0070 0.0005           |
| A3921095            | 71 (16.6)                                         | 4 (3.6)                                             | 13.0 (8.1, 17.9)        |                         |
| Pooled              | 159 (17.6)                                        | 14 (6.0)                                            | 11.6 (7.7, 15.5)        | <0.0001                 |
| Local Read A3921094 | 118 (24.8)                                        | 14 (11.5)                                           | 13.3 (6.5, 20.2)        | 0.0017                  |
| A3921095 Pooled     | 89 (20.7)                                         | 6 (5.4)                                             | 15.4 (9.7, 21.1)        | 0.0002                  |
|                     | 207 (22.9)                                        |                                                     |                         |                         |
|                     |                                                   |                                                     | 14.3 (9.8,18.8)         |                         |
|                     |                                                   | 20 (8.5)                                            |                         |                         |
|                     |                                                   |                                                     |                         | <0.0001                 |

Sources: 5.3.5.1 A3921094-report-body Table 14.2.2.1; Table 14.2.2.2; 5.3.5.1 A3921095-rep0rt-body Table 14.2.2.1; Table 14.2.2.2; 5.3.5.3 SCE Table 14.2.2.1.p: Table 14.2.2.3.p.

Abbreviations: BID = twice a day; CI = confidence interval; FAS = full analysis set; N = number of subjects in the analysis set; n = number of subjects meeting the endpoint criteria; N/A = not available; NRI = nonresponder imputation; TNFi = tumor necrosis factor inhibitor.

Remission was defined by a Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of O. The primary endpoint analysis was based on the centrally read endoscopicscore.

- a. The 95% CI is based on the normal approximation for the difference in binomial proportions.
2. The p-value is based on Cochran-Mantel-Haenzel (CMH) Chi-squared test stratified by prior treatment with TNFi, corticosteroid use at baseline, and geographic region. Pooled analyses were also stratified by study.

In both Studies A3921094 and A3921095, the proportion of subjects with mucosal healing at Week 8 was significantly greater in the tofacitinib 10 mg BID group compared with the placebo group (p=0.0005 and p=0.0002, respectively).

Mucosal Healing at Week 8 in Studies A3921094 and A3921095 (FAS, NRI)

<div style=\"page-break-after: always\"></div>

|            | Tofacitinib 10 mg BID N=476 (1094) N=429 (1095) N=905 (Pooled)   | Placebo N=122 (1094) N=112 (1095) N=234 (Po0led)   | DifferenceFrom Placebo   | DifferenceFrom Placebo   |
|------------|------------------------------------------------------------------|----------------------------------------------------|--------------------------|--------------------------|
| Read       |                                                                  |                                                    | Difference (95% CI)a     | P-valueb                 |
| Study      |                                                                  |                                                    |                          |                          |
|            |                                                                  | n (%)                                              |                          |                          |
|            | n (%)                                                            |                                                    |                          |                          |
| A3921094   | 149 (31.3)                                                       | 19 (15.6)                                          | 15.7 (8.1, 23.4)         | 0.0005                   |
| A3921095   | 122 (28.4)                                                       | 13 (11.6)                                          | 16.8 (9.5, 24.1)         | 0.0002                   |
| Pooled     | 271 (29.9)                                                       | 32 (13.7)                                          | 16.3 (11.0, 21.6)        | <0.0001                  |
| Local Read |                                                                  |                                                    |                          |                          |
| A3921094   | 202 (42.4)                                                       | 28 (23.0)                                          | 19.5 (10.8, 28.2)        | <0.0001                  |
| A3921095   | 156 (36.4)                                                       | 17 (15.2)                                          | 21.2 (13.1, 29.2)        | <0.0001                  |
| Pooled     | 358 (39.6)                                                       | 45 (19.2)                                          | 20.3 (14.4, 26.3)        | <0.0001                  |

Sources: 5.3.5.1 A3921094-report-body Table 14.2.3.1; Table 14.2.3.2; 5.3.5.1 A3921095-rep0rt-body Table 14.2.3.1; Table 14.2.3.2; and 5.3.5.3 SCE Table 14.2.3.1.p: Table 14.2.3.3.p.

- Abbreviations: BID = twice a day; CI = confidence interval; FAS = full analysis set; N = number of subjects in the analysis set; n = number of subjects meeting the endpoint criteria; N/A = not available; NRI = nonresponder imputation; TNFi = tumor necrosis factor inhibitor.

Mucosal healing was defined by a Mayo endoscopic subscore of 0 or 1. The key secondary endpoint analysis was based on the centrally read endoscopic score.

- a. The 95% CI is based on the normal approximation for the difference in binomial proportions.
- b.  The p-value is based on Cochran-Mantel-Haenzel (CMH) Chi-squared test stratified by prior treatment with TNFi, corticosteroid use at baseline, and geographic region. Pooled analyses were also stratified by study.

<div style=\"page-break-after: always\"></div>

## Binary Efficacy Endpoints at Week 8 in Studies A3921094 and A3921095 (FAS, NRI, Central Read)

|                       | Tofacitinib 10 mg BID N=476 (1094)   | Placebo N=122 (1094) N=112 (1095)   | DifferenceFromPlacebo   | DifferenceFromPlacebo   |
|-----------------------|--------------------------------------|-------------------------------------|-------------------------|-------------------------|
| Endpoint Study        | N=429 (1095) N=905 (Pooled) n (%)    | N=234 (Po0led) n (%)                | Difference (95% CI)a    | P-valueb                |
| Clinical Response     |                                      |                                     |                         |                         |
| A3921094              | 285 (59.9)                           | 40 (32.8)                           | 27.1 (17.7, 36.5)       | <0.0001                 |
| A3921095              | 236 (55.0)                           | 32 (28.6)                           | 26.4 (16.8, 36.0)       | <0.0001                 |
| Pooled                | 521 (57.6)                           | 72 (30.8)                           | 26.8 (20.1, 33.5)       | <0.0001                 |
| Symptomatic Remission |                                      |                                     |                         |                         |
| A3921094              | 56 (11.8)                            | 7 (5.7)                             | 6.0 (1.0, 11.1)         | 0.0601                  |
| A3921095              | 46 (10.7)                            | 3 (2.7)                             | 8.0 (3.9, 12.2)         | 0.0090                  |
| Pooled                | 102 (11.3)                           | 10 (4.3)                            | 7.0 (3.7, 10.3)         | 0.0017                  |
| Endoscopic Remission  |                                      |                                     |                         |                         |
| A3921094              | 32 (6.7)                             | 2 (1.6)                             | 5.1 (1.9, 8.3)          | 0.0345                  |
| A3921095              | 30 (7.0)                             | 2 (1.8)                             | 5.2 (1.8, 8.6)          | 0.0425                  |
| Pooled                | 62 (6.9)                             | 4 (1.7)                             | 5.1 (2.8, 7.5)          | 0.0034                  |

Abbreviations: BID = twice a day; CI = confidence interval; FAS = full analysis set; N = number of subjects in the analysis set; n = number of subjects meeting the endpoint criteria; NRI = non-responder imputation; TNFi = tumor necrosis factor inhibitor.

Sources: 5.3.5.1 A3921094-report-body Table 14.2.4.1; 5.3.5.1 A3921095-report-body Table 14.2.4.1; and 5.3.5.3 SCE Table 14.2.5.1.p: Table 14.2.8.1.p; Table 14.2.6.1.p.

- a. The 95% CI is based on the normal approximation for the difference in binomial proportions.
2. The p-value is based on Cochran-Mantel-Haenzel (CMH) Chi-squared test stratified by prior treatment with TNFi, corticosteroid use at baseline, and geographic region. Pooled analyses were also stratified by study.

Summary of efficacy endpoints at week 8: Study A3921094 and Study A3921095 Pooled (FAS, NRI):

<div style=\"page-break-after: always\"></div>

|                              | Tofacitinib 10 mg BID N=476 (1094) N=429 (1095) N=905 (Po0led) n (%)   | Placebo N=122 (1094) N=112(1095) N=234 (P00led) n (%)   | Differencefrom placebo (95% CI)a   | p-valueb   |
|------------------------------|------------------------------------------------------------------------|---------------------------------------------------------|------------------------------------|------------|
| Remission, centralread       | 159 (17.6)                                                             | 14 (6.0)                                                | 11.6 (7.7, 15.5)                   | <0.0001    |
| Remission,localread          | 207 (22.9)                                                             | 20 (8.5)                                                | 14.3 (9.8, 18.8)                   | <0.0001    |
| Mucosalhealing,centralread   | 271 (29.9)                                                             | 32 (13.7)                                               | 16.3 (11.0, 21.6)                  | <0.0001    |
| Mucosalhealing,localread     | 358 (39.6)                                                             | 45 (19.2)                                               | 20.3 (14.4, 26.3)                  | <0.0001    |
| clinicalresponse,centralread | 521 (57.6)                                                             | 72 (30.8)                                               | 26.8 (20.1, 33.5)                  | <0.0001    |
| clinicalresponse,localread   | 538 (59.4)                                                             | 75 (32.1)                                               | 27.4 (20.6, 34.2)                  | <0.0001    |

RemissionwasdefinedbyatotalMayoscoreof2pointsorlower,withnoindividualsubscoreexceeding1pointandarectal centrallyreadendoscopicscore.

Clinical response was defined by a decrease from baseline in Mayo score of at least 3 points and at least 30%,with an accompanying decrease in the rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1.

BID = twice daily; CI = confidence interval; CMH = Cochran-Mantel-Haenzel; FAS = full analysis set; n = number of subjects s factor inhibitor.

a. 95% CI is based on the normal approximation for the difference in binomial proportions.

use at baseline and geographical region. Pooled analyses were also stratified by study.

## Supportive study

## Open-Label, Long-Term Extension Study A3921139

Study Design

Study A3921139 was a Phase 3, multicentre, open-label study in subjects who had completed or demonstrated treatment failure in the maintenance study (A3921096), or who were non-responders after completing 8 weeks of treatment in the induction studies (A3921094 or A3921095). Subjects in remission at baseline of Study A3921139 were initially assigned to tofacitinib 5 mg BID; all other subjects were initially assigned to tofacitinib 10 mg BID.

The primary objective of this study was to assess the safety and tolerability of long-term tofacitinib therapy in subjects with ulcerative colitis (UC). The secondary objectives of this study were to evaluate the efficacy of long-term tofacitinib therapy in subjects with UC and to evaluate the effect of long-term tofacitinib therapy on quality of life in subjects with UC.

Subjects from the induction Studies A3921094 and A3921095 (i.e., non-responders) who failed to demonstrate clinical response at Month 2 of Study A3921139 were to be withdrawn from the study.

This study is currently ongoing and thus an interim report has been presented.

Disposition of Subjects

Among subjects eligible for the study (those who completed or demonstrated treatment failure in maintenance Study A3921096 or who were non responders after completing induction Studies A3921094 or A3921095), a total of 944 subjects were enrolled and assigned to study treatment as of 08 July 2016. Of those, 914 subjects were enrolled for at least 2 months prior to 08 July 2016. 156 subjects were assigned to

<div style=\"page-break-after: always\"></div>

the tofacitinib 5 mg BID group and 758 subjects were assigned to the tofacitinib 10 mg BID group at the beginning of Study A3921139. All 914 subjects received at least 1 dose of study drug and were included in the FAS. As of 08 July 2016, the median duration of treatment was 338 days for the tofacitinib 5 mg BID group and 369 days for the tofacitinib 10 mg BID group.

Of the 914 subjects in the FAS, 381 subjects (41.7%) discontinued and 533 subjects (58.3%) were ongoing as of 08 July 2016. Of the subjects who received tofacitinib 5 mg BID, 17/156 (10.9%) discontinued from the study, and 364/758 (48.0%) of subjects who received tofacitinib 10 mg BID discontinued.

## Efficacy Results

Analyses were conducted on data through Month 24, however a relatively small number of subjects had reached Month 24 of Study A3921139 as of 08 July 2016; therefore, it is difficult to draw conclusions from the Month 24 data.

In subjects who received tofacitinib 5 mg BID or 10 mg BID and were in remission at the end of the 52-week maintenance Study A3921096 (i.e., the maintenance remission subpopulation of the FAS), treatment with tofacitinib 5 mg BID in the open-label Study A3921139 showed persistence of tofacitinib efficacy, with approximately 75% of subjects maintaining remission at Month 12 (NRI analysis).

In the subpopulation of subjects with treatment failure on tofacitinib 5 mg BID or placebo in maintenance Study A3921096 and who received tofacitinib 10 mg BID in induction Study A3921094 or A3921095 (i.e., the maintenance treatment failures subpopulation of the FAS), dose escalation or retreatment with tofacitinib 10 mg BID in Study A3921139 recaptured tofacitinib efficacy. After 2 months of treatment with tofacitinib 10 mg BID in Study A3921139, 34.5% and 40.4% of subjects who received either tofacitinib 5 mg BID or placebo in the maintenance study, respectively, achieved remission. At Month 12, 52.1% and 43.4% of subjects, who received either tofacitinib 5 mg BID or placebo in the maintenance study, respectively, achieved remission (NRI analysis).

In subjects failing to achieve a clinical response after 8 weeks of blinded tofacitinib 10 mg BID in induction Studies A3921094 and A3921095 (i.e., the induction non-responders subpopulation of the FAS), continued treatment with tofacitinib 10 mg BID for an additional 2 months in Study A3921139 resulted in clinical response in 60.1% (observed case analysis) and 52.9% (NRI analysis) of these subjects.

Persistence of remission with tofacitinib long-term treatment was shown in the open-label LTE study, A3921139. Among the 144 subjects in the subpopulation of Maintenance Remitters that entered Study A3921139 (i.e., those subjects who took either tofacitinib 5 mg or 10 mg BID in Study A3921096 and completed the study having achieved remission and received tofacitinib 5 mg BID in Study A3921139), only 15 subjects (10.4%) discontinued from Study A3921139 study as 08 July 2016.

The potential of retreatment with tofacitinib 10 mg BID to regain treatment efficacy after treatment withdrawal was examined in the cohort of subjects who received tofacitinib 10 mg BID during induction and who then experienced treatment failure while receiving placebo during the maintenance study, A3921096. After 2 months of retreatment with tofacitinib 10 mg BID, of the subjects remaining in the study at that timepoint, 40/88 (44.5%) had achieved remission and 56/91 (61.5%) had achieved mucosal healing. The corresponding observed proportions of subjects remaining in the study achieving remission and mucosal healing at Month 12 were 36/60 (60.0%) and 45/61 (73.8%), respectively.

<div style=\"page-break-after: always\"></div>

## Remission for the Maintenance Treatment Failures Subpopulation who Received Tofacitinib 10 mg BID in Study A3921139 (Local Read, FAS)

|          |                                     | Observed Case   | Observed Case   | Non-Responder Imputationb   | Non-Responder Imputationb   |
|----------|-------------------------------------|-----------------|-----------------|-----------------------------|-----------------------------|
| Visit    | Induction/Maintenance Treatments?   | N1              | n (%)           | N1                          | n (%)                       |
| Baseline | Induction 10 mg/Maintenance 5 mg    | 58              | 0               | 58                          | 0                           |
|          | Induction 10 mg/Maintenance Placebo | 100             | 0               | 101                         | 0                           |
| Month 2  | Induction 10 mg/Maintenance 5 mg    | 49              | 20 (40.8)       | 58                          | 20 (34.5)                   |
|          | Induction 10 mg/Maintenance Placebo | 88              | 40 (45.5)       | 99                          | 40 (40.4)                   |
| Month 12 | Induction 10 mg/Maintenance 5 mg    | 34              | 25 (73.5)       | 48                          | 25 (52.1)                   |
|          | Induction 10 mg/Maintenance Placebo | 60              | 36 (60.0)       | 83                          | 36 (43.4)                   |
| Month 24 | Induction 10 mg/Maintenance 5 mg    | 8               | 5 (62.5)        | 16                          | 5 (31.3)                    |
|          | Induction 10 mg/Maintenance Placebo | 15              | 9 (60.0)        | 29                          | 9 (31.0)                    |

Sources: 5.3.5.2 A3921139-interim-report-body Table 14.2.2.2.2; Table 14.2.2.2.7.

Abbreviations: BID = twice a day; FAS = full analysis set; N1 (Observed Case) = number of subjects in the specified category with non-missing values; N1 (Non-Responder Imputation) = number of subjects who, based on their enrollment dates and last non-missing full Mayo score (Endoscopy for Mucosal Healing) (for ongoing subjects), could have reached the specified timepoint as of 08 July 2016; n = number of subjects = %  a  m sdsa ds  m

- a. Treatment in induction Study A3921094 or A3921095 and in maintenance Study A3921096.
- b. Non-responder imputation for missing data, but no imputation was used for ongoing subjects.

## 2.5.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

This application for tofacitinib is to include an additional therapeutic indication for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

The Applicant has conducted 3 pivotal Phase 3 studies (2 identical 8-week induction studies [A3921094 and A3921095] and one 52-week maintenance study [A3921096]), and an ongoing Phase 3 open-label LTE study (A3921139). The phase 3 trials studied both the induction treatment of active disease and maintenance treatment; which are in line with the proposed indication and the CHMP/EWP/18463/2006 Guideline on the development of new medicinal products for the treatment of Ulcerative Colitis. All three studies A3921094, A3921095 and A3921096 were multi-centre, randomised, double-blind, placebo-controlled efficacy and safety studies.

The study designs of a randomised double blind parallel group placebo comparison were acceptable in the two inductions and one maintenance studies.  Whilst in the SAWP advice the initial advice was to conduct a three-arm active comparator study; the feasibility of this approach was discussed and this was not explicitly requested.  Placebo was considered an acceptable comparator in the clinical studies due to the proposed indication. Inclusion and exclusion criteria were generally acceptable.

Subjects were selected based on a diagnosis of UC &gt;4 months prior to entry into the study, with a histological conformation. Moderately to severely active disease was defined by a total Mayo score of &gt;6,

<div style=\"page-break-after: always\"></div>

with a rectal bleeding score of &gt;1, and an endoscopic subscore of &gt;2 on the Mayo score determined within 10 days of baseline visit. Appropriate measures of diagnosis and disease severity were utilised for subject selection.

Subjects had failed or been intolerant of at least 1 of the following: oral or intravenous (IV) corticosteroids; Azathioprine, 6-MP; or TNFi therapy: infliximab or adalimumab. The applicant has provided sufficient data to confirm that subjects received optimum therapy in accordance with guidelines prior to being randomised into the tofacitinib trial programme.

At entry into the induction studies, subjects were permitted to continue oral corticosteroids or 5-ASA for UC. The continuation of background therapy was acceptable, considering the proposed indication, and is consistent with CHMP guidance CHMP/EWP/18463/2006 Guideline on the development of new medicinal products for the treatment of Ulcerative Colitis. Chronic treatment for UC with antibiotics was permitted; however it would be expected that antibiotic use would be excluded. The applicant noted that some treating clinicians may use antibiotics in select UC patients who have failed to otherwise attain acceptable clinical response to their current treatment regimen in the hope of having an effect on the patient's microbiome and attaining potential additional clinical benefit, even if there are no controlled studies supporting this treatment regimen. It was clarified that the number of patients who received concomitant antibiotics for UC treatment was 6/905 (0.7%) of the patients receiving tofacitinib 10mg BID in the induction studies, and it is accepted that these few subjects are unlikely to have had a significant effect on the overall results of the studies.

Patients were stratified depending on their previous treatment and efficacy sub-analysis for each subpopulation was evaluated separately. This was useful as the studied population was heterogeneous.

Symptomatic relief was evaluated with patient related outcomes, and the MAH has provided a discussion summarising key evidence for the reliability and validity of the SF-36v2, IBDQ and WPAI instruments for UC populations. These PRO measures are widely used and are acceptable for use in this setting.

Disease activity was measured by the Mayo Scoring System to evaluate efficacy in the tofacitinib UC clinical development program. Endoscopic appearance was read by both study site investigator (locally read) and by a central reader through video recorded during the procedure.  Centrally read endoscopic subscores were used for both eligibility and primary efficacy analyses which allowed for adjudication of endoscopic activity.

The applicant refers throughout the clinical study reports for all the studies to Total Mayo score however in the Clinical Efficacy summary there is reference to the point that the Mayo score was adapted to remove the physician's global assessment (PGA) upon scientific advice from the FDA. It was confirmed that the total Mayo score was used in the clinical studies, and that additional sensitivity analyses using modified Mayo score, excluding PGA, were also performed.

For the induction studies A3921094 and A3921095 the primary efficacy endpoint in the induction studies was remission which was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Ideally the co-primary endpoints on both symptomatic relief and endoscopic healing would have been utilised in line with the CHMP/EWP/18463/2006 Guideline on the development of new medicinal products for the treatment of Ulcerative Colitis. The total Mayo score including the PGA is not of primary interest. It is however noted that the chosen definition of remission did refer to all sub scores of the Mayo score and as such did encompass both symptomatic and endoscopic evaluation and in addition included cessation of rectal bleeding in the definition and as such is acceptable.

The maintenance Study A3921096 was a separate follow up study from the induction studies. The primary analysis population in the maintenance study includes all responders to induction treatments, i.e. both active

<div style=\"page-break-after: always\"></div>

and placebo; which was endorsed by the SAWP. Subjects who completed either of the induction studies and achieved clinical response or remission irrespective of treatment were re-randomized into the maintenance study. It is noted that both responders and remitters were included in the trial. The inclusion of responders in a maintenance study is useful as it is relevant to study if continued treatment in responders may eventually lead to remission. To evaluate a claim of 'maintenance of remission' the primary interest is in patients who were in remission at baseline. This can be achieved by looking at subgroups analyses for those in remission at baseline. The recommended primary endpoint in the draft CHMP guideline CHMP/EWP/18463/2006 Rev.1 Guideline on the development of new medicinal products for the treatment of Ulcerative Colitis is steroid free remission maintained without surgery throughout at least 12 months. One of the key secondary endpoints is sustained corticosteroid-free remission at both Weeks 24 and 52 among subjects in remission at baseline.

## Efficacy data and additional analyses

## Phase 3 Induction Study Treatment: A3921094 and A3921095:

The primary efficacy endpoint in the induction studies was remission, defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and rectal bleeding subscore of 0.

Subjects were randomized to either tofacitinib 10 mg BID or placebo BID, with a treatment allocation ratio of 4:1. Subjects were stratified by previous treatment with TNFi therapy, oral corticosteroid use at baseline, and geographic region. Active treatment in the study continued for 8 weeks which was an acceptable length of time.

The chosen study populations were reflective and appropriate to the proposed indication. The study populations were well characterised in terms of disease extent, duration, disease activity, prior treatment, smoking status, clinical characteristics and prior treatment.  Previous treatment with TNFi agents, corticosteroids was similar between treatment group. Prior failure to corticosteroid or TNFi treatment for UC was similar across treatment groups.

Statistically significantly higher proportions of subjects in the tofacitinib 10 mg BID group achieved the primary endpoint of remission as well as the key secondary endpoint of mucosal healing at Week 8 compared with placebo in the induction studies. The tofacitinib 10 mg BID group also had statistically significantly higher proportions of subjects with the secondary endpoints of clinical remission, clinical response, and endoscopic remission at Week 8 as compared with placebo. In addition, in the exploratory end points of Patient Related Outcome which were assessed with IBDQ (total and all individual domains) and SF-36 (all component and domain scores) tofacitinib 10 mg BID had significantly greater improvement.

Symptomatic improvements were observed at an early stage. Tofacitinib 10 mg BID showed significantly greater improvement from baseline of partial Mayo score compared with placebo by Week 2.

The results of the 2 replicate induction studies show consistent and statistically significant findings with similar magnitudes of placebo-adjusted treatment effect for tofacitinib 10 mg BID across endpoints.

Across endpoints, treatment effect was observed in the refractory TNFi subgroups, including subjects with prior TNFi exposure or failure, those subjects with prior failure to 2 or more TNFi agents, and those with primary non-response to TNFi. The magnitude of observed treatment effect for these endpoints was similar in the subgroups of subjects with prior TNFi exposure or failure as compared to those without prior TNFi exposure or failure.

## Phase 3 Maintenance Study Treatment A3921096:

<div style=\"page-break-after: always\"></div>

Subjects were randomized to either tofacitinib 10 mg BID, tofacitinib 5 mg BID or placebo BID with an allocation ratio of 1:1:1.  The study was conducted as a 52-week double-blind treatment period followed by a 4 week safety follow-up for subjects who did not participate in the open-label study (A3921139).

Subjects were stratified according to their prior treatment assignment in induction study (A3921094 or A3921095), and whether they achieved remission status at the end of the induction study. Subjects taking oral corticosteroids at baseline were required to taper off the corticosteroids per the protocol-specified tapering regimen starting the first week after entering the study.

It was noted that there were higher rates of discontinuation due to insufficient clinical response, especially in the 5mg group, and this was considered of relevance in reference to the proposed posology of the product in the maintenance phase. Data were provided that show that for patients treated with tofacitinib, higher discontinuation rates due to inadequate clinical response (ICR) were seen in the 5mg BID cohort (35.4%) compared to the 10mg BID cohort (27.0%), and particularly driven by the 5mg BID subset of patients with prior TNFi failure (41.1%) rather than those without prior TNFi failure (30.6%). The MAH acknowledged that the discontinuation rate due to ICR is analogous to the clinical efficacy results, whereby the increment in efficacy between 5mg BID and 10mg BID regimens was larger in those with a history of TNFi failure, especially for the highly relevant endpoint of sustained corticosteroid-free remission amongst remitters. It is considered that the data on discontinuation of therapy are analogous to the efficacy data, and are supportive of the recommendation to consider maintenance dosing with 10 mg BID in the sub-population of prior TNFi failure.

The primary efficacy endpoint was remission at Week 52, defined by a Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and rectal bleeding subscore of 0. The key secondary endpoints were mucosal healing at Week 52, defined by a Mayo endoscopic subscore of 0 or 1; and sustained corticosteroid-free remission at both Weeks 24 and 52 among subjects in remission at baseline defined by a Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0, in addition to not requiring any treatment with corticosteroids for at least 4 weeks prior to the visit. CHMP Draft guidelines CHMP/EWP/18463/2006 Rev.1 Guideline on the development of new medicinal products for the treatment of Ulcerative Colitis, advise that the primary endpoint should be the number of patients in clinical and endoscopic remission in whom steroids could be withdrawn. As such the relevance of the second key secondary efficacy endpoint was highlighted and is viewed as a primary endpoint in assessment.

Statistically significantly greater treatment effects were demonstrated for both treatment groups versus placebo for the primary endpoint of remission at Week 52, and key secondary endpoints of mucosal healing at Week 52. This was seen in the FAS and in the subgroup of patients in remission at baseline. A statistically significant benefit was also seen for sustained corticosteroid free remission among subjects in remission at baseline. The observed treatment effect was higher in the tofacitinib 10 mg BID group than the tofacitinib 5 mg BID group for primary and key secondary endpoints. According to the draft CHMP guideline CHMP/EWP/18463/2006 Rev.1 Guideline on the development of new medicinal products for the treatment of Ulcerative Colitis in order to obtain an indication for 'treatment of active ulcerative colitis', efficacy in both 'induction of remission' as well as 'maintenance of remission' should be demonstrated.

Depending on the properties of the drug (i.e. not suitable for long term treatment or not suitable for acute treatment) separate indications for 'induction of remission' or 'maintenance of remission' may be granted.

The applicant initially claimed separate indications on induction and maintenance of remission however agreed on CHMP request to update the wording to treatment of  adult patients with moderately to severely

<div style=\"page-break-after: always\"></div>

active ulcerative colitis (UC) to fulfil the draft EMA UC guideline as well as to be consistent with the wording of others biologic therapies.

Time to treatment failure was statistically significantly different in the tofacitinib 5 mg BID and 10 mg BID treatment groups compared with placebo, with earlier and more frequent events in the placebo group.

With regards to patient related outcomes, there were statistically significant improvements in the IBDQ, SF36, and WPAI scores for both treatment groups versus placebo from the first measured timepoint through Week 52.

Across the primary and key secondary endpoints, treatment effect was observed in the TNFi subgroups, including subjects with prior TNFi exposure or failure and those with primary non-response to TNFi. The magnitude of observed treatment effects was similar for subjects treated with tofacitinib 5 mg BID and tofacitinib 10 mg BID in the subgroups of subjects without prior TNFi exposure or failure. In contrast, there was a clinically meaningful observed treatment difference between tofacitinib 10 mg BID and 5 mg BID in the subgroup of subjects with prior TNFi failure, with differences between the 2 tofacitinib groups ranging from 9.7 to 16.7 percentage points across the primary and key secondary endpoints. Data shows that for endpoint of sustained corticosteroid-free remission at both weeks 24 and 52 in study A3921096 among subjects in remission at baseline for tofacitinib 5 mg BID or 10 mg BID versus placebo in those with prior TNFi failure figures were 22.2%, 38.9% and 4.8% respectively. Compared to 40.4%, 51.4% and 4.3% in those who had not failed TNFi previously.

Sub-group analyses for maintenance of remission were subsequently provided by the applicant for subjects by prior TNFi failure. These demonstrated that for the key endpoint of sustained corticosteroid free remission in those at remission at baseline, the efficacy of the 10 mg BID maintenance dosing schedule was greater than for the 5 mg BID dosing. While a trend toward superiority over placebo was reported for the 5 mg BID maintenance posology, the 95% CIs precluded a statistical claim of superiority. For the higher, 10 mg BID maintenance posology, superiority was clearly demonstrated over placebo, particularly in the sub-group of patients with only 1 prior TNFi failure and in secondary TNFi non-responders, although favourable trends were seen in other sub-populations.

The Applicant has proposed that the recommended dose for induction of patients with moderate to severe UC is 10 mg BID for up to 16 weeks. Although this recommendation deviated from the CHMP Scientific Advice (EMEA/H/SA/1219/4/FU/1/2016/II), the applicant provided an efficacy and safety justification for this extended 10mg BID induction period for patients with an inadequate clinical response to an initial 8-week regimen, based upon the results of the open-label LTE study. This indicated an incremental efficacy response between 8 and 16 weeks that would not otherwise be achievable with a 12-week cut-off, and no significant additional safety risks were evident in the subsequent 8-weeks compared to the initial 8-weeks.

The design of the UC program included conversion from active (tofacitinib) treatment to placebo in some subjects during re-randomization at the time of entry into the maintenance study. There were no reports of pharmacological effects of withdrawal or rebound in the UC program.

The MAH provided a comprehensive evaluation regarding extra-intestinal manifestations in the UC programme, including efficacy analyses by prior history or baseline presence of EIMs and also an analysis of the effects of tofacitinib on changes from baseline in EIM activity. For the former, no clear difference was noted in the efficacy of tofacitinib between EIM subgroups. The clinical efficacy advantage of the 10mg BID dosing over the 5mg BID dosing in the maintenance study was more pronounced for the patients with prior or active EIMs. Data regarding the numbers of patients with change in status of EIMs during the induction and maintenance studies were limited, although it was noted that among subjects with peripheral arthritis at

<div style=\"page-break-after: always\"></div>

induction baseline, more patients in general improved on tofacitinib treatment than worsened. It is agreed that it is not possible to make general conclusions regarding the specific effects of tofacitinib on EIMs and there is no evidence to suggest any effects that may alter the outcome of efficacy and safety assessments.

## 2.5.4. Conclusions on the clinical efficacy

The pivotal induction studies A3921094 and A3921095 were appropriately designed. For the primary endpoint of remission superiority has been demonstrated to placebo for tofacitinib 10 mg BID for 8 weeks; in induction treatment in subjects with moderately to severely active UC who failed or were intolerant to at least 1 protocol specified UC treatment, either corticosteroids, AZA/6-MP, or TNFi therapy. Statistical significantly benefit was also demonstrated for the relevant secondary endpoints. An appropriate justification has been provided in support of an extended, 16-week total induction period for patients with inadequate clinical response during the initial 8-week induction phase.

For the pivotal maintenance study A3921096, the primary endpoint presented was remission at 52 weeks. However, though sustained corticosteroid steroid free remission in those at remission at baseline was presented as a secondary endpoint, in line with the CHMP guidance this should be viewed as a primary analysis endpoint. The applicant initially claimed separate indications on induction and maintenance of remission however agreed on CHMP request to update the wording to treatment of  adult patients with moderately to severely active ulcerative colitis (UC) to fulfil the draft EMA UC guideline as well as to be consistent with the wording of others biologic therapies.

The proportion of subjects in sustained corticosteroid-free remission among subjects in remission at baseline was statistically significantly greater in both the tofacitinib 5 mg BID group and the tofacitinib 10 mg BID group compared with the placebo group. Tofacitinib 5 mg BID and Tofacitinib 10 mg BID were also superior to placebo for the primary endpoint of remission at Week 52, and other relevant secondary endpoints. The incremental benefit of 10 mg BID maintenance dosing over the 5 mg BID maintenance dosing is particularly pronounced in patients who have failed previous TNFi therapy, and it is acknowledged that the trial evidence supports the posology recommendation that the 10 mg BID maintenance schedule should be considered in this sub-group of TNFi-refractory patients.

Overall the clinical efficacy of tofacitinib in the treatment of UC has been adequately demonstrated.

## 2.6. Clinical safety

Tofacitinib is already approved for the treatment of moderate to severe rheumatoid arthritis (RA). In the RA program it was identified that Tofacitinib causes neutropenia and lymphopenia, and is associated with a risk of serious infections (e.g. pneumonia) and opportunistic infections (OI) (e.g. herpes zoster (HZ)). The incidence rate for serious infection was 3.6 per 100 patient year (PY) during the RA programme compared to 1.7 for placebo; there was a higher incidence in the elderly. Neoplasms represent an important potential risk due to the mechanism of action. Common ADRs include headache, URTI, nasopharyngitis, diarrhoea, nausea, and hypertension.

<div style=\"page-break-after: always\"></div>

## Patient exposure

The safety data of the UC program were analysed as 3 cohorts and an induction non-responder (IndNR) subgroup:

Cohort 1 (Phase 2, Phase 3 [P2P3] Induction) consists of 1220 subjects in the Phase 2 and Phase 3 induction studies, and evaluates short-term safety of induction therapy with tofacitinib 10 mg BID versus placebo for up to 8 weeks.

Cohort 2 (P3 Maintenance) consists of 592 subjects in the Phase 3 maintenance study, and evaluates longerterm safety of maintenance therapy with tofacitinib 5 mg BID and tofacitinib 10 mg BID versus placebo for up to 52 weeks.

The IndNR subgroup consists of subjects who failed to show clinical response at the end of a Phase 3 induction study and then entered the LTE Study A3921139 to be treated with open-label tofacitinib 10 mg BID. The entire IndNR subgroup, with data captured for up to 53 weeks into Study A3921139, are used to supplement the assessment of the safety profile of the tofacitinib 10 mg BID group in Cohort 2 (P3 Maintenance).

Cohort 3 (Phase 2, Phase 3, long-term extension [P2P3LTE] Tofacitinib) consists of all 1157 subjects who received tofacitinib 5 mg BID or 10 mg BID in the UC development program (including all induction, maintenance and LTE studies), and provides assessment of the entire safety experience with tofacitinib for up to 4.4 years. For Cohort 3 (P2P3LTE Tofacitinib), primary analyses were performed for all subjects who received tofacitinib (the Tofacitinib All group), with supplemental analyses performed for the Predominant Dose (PD) groups and Post-induction Dose (PInd) groups. Most subjects were categorized to the PD 10 mg BID group (84%) in the PD dose groups, and to the PInd 10 mg BID group (78%) in the PInd dose groups.

External independent adjudication committees were established for reviews of potential AEs of opportunistic infections (OIs), malignancies, cardiovascular (CV) events, hepatic events, and gastrointestinal (GI) perforations.

## Adverse events

## Cohort 1 (P2P3 Induction)

In the induction studies, the proportions of subjects with AEs, SAEs, and severe AEs were similar between the placebo group and the tofacitinib group over the 9-week study treatment. The system organ classifications (SOCs) in which AEs occurred most frequently (all causality) among tofacitinib-treated subjects were Gastrointestinal disorders (17.7%) and Infections and infestations (21.1%; compared to 21.6% and 15.2%, respectively, for placebo.

Treatment Emergent Adverse Events (All Causality) Occurring in ≥ 2% of Subjects in any Treatment Group by System Organ Class SOC and Preferred Term PT in Cohort 1:

<div style=\"page-break-after: always\"></div>

| SOC PT                                          | Placebo (N=282)   | Tofacitinib10mgBID (N=938)   |
|-------------------------------------------------|-------------------|------------------------------|
|                                                 | n (%)             | n (%)                        |
| Bloodandlymphaticsystemdisorders                | 9 (3.19)          | 22 (2.35)                    |
| Anaemia                                         | 9 (3.19)          | 22 (2.35)                    |
| Gastrointestinaldisorders                       | 40 (14.18)        | 72 (7.68)                    |
| Abdominal pain                                  | 11 (3.90)         | 25 (2.67)                    |
| Colitis ulcerative                              | 20 (7.09)         | 26 (2.77)                    |
| Nausea                                          | 11 (3.90)         | 28 (2.99)                    |
| Generaldisordersandadministrativesiteconditions | 4 (1.42)          | 24 (2.56)                    |
| Pyrexia                                         | 4 (1.42)          | 24 (2.56)                    |
| Infections and infestations                     | 20 (7.09)         | 82 (8.74)                    |
| Nasopharyngitis                                 | 14 (4.96)         | 56 (5.97)                    |
| Upper respiratory tract infection               | 6 (2.13)          | 26 (2.77)                    |
| Investigations                                  | 3 (1.06)          | 25 (2.67)                    |
| Bloodcreatinephosphokinaseincreased             | 3 (1.06)          | 25 (2.67)                    |
| Musculoskeletalandconnectivetissuedisorders     | 12 (4.26)         | 27 (2.88)                    |
| Arthralgia                                      | 12 (4.26)         | 27 (2.88)                    |
| Nervoussystemdisorders                          | 19 (6.74)         | 73 (7.78)                    |
| Headache                                        | 19 (6.74)         | 73 (7.78)                    |
| Respiratory, thoracic and mediastinal disorders | 7 (2.48)          | 13 (1.39)                    |
| Cough                                           | 7 (2.48)          | 13 (1.39)                    |
| Skinandsubcutaneoustissuedisorders              | 1 (0.35)          | 25 (2.67)                    |
| Acne                                            | 1 (0.35)          | 25 (2.67)                    |

Abbreviations: BID = twice daily; MedDRA = Medical Dictionary for Regulatory Activities; P2P3 = Phase 2, Phase 3;

PT = preferred term; SOC = system organ class; TEAE = treatment-emergent adverse event.

Subjects are only counted onceper treatmentforeachrow.

Only MedDRA preferred terms with an incidence of ≥2% of subjects in any treatment group are counted in the summary table.

Source:5.3.5.3SCS Table14.2.2.8.c1

The commonest AEs by preferred term (PT) among tofacitinib-treated subjects were Headache (7.8%) and Nasopharyngitis (6.0%) compared to 6.7% and 5.0%, respectively, in placebo.

In the complete treatment population with tofacitinib, the most commonly reported infection was nasopharyngitis, occurring in 18.2% of patients (211 patients). In the entire treatment experience with Xeljanz, the overall incidence rate of infections was 60.3 events per 100 patient-years (involving 49.4% of patients; total 572 patients).

## Cohort 2 (P3 Maintenance)

In the maintenance study, the proportions of subjects with AEs, SAEs, and severe AEs were also similar among the placebo group and the tofacitinib groups regardless of the tofacitinib dose. In the tofacitinib All group in Cohort 2 (P3 Maintenance), the SOCs in which AEs most frequently occurred (all causality) were Gastrointestinal disorders SOC and Infections and infestations SOC, and the most frequently reported PTs for AEs among tofacitinib-treated subjects were Colitis ulcerative and Nasopharyngitis.

## IndNR Subgroup

The proportions of subjects with AEs, severe AEs and discontinuations due to AEs were generally similar between the entire IndNR subgroup (data captured for up to 53 weeks into LTE Study A3921139) and the tofacitinib 10 mg BID group in Cohort 2 (P3 Maintenance). The proportion of subjects with SAEs was numerically higher in the IndNR subgroup than the tofacitinib 10 mg BID group in Cohort 2 (10.0% versus 5.6%).

<div style=\"page-break-after: always\"></div>

## Treatment Emergent Adverse Events (All Causality) Occurring in ≥ 2% of Subjects in any Treatment Group by System Organ Class SOC and Preferred Term PT in Cohort 2:

| SOC PT                                               | Placebo (N =198)   | Tofacitinib 5 mgBID (N = 198)   | Tofacitinib 10 mg BID (N =196)   | Tofacitinib AlI (N =394)   | IndNR Subgroup Tofacitinib 10 mg BID (N=429)   |
|------------------------------------------------------|--------------------|---------------------------------|----------------------------------|----------------------------|------------------------------------------------|
|                                                      | n (%)              | n(%)                            | n (%)                            | n (%)                      | n(%)                                           |
| Blood and lymphatic system disorders                 | 3 (1.52)           | 8 (4.04)                        | 4 (2.04)                         | 12 (3.05)                  | 17 (3.96)                                      |
| Anaemia                                              | 3 (1.52)           | 8 (4.04)                        | 4 (2.04)                         | 12 (3.05)                  | 17 (3.96)                                      |
| Gastrointestinal disorders                           | 86 (43.43)         | 51 (25.76)                      | 51 (26.02)                       | 102 (25.89)                | 115 (26.81)                                    |
| Abdominal pain                                       | 11 (5.56)          | 5 (2.53)                        | 7 (3.57)                         | 12 (3.05)                  | 21 (4.90)                                      |
| Abdominal pain upper                                 | 4 (2.02)           | 0                               | 2 (1.02)                         | 2 (0.51)                   | VN                                             |
| Colitis ulcerative                                   | 71 (35.86)         | 36 (18.18)                      | 29 (14.80)                       | 65 (16.50)                 | 60 (13.99)                                     |
| Constipation                                         | VN                 | NA                              | VN                               | VN                         | 9 (2.10)                                       |
| Diarrhoea                                            | 5 (2.53)           | 3 (1.52)                        | 9 (4.59)                         | 12 (3.05)                  | 13 (3.03)                                      |
| Dyspepsia                                            | 2 (1.01)           | 4 (2.02)                        | 1 (0.51)                         | 5 (1.27)                   | NA                                             |
| Flatulence                                           | NA                 | NA                              | NA                               | NA                         | 9 (2.10)                                       |
| Frequent bowel movements                             | 4 (2.02)           | 3 (1.52)                        | 1 (0.51)                         | 4 (1.02)                   | VN                                             |
| Gastrooesophageal reflux disease                     | 1 (0.51)           | 3 (1.52)                        | 5 (2.55)                         | 8 (2.03)                   | VN                                             |
| Haemorrhoids                                         | VN                 | VN                              | VN                               | VN                         | 9 (2.10)                                       |
| Nausea                                               | 5 (2.53)           | 1 (0.51)                        | 8 (4.08)                         | 9 (2.28)                   | 12 (2.80)                                      |
| Vomiting                                             | 2 (1.01)           | 3 (1.52)                        | 6 (3.06)                         | 9(2.28)                    | 12 (2.80)                                      |
| General disorders and administration site conditions | 20 (10.10)         | 18 (9.09)                       | 19 (9.69)                        | 37 (9.39)                  | 28 (6.53)                                      |
| Asthenia                                             | 4 (2.02)           | 3 (1.52)                        | 2 (1.02)                         | 5 (1.27)                   | VN                                             |
| Chest pain                                           | 0                  | 2 (1.01)                        | 5 (2.55)                         | 7 (1.78)                   | VN                                             |
| Fatigue                                              | 11 (5.56)          | 8 (4.04)                        | 4 (2.04)                         | 12 (3.05)                  | 17 (3.96)                                      |
| Influenza like illness                               | 1 (0.51)           | 4 (2.02)                        | 3 (1.53)                         | 7 (1.78)                   | VN                                             |
| Pyrexia                                              | 5 (2.53)           | 3 (1.52)                        | 6 (3.06)                         | 9(2.28)                    | 11 (2.56)                                      |
| Infections and infestations                          | 38 (19.19)         | 58 (29.29)                      | 70 (35.71)                       | 128 (32.49)                | 112 (26.11)                                    |
| Bronchitis                                           | 3 (1.52)           | 5 (2.53)                        | 6 (3.06)                         | 11 (2.79)                  | NA                                             |
| Cystitis                                             | 0                  | 1 (0.51)                        | 4 (2.04)                         | 5 (1.27)                   | NA                                             |
| Folliculitis                                         | 1 (0.51)           | 2 (1.01)                        | 5 (2.55)                         | 7 (1.78)                   | VN                                             |
| Gastroenteritis                                      | 5 (2.53)           | 6 (3.03)                        | 8 (4.08)                         | 14 (3.55)                  | 15 (3.50)                                      |
| Herpes zoster                                        | 1 (0.51)           | 2 (1.01)                        | 10 (5.10)                        | 12 (3.05)                  | 9 (2.10)                                       |
| Influenza                                            | 7 (3.54)           | 4 (2.02)                        | 7 (3.57)                         | 11 (2.79)                  | 12 (2.80)                                      |
| Nasopharyngitis                                      | 11 (5.56)          | 19 (9.60)                       | 27 (13.78)                       | 46 (11.68)                 | 56 (13.05)                                     |
| Oral herpes                                          | 0                  | 4 (2.02)                        | 5 (2.55)                         | 9 (2.28)                   | NA                                             |
| Pharyngitis                                          | 3 (1.52)           | 6 (3.03)                        | 1 (0.51)                         | 7 (1.78)                   | VN                                             |
| Sinusitis                                            | 2 (1.01)           | 6 (3.03)                        | 2 (1.02)                         | 8 (2.03)                   | VN                                             |
| Tooth abscess                                        | 0                  | 2 (1.01)                        | 4 (2.04)                         | 6 (1.52)                   | NA                                             |

| SOC PT                                        | Placebo (N =198)   | Tofacitinib 5 mgBID (N =198)   | Tofacitinib 10 mg BID (N =196)   | Tofacitinib All (N =394)   | IndNR Subgroup Tofacitinib 10 mgBID (N=429)   |
|-----------------------------------------------|--------------------|--------------------------------|----------------------------------|----------------------------|-----------------------------------------------|
| Upperrespiratory tractinfection               | 7 (3.54)           | 13 (6.57)                      | 12 (6.12)                        | 25 (6.35)                  | 29 (6.76)                                     |
| Urinary tract infection                       | 4 (2.02)           | 5 (2.53)                       | 6 (3.06)                         | 11 (2.79)                  | 13 (3.03)                                     |
| Investigations                                | 4 (2.02)           | 10 (5.05)                      | 21 (10.71)                       | 31 (7.87)                  | 22 (5.13)                                     |
| Alanine aminotransferase increased            | 0                  | 1 (0.51)                       | 4 (2.04)                         | 5 (1.27)                   | VN                                            |
| Blood creatine phosphokinase increased        | 4 (2.02)           | 6 (3.03)                       | 13 (6.63)                        | 19 (4.82)                  | 22 (5.13)                                     |
| Weight increased                              | 0                  | 3 (1.52)                       | 4 (2.04)                         | 7 (1.78)                   | VN                                            |
| Metabolism andnutritiondisorders              | 2 (1.01)           | 4 (2.02)                       | 11 (5.61)                        | 15 (3.81)                  | 15 (3.50)                                     |
| Hypercholesterolaemia                         | 2 (1.01)           | 4 (2.02)                       | 11 (5.61)                        | 15 (3.81)                  | 15 (3.50)                                     |
| Musculoskeletal andconnectivetissue disorders | 29 (14.65)         | 28 (14.14)                     | 26 (13.27)                       | 54 (13.71)                 | 32 (7.46)                                     |
| Arthralgia                                    | 19 (9.60)          | 17 (8.59)                      | 17 (8.67)                        | 34 (8.63)                  | 24 (5.59)                                     |
| Back pain                                     | 4 (2.02)           | 5 (2.53)                       | 6 (3.06)                         | 11 (2.79)                  | 11 (2.56)                                     |
| Musculoskeletal pain                          | 5 (2.53)           | 1 (0.51)                       | 2 (1.02)                         | 3 (0.76)                   | NA                                            |
| Myalgia                                       | 4 (2.02)           | 6 (3.03)                       | 1 (0.51)                         | 7 (1.78)                   | NA                                            |
| Pain in extremity                             | 2 (1.01)           | 6 (3.03)                       | 2 (1.02)                         | 8 (2.03)                   | NA                                            |
| Nervoussystem disorders                       | 12 (6.06)          | 17 (8.59)                      | 6 (3.06)                         | 23 (5.84)                  | 17 (3.96)                                     |
| Headache                                      | 12 (6.06)          | 17 (8.59)                      | 6 (3.06)                         | 23 (5.84)                  | 17 (3.96)                                     |
| Psychiatric disorders                         | 1 (0.51)           | 4 (2.02)                       | 1 (0.51)                         | 5 (1.27)                   | NA                                            |
| Depression                                    | 1 (0.51)           | 4 (2.02)                       | 1 (0.51)                         | 5 (1.27)                   | NA                                            |
| Respiratory,thoracic andmediastinal disorders | 6 (3.03)           | 9 (4.55)                       | 10 (5.10)                        | 19 (4.82)                  | 9 (2.10)                                      |
| Cough                                         | 5 (2.53)           | 6 (3.03)                       | 5 (2.55)                         | 11 (2.79)                  | 9 (2.10)                                      |
| Oropharyngeal pain                            | 1 (0.51)           | 3 (1.52)                       | 7 (3.57)                         | 10 (2.54)                  | NA                                            |
| Skin and subcutaneous tissue disorders        | 19 (9.60)          | 18 (9.09)                      | 22 (11.22)                       | 40 (10.15)                 | 31 (7.23)                                     |
| Acne                                          | 2 (1.01)           | 5 (2.53)                       | 1 (0.51)                         | 6 (1.52)                   | 12 (2.80)                                     |
| Dermatitis                                    | 0                  | 1 (0.51)                       | 4 (2.04)                         | 5 (1.27)                   | NA                                            |
| Dermatitis acneiform                          | 0                  | 1 (0.51)                       | 4 (2.04)                         | 5 (1.27)                   | NA                                            |
| Dry skin                                      | 6 (3.03)           | 1 (0.51)                       | 1 (0.51)                         | 2 (0.51)                   | NA                                            |
| Pruritus                                      | 6 (3.03)           | 1 (0.51)                       | 1 (0.51)                         | 2 (0.51)                   | NA                                            |
| Rash                                          | 8 (4.04)           | 6 (3.03)                       | 11 (5.61)                        | 17 (4.31)                  | 19 (4.43)                                     |
| Rosacea                                       | 0                  | 4 (2.02)                       | 1 (0.51)                         | 5 (1.27)                   | NA                                            |
| Vascular disorders                            | 1 (0.51)           | 4 (2.02)                       | 4 (2.04)                         | 8 (2.03)                   | NA                                            |
| Hypertension                                  | 1 (0.51)           | 4 (2.02)                       | 4 (2.04)                         | 8 (2.03)                   | NA                                            |

<div style=\"page-break-after: always\"></div>

In the tofacitinib All group in Cohort 2 (P3 Maintenance), the SOCs in which AEs most frequently occurred (all causality) were Gastrointestinal disorders SOC and Infections and infestations SOC, and the most frequently reported PTs for AEs among tofacitinib-treated subjects were Colitis ulcerative and Nasopharyngitis.

IndNR Subgroup :The proportions of subjects with AEs, severe AEs and discontinuations due to AEs were generally similar between the entire IndNR subgroup (data captured for up to 53 weeks into LTE Study A3921139) and the tofacitinib 10 mg BID group in Cohort 2 (P3 Maintenance). The proportion of subjects with SAEs was numerically higher in the IndNR subgroup than the tofacitinib 10 mg BID group in Cohort 2 (10.0% versus 5.6%).

## Cohort 3 (P2P3LTE Tofacitinib) Treatment Emergent Adverse Events (All Causality) Occurring in ≥ 2% of Subjects in any Treatment Group by System Organ Class SOC and Preferred Term PT in Cohort 3:

| SOC PT                                                      | Tofacitinib AIl (N = 1157)        | Predominant Dose 5mgBID (N = 186)   | Predominant Dose 10 mgBID (N = 971)   | Post-InductionDose 5mg BID (N =220)   | Post-InductionDose 10 mg BID (N = 771)   |
|-------------------------------------------------------------|-----------------------------------|-------------------------------------|---------------------------------------|---------------------------------------|------------------------------------------|
| Bloodandlymphaticsystemdisorders Anaemia                    | n (%) 60 (5.19) 60 (5.19)         | n (%) 9 (4.84) 9 (4.84)             | n (%) 51 (5.25) 51 (5.25)             | n (%) 13 (5.91) 13 (5.91)             | n (%) 42 (5.45) 42 (5.45)                |
| Gastrointestinaldisorders Abdominal pain Colitis ulcerative | 440 (38.03) 80 (6.91) 224 (19.36) | 64 (34.41) 12 (6.45) 34 (18.28)     | 376 (38.72) 68 (7.00) 190 (19.57)     | 75 (34.09) 11 (5.00) 47 (21.36)       | 292 (37.87) 56 (7.26)                    |
| Nausea Generaldisordersandadministration site               | 57 (4.93) 149 (12.88)             | 3 (1.61)                            | 54 (5.56) 123 (12.67)                 | 5 (2.27) 24 (10.91)                   | 129 (16.73) 39 (5.06)                    |
| conditions Fatigue                                          |                                   |                                     | 47 (4.84)                             | 12 (5.45)                             |                                          |
| Infections andinfestations                                  | 54 (4.67)                         | 26 (13.98)                          |                                       |                                       | 93 (12.06)                               |
|                                                             | 495 (42.78)                       |                                     |                                       |                                       |                                          |
|                                                             |                                   | 7 (3.76) 101 (54.30)                |                                       | 88 (40.00)                            | 36 (4.67)                                |
| Gastroenteritis                                             | 60 (5.19)                         | 7(3.76)                             | 394 (40.58) 53 (5.46)                 | 7 (3.18)                              | 339 (43.97) 47 (6.10)                    |
| Herpes zoster Influenza                                     | 61 (5.27) 67 (5.79)               | 12 (6.45) 11 (5.91)                 | 49 (5.05) 56 (5.77)                   | 9 (4.09) 7 (3.18)                     | 42 (5.45) 48 (6.23)                      |
| Nasopharyngitis                                             | 211 (18.24)                       | 44 (23.66)                          | 167 (17.20)                           | 35 (15.91) 20 (9.09)                  | 153 (19.84)                              |
|                                                             | 103 (8.90)                        |                                     |                                       |                                       | 76 (9.86)                                |
| Upper respiratory tract infection                           |                                   | 17 (9.14)                           | 86 (8.86)                             | 23 (10.45)                            | 95 (12.32)                               |
|                                                             | 163 (14.09)                       | 34 (18.28)                          | 129 (13.29)                           |                                       |                                          |
| Investigations Blood creatine phosphokinase increased       | 115 (9.94)                        | 20 (10.75)                          | 95 (9.78)                             | 17 (7.73)                             | 83 (10.77)                               |
| Metabolismandnutritiondisorders                             | 60 (5.19)                         | 11 (5.91)                           | 49 (5.05)                             | 8 (3.64)                              | 47 (6.10)                                |
| Hypercholesterolaemia                                       | 60 (5.19)                         | 11 (5.91)                           | 49 (5.05)                             | 8 (3.64)                              | 47 (6.10)                                |
| Musculoskeletalandconnectivetissue                          | 179 (15.47)                       | 34 (18.28)                          | 145 (14.93)                           | 38 (17.27)                            | 125 (16.21)                              |
| disorders Arthralgia                                        | 122 (10.54)                       | 23 (12.37)                          | 99 (10.20)                            | 23 (10.45)                            | 84 (10.89)                               |
|                                                             | 142 (12.27)                       | 25 (13.44)                          | 117 (12.05)                           | 32 (14.55)                            | 83 (10.77)                               |
| Nervoussystemdisorders Headache                             | 121 (10.46)                       | 23 (12.37)                          | 98 (10.09)                            | 30 (13.64)                            | 74 (9.60)                                |
| Skin andsubcutaneoustissuedisorders Rash                    | 127 (10.98) 63 (5.45)             | 22 (11.83) 9 (4.84)                 | 105 (10.81) 54 (5.56)                 | 20 (9.09) 8 (3.64)                    | 89 (11.54) 48 (6.23)                     |

AEs were reported in 82.1% of subjects, and the most frequently occurring AEs (all causalities) were in the Infections and infestations System Organ Class (SOC) (42.8% of subjects) and GI disorders SOC (38.0% of subjects), and the most frequently occurring preferred terms (PTs) for AEs were Colitis ulcerative (19.4% of subjects) and Nasopharyngitis

## AEs in Subjects Who Received Induction Treatment with Tofacitinib 15 mg BID

71 subjects received tofacitinib 15 mg BID for induction therapy (49 in Study A3921063, 16 in Study A3921094, and 6 in Study A3921095). There were no deaths, no serious infections, no herpes zoster cases, and no malignancies (either NMSC or malignancies [excluding NMSC]). Two (2) of these 71 subjects reported SAEs (2 events related to worsening UC in 2 subjects) during induction treatment. In the Phase 3 induction Studies A3921094 and A3921095, none of the 22 subjects who received tofacitinib 15 mg BID had AEs confirmed to be OI, MACE or GI perforation by external adjudication committees. In the Phase 2 induction

<div style=\"page-break-after: always\"></div>

Study A3921063, where external adjudication committees were not employed, none of the 49 subjects who received tofacitinib 15 mg BID had AEs suggestive of OI, MACE or GI perforation.

Summary of Treatment-Emergent Adverse Events (All Causality) in Tofacitinib UC Program

<div style=\"page-break-after: always\"></div>

| Cohort 1(P2P3 Induction)                                                   | Cohort 1(P2P3 Induction)   | Cohort 1(P2P3 Induction)      |
|----------------------------------------------------------------------------|----------------------------|-------------------------------|
|                                                                            | Placebo (N = 282)          | Tofacitinib 10mgBID (N = 938) |
| Subjects evaluable for AE                                                  | 282                        | 938                           |
| Number of AEs                                                              | 319                        | 1171                          |
| Subjects with AE, n (%)                                                    | 155 (55.0)                 | 515 (54.9)                    |
| Subjects with SAE, n (%)                                                   | 18 (6.4)                   | 36 (3.8)                      |
| Subjects with severe AE, n (%)                                             | 15 (5.3)                   | 38 (4.1)                      |
| Subjects discontinued due to AE, n (%)                                     | 14 (5.0)                   | 36 (3.8)                      |
| Subjects with dose reduction or temporary discontinuation due to AE, n (%) | 5 (1.8)                    | 16 (1.7)                      |

## Cohort 2 (P3 Maintenance)

|                                                                            | Placebo (N = 198)   | Tofacitinib 5 mg BID (N =198)   | Tofacitinib 10 mg BID (N =196)   | Tofacitinib All (N = 394)   | IndNR Subgroup Tofacitinib 10 mg BID (N = 429)a   |
|----------------------------------------------------------------------------|---------------------|---------------------------------|----------------------------------|-----------------------------|---------------------------------------------------|
| Subjects evaluable for AE                                                  | 198                 | 198                             | 196                              | 394                         | 429                                               |
| Number of TEAEs                                                            | 406                 | 474                             | 525                              | 999                         | 1023                                              |
| Subjects with AE, n (%)                                                    | 149 (75.3)          | 143 (72.2)                      | 156 (79.6)                       | 299 (75.9)                  | 318 (74.1)                                        |
| Subjects with SAE, n (%)                                                   | 13 (6.6)            | 10 (5.1)                        | 11 (5.6)                         | 21 (5.3)                    | 43 (10.0)                                         |
| Subjects with severe AE, n (%)                                             | 19 (9.6)            | 14 (7.1)                        | 15 (7.7)                         | 29 (7.4)                    | 32 (7.5)                                          |
| Subjects discontinued due to AE, n (%)                                     | 37 (18.7)           | 18 (9.1)                        | 19 (9.7)                         | 37 (9.4)                    | 51 (11.9)                                         |
| Subjects with dose reduction or temporary discontinuation due to AE, n (%) | 4 (2.0)             | 6 (3.0)                         | 15 (7.7)                         | 21 (5.3)                    | 11 (2.6)                                          |

## Cohort 3 (P2P3LTE)

|                                                                            | Tofacitinib All (N = 1156)   | Predominant Dose 5 mg BID (N = 172)   | Predominant Dose 10 mg BID (N = 984)   | Post-Induction Dose 5 mg BID (N = 216)   | Post-Induction Dose 10 mg BID (N = 768)   |
|----------------------------------------------------------------------------|------------------------------|---------------------------------------|----------------------------------------|------------------------------------------|-------------------------------------------|
| Subjects evaluablefor AE                                                   | 1157                         | 186                                   | 971                                    | 220                                      | 771                                       |
| Number of TEAEs                                                            | 4728                         | 840                                   | 3888                                   | 818                                      | 3221                                      |
| Subjects with AE, n (%)                                                    | 950 (82.1)                   | 166 (89.2)                            | 784 (80.7)                             | 180 (81.8)                               | 652 (84.6)                                |
| Subjects with SAEs, n (%)                                                  | 169 (14.6)                   | 20 (10.8)                             | 149 (15.3)                             | 19 (8.2)                                 | 103 (13.4)                                |
| Subjects with severe AE, n (%)                                             | 144 (12.4)                   | 19 (10.2)                             | 125 (12.9)                             | 18 (8.2)                                 | 85 (11.0)                                 |
| Subjects with dose reduction or temporary discontinuation due to AE, n (%) | 78 (6.7)                     | 21 (11.3)                             | 57 (5.9)                               | 14 (6.4)                                 | 57 (7.4)                                  |

Sources: 2.7.4 Table 10; Table 11; Table 12.

Abbreviations: AE = adverse event; BID = twice a day; IndNR = induction non-responder; N = number of subjects randomized and treated; n = number of subjects with events; P3 = Phase 3; P2P3 = Phase 2.

Phase 3; P2P3LTE = Phase 2, Phase 3, long-term extension; SAE = serious adverse event; TEAE =

treatment-emergent adverse event; UC = ulcerative colitis.

The subjects who permanently discontinued the study drug due to AEs, including AEs related to worsening UC, are summarized.

- a. IndNR subgroup data are data captured through 53 weeks into Study A3921139.

<div style=\"page-break-after: always\"></div>

There are no AEs with increased incidence for tofacitinib compared to placebo, which are not already considered an ADR of tofacitinib (common or very common), as listed in the current approved SmPC (RA indication).

Dose dependency for the risk of Herpes Zoster (HZ) and opportunistic infections (OIs) (mainly HZ) and NMSC was observed in the overall population treated with tofacitinib in the UC program. There was a trend toward an increased risk of HZ and NMSC in the TNFi-failure subgroup compared with the non-TNFi-failure subgroup.

The IR of opportunistic infections (OIs) and Herpes Zoster (HZ) in UC Cohort 3 (P2P3LTE Tofacitinib i.e all subjects who had received at least 1 dose of tofacitinib in the UC program) was higher than in the RA or PsO programs. The MAH reports that subjects in the UC programme differ from subjects in the RA and PsO programmes in selected demographics and baseline characteristics (e.g. concomitant medicines), and such variations may affect the propensity to develop specific safety events, eg, NMSC in UC patients who received prior immunosuppressants , and PsO patients who received prior phototherapy. There may also be other differences among patients in the UC, RA, and PsO programs that affect the susceptibility of these patients to infections or other adverse events (AEs), eg, differences in systemic inflammatory burdens or comorbidities. Such differences among these heterogeneous patient populations may contribute to some degree of variability in IRs of AEs of special interest reported across indications.

Table 1. Cumulative Incidence Rates (per 100 Patient-Years) for Herpes Zoster in Subjects Treated With Tofacitinib (All Doses Combined) in the UC Cohort 3 (P2P3LTE Tofacitinib), RA (All Exposure), and PsO (All Exposure) Programs

| Safety Event   | UC (Cohort 3) N = 1157 Exposure = 1613 PY   | UC (Cohort 3) N = 1157 Exposure = 1613 PY   | RA (All Exposure) N = 7061 Exposure = 22,875 PY   | RA (All Exposure) N = 7061 Exposure = 22,875 PY   | PsO (All Exposure) N = 3663 Exposure = 8955 PY   | PsO (All Exposure) N = 3663 Exposure = 8955 PY   |
|----------------|---------------------------------------------|---------------------------------------------|---------------------------------------------------|---------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
|                | n (%)                                       | IR (95% CI)                                 | n (%)                                             | IR (95% CI)                                       | n (%)                                            | IR (95% CI)                                      |
| Herpes zoster  | 65 (5.6)                                    | 4.07 (3.14, 5.19)                           | 782 (11.1)                                        | 3.63 (3.38,3.90)                                  | 209 (5.7)                                        | 2.35 (2.04, 2.69)                                |

Sources: S0012 2.7.4 SCS Table 67; 5.3.5.3 RA Table 1295.1.3.2; 5.3.5.3 PsO Table 198c.1.1; Table 198c.2.1.1

Abbreviations: CI = confidence interval; IR = incidence rate; N = number of evaluable subjects ; n = number of subjects with events; P2P3LTE = Phase 2, Phase 3, long-term extension; PsO = psoriasis; PY = patient-years; RA = rheumatoid arthritis; UC = ulcerative colitis.

Includes RA Studies A3921019, A3921024, A3921025, A3921032, A3921035, A3921039, A3921040, A3921041, A3921044, A3921045, A3921046, A3921064, A3921068, A3921069, A3921073, A3921109, A3921129, A3921130, A3921152 and A3921237.

Includes psoriasis Studies A3921078, A3921079, A3921080, A3921111, A3921047, A3921147, and A3921061. Events occurring within 28 days following the last dose were included.

UC data as of 16 December 2016; RA data as of 02 March 2017; PsO data based on database finalized on 18 August 2016

The differences in IRs for HZ among indications could be attributable to differences in program design and/or patient characteristics. For example, the percentage of subjects in the UC program who received tofacitinib 10 mg BID (rather than tofacitinib 5 mg BID) most of the time during tofacitinib treatment was higher in the UC program.  In addition, treatment with corticosteroids is a known risk factor for HZ. The mean dose of oral corticosteroids at baseline of UC Cohort 2 (P3 Maintenance) was over twice as high as that at baseline of the RA randomized Phase 3 studies (14.7 versus 6.7 mg/day prednisone-equivalent among subjects who received baseline oral corticosteroids) (S0012 2.7.4 SCS Table 64).  These differences could have contributed to the numerically higher IR of HZ reported in the UC program compared with RA and PsO.

<div style=\"page-break-after: always\"></div>

The IRs of HZ in UC Cohort 2 (P3 Maintenance) demonstrated dose-dependency (placebo 0.97/100 PY, tofacitinib 5 mg BID 2.05/100 PY, tofacitinib 10 mg BID 6.64/100 PY), with statistically significant difference shown between placebo and tofacitinib 10 mg BID.  This assessment of dose-dependency in the risk of HZ in the UC program is consistent with the findings in the RA and PsO programs.  Given the dose-dependency of HZ, the risk of HZ with tofacitinib 10 mg BID may be higher than that associated with 5 mg BID. HZ is a recognized risk of tofacitinib treatment.

Despite dose-dependent increase in the risk of HZ, the majority of HZ events in the UC program were limited to cutaneous involvement. In Cohort 3 (P2P3LTE Tofacitinib), a total of 69 events of HZ occurred in 65 subjects.  Among these events, 3 were severe AEs, and 4 were SAEs.  Herpes zoster resulted in subject discontinuation in 5 (7.7%) of the 65 subjects.  Post-herpetic neuralgia was reported by 3 (4.6%) subjects who developed HZ.  Among the 69 HZ events, 66 events (95.7%) were limited to cutaneous involvement. Visceral HZ was reported in 1 subject (a case of HZ meningitis/encephalitis), which was reported as resolved without neurological sequelae after anti-viral treatment.

Table 1. Cumulative Incidence Rates (per 100 Patient-Years) for Opportunistic Infection in Subjects Treated With Tofacitinib (All Doses Combined) in the UC Cohort 3 (P2P3LTE Tofacitinib), RA (All

## Exposure), and PsO (All Exposure) Programs

| Safety Event                                | UC (Cohort 3) N = 1157 Exposure = 1613 PY   | UC (Cohort 3) N = 1157 Exposure = 1613 PY   | RA (All Exposure) N = 7061 Exposure = 22,875 PY   | RA (All Exposure) N = 7061 Exposure = 22,875 PY   | PsO (All Exposure) N = 3663 Exposure = 8955 PY   | PsO (All Exposure) N = 3663 Exposure = 8955 PY   |
|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------------|---------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| Safety Event                                | n (%)                                       | IR (95% CI)                                 | n (%)                                             | IR (95% CI)                                       | n (%)                                            | IR (95% CI)                                      |
| Opportunistic infection a                   | 21 (1.9)                                    | 1.28 (0.79, 1.96)                           | 90 (1.3)                                          | 0.39 (0.31,0.47)                                  | 29 ( 0.8)                                        | 0.31 (0.21, 0.45)                                |
| Herpes zoster opportunistic infection a     | 17 (1.5)                                    | 1.04 (0.60, 1.66)                           | 56 (0.8)                                          | 0.24 (0.18,0.31)                                  | 25( 0.7)                                         | 0.27 (0.18, 0.40)                                |
| Non-herpes zoster opportunistic infection a | 4 (0.4)                                     | 0.24 (0.07, 0.61)                           | 34 (0.5)                                          | 0.15 (0.10,0.20)                                  | 4 (0.1)                                          | 0.04 (0.01, 0.11)                                |

Sources: S0012 2.7.4 SCS Table 27, Table 67; 5.3.5.3 RA Table 1295.1.3.4, 1403.2.1, 1403.3.1; PsO Tables 198c.1.1, 198c.2.1.1, 198c.2.1.7, 198c.2.1.8

Includes RA Studies A3921019, A3921024, A3921025, A3921032, A3921035, A3921039, A3921040, A3921041, A3921044, A3921045, A3921046, A3921064, A3921068, A3921069, A3921073, A3921109, A3921129, A3921130, A3921152 and A3921237.

Includes psoriasis Studies A3921078, A3921079, A3921080, A3921111, A3921047, A3921147, and A3921061. Events occurring within 28 days following the last dose were included.

## A consistent definition of OI was applied to the UC, RA and PsO programs.

UC data as of 16 December 2016; RA data as of 02 March 2017; PsO data based on final database on 18 August 2016

Abbreviations: CI = confidence interval;  IR = incidence rate; N = number of evaluable subjects ; n = number of subjects with events; OI = opportunistic infection; P2P3LTE = Phase 2, Phase 3, long-term extension; PsO = psoriasis; PY = patient-years; RA = rheumatoid arthritis; UC = ulcerative colitis. a. Adjudicated events.  Percentage (%) was calculated based on the number of subjects in studies in which adjudication was performed.

The IR of OI in UC Cohort 3 (P2P3LTE Tofacitinib) was higher than those in the RA and PsO programs (all exposure) (Table above).  The higher IR of OI in the UC program was predominantly due to the higher IR of HZ events adjudicated to be OIs (ie, HZ OIs) in the UC program (1.04/100 PY) compared with RA/PsO (all exposure) (0.24/100 PY and 0.27/100 PY, respectively).  The IR of non-HZ OI was &lt;0.3/100 PY across indications in the RA and PsO programs (all exposure).

The applicant suggests that as the UC program was conducted at a later time than the RA and PsO programs, the higher IR of HZ OI reported in the UC program may reflect a period effect.  With the accumulation of clinical experience and publications on tofacitinib in RA and PsO studies, there have been increased awareness and understanding of the risk of HZ associated with tofacitinib treatment.  Compared with the

<div style=\"page-break-after: always\"></div>

earlier RA and PsO studies, increased vigilance in monitoring and increased frequency and details of reporting by study sites the UC studies could also have contributed to the higher reported IR of HZ OI in the UC program. Since the risk of developing HZ increased with tofacitinib dose, and most of the OIs were HZ events, the IR of OIs also increased with tofacitinib dose in Cohort 2 (P3 Maintenance (placebo 0.97/100 PY, tofacitinib 5 mg BID 1.36/100 PY, tofacitinib 10 mg BID 2.60/100 PY).  These data are indicative of dosedependency in the risk of OI in the UC program, driven by the dose-dependency in HZ OI.

Non-herpes zoster OIs occurred in 4 subjects in UC Cohort 3, and consisted of 1 event each of pulmonary cryptococcosis, pulmonary histoplasmosis, cytomegalovirus (CMV) hepatitis, and CMV colitis.  The infrequent occurrence of visceral HZ and non-HZ OIs is consistent across indications in the broader tofacitinib development program.

The applicant has provided a comparative evaluation of AEs for the subpopulation undergoing the extended 16-week induction regimen and the 8-week induction cohort. The safety profile of the 2 nd 8 weeks (first part of the LTE) was very similar to that of the initial 8-week induction period. The safety profile of the cumulative 16-week extended induction period did report a higher overall rate of AEs (71.9%) compared to the initial 8week cohort (54.9%) and a slightly higher rate of SAEs (4.7% vs 3.8%) but a comparable rate of discontinuations due to AEs.

## Serious adverse event/deaths/other significant events

## Deaths

As of 16 December 2016, a total of 4 deaths occurred in the entire UC program. After 16 December 2016, death was reported in a subject in the LTE Study A3921139 receiving tofacitinib 10 mg BID. The subject developed cutaneous melanoma, death occurred approximately 5 months after the last dose of tofacitinib.

Summary of Deaths in Tofacitinib UC Program:

<div style=\"page-break-after: always\"></div>

| SSID in Study at Event Onset/ Treatment Group in Study atEventOnset   | PD Treatment Group in Cohort3   | Induction Study SSID   | Country       |   Ageat Baseline of Induction Study (Years) | Gender/ Race   |   Day of Death |   Last Known Dose Day | Medical History                  | EventwithFatal Outcome Preferred Term [Verbatim Term]                                                              | Cause of Death PreferredTerm [VerbatimTerm]                           |
|-----------------------------------------------------------------------|---------------------------------|------------------------|---------------|---------------------------------------------|----------------|----------------|-----------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|
| A3921139 11191001/ Tofacitinib 10 mg BID                              | PD 10mg BID                     | A3921094 11191005      | Italy         |                                          52 | Male / White   |            232 |                   187 | Visceral leishmaniasis           | Hepatic angiosarcoma? [Liver infiltration of angiosarcoma epithelioid]                                             | Hepatic angiosarcoma [liver infiltration of angiosarcoma epithelioid] |
| A3921094 12171003/ Tofacitinib 10 mg BID                              | PD 10 mg BID                    | A3921094 12171003      | Ukraine       |                                          39 | Male / White   |             31 |                    31 | No relevant past medical history | Aortic dissection [Dissecting aortic aneurysm]                                                                     | Aortic dissection [dissecting aortic aneurysm]                        |
| A3921139 12411003/ Tofacitinib 10 mg BID                              | PD 10 mg BID                    | A3921095 12411007      | United States |                                          52 | Male / White   |            398 |                   347 | No relevant past medical history | Acute myeloid leukaemia² [Acute myeloid leukemia]                                                                  | Acute myeloid leukaemia [acute myeloid leukemia]                      |
| A3921139 12671003/ Tofacitinib 10 mg BID                              | PD 10 mg BID                    | A3921094 12671004      | United States |                                          68 | Male / White   |            384 |                   378 | No relevant past medical history | Pulmonary embolism [Cholangio- carcinoma, Peritoneal Carcinomatosis, And Pulmonary Embolism Which ResultedInDeath] | Pulmonary embolism [pulmonary embolism]                               |

Sources:5.3.5.3 SCS Table 14.2.6.c3b; Table 16.5.c3;5.3.5.1 A3921094-report-body Table 14.1.1.3.4; Table 16.2.4.1; Table 16.2.4.3; A3921095-report-body Table 14.1.1.3.4; Table16.2.4.1;Table16.2.4.3

The mortality rate (0.12/100 PY from primary analysis based on 2 deaths occurring within 28 days after last dose, and 0.24/100 PY from sensitivity analysis based on 4 deaths) in the Tofacitinib All group of Cohort 3 (P2P3LTE Tofacitinib) was similar to those reported for the RA (0.26/100 PY) and PsO (0.19/100 PY) programs based on deaths occurring within 28 days after last dose and for UC patients in external observational data .

Proportions and Incidence Rates of Deaths in Cohort 1 (P2P3 Induction), Cohort 2 (P3 Maintenance), the IndNR Subgroup, and Cohort 3 (P2P3LTE Tofacitinib):

<div style=\"page-break-after: always\"></div>

|                                               | Placebo                                       | Tofacitinib 5 mg BID                          | Tofacitinib 10 mg BID                         | Tofacitinib All                               | IndNR Subgroup Tofacitinib 10mgBID            |
|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Cohort1(P2P3Induction)                        |                                               |                                               |                                               |                                               |                                               |
| Totalnumberofsubjects                         | 282                                           | NA                                            | 938                                           | NA                                            | NA                                            |
| Number (%) of subjects with events            | 0                                             | NA                                            | 1 (0.1)                                       | NA                                            | NA                                            |
| Cohort 2 (P3Maintenance) and theIndNRSubgroup | Cohort 2 (P3Maintenance) and theIndNRSubgroup | Cohort 2 (P3Maintenance) and theIndNRSubgroup | Cohort 2 (P3Maintenance) and theIndNRSubgroup | Cohort 2 (P3Maintenance) and theIndNRSubgroup | Cohort 2 (P3Maintenance) and theIndNRSubgroup |
|                                               | Placebo                                       | Tofacitinib 5 mg BID                          | Tofacitinib 10 mg BID                         | Tofacitinib AIl                               | IndNR Subgroup Tofacitinib 10 mg BID          |
| Total number of subjects                      | 198                                           | 198                                           | 196                                           | 394                                           | 429                                           |
| Exposure (PY)                                 | 103.4                                         | 148.8                                         | 157.3                                         | 306.1                                         | 305.5                                         |
| Number (%) of subjects with events            | 0                                             | 0                                             | 0                                             | 0                                             | 0                                             |
| IR (95% CI)                                   | 0.00                                          | 0.00                                          | 0.00                                          | 0.00                                          | 0.00                                          |
|                                               | (0.00, 3.57)                                  | (0.00, 2.48)                                  | (0.00, 2.35)                                  | (0.00, 1.21)                                  | (0.00, 1.21)                                  |
| Cohort3(P2P3LTETofacitinib)                   | Cohort3(P2P3LTETofacitinib)                   | Cohort3(P2P3LTETofacitinib)                   | Cohort3(P2P3LTETofacitinib)                   | Cohort3(P2P3LTETofacitinib)                   | Cohort3(P2P3LTETofacitinib)                   |
|                                               | Tofacitinib All                               | Predominant Dose 5 mg BID                     | Predominant Dose10mgBID                       | Post-Induction Dose5mgBID                     | Post-Induction Dose10mgBID                    |
| Total number of subjects                      | 1157                                          | 186                                           | 971                                           | 220                                           | 771                                           |
| Primary analysis                              |                                               |                                               |                                               |                                               |                                               |
| Exposure (PY)                                 | 1669.28                                       | 369.14                                        | 1300.14                                       | 295.59                                        | 1117.89                                       |
| Number (%) of subjects with events            | 2 (0.2)                                       | 0                                             | 2 (0.2)                                       | 0 (0.0)                                       | 1 (0.1)                                       |
| IR (95% CI)                                   | 0.12 (0.01, 0.43)                             | 0.00 (0.00, 1.00)                             | 0.15 (0.02,0.56)                              | 0.00 (0.00, 1.25)                             | 0.09 (0.00, 0.50)                             |
| Sensitivity analysis                          |                                               |                                               |                                               |                                               |                                               |
| Exposure (PY)                                 | 1669.39                                       | 369.14                                        | 1300.25                                       | 295.59                                        | 1118.00                                       |
| Number (%) of subjects with events            | 4 (0.3)                                       | 0                                             | 4 (0.4)                                       | 0                                             | 3 (0.4)                                       |
| IR (95% CI)                                   | 0.24                                          | 0.00                                          | 0.31                                          | 0.00                                          | 0.27                                          |
| IR (95% CI)                                   | (0.07, 0.61)                                  | (0.00, 1.00)                                  | (0.08, 0.79)                                  | (0.00, 1.25)                                  | (0.06, 0.78)                                  |

Abbreviations: BID = twice daily; CI= confidence interval;IndNR =induction non-responder;IR =incidence rate (number of subjects with events per 100 subject-years); LTE = long-term extension; NA = not applicable; P2P3 = Phase 2, Phase 3; PY = patient-years.

Deaths occurring more than 28 days after the last dose were included in sensitivity analysis.

Sources: 5.3.5.3 SCS Table 14.2.6.1.c1; Table 14.2.6.1.c2; Table 14.2.6.1.inr; Table 14.2.6.1.c3b; Table 14.2.6.1.c3a; Table14.2.6.2.c3b;Table14.2.6.2.c3a

## Serious adverse events

In the Tofacitinib All group of Cohort 3 (P2P3LTE Tofacitinib), the proportion of subjects with SAEs was 14.6%. The proportion of subjects with SAEs was 10.8% for predominant dose (PD) 5 mg BID and 15.3% for PD 10 mg BID. The proportion of subjects with SAEs was 8.6% for PInd 5 mg BID and 13.4% for PInd 10 mg BID

The most frequently reported SOC for SAEs in the Tofacitinib All group in Cohort 3 (P2P3LTE Tofacitinib) was Gastrointestinal disorders, occurring in 6.5% of subjects in the Tofacitinib All group in Cohort 3 (P2P3LTE Tofacitinib).

Similar to Cohort 1 (P2P3 Induction) and Cohort 2 (P3 Maintenance), the most frequently reported PT for SAEs in Cohort 3 (P2P3LTE Tofacitinib) was Colitis ulcerative.

<div style=\"page-break-after: always\"></div>

## Summary of SAEs (All Causality) by SOC and MedDRA PT Occurring in ≥ 2 Subjects in the Tofacitinib All Group in Cohort 3 (P2P3LTE Tofacitinib)

| SOC PT                                                              | Tofacitinib All (N = 1157)   | Predominant Dose5mgBID (N = 186)   | Predominant Dose 10 mg BID (N = 971)   | Post- Induction Dose 5 mg BID (N = 220)   | Post- Induction Dose 10 mg BID (N =771)   |
|---------------------------------------------------------------------|------------------------------|------------------------------------|----------------------------------------|-------------------------------------------|-------------------------------------------|
|                                                                     | n (%)                        | n (%)                              | n (%)                                  | n (%)                                     | n (%)                                     |
| Bloodandlymphaticsystem disorders                                   | 2 (0.2)                      | 0                                  | 2 (0.2)                                | 0                                         | 2 (0.3)                                   |
| Anaemia                                                             | 2 (0.2)                      | 0                                  | 2 (0.2)                                | 0                                         | 2 (0.3)                                   |
| Cardiac disorders                                                   | 7 (0.6)                      | 4 (2.2)                            | 3 (0.3)                                | 3 (1.4)                                   | 3 (0.4)                                   |
| Angina pectoris                                                     | 2 (0.2)                      | 1 (0.5)                            | 1 (0.1)                                | 1 (0.5)                                   | 1 (0.1)                                   |
| Gastrointestinaldisorders                                           | 75 (6.5)                     | 7 (3.8)                            | 68 (7.0)                               | 7 (3.2)                                   | 40 (5.2)                                  |
| Abdominal pain                                                      | 5 (0.4)                      | 0                                  | 5 (0.5)                                | 0                                         | 5 (0.6)                                   |
| Colitis ulcerative                                                  | 54 (4.7)                     | 4 (2.2)                            | 50 (5.1)                               | 4 (1.8)                                   | 25 (3.2)                                  |
| Diarrhoea                                                           | 2 (0.2)                      | 0                                  | 2 (0.2)                                | 0                                         | 2 (0.3)                                   |
| Proctalgia                                                          | 2 (0.2)                      | 1 (0.5)                            | 1 (0.1)                                | 1 (0.5)                                   | 0                                         |
| Proctitis                                                           | 2 (0.2)                      | 0                                  | 2 (0.2)                                | 0                                         | 2 (0.3)                                   |
| General disorders and administrationsiteconditions                  | 6 (0.5)                      | 1 (0.5)                            | 5 (0.5)                                | 1 (0.5)                                   | 3 (0.4)                                   |
| Chest pain                                                          | 2 (0.2)                      | 1 (0.5)                            | 1 (0.1)                                | 1 (0.5)                                   | 1 (0.1)                                   |
| Immunesystemdisorders                                               | 2 (0.2)                      | 0                                  | 2 (0.2)                                | 0                                         | 0                                         |
| Drughypersensitivity                                                | 2 (0.2)                      | 0                                  | 2 (0.2)                                | 0                                         | 0                                         |
| Infections andinfestations                                          | 34 (2.9)                     | 7 (3.8)                            | 27 (2.8)                               | 6 (2.7)                                   | 18 (2.3)                                  |
| Anal abscess                                                        | 2 (0.2)                      | 0                                  | 2 (0.2)                                | 0                                         | 0                                         |
| Appendicitis                                                        | 4 (0.3)                      | 1 (0.5)                            | 3 (0.3)                                | 1 (0.5)                                   | 3 (0.4)                                   |
| Clostridium difficile infection                                     | 2 (0.2)                      | 0                                  | 2 (0.2)                                | 0                                         | 1 (0.1)                                   |
| Herpes zoster                                                       | 3 (0.3)                      | 1 (0.5)                            | 2 (0.2)                                | 1 (0.5)                                   | 2 (0.3)                                   |
| Injury,poisoning and procedural complications                       | 12 (1.0)                     | 0                                  | 12 (1.2)                               | 2 (0.9)                                   | 8 (1.0)                                   |
| Lower limb fracture                                                 | 2 (0.2)                      | 0                                  | 2 (0.2)                                | 1 (0.5)                                   | 1 (0.1)                                   |
| Spinal compressionfracture                                          | 2 (0.2)                      | 0                                  | 2 (0.2)                                | 0                                         | 2 (0.3)                                   |
| Musculoskeletalandconnective                                        | 7 (0.6)                      | 3 (1.6)                            | 4 (0.4)                                | 1 (0.5)                                   | 4 (0.5)                                   |
| tissue disorders Back pain                                          | 2 (0.2)                      | 0                                  | 2 (0.2)                                | 0                                         | 2 (0.3)                                   |
| Osteoarthritis                                                      | 2 (0.2)                      | 1 (0.5)                            | 1 (0.1)                                | 0                                         | 2 (0.3)                                   |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 16 (1.4)                     | 0                                  | 16 (1.6)                               | 0                                         | 13 (1.7)                                  |
| Adenocarcinoma ofcolon                                              | 2 (0.2)                      | 0                                  | 2 (0.2)                                | 0                                         | 1 (0.1)                                   |
| Basal cell carcinoma                                                | 2 (0.2)                      | 0                                  | 2 (0.2)                                | 0                                         | 1 (0.1)                                   |
| Nervous system disorders                                            | 9 (0.8)                      | 2 (1.1)                            | 7 (0.7)                                | 1 (0.5)                                   | 7 (0.9)                                   |
| Sciatica                                                            | 2 (0.2)                      | 0                                  | 2 (0.2)                                | 0                                         | 2 (0.3)                                   |
| Pregnancy,puerperium and perinatal conditions                       | 2 (0.2)                      | 0                                  | 2 (0.2)                                | 1 (0.5)                                   | 1 (0.1)                                   |
| Abortion spontaneous                                                | 2 (0.2)                      | 0                                  | 2 (0.2)                                | 1 (0.5)                                   | 1 (0.1)                                   |
| Renal andurinarydisorders                                           | 7 (0.6)                      | 1 (0.5)                            | 6 (0.6)                                | 1 (0.5)                                   | 6 (0.8)                                   |
| Renal colic                                                         | 2 (0.2)                      | 0                                  | 2 (0.2)                                | 0                                         | 2 (0.3)                                   |
| Ureterolithiasis                                                    | 2 (0.2)                      | 0                                  | 2 (0.2)                                | 0                                         | 2 (0.3)                                   |
| Respiratory,thoracic and mediastinal disorders                      | 6 (0.5)                      | 0                                  | 6 (0.6)                                | 0                                         | 5 (0.6)                                   |
| Pulmonary embolism                                                  | 4 (0.3)                      | 0                                  | 4 (0.4)                                | 0                                         | 4 (0.5)                                   |

Abbreviations: BID = twice daily; MedDRA = Medical Dictionary for Regulatory Activities; N = number of subjects randomized and treated; n = number of subjects with events; P2P3LTE = Phase 2, Phase 3, long-term extension; PT = preferred term; SAE = serious adverse event; SOC = system organ class.

<div style=\"page-break-after: always\"></div>

In the placebo-controlled studies (Cohort 1 [P2P3 Induction] and Cohort 2 [P3 Maintenance]), the proportion of subject with SAEs were similar among the placebo and the tofacitinib groups.

In Cohort 2 (P3 Maintenance), there was no apparent dose dependency in the risk of developing SAEs in tofacitinib-treated subjects.

In Cohort 3 (P2P3LTE Tofacitinib), the most frequently reported SOC for SAE was Gastrointestinal disorders SOC, and the most frequently reported PT for SAE was Colitis ulcerative.

With the exception of the preferred term (PT) Colitis ulcerative, there was no clustering of SAEs into specific PTs.

## Adverse events of special interest

The identified AEs of special interest include, Infections (including serious infections, opportunistic infections OIs, herpes zoster [all], and tuberculosis [TB]); Malignancies (excluding NMSC), NMSC, major adverse cardiovascular event MACE, Hepatic injury cases, including events adjudicated to be Hy's law cases and those assessed to be potential drug-induced liver injury (DILI) cases; GI perforation (all cases) and GI perforation (revised definition);  Interstitial lung disease (ILD); Select hematologic events (anaemia, neutropenia, lymphopenia); AEs of renal impairment and  AEs of CK elevation and rhabdomyolysis.

## Infections (including serious infections, OIs, herpes zoster [all], and tuberculosis [TB]):

Inflammatory bowel disease (IBD) patients are predisposed to infections, due to a number of factors including older age and concomitant immunomodulatory therapy.

There were a smaller number of infection events in the UC program compared with the tofacitinib RA program, differences in study design could contribute to differences in findings from risk factor analyses between the UC and RA programs. For example, in the RA program, a post-baseline confirmed nadir ALC &lt;0.5 × 109/L was identified as a risk factor for serious infections. Due to this finding in the RA program, subjects with screening ALC &lt;0.5 × 109/L were excluded from the Phase 3 UC induction studies, and subjects with confirmed ALC &lt;0.5 × 109/L during treatment were required to be discontinued from the UC studies. This would compromise the ability to observe an association between serious infection risk and confirmed ALC &lt;0.5 × 109/L in the UC program.

Proportions and Incidence Rates of Serious Infections in Cohort 1 (P2P3 Induction), Cohort 2 (P3 Maintenance), the IndNR Subgroup, and Cohort 3 (P2P3LTE Tofacitinib)

<div style=\"page-break-after: always\"></div>

| Cohort1(P2P3Induction)                 | Placebo                                | Tofacitinib 5mgBID      | Tofacitinib 10 mg BID    | Tofacitinib                | IndNR Subgroup                      |
|----------------------------------------|----------------------------------------|-------------------------|--------------------------|----------------------------|-------------------------------------|
| Total number of subjects               | 282                                    | NA                      | 938                      | AlI NA                     | Tofacitinib 10 mg BID NA            |
| Number (%) of subjects with events     | 0                                      | NA                      | 8 (0.9)                  | NA                         | NA                                  |
| % difference versus placebo (95% CI)   | NA                                     | NA                      | 0.9 (-0.40, 1.72)        | NA                         | NA                                  |
| Cohort2(P3Maintenance)andIndNRSubgroup | Cohort2(P3Maintenance)andIndNRSubgroup |                         |                          |                            |                                     |
|                                        | Placebo                                | Tofacitinib 5mgBID      | Tofacitinib 10 mg BID    | Tofacitinib All            | IndNRSubgroup Tofacitinib 10 mg BID |
| Total number of subjects               | 198                                    | 198                     | 196                      | 394                        | 429                                 |
| Exposure (PY)                          | 103.25                                 | 148.39                  | 157.22                   | 305.61                     | 303.16                              |
| Number (%) of subjects with events     | 2 (1.0)                                | 2 (1.0)                 | 1 (0.5)                  | 3 (0.8)                    | 5 (1.2)                             |
| IR (95% CI)                            | 1.94 (0.23, 7.00)                      | 1.35 (0.16, 4.87)       | 0.64 (0.02,3.54)         | 0.98 (0.20,2.87)           | 1.65 (0.54, 3.85)                   |
| IR difference versus placebo           | NA                                     | -0.59 (-3.86, 2.68)     | -1.30 (-4.26, 1.66)      | -0.96 (-3.86, 1.95)        | NA                                  |
| IRdifferenceversustofacitinib5mgBID    | NA                                     | NA                      | -0.71 (-2.96, 1.53)      | NA                         | NA                                  |
| Cohort3(P2P3LTETofacitinib)            | Cohort3(P2P3LTETofacitinib)            |                         |                          |                            |                                     |
|                                        | TofacitinibAll                         | PredominantDose 5 mgBID | PredominantDose 10 mgBID | Post-InductionDose 5 mgBID | Post-Induction Dose 10 mg BID       |
| Total number of subjects               | 1157                                   | 186                     | 971                      | 220                        | 771                                 |
| Exposure (PY)                          | 1659.35                                | 367.17                  | 1292.18                  | 293.74                     | 1110.43                             |
| Number(%)of subjects with events       | 33 (2.9)                               | 7 (3.8)                 | 26 ( 2.7)                | 6 (2.7)                    | 18 (2.3)                            |
| IR (95% CI)                            | 1.99 (1.37, 2.79)                      | 1.91 (0.77,3.93)        | 2.01 (1.31, 2.95)        | 2.04 (0.75, 4.45)          | 1.62 (0.96, 2.56)                   |

Sources: 5.3.5.3 SCS Table 14.2.8.cl;Table 14.2.8.c2;Table 14.2.8.inr;Table 14.2.8.c3b;Table 14.2.8.c3a

Continuation of tofacitinib 10 mg BID for up to an additional 2 months beyond the 8-week induction treatment duration evaluated in the Phase 3 induction studies was not associated with an increase in the risk of serious infection (0.7% [2 subjects] in tofacitinib-induction subset of IndNR subgroup data).

The IR of serious infections in the Tofacitinib All group in Cohort 3 was similar to those reported in the placebo group in Cohort 2 (P3 Maintenance). These data do not suggest an increasing risk of serious infection with longer duration of tofacitinib treatment.

A risk factor analysis showed that the incidence rate of serious infection was higher in subjects with a baseline total Mayo score ≥ 9, BMI ≥ 30, average post-baseline ANC 1.5 to &lt;2 × 109/L and baseline ALC &lt;1 × 109/L

## Incidence Rates of Serious Infections in Select Subgroups in Cohort 3 (P2P3LTE Tofacitinib), Tofacitinib All:

<div style=\"page-break-after: always\"></div>

| Baseline Characteristic                  | Subgroup        |    N | n (%)     | IR (95% CI)           |
|------------------------------------------|-----------------|------|-----------|-----------------------|
| Age                                      | <65 years       | 1080 | 31(2.9)   | 2.02 (1.37, 2.87)     |
|                                          | ≥65 years       |   77 | 2 (2.6)   | 1.60 (0.19, 5.79)     |
| History of diabetes mellitus at baseline | Yes             |   48 | 1 (2.1)   | 1.23 (0.03, 6.87)     |
|                                          | No              | 1109 | 32 (2.9)  | 2.03 (1.39,2.86)      |
| Oral corticosteroiduseatbaseline         | Yes             |  523 | 11 (2.1)  | 1.59 (0.79, 2.85)     |
|                                          | No              |  634 | 22 (3.5)  | 2.27 (1.42, 3.44)     |
| Prior TNFi failure                       | Yes             |  583 | 17 (2.9)  | 2.11 (1.23, 3.39)     |
|                                          | No              |  541 | 14 (2.6)  | 1.65 (0.90, 2.77)     |
| Priorimmunosuppressant treatment         | Yes             |  838 | 24 (2.9)  | 1.92 (1.23, 2.85)     |
|                                          | No              |  286 | 7 (2.4)   | 1.75 (0.70, 3.60)     |
| Disease severity (total Mayo score)      | <9              |  469 | (6:D) 6   | 1.28 (0.59,2.43)      |
|                                          | ≥9              |  686 | 24 (3.5)  | 2.51 (1.61, 3.74)     |
| BMI (kg/m²)                              | <25             |  681 | 17 (2.5). | 1.74 (1.02, 2.79)     |
|                                          | 25-<30          |  316 | 9 (2.8)   | 2.04 (0.93, 3.87)     |
|                                          | ≥30             |  159 | 7 (4.4)   | 2.88 (1.16, 5.93)     |
| Average post-baseline ANC                | 1.5 to <2×10%/L |    4 | 3 (75.0)  | 55.45 (11.44, 162.06) |
|                                          | ≥2 ×10%/L       | 1145 | 30 (2.6)  | 1.81 (1.22, 2.59)     |
| Baseline ALC                             | <1 ×10%L        |  128 | 4 (3.1)   | 2.73 (0.74, 7.00)     |
|                                          | 1 to<2×109/L    |  619 | 22 (3.6)  | 2.40 (1.50, 3.63)     |
|                                          | ≥2 ×10%/L       |  408 | 7 (1.7)   | 1.18 (0.47, 2.43)     |

CI = confidence interval; IR = incidence rate; N = number of subjects randomized and treated; n=number of subjects with events; P2P3LTE = Phase 2, Phase 3, 1ong-term extension; TNFi = tumor necrosis factor inhibitor.

Abbreviations: ALC = absolute lymphocyte count; ANC = absolute neutrophil count; BM = body mass index;

Source:5.3.5.3SCSTable14.2.8.1.c3b

Serious infections events occurred less frequently in the UC program compared to the RA program.  It is noted that in the UC program subjects with screening ALC &lt;0.5 × 109/L were excluded from the Phase 3 UC induction studies, and subjects with confirmed ALC &lt;0.5 × 109/L during treatment were required to be discontinued from the UC studies; this was the case in the RA program.

The IR of serious infection was much higher in the subgroup Average post-baseline ANC 1.5 to &lt;2 ×109/L. However, it is noted there were only 4 subjects in this category.

The current SPC includes a recommendation not to initiate dosing in patients with an absolute lymphocyte count (ALC) less than 750 cells/mm3 or an absolute neutrophil count (ANC) less than 1,000 cells/mm3.

## Herpes Zoster

An increased IR of herpes zoster (all) was observed with tofacitinib treatment in the RA and PsO programs. This is of relevance since data suggests that IBD patients appear to be at higher risk of developing shingles (herpes zoster) than healthy subjects.

There were higher incidence rates for subjects aged over 65 years; those with Diabetes mellitus at baseline, those with a history of prior, TNFi experience (versus the TNFi naïve population) and Asian ethnicity.

Proportions and Incidence Rates of Herpes Zoster (All) in Cohort 1 (P2P3 Induction), Cohort 2 (P3 Maintenance), the IndNR Subgroup, and Cohort 3 (P2P3LTE Tofacitinib)

<div style=\"page-break-after: always\"></div>

| Cohort1(P2P3Induction)                       |                                          |                                          | Tofacitinib                              |                                          |                                          |
|----------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|
|                                              | Placebo                                  | Tofacitinib 5 mgBID                      | 10 mg BID                                | Tofacitinib All                          | IndNRSubgroup Tofacitinib 10 mg BID      |
| Total numberof subjects                      | 282                                      | NA                                       | 938                                      | NA                                       | NA                                       |
| Number (%) of subjects with events           | 1 (0.4)                                  | NA                                       | 6 (0.6)                                  | NA                                       | NA                                       |
| % Difference (95% CI)                        | NA                                       | NA                                       | 0.3 (-1.30. 1.16)                        | NA                                       | NA                                       |
| Cohort 2(P3Maintenance)and IndNRSubgroup     | Cohort 2(P3Maintenance)and IndNRSubgroup | Cohort 2(P3Maintenance)and IndNRSubgroup | Cohort 2(P3Maintenance)and IndNRSubgroup | Cohort 2(P3Maintenance)and IndNRSubgroup | Cohort 2(P3Maintenance)and IndNRSubgroup |
|                                              | Placebo                                  | Tofacitinib 5 mgBID                      | Tofacitinib 10 mg BID                    | Tofacitinib All                          | IndNRSubgroup Tofacitinib 10 mgBID       |
| Total number of subjects                     | 198                                      | 198                                      | 196                                      | 394                                      | 429                                      |
| Exposure (PY)                                | 102.73                                   | 146.00                                   | 150.51                                   | 296.51                                   | 299.89                                   |
| Number (%) of subjects with events           | 1 (0.5)                                  | 3 (1.5)                                  | 10 (5.1)                                 | 13 (3.3)                                 | 11 (2.6)                                 |
| IR (95% CI)                                  | 0.97 (0.02.5.42)                         | 2.05 (0.42, 6.00)                        | 6.64 (3.19,12.22)                        | 4.38 (2.33,7.50)                         | 3.67 (1.83, 6.56)                        |
| IR difference versus placebo(95%CI)          | NA                                       | 1.08 (-1.93, 4.09)                       | 5.67 (1.13, 10.21)                       | 3.41 (0.36. 6.46)                        | NA                                       |
| IRdifferenceversustofacitinib5mgBID (95% CI) | NA                                       | NA                                       | 4.59 (-0.14, 9.32)                       | NA                                       | NA                                       |
| Colort3P2P3LTETofacitinib                    | Colort3P2P3LTETofacitinib                | Colort3P2P3LTETofacitinib                | Colort3P2P3LTETofacitinib                | Colort3P2P3LTETofacitinib                | Colort3P2P3LTETofacitinib                |
|                                              | TofacitinibAll                           | PredominantDose 5 mg BID                 | PredominantDose 10 mgBID                 | Post-Induction Dose 5 mg BID             | Post-Induction Dose 10mgBID              |
| Total number of subjects                     | 1157                                     | 186                                      | 971                                      | 220                                      | 771                                      |
| Exposure (PY)                                | 1595.75                                  | 348.01                                   | 1247.74                                  | 282.20                                   | 1074.54                                  |
| Number (%) of subjects with events           | 65 (5.6)                                 | 12 ( 6.5)                                | 53 (5.5)                                 | 10 ( 4.5)                                | 45 (5.8)                                 |
| IR (95% CI)                                  | 4.07 (3.14, 5.19)                        | 3.45 (1.78, 6.02)                        | 4.25 (3.18, 5.56)                        | 3.54 (1.70. 6.52)                        | 4.19 (3.05, 5.60)                        |

extension:PY=patient-year.

Abbreviations: BID = twice daily: CI= confidence interval; IndNR = induction non-responder; IR = incidence rate: NA =not applicable: P2P3LTE =Phase 2. Phase 3,long-term

IR =number of subjects with events per 100 PY.

Events occurringwithin28daysfollowing the lastdosewere included.

Sources:5.3.5.3SCS Table 14.2.8.cl;Table14.2.8.c2:Table 14.2.8.inr:Table14.2.8.c3b;Table14.2.8.c3a

<div style=\"page-break-after: always\"></div>

## Incidence Rates of Herpes Zoster (All) by Subgroup in Cohort 3 (P2P3LTE), Tofacitinib All

<!-- image -->

| Baseline Characteristic                                                                                                                                                                                                                                                  | Subgroup                                                                                                                                                                                                                                                                 | N                                                                                                                                                                                                                                                                        | n (%)                                                                                                                                                                                                                                                                    | IR (95% CI)                                                                                                                                                                                                                                                              |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Age                                                                                                                                                                                                                                                                      | <65 years                                                                                                                                                                                                                                                                | 1080                                                                                                                                                                                                                                                                     | 54 (5.0)                                                                                                                                                                                                                                                                 | 3.65 (2.74, 4.76)                                                                                                                                                                                                                                                        |
|                                                                                                                                                                                                                                                                          | ≥65 years                                                                                                                                                                                                                                                                | 77                                                                                                                                                                                                                                                                       | 11 (14.3)                                                                                                                                                                                                                                                                | 9.55 (4.77, 17.08)                                                                                                                                                                                                                                                       |
| Historyof diabetesmellitus at baseline                                                                                                                                                                                                                                   | Yes                                                                                                                                                                                                                                                                      | 48                                                                                                                                                                                                                                                                       | 6 (12.5)                                                                                                                                                                                                                                                                 | 8.06 (2.96, 17.55)                                                                                                                                                                                                                                                       |
|                                                                                                                                                                                                                                                                          | No                                                                                                                                                                                                                                                                       | 1109                                                                                                                                                                                                                                                                     | 59 (5.3)                                                                                                                                                                                                                                                                 | 3.88 (2.95,5.00)                                                                                                                                                                                                                                                         |
| Oralcorticosteroiduseatbaseline                                                                                                                                                                                                                                          | Yes                                                                                                                                                                                                                                                                      | 523                                                                                                                                                                                                                                                                      | 34 (6.5)                                                                                                                                                                                                                                                                 | 5.14 (3.56, 7.18)                                                                                                                                                                                                                                                        |
|                                                                                                                                                                                                                                                                          | No                                                                                                                                                                                                                                                                       | 634                                                                                                                                                                                                                                                                      | 31 (4.9)                                                                                                                                                                                                                                                                 | 3.32 (2.26, 4.71)                                                                                                                                                                                                                                                        |
| Prior TNFi failure                                                                                                                                                                                                                                                       | Yes                                                                                                                                                                                                                                                                      | 583                                                                                                                                                                                                                                                                      | 41 (7.0)                                                                                                                                                                                                                                                                 | 5.38 (3.86, 7.29)                                                                                                                                                                                                                                                        |
|                                                                                                                                                                                                                                                                          | No                                                                                                                                                                                                                                                                       | 541                                                                                                                                                                                                                                                                      | 23 (4.3)                                                                                                                                                                                                                                                                 | 2.78 (1.77, 4.18)                                                                                                                                                                                                                                                        |
| Priorimmunosuppressanttreatment                                                                                                                                                                                                                                          | Yes                                                                                                                                                                                                                                                                      | 838                                                                                                                                                                                                                                                                      | 50 (6.0)                                                                                                                                                                                                                                                                 | 4.18 (3.10, 5.51)                                                                                                                                                                                                                                                        |
|                                                                                                                                                                                                                                                                          | No                                                                                                                                                                                                                                                                       | 286                                                                                                                                                                                                                                                                      | 14 (4.9)                                                                                                                                                                                                                                                                 | 3.57 (1.95,5.99)                                                                                                                                                                                                                                                         |
| Race                                                                                                                                                                                                                                                                     | White                                                                                                                                                                                                                                                                    | 927                                                                                                                                                                                                                                                                      | 44 (4.7)                                                                                                                                                                                                                                                                 | 3.50 (2.54, 4.70)                                                                                                                                                                                                                                                        |
|                                                                                                                                                                                                                                                                          | Black                                                                                                                                                                                                                                                                    | 10                                                                                                                                                                                                                                                                       | 0 (0.0)                                                                                                                                                                                                                                                                  | 0.00(0.00,23.30)                                                                                                                                                                                                                                                         |
|                                                                                                                                                                                                                                                                          | Asian                                                                                                                                                                                                                                                                    | 144                                                                                                                                                                                                                                                                      | 14 (9.7)                                                                                                                                                                                                                                                                 | 6.49 (3.55, 10.89)                                                                                                                                                                                                                                                       |
|                                                                                                                                                                                                                                                                          | Other                                                                                                                                                                                                                                                                    | 42                                                                                                                                                                                                                                                                       | 4 (9.5)                                                                                                                                                                                                                                                                  | 6.31 (1.72, 16.16)                                                                                                                                                                                                                                                       |
| Abbreviations: CI = confidence interval; IR =incidence rate; N=number of subjects randomized and treated; n= number of subjects with events; P2P3LTE = Phase 2, Phase 3, long-term extension; TNFi = tumor necrosis factor imhibitor. Source:5.3.5.3SCSTable14.2.8.1.c3b | Abbreviations: CI = confidence interval; IR =incidence rate; N=number of subjects randomized and treated; n= number of subjects with events; P2P3LTE = Phase 2, Phase 3, long-term extension; TNFi = tumor necrosis factor imhibitor. Source:5.3.5.3SCSTable14.2.8.1.c3b | Abbreviations: CI = confidence interval; IR =incidence rate; N=number of subjects randomized and treated; n= number of subjects with events; P2P3LTE = Phase 2, Phase 3, long-term extension; TNFi = tumor necrosis factor imhibitor. Source:5.3.5.3SCSTable14.2.8.1.c3b | Abbreviations: CI = confidence interval; IR =incidence rate; N=number of subjects randomized and treated; n= number of subjects with events; P2P3LTE = Phase 2, Phase 3, long-term extension; TNFi = tumor necrosis factor imhibitor. Source:5.3.5.3SCSTable14.2.8.1.c3b | Abbreviations: CI = confidence interval; IR =incidence rate; N=number of subjects randomized and treated; n= number of subjects with events; P2P3LTE = Phase 2, Phase 3, long-term extension; TNFi = tumor necrosis factor imhibitor. Source:5.3.5.3SCSTable14.2.8.1.c3b |

Herpes zoster reactivation' as an important identified risk for tofacitinib. Increased rates were seen in subjects of Asian race.

The MAH has conducted a cross-study comparison which shows that the IR of HZ is higher than those reported for biologic agents in UC patients in external observational data.

## Opportunistic Infections OI

Most of the OIs were herpes zoster infections limited to cutaneous involvement, which accounted for 15 out of the 22 OI events. Non-herpes zoster OIs consisted of 1 event each of pulmonary cryptococcosis, pulmonary histoplasmosis, CMV hepatitis, and CMV colitis.

In Cohort 1, OI occurred in 3 (0.3%) subjects in the tofacitinib 10 mg BID group compared with none in the placebo group. Continuation of tofacitinib 10 mg BID for up to an additional 2 months beyond the 8-week induction treatment duration evaluated in the Phase 3 induction studies was not associated with an increase in the risk of OI.

In Cohort 2, the IR of OI in the tofacitinib 10 mg BID group (2.60 / 100 PY, 4 subjects) was higher than in the placebo group (0.97 / 100 PY, 1 subject) or the tofacitinib 5 mg BID group (1.36 / 100 PY, 2 subjects), suggesting dose dependency in the risk of developing OI.

In Cohort 3, the IR of OI (1.28 / 100 PY, 21 subjects) was within the range observed in Cohort 2 (P3 Maintenance). These data do not suggest an increasing risk of OI with longer duration of tofacitinib treatment.

<div style=\"page-break-after: always\"></div>

## Proportions and Incidence Rates of Opportunistic Infections in Cohort 1 (P2P3 Induction), Cohort 2 (P3 Maintenance), the IndNR Subgroup, and Cohort 3 (P2P3LTE Tofacitinib)

| Cohort3(P2P3LTETofacitinib)        | TofacitinibAll    | PredominantDose 5 mgBID 186   | PredominantDose 10 mgBID   | Post-InductionDose 5 mgBID   | Post-Induction Dose 10 mg BID   |
|------------------------------------|-------------------|-------------------------------|----------------------------|------------------------------|---------------------------------|
| Total number of subjects           | 1157              |                               | 971                        | 220                          | 771                             |
| 10IIV                              |                   |                               |                            |                              |                                 |
| Exposure (PY)                      | 1638.52           | 358.87                        | 1279.65                    | 290.41                       | 1106.24                         |
| Number (%) of subjects with events | 21 (1.9)          | 5 (2.7)                       | 16 (1.7)                   | 4 (1.8)                      | 16 (2.1)                        |
| IR (95% CI)                        | 1.28 (0.79, 1.96) | 1.39 (0.45, 3.25)             | 1.25 (0.71, 2.03)          | 1.38(0.38,3.53)              | 1.45 (0.83,2.35)                |
| Herpes zoster O1                   |                   |                               |                            |                              |                                 |
| Exposure (PY)                      | 1639.66           | 359.00                        | 1280.66                    | 290.54                       | 1107.24                         |
| Number (%) of subjects with events | 17 (1.5)          | 4 (2.2)                       | 13 (1.4)                   | 3 (1.4)                      | 13 (1.7)                        |
| IR (95%CI)                         | 1.04 (0.60.1.66)  | 1.11 (0.30,2.85)              | 1.02 (0.54, 1.74)          | 1.03 (0.21, 3.02)            | 1.17 (0.63, 2.01)               |
| Non-herpes zoster OI               |                   |                               |                            |                              |                                 |
| Exposure (PY)                      | 1660.70           | 369.01                        | 1291.69                    | 295.46                       | 1116.89                         |
| Number (%) of subjects with events | 4 (0.4)           | 1 (0.5)                       | 3 (0.3)                    | 1 (0.5)                      | 3 (0.4)                         |
| IR (95% CI)                        | 0.24 (0.07,0.62)  | 0.27 (0.01, 1.51)             | 0.23 (0.05,0.68)           | 0.34 (0.01, 1.89)            | 0.27 (0.06, 0.78)               |

P2P3LTE =Phase 2.Phase 3,long-term extension:PY=patient-year.

Abbreviations:BID= twice daily; CI=confidence interval:IndNR= induction non-responder:IR= incidence rate:NA = not applicable: OI = opportunistic infection:

IR = number of subjects with events per 100 PY.

Excludestuberculosis andherpeszosterwithtwoadjacentdermatomes.

Endpoints based on adjudicated opportunistic infection datafromA3921094and A3921095for Cohort 1 (P2P3Induction).

Sources:5.3.5.3 SCSTable 14.2.8.cl:Table14.2.8.c2:Table14.2.8.inr,Table14.2.8.c3b;Table 14.2.8.c3a

Events are counted up to28daysbeyond thelast dose(except in subjects that are ongoing inStudy A3921139).

The IR of OI was higher in those subjects over 65 years, those with Diabetes mellitus at baseline, subjects from North America region UC duration ≥ 6 years and an average post-baseline ALC &lt;1 × 109/L.

## Incidence Rates of Opportunistic Infections in Select Subgroups in Cohort 3 (P2P3LTE), Tofacitinib All

<div style=\"page-break-after: always\"></div>

| Baseline Characteristic                  | Subgroup          |    N | n (%)    | IR (95% CI)        |
|------------------------------------------|-------------------|------|----------|--------------------|
| Age                                      | <65 years         | 1048 | 18 (1.7) | 1.19 (0.70, 1.88)  |
|                                          | ≥65 years         |   76 | 3 (3.9)  | 2.43 (0.50, 7.09)  |
| History of diabetes mellitus at baseline | Yes               |   46 | 4 (8.7)  | 5.17 (1.41, 13.25) |
|                                          | No                | 1078 | 17 (1.6) | 1.09 (0.63, 1.74)  |
| Oralcorticosteroiduseatbaseline          | Yes               |  505 | 8 (1.6)  | 1.17 (0.51, 2.31)  |
|                                          | No                |  619 | 13 (2.1) | 1.36 (0.72, 2.32)  |
| Prior TNFi failure                       | Yes               |  583 | 13( 2.2) | 1.64 (0.87,2.81)   |
|                                          | No                |  541 | 8 (1.5)  | 0.94 (0.41, 1.86)  |
| Prior immumosuppressant treatment        | Yes               |  838 | 14 (1.7) | 1.13 (0.62, 1.90)  |
|                                          | No                |  286 | 7 (2.4)  | 1.75 (0.70, 3.60)  |
| Geographical regions                     | North America     |  241 | 9 (3.7)  | 2.72 (1.24, 5.16)  |
|                                          | Europe            |  656 | 9 (1.4)  | 0.95 (0.43, 1.80)  |
|                                          | Rest of the World |  227 | 3 (1.3)  | 0.84 (0.17, 2.45)  |
| Disease severity (total Mayo score)      | <9                |  451 | 7 (1.6)  | 1.01 (0.41, 2.08)  |
|                                          | 29                |  671 | 14 (2.1) | 1.49 (0.81, 2.49)  |
| UC duration                              | <6 years          |  542 | 6 (1.1)  | 0.79 (0.29, 1.71)  |
|                                          | ≥6 years          |  582 | 15( 2.6) | 1.71 (0.96, 2.83)  |
| Average post-baseline ALC                | ALC<1 ×10%L       |   85 | 4 (4.7)  | 3.48 (0.95, 8.92)  |
|                                          | ALC 1to<2×109/L   |  716 | 11 (1.5) | 0.97 (0.49, 1.74)  |
|                                          | ALC ≥2x109/L      |  315 | 6 (1.9)  | 1.52 (0.56, 3.32)  |

Abbreviations: ALC = absolute lymphocyte count; CI = confidence interval; IR = incidence rate; N = number of subjects randomized and treated; n = number of subjects with events; P2P3LTE = Phase 2, Phase 3, long-term extension; TNFi = tumor necrosis factor imhibitor; UC = ulcerative colitis.

Opportumistic infection excludes tuberculosis and herpes zoster with 2 adjacent dermatomes. Endpoints based on adjudicated opportumistic infection data fromA3921094,A3921095,A3921096,andA3921139. Average post-baseline ALC was based on ALC at all post-baseline time-points.

Source:5.3.5.3 SCSTable 14.2.8.1.c3b

The IR of OI in the Tofacitinib All group in Cohort 3 was higher than that reported in the RA and PsO programs.

There was a trend towards an increased IR of OI, driven by herpes-zoster-related OIs, in the TNFi failure subgroup for tofacitinib 10 mg BID compared with the non-TNFi failure subgroup.

## Tuberculosis (TB)

Subjects in the Phase 3 studies were screened for latent and active tuberculosis (TB) infections

One event of suspected active TB (PT Tuberculosis) was reported in a subject who received tofacitinib 10 mg BID in Study A3921139. The event was reviewed by the Opportunistic Infection Review Committee and was not confirmed as a TB event.

The event TB was assessed to be a SAE based on the criterion of medically significant event.

## Malignancies (Excluding Non-melanoma skin cancer NMSC)

The risk of colorectal cancer has been reported to increase in UC. Risk factors that have been reported to predispose to colorectal cancer in patients with IBD include longer duration of disease, greater anatomic extent of colitis, greater degree of inflammation, presence of primary sclerosing cholangitis, and a family history of colorectal cancer. An increased risk of lymphoma has been reported to be associated with concurrent use of thiopurines in IBD patients. Cervical dysplasia has also been reported at an increased rate in women with IBD. In IBD patients, an increased risk of NMSC has been associated with past or concurrent thiopurine therapy.

<div style=\"page-break-after: always\"></div>

All events identified as potential malignancies were assessed by a Malignancy Adjudication Committee.

In Cohort 2 (P3 Maintenance), there were no malignancies (excluding NMSC) in either the tofacitinib 5 mg BID or tofacitinib 10 mg BID group.

In Cohort 3 (P2P3LTE Tofacitinib), malignancies were reported in 11 subjects, including 1 subject with lymphoma. The IR from primary analysis of 8 subjects with events was 0.48 / 100 PY, and the IR from sensitivity analysis of 11 subjects with events was 0.66 / 100 PY.

There was no clustering of malignancies (excluding NMSC) in tofacitinib-treated subjects into specific types of cancer.

The IR of malignancies (excluding NMSC) in the Tofacitinib All group in Cohort 3 (P2P3LTE Tofacitinib) was similar to those reported for the RA and PsO programs (all exposure) and for biologic agents in UC patients in external observational data.

<div style=\"page-break-after: always\"></div>

## Proportions and Incidence Rates of Malignancies (Excluding NMSC) in Cohort 3 (P2P3LTE Tofacitinib)

|                                        | Tofacitinib All   | PredominantDose Tofacitinib 5mgBID   | PredominantDose Tofacitinib 10mgBID   | Post-InductionDose Tofacitinib 5mgBID   | Post-InductionDose Tofacitinib 10 mgBID   |
|----------------------------------------|-------------------|--------------------------------------|---------------------------------------|-----------------------------------------|-------------------------------------------|
| All malignancies(excludingNMSC)        |                   |                                      |                                       |                                         |                                           |
| Total number of subjects               | 1124              | 186                                  | 938                                   | 220                                     | 771                                       |
| Primary analysis                       |                   |                                      |                                       |                                         |                                           |
| Exposure (PY)                          | 1659.64           | 369.14                               | 1290.50                               | 295.59                                  | 1115.87                                   |
| Number(%o)ofsubjectswithevents         | 8 (0.7)           | 0                                    | 8 (0.9)                               | 0                                       | 6(0.8)                                    |
| IR (95% CI)                            | 0.48 (0.21, 0.95) | 0.00 (0.00, 1.00)                    | 0.62 (0.27, 1.22)                     | 0.00 (0.00,1.25)                        | 0.54 ( 0.20, 1.17)                        |
| Sensitivity analysis #2                |                   |                                      |                                       |                                         |                                           |
| Exposure (PY)                          | 1659.71           | 369.14                               | 1290.57                               | NA                                      | NA                                        |
| Number (%) of subjects with events     | 11 (1.0)          | 0                                    | 11 (1.2)                              | NA                                      | NA                                        |
| IR (95% CI)                            | 0.66 (0.33, 1.19) | 0.00 (0.00, 1.00)                    | 0.85 (0.43, 1.53)                     | NA                                      | NA                                        |
| Colorectal cancer                      |                   |                                      |                                       |                                         |                                           |
| Exposure (PY)                          | 1661.78           | 369.14                               | 1292.64                               | 295.59                                  | 1117.89                                   |
| Number (%) of subjects with events     | 1 (0.1)           | 0                                    | 1 (0.1)                               | 0                                       | 0                                         |
| IR (95% CI)                            | 0.06 (0.00,0.34)  | 0.00 (0.00,1.00)                     | 0.08 (0.00,0.43)                      | 0.00 (0.00,1.25)                        | 0.00 (0.00,0.33)                          |
| Lymphoma andlymphoproliferativedisease |                   |                                      |                                       |                                         |                                           |
| Exposure (PY)                          | 1661.77           | 369.14                               | 1292.64                               | 295.59                                  | 1117.83                                   |
| Number(%) of subjects with events      | 1 (0.1)           | 0 (0.0)                              | 1 (0.1)                               | 0                                       | 1 (0.1)                                   |
| IR (95% CI)                            | 0.06 (0.00,0.34)  | 0.00 (0.00,1.00)                     | 0.08 (0.00,0.43)                      | 0.00 (0.00,1.25)                        | 0.09 (0.00,0.50)                          |

Sources:5.3.5.3SCSTable14.2.10.c3b:Table14.2.10.c3a:Table14.2.10.6.c3b

Malignancies (1 event of hepatic angiosarcoma and 1 event of AML) were reported to be the cause of death in 2 tofacitinib-treated subjects. In addition, 1 subject who developed cholangiocarcinoma and metastases to the peritoneum died, with the cause of death reported to be pulmonary embolism. All 3 deaths occurred in the LTE Study A3921139 in subjects assigned to tofacitinib 10 mg BID.

Among the 11 subjects with malignancies (excluding NMSC), each of the following primary malignancy cancer types and PTs was reported in a subject:

- Cervical cancer (PT Cervical dysplasia)
- Soft tissue sarcoma (PT Hepatic angiosarcoma)
- Gallbladder and extrahepatic bile duct cancer (PT Cholangiocarcinoma)
- Soft tissue sarcoma (cutaneous leiomyosarcoma)
- Lymphoma/non-Hodgkin lymphoma (PT Epstein-Barr virus associated lymphoma)
- Renal cancer (PT Renal cell carcinoma)
- Myeloproliferative neoplasms (PT Essential thrombocythaemia)
- AML and related precursor neoplasms (PT Acute myeloid leukaemia)
- Colorectal cancer (PT Adenocarcinoma of colon)
- Lung cancer (PT Pulmonary mass)
- Breast cancer (PT Invasive ductal breast carcinoma)

A total of 12 malignancy events have been identified for the UC programme. All malignancies occurred in subjects in the predominant dose 10 mg BID group. Dose dependency for the risk of malignancies with longterm tofacitinib treatment in UC patients cannot be excluded.

<div style=\"page-break-after: always\"></div>

Malignancy remains an important potential risk, for which there are additional pharmacovigilance activities in place.

Table 9. CunulativeIncidenceRates (per 1ooPatient-Years)forSelectSafetyEvents inSubjects Treated With Tofacitinib (All Doses Combined) in the UC Cohort 3 (P2P3LTE Tofacitinib), Rheumatoid Arthritis (All Exposure), and Psoriasis (All Exposure) Prograns

| Safety Event                              | UC (Cohort 3) N=1157 Exposure = 1613 PY   | UC (Cohort 3) N=1157 Exposure = 1613 PY   | RA (All Exposure) N= 6300 Exposure = 21,886 PY   | RA (All Exposure) N= 6300 Exposure = 21,886 PY   | Psoriasis (All Exposure) N=3662 Exposure = 8537 PY   | Psoriasis (All Exposure) N=3662 Exposure = 8537 PY   |
|-------------------------------------------|-------------------------------------------|-------------------------------------------|--------------------------------------------------|--------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                           | n (%)                                     | IR (95% CI)                               | n (%)                                            | IR (95% CI)                                      | n (%)                                                | IR (95% CI)                                          |
| Death (all cause)                         | 2 (0.2)                                   | 0.12 (0.01, 0.43)                         | 58 (0.9)                                         | 0.26 (0.20, 0.33)                                | 17 (0.5)                                             | 0.19 (0.11, 0.31)                                    |
| Serious infection                         | 33 (2.9)                                  | 1.99 (1.37, 2.79)                         | 546 (8.7)                                        | 2.47 (2.26, 2.68)                                | 111 (3.0)                                            | 1.27 (1.05,1.53)                                     |
| Herpes zoster                             | 65 (5.6)                                  | 4.07 (3.14, 5.19)                         | 747 (11.9)                                       | 3.64 (3.38, 3.91)                                | 201 (5.5)                                            | 2.38 (2.06, 2.74)                                    |
| Serious herpes zoster                     | 4 (0.3)                                   | 0.24 (0.07, 0.61)                         | 55 (0.9)                                         | 0.25 (0.19, 0.32)                                | 11 (0.3)                                             | 0.13 (0.06, 0.22)                                    |
| Opportunisticinfectiona                   | (6' 1) q17                                | 1.28 (0.79, 1.96)                         | 70 (1.1)                                         | 0.31 (0.24, 0.40)                                | 26 (0.7)                                             | 0.30 (0.19, 0.44)                                    |
| Non-herpes zoster opportunistic infection | 4 (0.4)                                   | 0.24 (0.07, 0.61)                         | 23 (0.4)                                         | 0.10 (0.07, 0.15)                                | 4 (0.1)                                              | 0.05 (0.01, 0.12)                                    |
| Malignancy (excluding NMSC)a              | 8 (0.7)                                   | 0.48 (0.21, 0.95)                         | 168 (2.7)                                        | 0.75 (0.64, 0.87)                                | 56 (1.5)                                             | 0.64 (0.48, 0.83)                                    |
| NMSC*                                     | 11 (1.0)                                  | 0.67 (0.33, 1.19)                         | 121 (1.9)                                        | 0.55 (0.45, 0.65)                                | 51 (1.4)                                             | 0.59 (0.44, 0.77)                                    |
| MACE*                                     | 4 (0.4)                                   | 0.24 (0.07, 0.62)                         | 80 (1.4)                                         | 0.38 (0.30, 0.47)                                | 21 (0.6)                                             | 0.24 (0.15, 0.37)                                    |
| GI perforation (all cases)a               | 4 (0.4)                                   | 0.24 (0.07,0.62)                          | 27 (0.4)                                         | 0.12 (0.08, 0.18)                                | 6 (0.2)                                              | 0.07 (0.03, 0.15)                                    |

Source:2.7.4Table67.

Abbreviations: CI = confidence interval; GI = gastrointestinal; IR = incidence rate; MACE = major adverse cardiovascular event; N = number of evaluable subjects, n = number of subjects with events; NMSC = non-melanoma skin cancer; OI = opportunistic infection; P2P3LTE = Phase 2, Phase 3, long-term extension; PsO = psoriasis; PY = patient-year, RA = rheumatoid arthritis; UC = ulcerative colitis.

A3921064,A3921068,A3921069,A3921073,A3921109,A3921129,A3921130,A3921152,andA3921237).

Includes ps0riasis studies (A3921078, A3921079, A3921080, A3921111, A3921047, and A3921061).

Events occurring within 28 days following the last dose were included.

a. Adjudicated events. Percentage (%) was calculated based on the number of subjects in studies in which adjudication was performed.

b. In the UC Cohort 3, there were 22 OIs in 21 subjects. 15 out of 22 OIevents (68%) were herpes zoster OIs limited to cutaneous involvement. A consistent definition of OI was applied to the UC, RA and PsO programs.

## Nonmelanoma Skin Cancer (NMSC)

Cohort 1 (P2P3 Induction): Two (2) events of NMSC were reported in 2 subjects in the tofacitinib 10 mg BID group.

In Cohort 2 (P3 Maintenance): NMSC occurred in 3 subjects in the tofacitinib 10 mg BID group and in 1 subject in the placebo group.

In Cohort 2 (P3 Maintenance), there were no NMSC events in the tofacitinib 5 mg BID group, whereas the IR for tofacitinib 10 mg BID (1.91 / 100 PY, 3 subjects) was higher than for placebo (0.97 / 100 PY, 1 subject).

In Cohort 3 (P2P3LTE Tofacitinib), the SCC:BCC ratio of 7:6 in the Tofacitinib all group suggested an immunomodulatory effect. In addition, all SCC events occurred in the PD 10 mg BID dose group.

In Cohort 3 (P2P3LTE Tofacitinib), 18 NMSC malignancy terms were confirmed by adjudication in 11 subjects, including the 5 tofacitinib-treated subjects described above (2 in Cohort 1 [P2P3 Induction], and 3 in Cohort 2 [P3 Maintenance]). Ten (10) of these 11 subjects were in the PD 10 mg BID group. Among the 18 NMSC malignancy terms, 16 were AEs. The remaining 2 NMSC malignancy terms corresponded to excisions performed for previously reported NMSC events

There were trends of an increased incidence rate on NMSC in those subject ≥ 65 years, no oral corticosteroid use at baseline, prior TNFi failure, prior immunosuppressant treatment, those from North America region and those with a BMI ≥ 30

<div style=\"page-break-after: always\"></div>

## Proportions and Incidence Rates of NMSC in Cohort 3 (P2P3LTE Tofacitinib):

|                                    | TofacitinibAll (N =1124)   | Predominant Dose 5 mg BID (N = 186)   | Predominant Dose 10 mg BID (N = 938)   | Post-Induction Dose 5 mg BID (N = 220)   | Post- Induction Dose 10 mg BID (N = 771)   |
|------------------------------------|----------------------------|---------------------------------------|----------------------------------------|------------------------------------------|--------------------------------------------|
| AII NMSC                           |                            |                                       |                                        |                                          |                                            |
| Exposure (PY)                      | 1647.76                    | 368.59                                | 1279.16                                | 295.05                                   | 1105.71                                    |
| Number (%) of subjects with events | 11 (1.0)                   | 1 (0.5)                               | 10 (1.1)                               | 1 (0.5)                                  | 8 (1.0)                                    |
| IR (95% CI)                        | 0.67 (0.33, 1.19)          | 0.27 (0.01, 1.51)                     | 0.78 (0.37, 1.44)                      | 0.34 (0.01, 1.89)                        | 0.72 (0.31, 1.43)                          |
| Basal cell carcinoma               |                            |                                       |                                        |                                          |                                            |
| Exposure (PY)                      | 1655.79                    | 368.59                                | 1287.20                                | 295.05                                   | 1112.88                                    |
| Number (%) of subjects with events | 6 (0.5)                    | 1 (0.5)                               | 5 (0.5)                                | 1 (0.5)                                  | 3 (0.4)                                    |
| IR (95% CI)                        | 0.36 (0.13, 0.79)          | 0.27 (0.01, 1.51)                     | 0.39 (0.13, 0.91)                      | 0.34 (0.01, 1.89)                        | 0.27 (0.06, 0.79)                          |
| Squamouscellcarcinoma              |                            |                                       |                                        |                                          |                                            |
| Exposure (PY)                      | 1652.33                    | 369.14                                | 1283.19                                | 295.59                                   | 1109.49                                    |
| Number (%) of subjects with events | 7 (0.6)                    | 0                                     | 7 (0.7)                                | 0                                        | 6 (0.8)                                    |
| IR (95% CI)                        | 0.42                       | 0.00                                  | 0.55                                   | 0.00                                     | 0.54                                       |
|                                    | (0.17,0.87)                | (0.00, 1.00)                          | (0.22, 1.12)                           | (0.00, 1.25)                             | (0.20, 1.18)                               |

Abbreviations: BID = twice daily; CI = confidence interval; IR = incidence rate; N = number of subjects randomized and treated; P2P3LTE = Phase 2, Phase 3, long-term extension; PY = patient-year.

Sources:5.3.5.3SCSTable14.2.10.c3b;Table14.2.10.c3a

The IRs of NMSC observed for tofacitinib 5 mg BID and 10 mg BID in Cohort 2 were similar to the IRs reported in Phase 3 randomized trials of the RA and PsO programs. The IR of NMSC for tofacitinib 5 mg BID in Cohort 2 was similar to those of biologic agents in UC patients in published RCTs, while the IR for tofacitinib 10 mg BID in Cohort 2 was numerically higher than those of comparators in published RCTs.

NMSC is an important identified risk of tofacitinib, and is listed as an uncommon ADR in the SmPC. The increased risk of NMSC with the 10 mg BID dosing is reflected in the proposed update to the SmPC.

## Cardiovascular Safety

Major Adverse Cardiovascular Events MACE:

Major Adverse Cardiovascular Events (MACE) were adjudicated externally. MACE was reported in 2 subjects in the PD tofacitinib 5 mg BID group (IR 0.55 / 100 PY) and in 2 subjects in the PD tofacitinib 10 mg BID group (IR 0.15 / 100 PY).

In Cohort 2 (P3 Maintenance), the IRs of MACE was 0.68 / 100 PY (1 subject) for tofacitinib 5 mg BID, and was 0.64 / 100 PY (1 subject) for tofacitinib 10 mg BID compared with none in the placebo group. There was no evidence of dose dependency in the risk of MACE.

The IR of MACE in the Tofacitinib All group in Cohort 3 (P2P3LTE Tofacitinib) (0.24 / 100 PY, 4 subjects) was within the range reported in Cohort 2 (P3 Maintenance). These data do not suggest an increasing risk of MACE with longer duration of treatment with tofacitinib.

Based on medical history, 3 out of the 4 subjects with MACE had pre-existing cardiovascular risk factors.

<div style=\"page-break-after: always\"></div>

The IRs of MACE in the UC program were similar to the IRs reported in randomized Phase 3 trials of the RA and PsO programs. The IR of MACE in the Tofacitinib All group in Cohort 3 (P2P3LTE Tofacitinib) was similar to those reported for the RA and PsO programs (all exposure) and for biologic agents in UC patients in external observational data.

## GI Perforations

In the UC program, GI perforation was reported in 3 tofacitinib-treated subjects and in 2 placebo-treated subjects.

In Cohort 1 (P2P3 Induction), GI perforation occurred in 1 (0.1%) subject in the tofacitinib 10 mg BID group compared with 1 (0.4%) subject in the placebo group.

In Cohort 2 (P3 Maintenance), GI perforation was not reported in the tofacitinib groups but was reported in 1 subject (IR 0.97 / 100 PY) in the placebo group. There was no evidence of dose dependency of the risk of GI perforation

Two (2) of the 3 GI perforations reported in Cohort 3 (P2P3LTE Tofacitinib) occurred in subjects at high risk for GI perforation.

The IR of GI perforation in the Tofacitinib All group in Cohort 3 (0.18 / 100 PY) was within the range reported in Cohort 2 (P3 Maintenance). These data do not suggest an increasing risk of GI perforation with longer treatment duration with tofacitinib.

The IR of GI perforation (all cases) in the Tofacitinib All group in Cohort 3 (P2P3LTE Tofacitinib) was similar to that reported for biologic agents in UC patients in external observational data.

The IRs of GI perforation (all cases) for tofacitinib 5 mg BID and 10 mg BID in Cohort 2 (P3 Maintenance) were similar to the IRs reported in Phase 3 randomized trials of the RA and PsO programs. In Cohort 3 (P2P3LTE Tofacitinib), the IR of GI perforation was numerically higher than those reported for the RA and PsO programs.

The Gastrointestinal Perforation Review Committee (GI PRC), an external, independent adjudication committee assessed the occurrence of GI perforations in the tofacitinib UC program. Examination of the clinical details of these cases did not suggest a higher risk of GI perforation with tofacitinib treatment in subjects with UC.

The IR of GI perforation (all cases) in the Tofacitinib All group in Cohort 3 (P2P3LTE Tofacitinib) was similar to that reported for biologic agents in UC patients in external observational data.

Gastrointestinal perforation is retained as an important potential risk.

## Hepatotoxicity

Compared with placebo, treatment with tofacitinib was associated with small mean increases in transaminases.  There was no apparent effect on total bilirubin.  The proportion of subjects with increases in transaminases to AST or ALT ≥ 3 × ULN was low and similar among the tofacitinib groups and the placebo group. There were no confirmed Hy's law cases or DILI cases that were adjudicated to be probable, highly likely or definite. There were no AEs suggestive of hepatic failure.

<div style=\"page-break-after: always\"></div>

Number (%) of Subjects With Peak Liver Function Tests at Multiples of ULN - Cohort 3 (P2P3LTE Tofacitinib):

|                 |          | Tofacitinib All (N =1157)   | Predominant Dose 5 mg BID (N = 186)   | Predominant Dose 10 mg BID (N = 971)   | Post- Induction Dose 5 mg BID (N = 220)   | Post- Induction Dose 10 mg BID (N = 771)   |
|-----------------|----------|-----------------------------|---------------------------------------|----------------------------------------|-------------------------------------------|--------------------------------------------|
| ALT             | ≥2 x ULN | 68 (5.9)                    | 12 (6.5)                              | 56 (5.8)                               | 12 (5.5)                                  | 43 (5.6)                                   |
| ALT             | ≥3 x ULN | 22 (1.9)                    | 4 (2.2)                               | 18 (1.9)                               | 3 (1.4)                                   | 14 (1.8)                                   |
| ALT             | ≥5 x ULN | 3 (0.3)                     | 0                                     | 3 (0.3)                                | 0                                         | 2 (0.3)                                    |
| AST             | ≥2 x ULN | 46 (4.0)                    | 11 (5.9)                              | 35 (3.6)                               | 12 (5.5)                                  | 25 (3.2)                                   |
| AST             | ≥3 x ULN | 15 (1.3)                    | 2 (1.1)                               | 13 (1.3)                               | 3 (1.4)                                   | 9 (1.2)                                    |
| AST             | ≥5 x ULN | 8 (0.7)                     | 0                                     | 8 (0.8)                                | 0                                         | 4 (0.5)                                    |
| Total bilirubin | ≥2 × ULN | 21 (1.8)                    | 6 (3.2)                               | 15 (1.5)                               | 6 (2.7)                                   | 13 (1.7)                                   |
|                 | ≥3 × ULN | 3 (0.3)                     | 1 (0.5)                               | 2 (0.2)                                | 1 (0.5)                                   | 2 (0.3)                                    |
|                 | ≥5 x ULN | 2 (0.2)                     | 0                                     | 2 (0.2)                                | 0                                         | 2 (0.3)                                    |

Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; BID = twice daily; N = number of subjects randomized and treated; P2P3LTE = Phase 2, Phase 3, long-term extension; ULN = upper limit of normal. Only post-baseline data are summarized in this table.

Sources: 5.3.5.3 SCS Table 14.3.4.c3b; Table 14.3.4.c3a

The current SmPC lists ADRs of Hepatic steatosis (uncommon), Hepatic enzyme increased (common), Transaminases increased (uncommon), Liver function test abnormal (uncommon), and Gamma glutamyl transferase increased (uncommon). This is appropriate.

## Interstitial lung disease

No cases of adjudicated ILD were reported for the UC programme.

## Laboratory findings

The laboratory changes seen in the tofacitinib UC program were consistent with those seen previously. They include:

## Haemoglobin

In Cohort 1 (P2P3 Induction) and Cohort 2 (P3 Maintenance), tofacitinib treatment did not appear to be associated with an increased risk of decreased haemoglobin compared with placebo. Few subjects required early termination due to prespecified discontinuation criteria related to decreased haemoglobin.

## Neutrophils

At the end of 52 weeks of post-induction therapy, small decreases in absolute neutrophil count (ANC), generally similar in magnitude to that observed in the placebo group, were observed in tofacitinib-treated subjects. Post baseline confirmed ANC &lt;1.5 ×109/L occurred infrequently in Cohort 3 (P2P3LTE Tofacitinib).

## Absolute lymphocyte count

At the end of 52 weeks of post-induction therapy, mean decreases in absolute lymphocyte count (ALC) in tofacitinib-treated subjects were larger than that in the placebo group. In Cohort 3 (P2P3LTE Tofacitinib), 11.1% of subjects had ALC &lt;1.0 ×109/L prior to exposure to tofacitinib (i.e., at baseline). In the Tofacitinib

<div style=\"page-break-after: always\"></div>

All group, the proportion of subjects with post baseline confirmed ALC &lt;1.0 ×109/L was 19.3%, and 0.9% of subjects met the criterion of discontinuation related to decreased ALC (2 consecutive ALC &lt;0.5 × 109/L). The proportion of subjects with post baseline confirmed ALC &lt;1.0 ×109/L in Cohort 2 (P3 Maintenance) was similar to that observed for tofacitinib in randomized Phase 3 RA studies.

## Low-density lipoprotein cholesterol

Tofacitinib was associated with increases in low-density lipoprotein cholesterol (LDL-c), total-c, high-density lipoprotein cholesterol (HDL-c), and triglyceride levels in a dose dependent manner. However, tofacitinib was not associated with clinically relevant changes in the ratios of LDL-c/HDL-c or total-c/HDL-c. Taking into consideration the findings for placebo, the effect of tofacitinib on serum lipids in subjects with UC were generally similar to that reported for RA patients.

In the current approved SmPC, dyslipidaemia and hyperlipidaemia are listed as common ADRs, and LDL increased is listed as uncommon. A recommendation to monitor lipids is included in section 4.4. 'Lipid elevations and hyperlipidaemia' remains an important identified risk.

## Creatine kinase

Treatment with tofacitinib resulted in a dose-dependent increase in mean creatine kinase (CK) levels. The increase in CK began within the first 2 weeks of treatment and continued up to Week 8, with little change after Week 8. There were no reports of rhabdomyolysis in tofacitinib-treated subjects.

Blood creatine phosphokinase increased is included in the current SmPC as a common ADR. This remains acceptable.

## Safety in special populations

Intrinsic factors of age, gender, and race were analysed for all AEs, all SAEs, AEDCs, and AEs of special interest in subjects treated with tofacitinib in the UC program.

## Age:

The proportions of subjects with AEs, SAEs, or AEDCs were numerically higher in subjects ≥65 years of age compared with younger subjects, regardless of whether the subjects received tofacitinib or placebo. Increasing age was associated with an increased risk of OIs, herpes zoster (all), and NMSC in exploratory multivariate analysis using Cox regression.

The effect of age on proportion with AEs is similar for active treatment and placebo, reflecting increased morbidity in older subjects. The RMP safety specification includes the important potential risk 'Higher incidence and severity of adverse events in the elderly'. Section 4.4 includes the warning 'The elderly population in general has an increased risk of adverse events, of increased severity; caution should be used when treating the elderly, see section 4.8'. In addition, the increased frequency of serious infections in the elderly is covered in section 4.8. The SmPC wording concerning the elderly remains acceptable.

## Gender:

The proportion of subjects with AEs was numerically higher in female subjects than in male subjects, regardless of whether the subject received tofacitinib or placebo. However, there did not appear to be an

<div style=\"page-break-after: always\"></div>

effect of gender on the proportion of subjects with SAEs or AEs leading to discontinuation in tofacitinibtreated subjects.

## Race and Geographic Region :

Among subjects in Cohort 1 (P2P3 Induction), the majority (80.7%) were white, reflecting the epidemiology of UC. The other racial categories were Asian (11.6%), black (0.8%), other (3.9%), and unspecified (3.0%). There did not appear to be an effect of race on the proportion of subjects with AEs, SAEs or AEs leading to discontinuation in Cohort 2 (P2P3 Maintenance) or Cohort 3 (P2P3 LTE Tofacitinib).

Compared with the white race, non-white races appeared to be associated with an increased risk of developing herpes zoster (all) in the UC program in exploratory multivariate analysis using Cox regression analysis.

Data from the RA and PsO programs suggest that subjects from Japan and Korea have an increased risk of developing herpes zoster (all) compared with subjects enrolled from other geographic regions.

## Pregnancy and Lactation:

There are no adequate and well-controlled studies on the use of tofacitinib in pregnant women. Because embryofoetal toxicity, including malformations, occurred in embryofoetal development studies in rats and rabbits, females of reproductive potential are advised to use effective contraception during treatment with tofacitinib and for at least 4 weeks after the last dose.

Tofacitinib is contraindicated for use in pregnancy and lactation. Tofacitinib has no effect on male fertility, sperm motility, or sperm concentration.

## Exposure during Pregnancy in the UC Program

In the UC program, there were 25 cases of exposure during pregnancy with tofacitinib in the Phase 3 clinical trials. Of these 25 cases, 11 (44%) were cases of maternal exposure and 14 (56%) were cases of paternal exposure.

In all 11 maternal cases, exposure to tofacitinib occurred in the first trimester, and the dose of tofacitinib was 10 mg BID in 9 cases and 5 mg BID in 2 cases. The outcomes in the 11 cases were: 3 normal newborns (27%), 1 premature birth (gestational age at birth 36 weeks with normal newborn) (9%), 2 outcome pending (18%), 1 medical termination (9%), 2 spontaneous abortions (18%), 1 elective termination (9%) and 1 unknown (9%).

In all 14 cases of paternal exposure, exposure to tofacitinib occurred in the first trimester. The dose of tofacitinib was 10 mg BID in 11 cases and 5 mg BID in 3 cases. The outcomes of the 14 cases were 11 normal newborns (79%), 1 outcome pending (7%) and 2 refused consent for follow-up (14%).

'Effects on pregnancy and the foetus' is included as missing information in the RMP safety specification. Use in pregnancy and breastfeeding is contraindicated; this remains appropriate.

## Safety related to drug-drug interactions and other interactions

No new data is submitted

<div style=\"page-break-after: always\"></div>

## Safety related to drug-drug interactions and other interactions

No new data was submitted this was considered acceptable by the CHMP.

## Discontinuation due to adverse events

In Cohort 2 (P3 Maintenance), the proportion of subjects who discontinued from study overall was similar between the tofacitinib 5 mg BID and tofacitinib 10 mg BID groups (35.4% and 27.0%, respectively) but higher in the placebo group (66.7%). Excluding AEs related to worsening UC, study discontinuation due to AEs in placebo-controlled studies (Cohort 1 and Cohort 2) occurred in similar proportion (&lt;5%) of subjects among the placebo and tofacitinib treatment groups.

There was no apparent dose dependency in the frequency of discontinuation due to AEs in Cohort 2 (P3 Maintenance). In Cohort 3 (P2P3LTE Tofacitinib), excluding AEs related to worsening UC, most AEDCs had a single occurrence

The most frequent reason for study discontinuation in either Cohort 1 (P2P3 Induction) or Cohort 2 (P3 Maintenance) was insufficient clinical response (i.e., worsening UC).

## Post marketing experience

On 06 November 2012, XELANZ® (tofacitinib citrate) received its first regulatory approval in the US (US NDA 203214) at a dose of 5 mg BID for the treatment of adult patients with moderately to severely active RA who have had an inadequate response or intolerance to MTX.

As of 05 November 2016, cumulatively, there have been approximately 61,043 PY of exposure to tofacitinib from marketing experience (tofacitinib periodic safety update report [PSUR] 8, Executive Summary). There have been a total of 20,074 case reports received during the 4-year reporting period from 06 November 2012 through 05 November 2016. A total of 55,462 AEs have been reported, most of which, 54,960, were from spontaneous sources. The other 496 AEs were reported from non-interventional studies and other noninterventional solicited sources. Of the 55,462 AEs, the majority (45,839, 82.6%) were non-serious and the remainder (9623, 17.4%) were SAEs.

The most frequently reported AEs in the 20,074 cases (≥2%) were drug ineffective (14.0%), headache (8.2%), condition aggravated (7.1%), arthralgia (6.5%), pain (6.2%%), fatigue (5.9%), nausea (5.4%); diarrhoea (5.4%), pain in extremity (4.8%), product use issue (4.8%), malaise (4.1%), RA (3.9%), nasopharyngitis (3.7%), peripheral swelling (3.6%), joint swelling (3.2%), HZ (2.9%), abdominal discomfort (2.8%), abdominal pain upper (2.7%), cough (2.7%), dizziness (2.7%), musculoskeletal stiffness (2.5%), drug dose omission (2.5%), drug effect incomplete (2.4%), sinusitis (2.3%), pneumonia (2.3%), urinary tract infection (2.3%), rash (2.2%), weight increased (2.2%), dyspnea (2.1%), and pyrexia (2.0%).

The most frequently reported SAEs in the 20,074 cases were RA (3.9%), condition aggravated (3.3%), and pneumonia (2.3%).

The frequencies of headache, arthralgia, pain, fatigue, nausea, diarrhoea and pneumonia are consistent with the current SmPC table of ADRs.

<div style=\"page-break-after: always\"></div>

## 2.6.1. Discussion on clinical safety

As of 16 December 2016, a total of 1240 subjects with moderate-to-severe UC received at least 1 dose of placebo, tofacitinib 5 mg BID or tofacitinib 10 mg BID. Among these subjects, 1157 subjects received at least 1 dose of tofacitinib 5 mg BID or 10 mg BID, with 762 subjects exposed to tofacitinib for at least 6 months, and 653 subjects exposed for at least 12 months. In total, the UC program encompasses 1613 patient-years (PY) of exposure to tofacitinib, with up to 4.4 years of tofacitinib treatment. The exposure is adequate.

In the UC tofacitinib treatment group, AEs were reported in 82.1% of subjects, and the most frequently occurring AEs (all causalities) were in the Infections and infestations System Organ Class (SOC) (42.8% of subjects) and GI disorders SOC (38.0% of subjects), and the most frequently occurring preferred terms (PTs) for AEs were Colitis ulcerative (19.4% of subjects) and Nasopharyngitis.

In the tofacitinib treatment group the proportion of subjects with SAEs was 14.6%. The proportion of subjects with SAEs was 10.8% for PD 5 mg BID and 15.3% for PD 10 mg BID. The proportion of subjects with SAEs was 8.6% for PInd 5 mg BID and 13.4% for PInd 10 mg BID.  In the placebo-controlled studies, the proportion of subject with SAEs were similar among the placebo and the tofacitinib groups.

In Cohort 2 (P3 Maintenance), there was no apparent dose dependency in the risk of developing SAEs in tofacitinib-treated subjects.

The most frequently reported SOC for SAEs in the Tofacitinib All group in Cohort 3 (P2P3LTE Tofacitinib) was Gastrointestinal disorders, occurring in 6.5% of subjects in the Tofacitinib All group in Cohort 3 (P2P3LTE Tofacitinib).

There was no data do not suggest an increasing risk of serious infection with longer duration of tofacitinib treatment. The IR of serious infection was much higher in the subgroup average post-baseline Absolute Neutrophil Count 1.5 to &lt;2 ×109/L. However, it is noted there were only 4 subjects in this category.

The safety profile for tofacitinib 5 mg BID and 10 mg BID in the UC program (Cohort 3 [P2P3LTE Tofacitinib]), was consistent with that of the tofacitinib RA and PsO programs and was similar to that of biologic agents approved for treatment of UC. However, the exception was a higher IR of Herpes Zoster (HZ). Herpes zoster reactivation is an important identified risk for tofacitinib. Dose dependency for the risk of Herpes Zoster (HZ) and opportunistic infections (OIs) (mainly HZ) and NMSC was observed in the overall population treated with tofacitinib in the UC program. There was a trend toward an increased risk of HZ and NMSC in the TNFi-failure subgroup compared with the non-TNFi-failure subgroup. This is appropriately stated in the Product information.

The IRs of serious infection, HZ, and opportunistic infections (OI) in the Tofacitinib All group in Cohort 3 (P2P3LTE Tofacitinib) were similar to those reported in Cohort 2 (P3 Maintenance). The current data do not suggest an increasing risk of developing these safety events of special interest with longer duration of tofacitinib treatment and adequate risk minimisation activities are in place.

A total of 12 malignancy events have been identified for the UC programme. All malignancies occurred in subjects in the predominant dose 10 mg BID group. Dose dependency for the risk of malignancies with longterm tofacitinib treatment in UC patients cannot be excluded. Malignancy remains an important potential risk, for which there are additional pharmacovigilance activities in place.

The IRs of MACE in the UC program were similar to the IRs reported in randomized Phase 3 trials of the RA and PsO programs. The IR of MACE in the Tofacitinib All group in Cohort 3 (P2P3LTE Tofacitinib) was similar

<div style=\"page-break-after: always\"></div>

to those reported for the RA and PsO programs (all exposure) and for biologic agents in UC patients in external observational data.

As of 16 December 2016, a total of 4 deaths occurred in the entire UC program. After 16 December 2016, death was reported in a subject in the LTE Study A3921139. 3 of the deaths were related to malignancies.

The laboratory changes seen in the tofacitinib UC program were consistent with those seen previously.

In the UC program, there were 25 cases of exposure during pregnancy with tofacitinib, but no definite evidence of teratogenicity. Tofacitinib is contraindicated in pregnancy.

The most frequent reason for study discontinuation was insufficient clinical response.  In maintenance study, the proportion of subjects who discontinued due to insufficient clinical response was higher in the placebo group than in the tofacitinib groups. Excluding AEs related to worsening UC, study discontinuation due to AEs in placebo-controlled studies occurred in similar proportions (&lt;5%) of subjects among the placebo and tofacitinib treatment groups suggesting tofacitnib was well tolerated.

From the safety database all the adverse reactions reported in clinical trials and post-marketing have been included in the Summary of Product Characteristics.

## 2.6.2. Conclusions on the clinical safety

The observed safety profile for the UC database is in line with the known safety profile based on the RA clinical database and post-marketing experience and was similar to that of biologic agents approved for treatment of UC. However, the exception was a higher IR of Herpes Zoster (HZ).  Dose dependency for the risk of Herpes Zoster (HZ) and opportunistic infections (OIs) (mainly HZ) and NMSC was observed in the overall population treated with tofacitinib in the UC program.

Malignancy remains an important potential risk, for which there are additional pharmacovigilance activities in place.

## 2.7. Risk Management Plan

## Safety concerns

| Summary of Safety Concerns   | Summary of Safety Concerns                                         |
|------------------------------|--------------------------------------------------------------------|
| Important identified risks   | Serious and other important infections                             |
| Important identified risks   | Herpes zoster reactivation                                         |
| Important identified risks   | Decrease in neutrophil counts and neutropenia                      |
| Important identified risks   | Decrease in lymphocyte counts and lymphopenia                      |
| Important identified risks   | Decrease in haemoglobin levels and anaemia                         |
| Important identified risks   | Lipid elevations and hyperlipidaemia                               |
| Important identified risks   | Nonmelanoma skin cancer                                            |
| Important identified risks   | Transaminase elevation and potential for drug-induced liver injury |
| Important potential risks    | Malignancy                                                         |
| Important potential risks    | Cardiovascular risk                                                |
| Important potential risks    | Gastrointestinal perforation                                       |
| Important potential risks    | Interstitial lung disease                                          |
| Important potential risks    | Progressive multifocal leukoencephalopathy                         |
| Important potential risks    | Increased immunosuppression when used in combination with          |

<div style=\"page-break-after: always\"></div>

| Summary of Safety Concerns   | Summary of Safety Concerns                                                                                      |
|------------------------------|-----------------------------------------------------------------------------------------------------------------|
|                              | biologics and immunosuppressants including B lymphocyte depleting agents                                        |
|                              | Increased risk of adverse events when tofacitinib is administered in combination with MTX in RA or PsA patients |
|                              | Primary viral infection following live vaccination                                                              |
|                              | Increased exposure to tofacitinib when co-administered with CYP3A4 and CYP2C19 inhibitors                       |
|                              | Off-label use including children with JIA or IBD                                                                |
|                              | Higher incidence and severity of adverse events in the elderly                                                  |
| Missing information          | Effects on pregnancy and the foetus                                                                             |
| Missing information          | Use in breastfeeding                                                                                            |
| Missing information          | Effect on vaccination efficacy and the use of live/attenuated vaccines                                          |
| Missing information          | Use in patients with mild, moderate, or severe hepatic impairment                                               |
| Missing information          | Use in patients with moderate or severe renal impairment                                                        |
| Missing information          | Use in patients with evidence of hepatitis B or hepatitis C infection                                           |
| Missing information          | Use in patients with elevated transaminases                                                                     |
| Missing information          | Use in patients with malignancy                                                                                 |

## Pharmacovigilance plan

| Study/Activity Type, Title and Category (1-3)                                                                                                | Objectives                                                                                                                                                                          | Safety Concerns Addressed                                                                                                                                                                                                                                               | Status (Planned/Start ed)   | Date for Submission of Final Study Report (Planned or Actual)   |
|----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|-----------------------------------------------------------------|
| Study A3921133: Phase 3B/4 randomized safety endpoint study of 2 doses of tofacitinib in comparison to a TNF inhibitor in subjects with RA 3 | To continue to evaluate the 2 safety concerns that have a long latency period (ie, adjudicated MACE and adjudicated malignancies excluding NMSC of tofacitinib in patients with RA) | The safety of tofacitinib at 2 doses versus adalimumab (co- primary endpoints include adjudicated MACEs and adjudicated malignancies excluding NMSC, secondary endpoint will evaluate adjudicated opportunistic OI events including TB and adjudicated hepatic events). | Started                     | Submission of the protocol by 09/2017 2020 (planned)            |

<div style=\"page-break-after: always\"></div>

| Study/Activity Type, Title and Category (1-3)                       | Objectives                                                                                      | Safety Concerns Addressed                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Status (Planned/Start ed)   | Date for Submission of Final Study Report (Planned or Actual)   |
|---------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|-----------------------------------------------------------------|
| An EU-based survey for prescribers (RMM effectiveness assessment) 3 | To assess prescribers' knowledge and understanding of the key risks associated with tofacitinib | Serious and other important infections, HZ reactivation, malignancies (including NMSC), changes in laboratory parameters, GI perforation, liver injury, increased immunosuppressi on when tofacitinib is used with bDMARDS, increased risk of adverse events in patients treated with tofacitinib in combination use of MTX, primary viral infection following live vaccination, higher incidence and severity of adverse events in elderly patients, effects on pregnancy and the foetus, use in breastfeeding, effects on vaccination efficacy, use in populations with severe hepatic impairment | Planned                     | RA: October 2019 PsA: June 2021 UC: June 2021                   |

<div style=\"page-break-after: always\"></div>

| Study/Activity Type, Title and Category (1-3)                                                            | Objectives                                                                                                    | Safety Concerns Addressed                                                                                                                                                                                                                                        | Status (Planned/Start ed)   | Date for Submission of Final Study Report (Planned or Actual)   |
|----------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|-----------------------------------------------------------------|
| An EU-based drug utilization study using electronic health care records (RMM effectiveness assessment) 3 | To assess prescription trends over time, as well as evaluate compliance with risk minimisation measures       | Extent to which patient screening and laboratory monitoring recommendations and recommendations regarding limitations of use (and concurrent conditions, such as pregnancy, hepatic impairment, or concomitant use of bDMARDs) are followed, and off- label use. | Planned                     | RA: December 2021 PsA: March 2023 UC: March 2023                |
| Prospective, non- interventional active surveillance study embedded within the ARTIS RA registry 3       | To further understand and characterise the safety profile of tofacitinib within the clinical practice setting | Serious infections,HZ reactivation, NMSC, malignancy, CV risk, GI perforation, PML, increased risk of adverse events in patients treated with tofacitinib in combination use of MTX, higher incidence and severity of adverse events in elderly patients         | Planned                     | March 2024                                                      |
| Prospective, non- interventional active surveillance study embedded within the BSRBR RA registry 3       | To further understand and characterise the safety profile of tofacitinib within the clinical practice setting | Serious infections, HZ reactivation, NMSC, malignancy, CV risk, GI perforation, PML, increased risk of adverse events in patients treated with tofacitinib in combination use of MTX, higher incidence and severity of adverse events in elderly patients        | Planned                     | March 2024                                                      |

<div style=\"page-break-after: always\"></div>

| Study/Activity Type, Title and Category (1-3)                                                               | Objectives                                                                                                                                                                                                                                                                                                                                       | Safety Concerns Addressed                                                                                                                                                                                                                                                  | Status (Planned/Start ed)   | Date for Submission of Final Study Report (Planned or Actual)   |
|-------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|-----------------------------------------------------------------|
| Prospective, non- interventional active surveillance study embedded within the RABBIT RA registry 3         | To further understand and characterise the safety profile of tofacitinib within the clinical practice setting                                                                                                                                                                                                                                    | Serious infections, HZ reactivation, NMSC, malignancy, CV risk, GI perforation, PML, increased risk of adverse events in patients treated with tofacitinib in combination use of MTX, higher incidence and severity of adverse events in                                   | Planned                     | March 2024                                                      |
| Prospective, non- interventional active surveillance study embedded within the BIOBADASER RA registry 3     | To further understand and characterise the safety profile of tofacitinib within the clinical practice setting                                                                                                                                                                                                                                    | elderly patients Serious infections, HZ reactivation, NMSC, malignancy, CV risk, GI perforation, PML, increased risk of adverse events in patients treated with tofacitinib in combination use of MTX, higher incidence and severity of adverse events in elderly patients | Planned                     | March 2024                                                      |
| Prospective, non- interventional active surveillance pregnancy study embedded within the US OTIS registry 3 | To estimate the risk of birth defects and other adverse pregnancy outcomes occurring in offspring of patients exposed to tofacitinib during pregnancy, and to detect any increase in the prevalence or pattern of these outcomes among exposed pregnancies as compared with internally generated disease-matched and non-diseased control group. | Birth defects and other adverse pregnancy outcomes                                                                                                                                                                                                                         | Started                     | RA: 31 August 2018 PsA: March 2024                              |
| Prospective, non-                                                                                           | To provide                                                                                                                                                                                                                                                                                                                                       | Serious infections,                                                                                                                                                                                                                                                        | Started                     | October 2018                                                    |

<div style=\"page-break-after: always\"></div>

| Study/Activity Type, Title and Category (1-3)                                                                                                                                                                                                 | Objectives                                                                                                                                                                                                                                                                                       | Safety Concerns Addressed                                                                                                                                                                                                            | Status (Planned/Start ed)   | Date for Submission of Final Study Report (Planned or Actual)   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|-----------------------------------------------------------------|
| interventional active surveillance study embedded within the Corrona registry (RA) 3                                                                                                                                                          | additional longitudinal safety data regarding the use of tofacitinib in the US for RA patients.                                                                                                                                                                                                  | HZ reactivation, malignancies, NMSC, cardiovascular events, PML, GI perforation, increased risk of adverse events in patients treated with tofacitinib in combination use of MTX, higher incidence and severity of adverse events in |                             |                                                                 |
| Prospective, non- interventional active surveillance study using 1 or more European UC registries (assess feasibility of using Spanish ENEIDA Inflammatory Bowel Disease Registry, SWIBREG, and the United Kingdom Inflammatory Bowel Disease | To further understand and characterise the safety profile of tofacitinib within the clinical practice setting                                                                                                                                                                                    | elderly patients Serious infections, HZ reactivation, NMSC, malignancy, CV risk, GI perforation, PML, higher incidence and severity of adverse events in elderly patients                                                            | Planned                     | July 2025                                                       |
| Prospective, non- interventional active surveillance pregnancy study embedded within a registry (assess feasibility of using the US OTIS registry or US PIANO registry) for UC 3                                                              | To estimate the risk of birth defects and other adverse pregnancy outcomes occurring in offspring of patients exposed to tofacitinib during pregnancy, and to detect any increase in the prevalence or pattern of these outcomes among exposed pregnancies as compared with internally generated | Birth defects and other adverse pregnancy outcomes                                                                                                                                                                                   | Planned                     | September 2024                                                  |

<div style=\"page-break-after: always\"></div>

| Study/Activity Type, Title and Category (1-3)   | Objectives                               | Safety Concerns Addressed   | Status (Planned/Start ed)   | Date for Submission of Final Study Report (Planned or Actual)   |
|-------------------------------------------------|------------------------------------------|-----------------------------|-----------------------------|-----------------------------------------------------------------|
|                                                 | disease-matched and non-diseased control |                             |                             |                                                                 |

## Risk minimisation measures

| Safety Concern                                                     | Routine Risk Minimisation Measures   | Additional Risk Minimisation Measures                                                                                                                                                                               |
|--------------------------------------------------------------------|--------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risks                                         | Important Identified Risks           | Important Identified Risks                                                                                                                                                                                          |
| Serious and other important infections                             | Labelling                            | Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Treatment Checklists, Prescriber Brochure, safety educational website). |
| Herpes zoster reactivation                                         | Labelling                            | Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Prescriber Brochure, safety educational website).                       |
| Decrease in neutrophils counts and neutropenia                     | Labelling                            | Development of an educational programme including additional communication to prescribers (including Treatment Checklists, Prescriber Brochure, safety educational website).                                        |
| Decrease in lymphocyte counts and lymphopenia                      | Labelling                            | Development of an educational programme including additional communication to prescribers (including Treatment Checklists, Prescriber Brochure, safety educational website).                                        |
| Decrease in haemoglobin levels and anaemia                         | Labelling                            | Development of an educational programme including additional communication to prescribers (including Treatment Checklists, Prescriber Brochure, safety educational website).                                        |
| Lipid elevations and hyperlipidaemia                               | Labelling                            | Development of an educational programme including additional communication to prescribers (including Treatment Checklists, Prescriber Brochure, safety educational website).                                        |
| Nonmelanoma skin cancer                                            | Labelling                            | Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Prescriber Brochure, safety educational website).                       |
| Transaminase elevation and potential for drug-induced liver injury | Labelling                            | Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Treatment Checklists, Prescriber Brochure, safety educational website). |
| Important Potential Risks                                          | Important Potential Risks            | Important Potential Risks                                                                                                                                                                                           |
| Malignancy                                                         | Labelling                            | Development of an educational programme                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                                                                                     | Routine Risk Minimisation Measures   | Additional Risk Minimisation Measures                                                                                                                                                                                                    |
|------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                    |                                      | including additional communication to prescribers (including Treatment Checklists, Prescriber Brochure, safety educational website).                                                                                                     |
| Cardiovascular risk                                                                                                                | Labelling                            | None proposed                                                                                                                                                                                                                            |
| Gastrointestinal perforation                                                                                                       | Labelling                            | Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Treatment Checklists, Prescriber Brochure, safety educational website).                      |
| Interstitial lung disease                                                                                                          | Labelling                            | Development of an educational programme including additional communication to patients (Patient Alert Card) and prescribers (including Treatment Checklists, Prescriber Brochure, safety educational website).                           |
| Progressive multifocal leukoencephalopathy                                                                                         | None proposed                        | None proposed                                                                                                                                                                                                                            |
| Increased immunosuppression when used in combination with biologics and immunosuppressants including B lymphocyte depleting agents | Labelling                            | Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Treatment Checklists, Prescriber Brochure, safety educational website).                      |
| Increased risk of adverse events when tofacitinib is administered in combination with MTX in RA or PsA patients                    | Labelling                            | Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Prescriber Brochure, safety educational website).                                            |
| Primary viral infection following live vaccination                                                                                 | Labelling                            | Development of an educational programme including additional communication to prescribers (including Treatment Checklists, Prescriber Brochure, safety educational website).                                                             |
| Increased exposure to tofacitinib when co- administered with CYP3A4 and CYP2C19 inhibitors                                         | Labelling                            | Development of an educational programme including additional communication to patients (Patient Alert Card) and prescribers (including Prescriber Brochure, safety educational website).                                                 |
| Off-label use including children with JIA or IBD                                                                                   | Labelling                            | None proposed                                                                                                                                                                                                                            |
| Higher incidence and severity of adverse events in the elderly                                                                     | Labelling                            | Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Prescriber Brochure, safety educational website), specific to the higher risk of infections. |
| Missing Information                                                                                                                | Missing Information                  | Missing Information                                                                                                                                                                                                                      |
| Effects on pregnancy and the foetus                                                                                                | Labelling                            | Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Treatment Checklists, Prescriber Brochure, safety educational website).                      |
| Use in breastfeeding                                                                                                               | Labelling                            | Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Treatment Checklists, Prescriber Brochure, safety educational website).                      |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                         | Routine Risk Minimisation Measures   | Additional Risk Minimisation Measures                                                                                                                                                                          |
|------------------------------------------------------------------------|--------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Effect on vaccination efficacy and the use of live/attenuated vaccines | Labelling                            | Development of an educational programme including additional communication to patients (Patient Alert Card) and prescribers (including Treatment Checklists, Prescriber Brochure, safety educational website). |
| Use in patients with mild, moderate, or severe hepatic impairment      | Labelling                            | Development of an educational programme including additional communication to prescribers (including Treatment Checklists, Prescriber Brochure, safety educational website).                                   |
| Use in patients with moderate or severe renal impairment               | Labelling                            | None proposed                                                                                                                                                                                                  |
| Use in patients with evidence of hepatitis B or C infections           | Labelling                            | None proposed                                                                                                                                                                                                  |
| Use in patients with elevated transaminases                            | Labelling                            | None proposed                                                                                                                                                                                                  |
| Use in patients with malignancy                                        | Labelling                            | None proposed                                                                                                                                                                                                  |

## Conclusion

The CHMP and PRAC considered that the risk management plan version 5.0 is acceptable.

## 2.8. Pharmacovigilance

## Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the MAH fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.9. Product information

Please refer to the full PI in attachment. As a consequence of this new indication and the line extension sections 2, 3, 4.1, 4.2, 4.4, 4.8, 5.1, 5.2, 5.1., 6.1, 6.5. and 8  of the SmPC have been updated. The Package Leaflet has been updated accordingly.

Changes were also made to the PI to bring it in line with the current Agency/QRD template, SmPC guideline and other relevant guideline(s) [e.g. Excipients guideline, storage conditions, Braille, etc…], which were reviewed by QRD and accepted by the CHMP.

<div style=\"page-break-after: always\"></div>

## 2.9.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 2.9.2. Additional monitoring

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Xeljanz (tofacitinib) is included in the additional monitoring list as it contains a new active substance which, on 1 January 2011, was not contained in any medicinal product authorised in the EU.

Therefore the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The target indication applied for by the MAH is for the induction and maintenance of treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

UC is a chronic, relapsing, inflammatory disease of the colon characterized by alternating episodes of remission and spontaneous relapse. The primary treatment goal is to induce remission and then to maintain this state.

## 3.1.2. Available therapies and unmet medical need

Current therapy for the treatment of UC includes 5-aminosalicylic acid (5-ASA), systemic and/or topical corticosteroids, immunosuppressants such as azathioprine/6-mercaptopurine (6-MP) and cyclosporine, and tumour necrosis factor-alpha inhibitors (TNFis), and recently approved α4β7 integrin antagonist vedolizumab. A significant proportion of UC patients still require colectomy for refractory or severe fulminant disease, or in some cases for cancer prevention. At present, no current pharmacological therapy is able to provide a full cure for UC.

## 3.1.3. Main clinical studies

The main evidence of efficacy submitted are the pivotal phase 3 studies which consisted of two identically conducted studies to investigate efficacy in induction of remission (studies A3921094 and A3921095) and one examining efficacy in maintenance of remission study A3921096). All three studies A3921094, A3921095 and A3921096 were multi-centre, randomised, double-blind, placebo-controlled efficacy and safety studies in

<div style=\"page-break-after: always\"></div>

patients with moderate to severely active disease. Subjects were selected based on a diagnosis of UC for more than four months prior to entry into the study, with a histological conformation. Moderately to severely active disease was defined by a total Mayo score of &gt;6, with a rectal bleeding score of &gt;1, and an endoscopic subscore of &gt;2 on the Mayo score determined within 10 days of baseline visit. Appropriate measures of diagnosis and disease severity were utilised for subject selection.

In studies A3921094 and A3921095 subjects were randomized to either tofacitinib 10 mg BID or placebo BID, with a treatment allocation ratio of 4:1. Subjects were stratified by previous treatment with TNFi therapy, oral corticosteroid use at baseline, and geographic region. Active treatment in the study continued for 8 weeks

Subjects who completed either of the induction studies and achieved clinical response or remission irrespective of treatment were re-randomized into the maintenance study A3921096. Subjects were randomized to either tofacitinib 10 mg BID, tofacitinib 5 mg BID or placebo BID with an allocation ratio of 1:1:1.  The study was conducted as a 52-week double-blind treatment period followed by a 4 week safety follow-up for subjects who did not participate in the open-label study (A3921139).

## 3.2. Favourable effects

In the phase 3 induction studies A3921094 and A3921095 the primary endpoint was remission which was achieved in 18.5% in study A3921094 and 16.6% in study A3921095 of subjects on tofacitinib 10mg BID, placebo rates were 8.2%; difference 10.3; 95% CI 4.3, 16.3; p-value 0.0070 and 3.6%; difference 13.0; 95% CI 8.1, 19.7; P-value 0.0005 respectively. The key secondary endpoint was mucosal healing which in study A3921094 was achieved in 31.3% in the tofacitinib 10 mg BID group and 15.6% of the placebo group (difference 15.7, 95% CI 8.1, 23.4, P-value 0.0005). In study A3921095 mucosal healing was achieved in 28.4% in the 10mg BID tofacitinib group and 11.6% in the placebo group; difference 16.8 95% CI 9.5. 24.1 p= 0.0002).

The results of the 2 replicate induction studies show consistent and statistically significant findings with similar magnitudes of placebo-adjusted treatment effect for tofacitinib 10 mg BID across endpoints.

Across endpoints, treatment effect was observed in the refractory TNFi subgroups, including subjects with prior TNFi exposure or failure, those subjects with prior failure to 2 or more TNFi agents, and those with primary non-response to TNFi. In study A3921094 those with prior TNFi failure remission rates were 11.1% in the tofacitinib 10mg BID group compared to 1.6% in placebo. In those without prior TNFi failure remission was demonstrated in 26.2% in the treatment group and 15.5% in the placebo group. In study A3921095 those with prior TNFi failure remission rates were 11.7% in the tofacitinib 10mg BID group compared to 0.0% in placebo group. In those without prior TNFi failure remission was demonstrated in 21.7% in the treatment group and 7.7% in the placebo group.

In the phase 3 maintenance study A3921096 the primary endpoint was remission which in the tofacitinib 5mg BID group was 34.3%; 10mg BID 40.6% and placebo 11.1%. For the end point of sustained corticosteroidfree remission 35.4% in the tofacitinib 5 mg BID; 47.3 in tofacitinib 10 mg BID and 5.1 in placebo. Mucosal healing was achieved in 37.4 % in the 5mg tofacitinib; 45.7 in the 10mg tofacitinib and 13.1% in the placebo group. These three endpoints were all statistically different from placebo p&lt;0.0001.

Across the primary and key secondary endpoints, treatment effect was observed in the TNFi subgroups, including subjects with prior TNFi exposure or failure and those with primary non-response to TNFi. The magnitude of observed treatment effects was similar for subjects treated with tofacitinib 5 mg BID and

<div style=\"page-break-after: always\"></div>

tofacitinib 10 mg BID in the subgroups of subjects without prior TNFi exposure or failure. In contrast, there was a clinically meaningful observed treatment difference between tofacitinib 10 mg BID and 5 mg BID in the subgroup of subjects with prior TNFi failure, with differences between the 2 tofacitinib groups ranging from 9.7 to 16.7 percentage points across the primary and key secondary endpoints. Sustained corticosteroid free remission in those at remission at baseline was 22.2% in 5mg BID, 38.9% 10mg BID and 4.8 % placebo in those who had failed prior TNFi therapy. Compared to 40.4%, 51.4% and 5.3% in those who had not had prior failure to TNFi therapy.

With regards to patient related outcomes in both induction and maintenance studies there were improvements in the EuroQoL 5-Dimension (EQ-5D) and various domains of the Work Productivity and Activity Impairment (WPAI-UC) questionnaire. There was also greater improvement compared to placebo from baseline in in the total and all 4 domain scores of the Inflammatory Bowel Disease Questionnaire (IBDQ) for all three clinical studies.

Data from the ongoing LTE study provided evidence that an extended period of induction of 16 weeks (an additional 8 weeks of 10 mg BID dosing beyond the initial 8-week induction phase) is of benefit in patients failing to achieve an adequate response to the initial 8-weeks induction regimen. Of these subjects who failed to show a clinical response at 8 weeks induction who enrolled in the LTE (295/905 subjects), 51.2% achieved clinical response and 8.6% remission at 16 weeks (8 weeks of the LTE). In addition, further data are reported that show additional responders at 16 weeks that were not evident at 8 weeks.

## 3.3. Uncertainties and limitations about favourable effects

For the induction studies A3921094 and A3921095 the primary efficacy endpoint in the induction studies was remission which was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Ideally the co-primary endpoints on both symptomatic relief and endoscopic healing would have been utilised in line with the CHMP/EWP/18463/2006 Guideline on the development of new medicinal products for the treatment of Ulcerative Colitis. The total Mayo score including the PGA is not of primary interest. It is however noted that the chosen definition of remission did refer to all sub scores of the Mayo score and as such did encompass both symptomatic and endoscopic evaluation and in addition included cessation of rectal bleeding in the definition and as such is acceptable. It was noted that the remission rates in the induction studies were only 18.5% in study A3921094 and 16.6% in study A3921095.

For the maintenance study A3921096 the primary efficacy endpoint was remission at Week 52, defined by a Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. The key secondary endpoints were mucosal healing at Week 52, defined by a Mayo endoscopic subscore of 0 or 1; and sustained corticosteroid-free remission at both Weeks 24 and 52 among subjects in remission at baseline defined by a Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0, in addition to not requiring any treatment with corticosteroids for at least 4 weeks prior to the visit. CHMP Draft guidelines CHMP/EWP/18463/2006 Rev.1 Guideline on the development of new medicinal products for the treatment of Ulcerative Colitis, advise that the primary endpoint should be the number of patients in clinical and endoscopic remission in whom steroids could be withdrawn. As such the relevance of the second key secondary efficacy endpoint was highlighted and is viewed as a primary endpoint in assessment. In the maintenance study, there were a high number of subjects (51.0%) who discontinued the study (including 43.9% of subjects in the tofacitinib 5 mg BID group, 35.7% of subjects in the tofacitinib 10 mg BID group, and 73.2% in the placebo group).  The MAH acknowledged that the discontinuation rate due to ICR is analogous to the clinical efficacy results, whereby the increment in efficacy between 5mg BID

<div style=\"page-break-after: always\"></div>

and 10mg BID regimens was larger in those with a history of TNFi failure, especially for the highly relevant endpoint of sustained corticosteroid-free remission amongst remitters.

There was no direct active comparator in the clinical trials.  There are many challenges of indirect comparison of trials in UC with the variability in subject selection, previous therapies, concomitant medications endpoint definitions and study methodology, thus only limited conclusions with regards to efficacy or safety of tofacitinib with comparison to existing therapies can be made. Taking these limitations into account it could be inferred that the observed treatment effect of tofacitinib 10 mg BID in Studies A3921094 and A3921095 was at least similar to the historical Phase 3 results of Golimumab, Vedolizumab and Adalimumab for clinical remission. The treatment effect for tofacitinib was lower than of infliximab, although it should be noted that the study populations were different, including differences in prior treatment experience and allowed concomitant medicines, thus making clear conclusions difficult.  Clinical remission was defined as a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point, at week as opposed to the remission which included rectal bleeding, i.e. Remission was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0 at week 8.

## Estimated induction treatment effects (difference from placebo) for clinical remission :

<!-- image -->

|                     | %Prior TNFI   | Study Duration, Weeks   | Dose                | Difference fromPlacebo,% (95%CI)   | Difference fromPlacebo,% (95%CI)   | Difference fromPlacebo,% (95%CI)    | Active n/N (%)              | Placebo n/N(%)           |
|---------------------|---------------|-------------------------|---------------------|------------------------------------|------------------------------------|-------------------------------------|-----------------------------|--------------------------|
| Tofacitinib (2015)* | 53% 55%       | 8 8                     | 10mgBID 10mgBID     |                                    | A3921004 A3921095                  | 413.3(6.5,20.2) 15.6 (9.9,21.3)     | 118/476(24.8) 90/429 (21.0) | 14/122(11.5) 6/112 (5.4) |
| Golimumab (2014)    | 0%            | 6                       | 200/100mg 400/200mg | 中                                  |                                    | 11.4 (5.8, 17.0) 11.5 (5.9, 17.1)   | 45/253 (17.8) 46/257 (17.9) | 16/251 (6.4)             |
| Vedolizumab(2013)   | 48%           | 6                       | 300mg               |                                    |                                    | 11.5 (5.4, 17.6)                    | 38/225 (16.9)               | 8/149 (5.4)              |
| Adalimumab (2012)   | 40%**         | 8                       | 160/80/40mg         |                                    |                                    | 7.2 (1.3, 13.1)                     | 41/248 (16.5)               | 23/246 (9.3]             |
| Adalimumab(2010)    | %0            | 8                       | 160/80/40mg         |                                    |                                    | 9.2 (0.9, 17.6)                     | 24/130 (18.5)               | 12/130 (9.2)             |
| Infliximab (2005)   | 0%            | 8                       | 5mg/kg 10 mg/kg     |                                    | ACT1                               | 24.0 (13.2.34.7) 17.1 (6.7, 27.5)   | 47/121(38.8) 39/122 (32.0)  | 18/121 (14.9)            |
|                     | %0            | 8                       | 5 mg/kg 10 mg/kg    |                                    | ACT2                               | 28.2 (18.8, 37.6) 21.8 (12.8, 30.8) | 41/121 (33.9) 33/120 (27.5) | 7/123 (5.7)              |

-10

0

10

20

30

40

Sources: 5.3.5.1 A3921094-report-body Table 14.1.2.1.3;Table 14.2.4.2; 5.3.5.1 A3921095-report-body Table 14.1.2.1.3; Table 14.2.4.2; Sandbom et al (2014),Feagan et al (2013),Reinisch et al (2011), Sandbom et al (2012).Rutgeerts et al (2005).7

Analysis based on NRI using FAS data and local endoscopic reading.

Normal approximation for difference in binomial proportions was used to estimate 95% CIs.

Primary TNFi non-responders were excluded.

Abbreviations:ACT1 =Active Ulcerative Colitis Trial 1;ACT2=Active Ulcerative Colitis Trial 2;BID= twice a day;CI= confidence interval; FAS = full analysis set; NRI = non-responder imputation; TNFi = tumour necrosis factor inhibitor.

The observed induction treatment effect of tofacitinib 10 mg BID in subjects without prior failure or exposure to TNFi agents was considered at least similar to that of the same subgroup of subjects in the comparable development programs.  In addition, the observed induction treatment effect for tofacitinib in the subpopulation of patients with prior TNFi exposure or failure in the Phase 3 studies was numerically larger than that observed for adalimumab and vedolizumab.  There are no placebo controlled data available in this

<div style=\"page-break-after: always\"></div>

subpopulation (those with prior failure of TNFi agents) for infliximab or golimumab.  Furthermore, the exclusion of TNFi primary non-responders in the adalimumab trial in effect limited their TNFi failure subjects to only TNFi secondary non-responders, who are generally viewed as less refractory than TNFi primary nonresponders.

In the maintenance study, the observed treatment effect of tofacitinib 5 mg BID and tofacitinib 10 mg BID was similar to or greater than the observed treatment effects for the historical Phase 3 results of the currently approved treatments.

## Estimated maintenance treatment effects (difference from placebo) for clinical remission:

<!-- image -->

|             | Dose and Route    |   Year#TimePoint | Year#TimePoint   | Difference,% (95% C)   | Difference,% (95% C)   |               | Active Placebo n/N (%) n/N (%)   |
|-------------|-------------------|------------------|------------------|------------------------|------------------------|---------------|----------------------------------|
| Tofacitinib | 10 mg P0 BID      |             2016 | Week 52          |                        | 35.1 (26.7, 45.5)      | 95/197 (48.2) | 26/198 (13.1)                    |
| Tofacitinib | 5 mg PO BID       |             2016 | Week 52          |                        | 26.8 (18.5, 35.1)      | 79/198 (39.9) | 26/198 (13.1)                    |
| Vedolizumab | 300 mg IV Q8weeks |             2013 | Weck 52#         |                        | 25.9 (15.1, 36.8)      | 51/122 (41.8) | 20/126 (15.9)                    |
| Golimumab   | 100mg SC Q 4weeks |             2014 | Week 54          |                        | 11.7 (1.7, 21.7)       | 51/151 (33.8) | 34/154 (22.1)                    |
| Adalimumab* | 40 mg SC Q2weeks  |             2012 | Week 52          |                        | 8.8 (2.9, 14.7)        | 43/248 (17.3) | 21/246 (8.5)                     |
| Infliximab* | 5mg/kgIV Q8weeks  |             2005 | Week 54#         |                        | 18.2 (7.4, 28.9)       | 42/121 (34.7) | 20/131 (16.5)                    |

-10

0

10

20

30

40

05

Sources: A3921096-report-body Table 14.2.5.1.1; Sandbom et al (2014),Feagan et al (2013),Sandbom et al (2012), Rutgeerts et al (2005).

* Analysis based on NRI using FAS population and local endoscopic reading;

#Year=end ofclinical trial;

YInduction-maintenance treat-through designwithout re-randomizationbetween induction and maintenance phases; Vedolizumab:Week52includes 6week induction and 46week maintenance phases;Infliximab:Week54includes 8week induction and 46 week maintenance phases.

Normal approximation for difference in binomial proportions was used to estimate 95% CIs.

Abbreviations:BID=twicea day;CI=confidenceinterval;FAS=full analysis set;IV=intravenous:N=number of subjects in analysis set;n=number of subjects with specified response;PO=oral;Q=every;SC=subcutaneous.

As discussed the indirect comparison with second line agents for UC is challenging and only limited inferences may be made from the submitted data.

Similar to the tofacitinib induction studies, the endpoints of remission and clinical remission were nearly identical and results based on local reading were numerically higher than those based on central reading. The endpoint that is common across the development programs is clinical remission using local read. Among the approved therapies, vedolizumab appears to have the best treatment effect in maintenance.  Despite the differences in concomitant medications allowed, when tofacitinib is compared to vedolizumab, the difference from placebo in the proportion of clinical remitters for tofacitinib 5 and 10 mg BID was similar to that observed with vedolizumab.

## 3.4. Unfavourable effects

A total of 1,157 patients (Phase 2, 3, and long-term extension study) were treated with at least 1 dose of 5 mg or 10 mg twice daily with a mean duration of 1.4 years (based on up to 4.4 years of exposure), and 1,613 patient-years of accumulated total drug exposure to Xeljanz.

<div style=\"page-break-after: always\"></div>

In the UC tofacitinib treatment group, AEs were reported in 82.1% of subjects, and the most frequently occurring AEs (all causalities) were in the Infections and infestations System Organ Class (SOC) (42.8% of subjects) and GI disorders SOC (38.0% of subjects), and the most frequently occurring preferred terms (PTs) for AEs were Colitis ulcerative (19.4% of subjects) and Nasopharyngitis

In the entire treatment experience with XELJANZ, the most commonly reported infection was nasopharyngitis, occurring in 18.2% of patients (211 patients). In the entire treatment experience with Xeljanz, the overall incidence rate of infections was 60.3 events per 100 patient-years (involving 49.4% of patients; total 572 patients).

The safety profile for tofacitinib 5 mg BID and 10 mg BID in the UC program (Cohort 3 [P2P3LTE Tofacitinib]), was consistent with that of the tofacitinib RA and PsO programs and was similar to that of biologic agents approved for treatment of UC. However, the exception was a higher IR of Herpes Zoster (HZ). Herpes zoster reactivation is an important identified risk for tofacitinib.

Dose dependency for the risk of Herpes Zoster (HZ) and opportunistic infections (OIs) (mainly HZ) and NMSC was observed in the overall population treated with tofacitinib in the UC program. There was a trend toward an increased risk of HZ and NMSC in the TNFi-failure subgroup compared with the non-TNFi-failure subgroup. Patients with an ALC less than 1,000 cells/mm3 may have an increased risk of herpes zoster.

A total of 12 malignancy events have been identified for the UC programme. All malignancies occurred in subjects in the predominant dose 10 mg BID group. Dose dependency for the risk of malignancies with longterm tofacitinib treatment in UC patients cannot be excluded. Malignancy remains an important potential risk, for which there are additional pharmacovigilance activities in place.

The IRs of MACE in the UC program were similar to the IRs reported in randomized Phase 3 trials of the RA and PsO programs. The IR of MACE in the Tofacitinib All group was similar to those reported for the RA and PsO programs (all exposure) and for biologic agents in UC patients in external observational data.

As of 16 December 2016, a total of 4 deaths occurred in the entire UC program. After 16 December 2016, death was reported in a subject in the LTE Study A3921139. 3 of the deaths were related to malignancies.

The laboratory changes seen in the tofacitinib UC program were consistent with those seen previously.

Tofacitinib has been shown to be teratogenic in rats and rabbits, and to affect parturition and peri/postnatal development. In the UC program, there were 25 cases of exposure during pregnancy with tofacitinib, but no definite evidence of teratogenicity. Tofacitinib is contraindicated in pregnancy.

The most frequent reason for study discontinuation was insufficient clinical response.  In maintenance study, the proportion of subjects who discontinued due to insufficient clinical response was higher in the placebo group than in the tofacitinib groups. Excluding AEs related to worsening UC, study discontinuation due to AEs in placebo-controlled studies occurred in similar proportions (&lt;5%) of subjects among the placebo and tofacitinib treatment groups suggesting that tofacitinib was well tolerated.

## 3.5. Uncertainties and limitations about unfavourable effects

The risks of tofacitinib beyond 1 year among patients with ulcerative colitis are unknown. The safety profile for tofacitinib 5 mg BID and 10 mg BID in the UC program (Cohort 3 [P2P3LTE Tofacitinib]), was consistent with that of the tofacitinib RA and PsO programs and was similar to that of biologic agents approved for treatment of UC. The exception was a higher IR of Herpes Zoster (HZ). Herpes zoster reactivation' is an

<div style=\"page-break-after: always\"></div>

important identified risk for tofacitinib. The risk of Herpes Zoster is appropriately reflected in the SmPC and will be followed up upon in post authorisation registries together with the general long term safety profile of tofacitinib in Ulcerative Collitis.

## 3.6. Effects Table

| Effect                              | Short Description                                                                                                                                             | Unit               | Tofacitinib 10 mg BID   | Tofacitinib 10 mg BID   | Placebo BID        | Placebo BID                         | Uncertainties/ Strength of evidence                                                      | Refere nces        |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|-------------------------|-------------------------|--------------------|-------------------------------------|------------------------------------------------------------------------------------------|--------------------|
| Favourable Effects                  | Favourable Effects                                                                                                                                            | Favourable Effects | Favourable Effects      | Favourable Effects      | Favourable Effects | Favourable Effects                  | Favourable Effects                                                                       | Favourable Effects |
| Primary Efficacy point of Remission | Remission was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0 at week 8 | %                  | 18.5                    | 18.5                    | 8.2                | 8.2                                 | Placebo BID 122 Tofacitinib 10mg BID 476 Difference 10.3 95% CI 4.3, 16.3 P-value 0.0070 | Study A39210 94    |
| Primary Efficacy point of Remission | Remission was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0 at week 8 | %                  | 16.6                    | 16.6                    | 3.6                | 3.6                                 | Placebo BID 112 Tofacitinib 10mg BID 429 Difference 13.0 95% CI 8.1, 19.7 P-value 0.0005 | Study A39210 95    |
| Effect                              | Short Description                                                                                                                                             | Unit               | Tofaci tinib 5 mg BID   | Tofaci tinib 10 mg BID  | Place bo BID       | Uncertainties/ Strength of evidence | Uncertainties/ Strength of evidence                                                      | Refere nces        |

<div style=\"page-break-after: always\"></div>

| Effect    | Short Description                                                                                                                                        | Unit   | Tofacitinib 10 mg BID   | Tofacitinib 10 mg BID   | Placebo BID   | Uncertainties/ Strength of evidence                                                                             | Uncertainties/ Strength of evidence   | Refere nces   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------------------------|-------------------------|---------------|-----------------------------------------------------------------------------------------------------------------|---------------------------------------|---------------|
| Remission | Remission was defined by a Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0 at week 52 | %      | 34.3                    | 40.6                    | 11.1          | Tofacitinib 5 mg BID 198 Tofacitinib 10 mg BID 197 Placebo 198 Comparison Tofacitinib placebo Difference 95% CI | groups mg BID vs 23.2 15.3,           | A39210 96     |
|           |                                                                                                                                                          |        |                         |                         |               | Tofacitinib 10 mg BID vs placebo                                                                                | Tofacitinib 10 mg BID vs placebo      |               |
|           |                                                                                                                                                          |        |                         |                         |               | Difference                                                                                                      | 29.5                                  |               |
|           |                                                                                                                                                          |        |                         |                         |               | P-value                                                                                                         | <0.0001                               |               |

<div style=\"page-break-after: always\"></div>

| Effect                                                  | Short Description                                                                                                                                                                                                                                                                                                                                                                                             | Unit                 | Tofacitinib 10 mg BID   | Tofacitinib 10 mg BID   | Placebo BID          | Uncertainties/ Strength of evidence                                                                                                                                                                                                                                     | Refere nces          |
|---------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-------------------------|-------------------------|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| Key Secondar y Sustained corticoste roid-free remission | Sustained corticosteroid- free remission among subjects in remission at baseline of this study, (i.e., remission and corticosteroid- free at both Weeks 24 and 52), defined by a Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0, in addition to not requiring any treatment with corticosteroids for at least 4 weeks prior to the visit. | %                    | 35.4                    | 47.3                    | 5.1                  | Tofacitinib 5 mg BID 198 Tofacitinib 10 mg BID 197 Placebo 198 Comparison groups Tofacitinib 5 mg BID vs placebo Difference 30.3 95% CI 17.4, 43.2 P-value <0.0001 Comparison groups Tofacitinib 10 mg BID vs placebo Difference 42.2 95% CI 27.9, 56.5 P-value <0.0001 | A39210 96            |
| Unfavourable Effects                                    | Unfavourable Effects                                                                                                                                                                                                                                                                                                                                                                                          | Unfavourable Effects | Unfavourable Effects    | Unfavourable Effects    | Unfavourable Effects | Unfavourable Effects                                                                                                                                                                                                                                                    | Unfavourable Effects |
| Safety event                                            | Serious infection                                                                                                                                                                                                                                                                                                                                                                                             | %                    | 2.9                     |                         |                      | Total all doses combined Tofacitinib UC program N=1147 IR 1.99 95% CI (1.37, 2.79)                                                                                                                                                                                      |                      |

<div style=\"page-break-after: always\"></div>

| Effect       | Short Description             | Unit   |   Tofacitinib 10 mg BID | Placebo BID   | Uncertainties/ Strength of evidence                                               | Refere nces   |
|--------------|-------------------------------|--------|-------------------------|---------------|-----------------------------------------------------------------------------------|---------------|
| Safety event | Herpes zoster                 | %      |                     5.6 |               | Total all doses combined Tofacitinib UC program N=1147 IR 4.07 95% CI (3.14,5.19) |               |
| Safety event | Opportunistic infections      | %      |                     1.9 |               | Total all doses combined Tofacitinib UC program N=1147 IR 1.28 95% CI (0.79,1.96) |               |
| Safety event | Malignancy Excluding NMSC     | %      |                     0.7 |               | Total all doses combined Tofacitinib UC program N=1147 IR 0.48                    |               |
| Safety event | Non Melanoma Skin Cancer NMSC | %      |                     1   |               | Total all doses combined Tofacitinib UC program N=1147 IR 0.67 95% CI (0.33,1.19) |               |

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The pivotal induction studies A3921094 and A3921095 were appropriately designed. For the primary endpoint of remission superiority has been demonstrated to placebo for Tofacitinib 10 mg BID for 8 weeks; in induction treatment in subjects with moderately to severely active UC who failed or were intolerant to at least 1 protocol specified UC treatment, either corticosteroids, AZA/6-MP, or TNFi therapy. Statistical significantly benefit was also demonstrated for the relevant secondary endpoints.

For the pivotal maintenance study A3921096, the primary endpoint presented was remission at 52 weeks. However, though sustained corticosteroid steroid free remission in those at remission at baseline was presented as a secondary endpoint, in line with the CHMP guidance this should be viewed as a primary analysis endpoint. The applicant initially claimed separate indications on induction and maintenance of remission however agreed on CHMP request to update the wording to treatment of  adult patients with

<div style=\"page-break-after: always\"></div>

moderately to severely active ulcerative colitis (UC) to fulfil the draft EMA UC guideline as well as to be consistent with the wording of others biologic therapies. The proportion of subjects in sustained corticosteroid-free remission among subjects in remission at baseline was statistically significantly greater in both the tofacitinib 5 mg BID group and the tofacitinib 10 mg BID group compared with the placebo group. Tofacitinib 5 mg BID and Tofacitinib 10 mg BID were also superior to placebo for the primary endpoint of remission at Week 52, and other relevant secondary endpoints. For the refractory sub-group of patients who have previously failed TNFi agents, a clear treatment effect of tofacitinib was evident for induction of remission, and was particularly evident for maintenance of remission in the 10 mg BID dosing.

Overall the clinical efficacy has been adequately demonstrated. A clinically relevant benefit for tofacitinib has been demonstrated in patients with moderately to severely active UC who failed or were intolerant to at least one of the specified UC treatments of either corticosteroids, AZA/6-MP, or TNFi therapy. Tofacitinib offers a different mode of action to other targeted treatments in UC. The oral formulation may also be an advantage for some patients. The issue of compliance with oral therapy in relapsing/remitting conditions such as UC outside of the clinical trial setting is acknowledged.

The observed safety profile for the UC database is in line with the known safety profile based on the RA clinical database and post-marketing experience and was similar to that of biologic agents approved for treatment of UC. However, the exception was a higher IR of Herpes Zoster (HZ).  Dose dependency for the risk of Herpes Zoster, OI (predominantly due to HZ) and NMSC was observed in the overall population treated with tofacitinib in the UC program.

The risks of serious or opportunistic infections are important. However, these risks are mitigated by the precautions and warnings included in the SmPC, and these adverse reactions are generally manageable. The potential risk of malignancy continues to be investigated.

## 3.7.2. Balance of benefits and risks

The benefits of Xeljanz 5 mg and 10mg film-coated tablets outweigh the risks, for the treatment of adult patients with moderately to severely active UC who failed or were intolerant to at least one of the specified UC treatments of either corticosteroids, AZA/6-MP, or TNFi therapy.

## 3.8. Conclusions

The overall B/R of Xeljanz is positive.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the risk-benefit balance of, Xeljanz 10mg and 5mg, film-coated tablets  is favourable in the following indication:

XELJANZ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5.1)

<div style=\"page-break-after: always\"></div>

The CHMP therefore recommends the extension of the marketing authorisation for Xeljanz subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

## Conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## Additional risk minimisation measures

Prior to launch of XELJANZ in each Member State, the Marketing Authorisation Holder (MAH) must agree about the content and format of the educational programme, including communication media, distribution modalities, and any other aspects of the programme, with the National Competent Authority.

The main objective of the programme is to increase awareness about the risks of the product, specifically in regards to serious infections, herpes zoster, tuberculosis (TB) and other opportunistic infections, malignancy, gastrointestinal perforations, interstitial lung disease, and laboratory abnormalities.

The MAH shall ensure that in each Member State where XELJANZ is marketed, all healthcare professionals and patients/carers who are expected to prescribe or use XELJANZ have access to/are provided with the following educational package:

- Physician educational material

<div style=\"page-break-after: always\"></div>

- Patient information pack
- The physician educational material should contain:
- o The Summary of Product Characteristics
- o Guide for healthcare professionals
- o Prescriber checklist
- o Patient alert card
- o A reference to the website with the educational material and patient alert card
- The Guide for healthcare professionals shall contain the following key elements:
- o Relevant information of the safety concerns addressed by the aRMM (e.g., seriousness, severity, frequency, time to onset, reversibility of the AE as applicable)
- o Details of the population at higher risk for the safety concern addressed by the aRMM (i.e. contraindications, risk factors, increased risk by interactions with certain medicine)
- o Details on how to minimise the safety concern addressed by the aRMM through appropriate monitoring and management (i.e. what to do, what not do, and who is most likely be impacted according to different scenarios, like when to limit or stop prescribing/ingestion, how to administer the medicine, when to increase/decrease the dosage according to laboratory measurements, signs and symptoms)
- o Key message to convey in patients counselling
- o Instructions on how to handle possible adverse events
- o Information about the BSRBR, ARTIS, RABBIT and BIODABASER and UC registries and the importance of contributing to these
- The Prescriber checklist shall contain the following key messages:
- o Lists of tests to be conducted during the initial screening of the patient
- o Vaccination course to be completed before treatment
- o Relevant comorbidities for which caution is advised when XELJANZ is administered and conditions in which XELJANZ should not be administered
- o List of concomitant medications which are not compatible with treatment with XELJANZ
- o The need to discuss with the patients the risks associated with the use of XELJANZ, specifically in regards to infections, herpes zoster, tuberculosis (TB) and other opportunistic infections, malignancy, gastrointestinal perforations, interstitial lung disease, and laboratory abnormalities
- o
- The need to monitor for any signs and symptoms and laboratory abnormalities for early identification of the abovementioned risks.
- The patient alert card shall contain the following key messages:
- o A warning message for HCPs treating the patient at any time, including in conditions of emergency, that the patient is using XELJANZ
- o That treatment with XELJANZ may increase the risk of infections and non melanoma skin cancer
- o That patients should inform health professionals if they are planning to receive any vaccine or become pregnant
- o Signs or symptoms of the following safety concern and when to seek attention from a HCP: infections, herpes zoster reactivation, non-melanoma skin cancer, transaminase elevation and potential for drug-induced liver injury, gastrointestinal perforation, interstitial lung disease, increased immunosuppression when used in combination with biologics  and immunosuppressants including B lymphocyte depleting agents, increased risk of adverse events when XELJANZ is administered in combination with MTX, Increased exposure XELJANZ when co-administered with CYP3A4 and CYP2C19 inhibitors, effects on pregnancy and foetus, use in breastfeeding, effect on vaccination efficacy and the use of live/attenuated vaccines.
- o Contact details of the prescriber
- The centralised website shall contain:
- o The educational material in digital format
- o The patient alert card in digital format
- The patient information pack should contain:
- o Patient information leaflet

<div style=\"page-break-after: always\"></div>

- o The patient alert card

## Additional Data exclusivity/Marketing protection

Furthermore, the CHMP reviewed the data submitted by the Pfizer Limited, taking into account the provisions of Article 14(11) of Regulation (EC) No 726/2004 considers, that the new therapeutic indication brings significant clinical benefit in comparison with existing therapies (see appendix 1).

In addition, CHMP recommends the variation to the terms of the marketing authorisation, concerning the following changes:

| Variations requested   | Variations requested                                       | Type    | Annexes affected   |
|------------------------|------------------------------------------------------------|---------|--------------------|
| C.I.6.a                | Change(s) to therapeutic indication(s) - Addition of a new | Type II | I, II and IIIB     |

## Appendix

1. CHMP AR on the novelty of the indication/significant clinical benefit in comparison with existing therapies

<div style=\"page-break-after: always\"></div>

<!-- image -->

31 May 2018 EMA/CHMP/730755/2017 Committee for Medicinal Products for Human Use (CHMP)

CHMP assessment report on the significant clinical benefit in comparison with existing therapies in accordance with Article 14(11) of Regulation (EC) No 726/2004

Invented name: Xeljanz

International non-proprietary name: Tofacitinib

Procedure no.: EMEA/H/C/004214/X/0005/G

Marketing authorisation holder (MAH): Pfizer Limited

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Introduction ............................................................................................3          |                                                                                   |
|------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| 2. Justification of significant clinical benefit as presented by the MAH........3                                      | 2. Justification of significant clinical benefit as presented by the MAH........3 |
| 2.1. Demonstration of new therapeutic indication ...........................................................3          |                                                                                   |
| 2.2. Details of existing therapies...................................................................................3 |                                                                                   |
| 2.3. Significant clinical benefit based on improved efficacy...............................................6           |                                                                                   |
| 2.4. Significant clinical benefit based on improved safety...............................................11            |                                                                                   |
| 2.5. Significant clinical benefit based on major contribution to patient care ......................12                 |                                                                                   |
| 3. Assessment of the MAH's justification of significant clinical benefit .....13                                       | 3. Assessment of the MAH's justification of significant clinical benefit .....13  |
| 3.1. Demonstration of new therapeutic indication .........................................................13           |                                                                                   |
| 3.2. Details of existing therapies.................................................................................13  |                                                                                   |
| 3.3. Significant clinical benefit based on improved efficacy.............................................13            |                                                                                   |
| 3.4. Significant clinical benefit based on improved safety...............................................14            |                                                                                   |
| 3.5. Significant clinical benefit based on major contribution to patient care ......................14                 |                                                                                   |
| 4. Conclusion.............................................................................................16           |                                                                                   |
| 5. Recommendation...................................................................................17                 |                                                                                   |

<div style=\"page-break-after: always\"></div>

## 1. Introduction

In accordance with the provisions of Article 14(11) of Regulation (EC) No 726/2004, Marketing authorisation holder (MAH) Pfizer Limited has applied for an additional one year marketing protection period in the framework of Xeljanz procedure (EMEA/H/C/004214/X/0005/G).

The request was based on the MAH's position that Xeljanz represents a significant clinical benefit in the proposed indication of 'the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent' in comparison with existing therapies.

## 2. Justification of significant clinical benefit as presented by the MAH

## 2.1. Demonstration of new therapeutic indication

The European Commission granted a Marketing Authorisation for Xeljanz on 22 March 2017 in the treatment of rheumatoid arthritis with 5 mg film coated tablets. This is an application for a Grouped Type II Variation (new indication) / Line Extension (10 mg new tablet strength) for Xeljanz (tofacitinib) in the treatment of ulcerative colitis (UC).

The MAA for the initial authorisation of Xeljanz comprised the following indication: treatment of moderate to severe RA in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs.

The MAH now seeks the inclusion of the following proposed indication: for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

The variation application is based on the submission of 1 Phase 2 and 3 Phase 3 studies, and an interim clinical study report from an ongoing open-label, long-term extension study of tofacitinib in patients with UC. The phase 2 dose finding study evaluated a 30-fold dose range in moderately to severely active UC patients. The pivotal phase 3 studies consisted of two identically conducted studies to investigate efficacy in induction of remission and one study examining efficacy in maintenance of remission.

## 2.2. Details of existing therapies

Current therapy for the treatment of UC includes 5-aminosalicylic acid (5-ASA), systemic and/or topical corticosteroids, immunosuppressants such as azathioprine/6-mercaptopurine (6-MP) and cyclosporine, and tumour necrosis factor-alpha inhibitors (TNFis), and the α4β7 integrin antagonist vedolizumab.

<div style=\"page-break-after: always\"></div>

Table Al. Current Pharmacotherapy Options for Patients With Moderately to Severely Active Ulcerative Colitis in the EU

| Class/Drug/Action                | UC Indication                                                                                               | Route          | Efficacy/PatientResponse                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | SafetyConceins                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|----------------------------------|-------------------------------------------------------------------------------------------------------------|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Cortico- steroids26 27           | For use during critical period of disease; Not approved for longer- tem use.                                | pue AI Oral    | Induction efficacy for acute flare.$ Corticosteroid dependence orrefractorinessin approximately half of the patients over 1 year after receiving first course of corticosteroid                                                                                                                                                                                                                                                                                                                                                                           | Significant side effects,including extensive endocrine,metabolic,musculoskeletal, neurological and infectious complications, preclude long-term use. develop corticosteroid dependence. 29                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Imnuno- suppressants             |                                                                                                             |                | Onset of Action:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Azathioprine*/6- Mercapto-purine | Unapproved.                                                                                                 |                | Slow therapeutic response that may take several months.34 As monotherapy, less robust evidence of efficacy for induction or maintenance.More robustevidenceforinduction whentaken in combination with TNFi.35 A Cochrane meta-analysis on maintenance, considered 7 clinical trials on 302 patients. The quality of studies was judged as generally poor and the evidence for using thiopurines in UC was weaker than for CD.36 Additionally there is no demonstrated induction eficacy for moderately toseverely activeUCin randomizedcontrolled trials. | Thiopurine S-methyl transferase (TPMT) testing to identify patients with low or absent TPMT activity, who are at increased risk of developing severe,life-threatening myelotoxicity on AZA/6- MP.3 AZA: Lymphoma and other malignancies, particularly of the skin; hepatosplenic T-cell lymphoma mostly in adolescent and young adult males; severe leukopenia, thrombocytopenia, anemias including macrocytic anemia and/or pancytopenia; bone mairow suppression; serious infections, including progressive multifocal leukoencephalopathy (PML) 32 6-MP: Bone mairow toxicity, hepatotoxicity, intestinal ulceration, nausea, yomiting, anorexia, skin rash. |
| Cyclosporine                     | Steroid-refractory severe disease                                                                           | Oral and IV    | Generally proposed as induction therapy.Best discontinuedwithin6monthsbecauseofside effects.28,37                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Increases the risk of developing lymphomas and other malignancies,particularly those of the skin predisposes patients to the development of a variety of bacterial, fungal, parasitic and viral                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Class/Drug/Action                | UC Indication                                                                                               | Route          | Efficacy/PatientResponse A Cochrane review concluded that numbers in controlled trials were so few that there was limited evidence for cyclosporine being more effective than standard treatment alone for severe UC.3$                                                                                                                                                                                                                                                                                                                                   | Safety Concerns infections, often with opportunistic pathogens. Oneof themostsignificantconcernsassociated with the long-term(andperhaps short-term)use of high-dose cyclosporine is the potential for permanent nephrotoxicity. 39 AEs reported inIBD patients treated with high- dose cyclosporine include paresthesias (26%); (7%); nausea or vomiting (6%); renal insufficiency (6%); headache (5%); infection (3%); hepatotoxicity (3%); gingival hyperplasia (2%); seizure (1%); and anaphylaxis with IV cyclosporine (0.3%). Needs frequent and close monitoring of blood levels,renal function, and hepatic function as important safety measures.39    |
| Tacrolimus                       | Steroid-refractory severe disease                                                                           | Oral and IV    | Generally proposed as induction therapy.Best discontinued within 6months because of side effects.37,40                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Gastrointestinalperforation,increasedriskfor infections (viral, bacterial, fungal, protozoal). Benign as well as malignant neoplasms including EBV-associated 1lymphoproliferative disorders and skin malignancies, nephrotoxicity, diabetes mellitus, hyperkalaemia, hypertension, insommia, tremor,*\" paresthesia, headache, pruritus. 42 Patientstreatedwithtacrolimushavebeen reported to develop posterior reversible encephalopathy syndrome.f1 Whole blood tacrolimus concentrations and electrolytes should be measured weekly for the first month, biweekly for the second month, and monthly thereafter.42                                            |
| TNF Inhibitors                   | TNF Inhibitors                                                                                              | TNF Inhibitors | TNF Inhibitors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | TNF Inhibitors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Infliximab                       | For treatment of moderatelytoseverely active ulcerative colitisin adult patients who have had an inadequate | IV             | Clinical Efficacy (SnPC): 30% and 37% of subjects taking 5 mg/kg and 10 mg/kg, respectively, achieved clinical remission at Week 8. 19% and 24% of subjects taking 5 mg/kg and                                                                                                                                                                                                                                                                                                                                                                            | Seriousinfections(includingtuberculosis, bacterial sepsis, invasive fungal infections [such as histoplasmosis], and opportunistic infections), malignancies (including lymphoma HSTCL, melanoma, Merkell cell carcinoma), hepatitis B                                                                                                                                                                                                                                                                                                                                                                                                                           |

Invented name: Xeljanz

International non-proprietary name: tofacitinib

Procedure no.: EMEA/H/C/004214/X/0005/G

<div style=\"page-break-after: always\"></div>

|               | response to conventional therapy including corticosteroids and6-IMP or AZA, or who are intolerant to or have medical contraindications for such therapies.*3                                                                                                      |    | 10 mg/kg,respectively, achieved sustained clinical remission at Week 8 and Week 30-. 67% and 65% of subjects taking 5 mg/kg and 10 mg/kg, respectively, achieved clinical response at Week 8.                                                                                                                                                                                                                                      | virusreactivation,hepatotoxicity,hepatobiliary events,hypersensitivity(seriousinfusion reactionsincludinganaphylaxisorserum sickness-like reactions), infusion reactions including anaphylactic shock, cytopenias, demyelinating disease,heart failure,lupus-like syndrome, autoimmunity. Mostcommonadversereactionsinclude infections (eg, upper respiratory, sinusitis, viral infection),infusion-relatedreactions,headache, abdominalpainandnausea. Infliximabshould only be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of UC, to patients who are given the special alert card.3 Seriousinfectionsincludingtuberculosis(TB)   |
|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Adalimumab    | For treatment of moderatelytoseverely active ulcerativecolitisin adultpatientswhohave had an inadequate response to conventional therapy including corticosteroids and 6-MP or AZA, or who are intolerant toorhave medicalcontraindications for such therapies.26 | SC | Clinical Efficacy (SmPC): 18% and 17% of subjects on 160/80 mg achievedclinicalremissionatWeek8ineach of the twoinduction studies. 8%of subjectson160/80mg achieved sustained clinicalremission(clinicalremission at both Weeks 8 and 52).                                                                                                                                                                                         | bacterial sepsis, invasive fungal infections, and opportumistic infections, malignancies (including lymphoma, HSTCL, leukemia, NMSC), anaphylaxis or serious allergic reactions, hepatitis B virus reactivation, demyelinating disease, cytopenias/pancytopenia,heart failure,lupus-like syndrome. Most common adverse reactions include infections (nasopharyngitis, upper respiratory, andsinusitis),injectionsitereactions,headache andmusculoskeletalpain. Adalimumab should only be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of UC to patients who are given the special alert card.                                       |
| Golimumab     | For treatment of moderatelytoseverely activeulcerativecolitisin                                                                                                                                                                                                   | SC | Clinical Efficacy (SmPC): Study I; 200/100 mg 51% of subjects achieved clinical response at                                                                                                                                                                                                                                                                                                                                        | SeriousinfectionsincludingTB,invasivefungal infections,hepatitis Breactivation,malignancies (including lymphoma, leukemia, hepatosplenic T-                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|               | adult patientswhohave had an inadequate response to conventional therapy including corticosteroids and 6-mercapto-purine (6-MP) or azathioprine (AZA), or whoareintolerant to or have medical contraindications for such therapies.                               |    | Week 6. 18%of subjects achieved clinical remission at Week 6. 42% of subjects achieved improvement in 6. Study II; 100 mg 50% of subjects achieved clinical response throughWeek54. 28% of subjects achieved clinical remission at bothweek30andWeek54.                                                                                                                                                                            | cell lymphoma [HSTCL], melanoma and Merkell cell carcinoma), congestive heart failure, demyelinating disorders, hematologic cytopenias. Most common adverse reaction was upper respiratory tract infections(nasopharyngitis. pharyngitis, laryngitis and rhinitis). Golimumabshouldonlybeinitiatedand supervised by specialist physicians experienced in the diagnosis and treatment of UC, to patients Who are given the patient alert card.?7                                                                                                                                                                                                                                     |
| Anti-Integrin |                                                                                                                                                                                                                                                                   |    |                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Vedolizumab*  | For the treatment of adult patients with moderately toseverely activeUCwho havehad aninadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFi.+5                                                                   | IV | Onset of Action: Notviewed assufficientlyrapidforthese patients with moderately to severely active disease.411 Clinical Efficacy (SmPC): Study I 47% of subjects achieved clinical response at Week 6 17% of subjects achieved clinical remission at Week 6 StudyⅡ 42% of subjects achieved clinical remission at Week 52 57% of subjects achieved clinical response at bothWeeks6and52 52% of subjects achieved improvement of 52 | Infusion-relatedreactions,serious,potential for progressive multifocal leukoencephalopathy and potential for malignancies. Most common adverse reactions include nausea, nasopharyngitis, upper respiratory tract infection. arthralgia, pyrexia, fatigue, headache, cough and infusion-relatedreactions. Vedolizumabshouldonlybeinitiatedand supervised by specialist physicians experienced in the diagnosis and treatment of UC, to patients pes fejd ep uar ane o                                                                                                                                                                                                               |

Class/Drug/Action

UCIndication

Route

Efficacy/Patient Response

Source:EuropeanSmPCforadalimumab,infliximab,golimumab,andvedolizumab.

Safety Concerns

* As noted in the draft EMA guideline on UC23. 5-aminosalicylic acid (5-ASA) agents may be considered the \"mainstay of therapy for mild to moderate UC\", but are not specifically indicated for the treatment of moderately to severely active disease despite their frequent use as background therapies. Abbreviations:AC=Advisory Committee;AE=adverse event;AZA = azathioprine;HSTCL=hepatosplenicT-cell 1ymphoma;IV=intravenous; 6-MP=6mercaptopurine;PML=progressive multifocal leukoencephalopathy;SC=subcutaneous;SmPC=Summary of Product Characteristics;TB=tuberculosis;TDM= therapeutic dose monitoring;TNFi=tumor necrosisfactor inhibitor;TPMT=thiopurine S-methyl transferase;UC=ulcerative colitis.

Invented name: Xeljanz

International non-proprietary name: tofacitinib

Procedure no.: EMEA/H/C/004214/X/0005/G

<div style=\"page-break-after: always\"></div>

The MAH states that there are 2 main classes of drugs available to patients in Europe with UC that can be used for both induction and maintenance therapy for patients with moderately to severely active UC: TNFi and anti-integrin therapy.

The applicant has discussed the fact that a proportion of patients with moderately to severely active UC fail to respond to TNFi agents either initially (primary non-response) or lose their initial response (secondary non-response). 5,6,7

Vedolizumab, an anti-integrin, has documented efficacy in induction and maintenance ,4,11 . The induction benefit of vedolizumab in patients who have previously failed TNFi agents is induction remission rate 9.8% vedolizumab to 3.2% placebo.  12

The MAH cites a recent paper which discusses that patients who exhibit primary non-response to one TNFi are more likely to show poor response to a different TNFi, 15  and that secondary non-responders have poor response when switching to another TNFi. 15

The MAH has discussed the oral mode of administration of Xeljanz as a benefit. All currently approved therapies for both induction and maintenance of moderately to severely active UC are administered either intravenously or subcutaneously.

## 2.3. Significant clinical benefit based on improved efficacy

As supportive data to the justification for significant clinical benefit based on major contribution to patient care, the MAH has compared the UC tofacitinib data with historical data from currently approved treatments.

Figure 1 summarizes the treatment effects for clinical remission and their 95% CIs of tofacitinib 10 mg twice daily (BID) induction therapy for the overall population and historical Phase 3 data from currently approved treatments for patients with moderately to severely active UC. For consistency across studies, locally read endoscopy results are presented for tofacitinib.

Figure1. EstimatedInductionDifferencefromPlaceboforClinicalRemissionfor Tofacitinib 10 mg BID and Approved Biologics

<!-- image -->

Sources: 5.3.5.1 A3921094-report-body Table 14.1.2.1.3; Table 14.2.4.2; 5.3.5.1 A3921095-report-body Table 14.1.2.1.3; (2005).'

Analysis based on NRI using FAS data and local endoscopic reading.

I Normal approximation for difference in binomial proportions was used to estimate 95% CIs.

*Primary TNFi non-responders were excluded.

Abbreviations: ACT1 = Active Ulcerative Colitis Trial 1; ACT2 = Active Ulcerative Colitis Trial 2; BID = twice a day; CI = confidence interval; FAS = full analysis set; NRI = non-responder imputation; TNFi = tumour necrosis factor imhibitor.

Invented name: Xeljanz

International non-proprietary name: tofacitinib

Procedure no.: EMEA/H/C/004214/X/0005/G

<div style=\"page-break-after: always\"></div>

The observed treatment effect of tofacitinib 10 mg BID in Studies A3921094 and A3921095 was at least similar to the historical Phase 3 results of Golimumab, Vedolizumab and Adalimumab. The treatment effect for tofacitinib was lower than of infliximab, but the differences in endpoint definition, prior treatment experience and allowed concomitant medications are considered too large to ascertain whether the differences are due to drug activity or study design.

The submitted clinical phase 3 trials in the current application demonstrated induction efficacy in those with prior TNFi. Similar induction efficacy was shown between those with and those without prior TNFi failure.

Figure 2 summarizes the treatment effects for clinical remission and their 95% CIs of tofacitinib 10 mg BID induction therapy for the TNFi failure subpopulation and historical Phase 3 data from currently approved treatments for patients with moderately to severely active UC.

Figure 2. Estimated Induction Treatment Effects (Difference from Placebo) for Clinical Remission in Subjects With Prior TNFi (Tofacitinib and Approved Biologics)

<!-- image -->

Sources: 5.3.5.3 SCE Table 14.2.4.4.p; Essat et al (2016),2 Sandborm et al (2012).

Analysis based on NRI using FAS data and local endoscopic reading;

I Normal approximation for difference in binomial proportions was used to estimate 95% CIs.

Primary TNFi non-responders were excluded; # at Week 8 for tofacitinib and adalimumab; at Week 6 for vedolizumab.

Abbreviations: BID = twice a day; CI = confidence interval; FAS =full analysis set; N = number of subjects in the analysis set, n = subjects meeting specified criteria; NRI = non-responder imputation; TNFi = tumour-necrosis factor inhibitor.

Figure 3 summarizes the treatment effects at 1 year for clinical remission in maintenance and the 95% CIs for tofacitinib 5 mg BID and 10 mg BID and historical Phase 3 data from currently approved treatments for patients with moderately to severely active UC.

Invented name: Xeljanz

International non-proprietary name: tofacitinib

Procedure no.: EMEA/H/C/004214/X/0005/G

<div style=\"page-break-after: always\"></div>

Figure 3. Estimated Maintenance Treatment Effects (Difference from Placebo) for Clinical Remission (Tofacitinib and Approved Biologics)

<!-- image -->

|             | DoseandRoute         |      | Year#TimePoint   | Difference, % (95% Cl)   | Difference, % (95% Cl)   |               | Active Placebo n/N (%) n/N (%)   |
|-------------|----------------------|------|------------------|--------------------------|--------------------------|---------------|----------------------------------|
| Tofacitinib | 10 mg P0 BID         | 2016 | Week 52          |                          | 35.1 (26.7, 45.5) 26.8   | 95/197 (48.2) | 26/198 (13.1)                    |
|             | 5 mg PO BID          | 2016 | Week52           |                          | (18.5, 35.1)             | 79/198 (39.9) | 26/198 (13.1)                    |
| Vedolizumab | 300 mg IV Q 8 weeks  | 2013 | Week52#          |                          | 25.9 (15.1, 36.8)        | 51/122 (41.8) | 20/126 (15.9)                    |
| Golimumab   | 100mg SC Q 4 weeks   | 2014 | Week 54          |                          | 11.7 (1.7, 21.7)         | 51/151 (33.8) | 34/154 (22.1)                    |
| Adalimumab* | 40 mg SC Q 2 weeks   | 2012 | Week52           |                          | 8.8 (2.9, 14.7)          | 43/248 (17.3) | 21/246 (8.5)                     |
| Infliximab* | 5 mg/kg IV Q 8 weeks | 2005 | Week 54#         |                          | 18.2 (7.4, 28.9)         | 42/121 (34.7) | 20/131 (16.5)                    |

-10

0

10

20

30

40

50

Sources: A3921096-report-body Table 14.2.5.1.1; Sandborm et al (2014),° Feagan et al (2013),4 Sandbormn et al (2012), Rutgeerts et al (2005).

* Analysis based on NRI using FAS population and local endoscopic reading;

#Year= end of clinical trial;

￥ Induction-maintenance treat-through design without re-randomization between induction and maintenance phases; Vedolizumab: Week 52 includes 6 week induction and 46 week maintenance phases; Infliximab: Week 54 includes 8 week induction and 46weekmaintenancephases.

Abbreviations: BID = twice a day, CI = confidence interval; FAS = full analysis set; IV = intravenous; N = number of subjects in analysis set; n = number of subjects with specified response; PO = oral; Q = every, SC = subcutaneous.

f Normal approximation for difference in binomial proportions was used to estimate 95% CIs.

Although relatively limited, available results of maintenance clinical remission rates by various subgroups were provided for tofacitinib and the biologic agents using local endoscopy for the endpoint of clinical remission.  Due to differences in subgroup definitions, interpretation of results based on age and concomitant corticosteroid use should be approached with caution.

With regards to prior TNFi experience, vedolizumab exhibited the best response relative to other approved agents both in patients who had TNF failure and those who did not.  As noted above, vedolizumab is the development program that most resembles the tofacitinib development program for UC, but some differences such as the allowance of use of immunosuppressants with vedolizumab still exist.  When clinical remission maintenance results are analysed by prior TNFi experience, the placeboadjusted proportion of responders at either dose of tofacitinib was numerically higher than that of vedolizumab for patients who had not failed TNFi agents.  For patients with prior TNFi failure, the results for tofacitinib 5 mg BID were numerically lower that vedolizumab but numerically higher than adalimumab, while the results of tofacitinib 10 mg BID were similar to those observed with vedolizumab.

Invented name: Xeljanz

International non-proprietary name: tofacitinib

Procedure no.: EMEA/H/C/004214/X/0005/G

<div style=\"page-break-after: always\"></div>

Table 6. Maintenance Clinical Remission Results by Subgroups (Loeal Read)

| Compound                              | Study Number/ Title                   | Population                                                 | Study Duration, Weeles   | Dose        | Placebo m/N (%)   | Active Treatment nN (%6)   | Difference from Placebo (954h C1)   |
|---------------------------------------|---------------------------------------|------------------------------------------------------------|--------------------------|-------------|-------------------|----------------------------|-------------------------------------|
| Age                                   |                                       |                                                            |                          |             |                   |                            |                                     |
| Tofaciinib                            | A3921096                              | 30                                                         | 52                       | 10 mg BD    | 4/39 (10.3)       | 17/37 (45.9)               | 35.7 (17.0, 54.4)                   |
| (FAS)                                 |                                       |                                                            |                          | 5mgBD       |                   | 15/44 (34.1)               | 23.8 (6.9.40.8)                     |
|                                       |                                       | 30-~40                                                     |                          | 10 mg BD    | 9/48 (18.8)       | 23/56 (41.1)               | 22.3 (5.4, 39.3)                    |
|                                       |                                       |                                                            |                          | 5mgBD       |                   | 14/50 (28.0)               | 9.3 (-7.4,25.9)                     |
|                                       |                                       | 40-50                                                      |                          | 10 mg BD    | 4/40 (10.0)       | 16/42 (38.1)               | 28.1 (10.7,45.5)                    |
|                                       |                                       |                                                            |                          | 5mgBD       |                   | 20/46 (43.5)               | 33.5 (16.4, 50.6)                   |
|                                       |                                       | 250                                                        |                          | 10 mg BD    | 9/71(12.7)        | 39/62 (62.9)               | 50.2 (35.9, 64.5)                   |
|                                       |                                       |                                                            |                          | 5mgBD       |                   | 30/58 (51.7)               | 39.0 (24.0, 54.1)                   |
| Vedolizmab                            | GEMINII                               | 435                                                        | 52                       | 300 mg Q8Wk | 10/54 (18.5)      | 14/44 (31.8)               | 13.3 (-3.9, 30.5)                   |
|                                       |                                       | 235                                                        |                          |             | 10/72 (13.9)      | 37/78 (47.4)               | 33.5 (19.9.47.2)                    |
| Adalimmnbs                            | ULTRA2                                | 40                                                         | 52                       | 40 mg Q2Wk  | 11/118 (9.3)      | 27/136 (19.9)              | 10.5 (2.0. 19.0)                    |
|                                       |                                       | 40-64                                                      |                          |             | 9/116 (7.8)       | 16/105 (15.2)              | 7.5(-0.9, 15.9)                     |
|                                       |                                       | 265                                                        |                          |             | 1/12 (8.3)        | 0/7 (0.0)                  | -8.3(-24.0, 7.3)                    |
| Coucomitant Corticosteroid Use        | Coucomitant Corticosteroid Use        |                                                            |                          |             |                   |                            |                                     |
| Tofaciinib                            | A3921096                              | Corticosteroid use at                                      | 52                       | 10 mg BD    | 14/101 (13.9)     | 29/87 (33.3)               | 19.5(7.5, 31.5)                     |
| (FAS)                                 |                                       | maintenance baseline                                       |                          | 5mgBD       |                   | 101 34 (33.7)              | 19.8 (8.4. 31.2)                    |
| Vedolizmab                            | GEMINII                               | Concomitant corticosteroid use                             | 52                       | 300 mg Q8Wk | 11/72 (15.3)      | 25/70 (35.7)               | 20.4 (6.5,34.4)                     |
| Prior Corticosteroid Failure          | Prior Corticosteroid Failure          | Prior Corticosteroid Failure                               |                          |             |                   |                            |                                     |
| Tofacitinib (FAS)b                    | A3921096                              | Prior corticosteroid faihure (includes pts                 | 52                       | 10 mg BD    | 21/151 (13.9)     | 76/149 (51.0)              | 37.1 (27.4, 46.8)                   |
|                                       |                                       | with prior IMM and/or TNFi filure)                         |                          | 5mgBD       |                   | 58/145 (40.0)              | 26.1 (16.4,35.8)                    |
| Vedolizmab                            | GEMINII                               | Prior corticosteroid and/or MM filure without TNFi failure | 52                       | 300 mg Q8Wk | 15/79 (19.0)      | 33/72 (45.8)               | 26.8 (12.4. 41.2)                   |
| Without Prior TNFi Experience/Failure | Without Prior TNFi Experience/Failure | Without Prior TNFi Experience/Failure                      |                          |             |                   |                            |                                     |
| Tofacitinib                           | A3921096                              | TNFi Naive                                                 | 52                       | 10 mg BD    | 9/89 (10.1)       | 44/87 (50.6)               | 40.5 (28.2, 52.7)                   |
| (mFAS)                                |                                       |                                                            |                          | 5mgBD       |                   | 46/93 (49.5)               | 39.4 (27.4, 51.3)                   |
| Tofacitinib                           | A3921096                              | Without Prior TNFi                                         | 52                       | 10 mg BD    | 10/92 (10.9)      | 95 47 (49.5)               | 38.6 (26.7, 50.5)                   |
| (mFAS)b                               |                                       | Failure\"                                                   |                          | 5mgBD       |                   | 50/100 (50.0)              | 39.1 (27.4, 50.8)                   |
| Golimumab                             | PURSUIT- SC                           | TNFi Naive                                                 | 54                       | 100mg Q4Wk  | 34/154 (22.1)     | 51/151 (33.8)              | 11.7 (1.7, 21.7)                    |
| Vedolizumab                           | GEMINII                               | Without Prior TNFi Failure                                 | 52                       | 300 mg Q8Wk | 15/79 (19.0)      | 33/72 (45.8)               | 26.8 (12.4, 41.2)                   |
| Adalimumabs                           | ULTRA2                                | TNFi Naive                                                 | 53                       | 40 mg Q2Wk  | 18/145 (12.4)     | 33/150 (22.0)              | 9.6 (1.1, 18.1)                     |
| Infliximab                            | ACT1                                  | TNFi Naive                                                 | 54                       | 5 mgkg Q8Wk | 20/121 (16.5)     | 42/121 (34.7)              | 18.2 (7.4,28.9)                     |
| With Prior TNFiErperience/Failure     | With Prior TNFiErperience/Failure     | With Prior TNFiErperience/Failure                          |                          |             |                   |                            |                                     |
| Tofacitinib                           | A3921096                              | TNFi Experienced                                           | 52                       | 10 mg B     | 10/85 (11.8)      | 39/86 (45.3)               | 33.6 (21.0, 46.1)                   |
| (mFAS)*                               |                                       |                                                            | 52                       | 5mgBD       |                   | 23/83 (27.7)               | 15.9 (4.1.27.8)                     |
| Tofacilinib                           | A3921096                              | TNFi Failure                                               | 52                       | 10 mg BD    | 9/82 (11.0)       | 36/78 (46.2)               | 35.2(22.2,48.1)                     |
| (mFAS)                                |                                       |                                                            | 52                       | 5mgBD       |                   | 19/76 (25.0)               | 14.0 (2.2.25.9)                     |
| Vedolizumab                           | GEMINII                               | TNFi Failure                                               | 52                       | 300 mg Q8Wk | 2/38 (5.3)        | 16/43 (37.2)               | 31.9 (15.8. 48.0)                   |
| Adalimumaba                           | ULTRA2                                | TNFi Experienced                                           | 52                       | 40mg Q2Wk   | 3/101 (3.0)       | 10/98 (10.2)               | 7.2 (0.4, 14.1)                     |

placebo in the induction studies): n=number of subjects meeting specified criteria; N=number of subjects in the analysis set; NRI=non-responder imputation;

Abbreviations: BD=twice a day: CI=confidence interval; FAS=full analysis set; mFAS = modified full analyses set (ie, excluding subjects who received

Q=every:TNFi=tumor necrosis factor inhibitor, wk =weeks.

Clinical Remission = Mayo score of S2 points, with no individual subscore &gt;1 point.

b. Analysis bused on NRI

a. Normal approximation for difference in binomial proportions was used to estimate 95% CIs

c. Primary TNFi non-responders were excluded

Eugedpued tmog pallqrqord aram amsodsa luNf roud qun spalqns se uogeqndod lleano aq u spalqns ne sapupug 'a

Throughout the maintenance studies of tofacitinib and the biologic agents, the endpoint of remission has been assessed based on whether it was sustained and/or based on the ability to achieve steroidfree remission among subjects receiving steroids at baseline.  Results for these endpoints are included in the table below.  Where available, results are presented for the mFAS population for tofacitinib.  As previously discussed, the tofacitinib maintenance study was the first to include the endpoint of sustained (ie, at both Week 24 and Week 52) steroid-free remission among subjects in remission at baseline of the maintenance study. Close to half of the patients who entered into the maintenance study in remission achieved this endpoint.  The endpoint of sustained remission was analyzed in the maintenance studies for tofacitinib as well as all of the biologic studies.  Although there are differences

Invented name: Xeljanz

International non-proprietary name: tofacitinib

Procedure no.: EMEA/H/C/004214/X/0005/G

<div style=\"page-break-after: always\"></div>

in the timepoints evaluated, the treatment effects for both tofacitinib 5 mg BID and tofacitinib 10 mg BID were numerically larger than those for the biologic agents.

Table 7. Maintenance Remission-Related Endpoint Results(Local Read)

| Endpoint Compound                                                                    | Study Number! Title   | Timepoint (Weel)    | Dose                       | Placebo mN (%6)            | Active Treaiment D/N (96)               | Difference from Placebo (9546 C1)b                |
|--------------------------------------------------------------------------------------|-----------------------|---------------------|----------------------------|----------------------------|-----------------------------------------|---------------------------------------------------|
| Sustained Steroid-free Remission Among Subjects in Remission at Maintenance Baseline |                       |                     |                            |                            |                                         |                                                   |
| Tofacitinib (mFAS)                                                                   | A3921096              | 24 and 52           | 10 mgBD 5 mgBD             | 5/52 (9.6)                 | 30/53 (56.6) 29/60 (48.3)               | 47.0 (31.4,62.6) 38.7 (23.7. 53.7)                |
| Remission Among Subjects in Remission at Maintenance Baseline                        |                       |                     |                            |                            |                                         |                                                   |
| Tofacitinib (mFAS)                                                                   | A3921096              | 52                  | 10 mgBD 5mgB               | 5/52 (9.6)                 | 34/53 (64.2) 31/60 (51.7)               | 54.5 (39.3, 69.7) 42.1 (27.1.57.0)                |
| Adalimumabsr Sustained Steroid-Free Remission                                        | ULTRA?                | 52                  | 40 mg Q2Wk                 | 10/23 (43.5)               | 21/41 (51.2)                            | 7.7 (-17.6. 33.1)                                 |
| Among Subjects Receiving Steroids at Baseline                                        |                       |                     |                            |                            |                                         |                                                   |
| Tofcitinib (FAS)                                                                     | A3921096              | 24 and 52           | 10 mgBD 5 mgB              | 12/101 (11.9)              | 18/87 (20.7) 23/101 (22.8)              | 8.8 (-1.8. 19.4) 10.9 (0.6, 21.2)                 |
| Adalimwab'                                                                           | ULTRA?                | 32 and 52           | 40 mg Q2Wk                 | 2/140 (1.4)                | 15/150 (10.0)                           | 8.6 (3.4, 13.8)                                   |
| Steroid-free Remission Among Subjects Receiving Steroids At Baseline                 |                       |                     |                            |                            |                                         |                                                   |
| Tofacitinib (FAS)                                                                    | A3921096              | 52                  | 10 mgB 5 mg BD             | 14/101 (13.9)              | 27/87(31.0) 33/101 (32.7)               | 17.2 (5.3.29.0) 18.8 (7.5, 30.2)                  |
| Vedolizmab                                                                           | GEMINII               | 52                  | 300 mg Q8Wk                | 10/72 (13.9)               | 22/70 (31.4)                            | 17.5(4.0, 31.0)                                   |
| Adalimumab                                                                           | ULTRA2                | 52                  | 40 mg Q2Wk                 | 8/140 (5.7)                | 20/150 (13.3)                           | 7.6 (1.0. 14.3)                                   |
| Inflivinnb                                                                           | ACT2                  | 54                  | 5mgkgQ8Wk                  | 7/79 (8.9)                 | 18/70 (25.7)                            | 16.9 (4.8, 28.9)                                  |
| Remission Among Subjects Receiving Steroids at Baseline                              |                       |                     |                            |                            |                                         |                                                   |
| Tofacitinib (FAS)                                                                    | A3921096              | 52                  | 10 mgBD 5 mgBD             | 14/101 (13.9) 16/87 (18.4) | 28/87 (32.2) 34/101 (33.7) 19/82 (23.2) | 18.3 (6.4.30.2) 19.8 (8.4, 31.2) 4.8 (-7.5, 17.0) |
| Golimmab Sustained Remission Among Subjects in Remission at Maintenance Baseline     | PURSUIT-SC            | 54                  | 100 mg Q4Wk                |                            | 30/53 (56.6) 30/60 (50.0)               | 47.0 (31.4 62.6) 40.4 (25.4, 55.4)                |
| Tofacitinib (mFAS) Golimumab                                                         | A3921096 PURSUIT-SC   | 24 and 52 30 and 54 | 10 mgBD 5 mg BD 100 mgQ4Wk | 5/52 (9.6) 13/54 (24.1%)   | 21/54 (38.9)                            | 14.8 (-2.5.32.1)                                  |
| Sustained Chinical Remissiond Tofacitinib (mFAS)                                     | A3921096              | 24 and 52           | 10 mg BD 5 mgBD            | 14/174 (8.0)               | 65/173 (37.6) 53/176 (30.1)             | 29.5 (21.3.37.8) 22.1 (14.2,30.0)                 |
| Golimwab                                                                             | PURSUIT-SC            | 30 and 54           | 100 mg Q4Wk                | 24/154 (15.6)              | 42/151 (27.8)                           | 12.2 (3.1,21.4)                                   |
| Vedoliaumab                                                                          | GEMINII               | 6 and 52            | 300 mg QsWk                | 11/126 (8.7)               | 25/122 (20.5)                           | 11.8 (3.1.20.5)                                   |
| Adalimuwab\"                                                                          | ULTRA?                | 8 and 52            | 40 mg Q2Wk                 | 10/246 (4.1)               | 21/248 (8.5)                            | 4.4 (0.1.8.7)                                     |
| Infliximnb                                                                           | ACT1                  | 8.30.amd54          |                            | 8/121 (6.6)                | 24/121 (19.8)                           |                                                   |
|                                                                                      |                       |                     | 5mg/kgQ8Wk                 |                            |                                         | 13.2 (4.9.21.6)                                   |

Sources: Tofhcitimib: S0012 5.3.5.1 A3921096-report-body Table 14.2.5.1.3: Table 14.2.5.23: Table 14.2.5.1.1: Table 14.2.2.7: Table 14.2.2.8 Golimumab: Sandbom et al.

Vedolizumab: Feagan et al.*

Adalimumab: Sandbom et al.°: Adalimumab FDA BLA Table 26; Adalimuwab FDA AC BD Table 16

Infliximab: Rutgeerts et al.

Abbreviations: BID=twice a day: CI=confidence interval; FAS=full analysis set; mFAS = modified fill analyses set (ie, excluding subjects who received plhacebo in the induction shudies); n=number of subjects meeting specified criteria; N=number of subjects in the analysis set, NRI=non-responder imputation; Q = every: TNFi=tumor necrosis faclor inhibitor: wk = weeks.

b. Normal approximation for difference in binomial proportions was used to estimate 95% CIs

a. Unless otherwise noted, for tofacitinib, remission is defined as Mayo score of ≤2 points, with no individual subscore &gt;l point. For the biologic agents, remission (ie, clinical remission) is defined as Mayo score of S2 points, with no individual subscore &gt;1 point.

C.Amalysis based on NRI

e. Primary TNFi non-responders were excluded

d. Definition of clinical remission used for both tofacitinib and biologic agents

f. Based on analysis of subjects in remission at the Week 8 visit.

There are limitations to comparing results across studies.  The tofacitinib UC development program included patients who were highly treatment experienced, were required to taper corticosteroids and used more stringent definitions of response.  All these characteristics make the comparison of results between tofacitinib and biologics be conservative estimates of the true value of tofacitinib.  Despite all

Invented name: Xeljanz

International non-proprietary name: tofacitinib

Procedure no.: EMEA/H/C/004214/X/0005/G

<div style=\"page-break-after: always\"></div>

these considerations, the results observed with tofacitinib for clinical remission (in induction and maintenance), based both on the overall population as well as by various subgroups, were generally similar to or numerically larger than those of the biologic agents.  Overall, this is relevant for the discussion on the potential for tofacitinib to show significant clinical benefit in comparison to available therapies in patients who have failed TNF is, as this is a growing population in need of multiple new options.

The observed treatment effect of tofacitinib 5 mg BID and tofacitinib 10 mg BID was at least similar to the observed treatment effects for the historical Phase 3 results of the currently approved biologic treatments; in the induction and maintenance of treatment.

## 2.4. Significant clinical benefit based on improved safety

The safety data from the UC clinical program showed that the safety profile of tofacitinib treatment in the UC population appeared to be consistent with tofacitinib treatment in the RA population.

In general, the IRs of AEs of special interest were similar across the UC, RA and PsO indications, except for the IR of opportunistic infection (OI). The IR of OI in the overall tofacitinib UC program was higher than in the overall RA or PsO programs, primarily attributable to an increased rate of herpes zoster OIs. In the Phase 3 UC maintenance study, there was evidence of a dose response for HZ (all cases, OI or non-OI), which was consistent with previous observations in the tofacitinib RA and PsO indications.

Table 3. Cumulative Incidence Rates (per 1oo Patient-Years) for Select Safety Events in Subjects Treated With Tofacitinib(All Doses Combined) in the Overall (All Exposure) UC, Rheumatoid Arthritis, and Psoriasis Programs

| Safety Event                               | UC (All Exposure) N=1157 Exposure = 1613 PY   | UC (All Exposure) N=1157 Exposure = 1613 PY   | RA (All Exposure) N= 6300 Exposure = 21,886 PY   | RA (All Exposure) N= 6300 Exposure = 21,886 PY   | Psoriasis (All Exposure) N=3662 Exposure = 8537 PY   | Psoriasis (All Exposure) N=3662 Exposure = 8537 PY   |
|--------------------------------------------|-----------------------------------------------|-----------------------------------------------|--------------------------------------------------|--------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                            | n (%)                                         | IR (95% CI)                                   | n (%)                                            | IR (95% CI)                                      | n (%)                                                | IR (95% CI)                                          |
| Death (all cause)                          | 2(0.2)                                        | 0.12 (0.01, 0.43)                             | 58 (0.9)                                         | 0.26 (0.20, 0.33)                                | 17 (0.5)                                             | 0.19 (0.11, 0.31)                                    |
| Seriousinfection                           | 33 (2.9)                                      | 1.99 (1.37, 2.79)                             | 546 (8.7)                                        | 2.47 (2.26, 2.68)                                | 111 (3.0)                                            | 1.27 (1.05, 1.53)                                    |
| Herpes zoster                              | 65 (5.6)                                      | 4.07 (3.14, 5.19)                             | 747 (11.9)                                       | 3.64 (3.38, 3.91)                                | 201 (5.5)                                            | 2.38 (2.06, 2.74)                                    |
| Opportunistic infectiona                   | 21b (1.9)                                     | 1.28 (0.79, 1.96)                             | 70 (1.1)                                         | 0.31 (0.24, 0.40)                                | 26 (0.7)                                             | 0.30 (0.19, 0.44)                                    |
| Non-herpes zoster opportunisticinfectiona  | 4 (0.4)                                       | 0.24 (0.07, 0.61)                             | 23 (0.4)                                         | 0.10 (0.07, 0.15)                                | 4 (0.1)                                              | 0.05 (0.01, 0.12)                                    |
| Serious herpes zoster                      | 4 (0.3)                                       | 0.24 (0.07, 0.61)                             | 55 (0.9)                                         | 0.25 (0.19, 0.32)                                | 11 (0.3)                                             | 0.13 (0.06, 0.22)                                    |
| Malignancy (excluding NMSC)a               | 8 (0.7)                                       | 0.48 (0.21, 0.95)                             | 168 (2.7)                                        | 0.75 (0.64, 0.87)                                | 56 (1.5)                                             | 0.64 (0.48, 0.83)                                    |
| Colorectal cancera                         | 1 (0.1)                                       | 0.06 (0.00,0.34)                              | 11 (0.2)                                         | 0.05 (0.02,0.09)                                 | 3 (0.1)                                              | 0.03 (0.01,0.10)                                     |
| Lymphoma and lymphoproliferative disordera | 1 (0.1)                                       | 0.06 (0.00, 0.34)                             | 13 (0.2)                                         | 0.06 (0.03, 0.10)                                | 1 (0.0)                                              | 0.01 (0.00, 0.06)                                    |
| NMSCa                                      | 11 (1.0)                                      | 0.67 (0.33, 1.19)                             | 121 (1.9)                                        | 0.55 (0.45, 0.65)                                | 51 (1.4)                                             | 0.59 (0.44, 0.77)                                    |
| MACEa                                      | 4 (0.4)                                       | 0.24 (0.07, 0.62)                             | 80 (1.4)                                         | 0.38 (0.30, 0.47)                                | 21 (0.6)                                             | 0.24 (0.15, 0.37)                                    |
| GI perforation (all cases)a                | 4 ( 0.4)                                      | 0.24 (0.07, 0.62)                             | 27 (0.4)                                         | 0.12 (0.08, 0.18)                                | 6 (0.2)                                              | 0.07 (0.03, 0.15)                                    |

Abbreviations:CI=confidenceinterval;GI=gastrointestinal;IR=incidencerate;N=number ofevaluable subjects; n = number of subjects with events; P2P3LTE = Phase 2, Phase 3, long-term extension; MACE = major adverse cardiovascular event; N = number of evaluable subjects; NMSC = nonmelanoma skin cancer; OI = opportunistic infection; PsO = psoriasis; PY = patient-years; RA = rheumatoid arthritis; UC = ulcerative colitis. IncludesRAStudiesA3921019,A3921024,A3921025,A3921032,A3921035,A3921039,A3921040,

A3921041,A3921044,A3921045,A3921046,A3921064,A3921068,A3921069,A3921073,A3921109, A3921129,A3921130,A3921152andA3921237.

Includes ps0riasis Studies A3921078,A3921079, A3921080,A3921111,A3921047,A3921147, and A3921061.

Events occurring within 28 days following the last dose were included.

a. Adjudicated events. Percentage (%) was calculated based on the number of subjects in studies in which adjudication was performed.

b. In UC All Exposure, there were 22 OIs in 21 subjects. Fifteen (15) out of 22 OI events (68%) were herpes zoster OIs limited to cutaneous involvement. A consistent definition of OI was applied to the UC, RA and PsO programs. Sources: Module 2.7.4 Summary of Clinical Safety, Section 2.7.4.2.5, Table 67

Invented name: Xeljanz

International non-proprietary name: tofacitinib

Procedure no.: EMEA/H/C/004214/X/0005/G

<div style=\"page-break-after: always\"></div>

The MAH has compared external safety data from UC patients in a claims-based comparison cohort (Truven Marketscan database) with the safety findings from the UC program. Phase 2, Phase 3 and Long-Term Extension study data for tofacitinib were presented alongside data from the Truven comparison cohort (Table 4). The IRs of HZ for tofacitinib was higher than that of TNFi agents, whereas the IRs of serious infection and Nonmelanoma Skin Cancer (NMSC) for tofacitinib were numerically lower than those of TNFi agents. The IRs of other adverse events (AE) of special interest were similar between tofacitinib and TNFi agents.

Table 4. IRs of AEs of Special Interest in UC (All Exposure) and External Data for All TNFi (Truven Comparison Cohort)

| Safety Event                 | UC (All Exposure) TofacitinibAll   | ObservationalData Truven Comparison Cohort AIlI TNFi   |
|------------------------------|------------------------------------|--------------------------------------------------------|
|                              | IR (95% CI)                        | IR (95% CI)                                            |
| Serious infection            | 1.99 (1.37, 2.79)                  | 3.33 (2.73,4.02)                                       |
| Herpes zoster                | 4.07 (3.14, 5.19)                  | 1.77 (1.34, 2.29)                                      |
| Malignancy (excluding NMSC)a | 0.48 (0.21, 0.95)                  | 0.63 (0.43, 0.90)                                      |
| NMSC?                        | 0.67 (0.33, 1.19)                  | 1.69 (1.35, 2.10)                                      |
| MACE?                        | 0.24 (0.07, 0.62)                  | 0.51 (0.31, 0.79)                                      |
| GI perforation (all cases)a  | 0.24 (0.07, 0.62)                  | 0.23 (0.11, 0.44)                                      |

Sources: Module 2.7.4 Summary of Clinical Safety Table 72 for tofacitinib data; Pfizer, 2017 data on file for Truvencohortdata

Confidence intervals (CIs) (95%) for IRs were computed using an exact method.

Abbreviations: CI = confidence interval; GI = gastrointestinal; MACE = major adverse cardiovascular events;

NMSC = nonmelanoma skin cancer; P2P3LTE = Phase 2, Phase 3 long-term extension; PY = patient year;

TNFi =tumour necrosis factor inhibitor; UC =ulcerative colitis.

IR is expressed in events/100 PY.

For tofacitinib data, adverse events confirmed by an adjudication process conducted by independent review committeesblinded tostudytreatment

## 2.5. Significant clinical benefit based on major contribution to patient care

The Applicant states that there is a significant unmet need in patients with moderately to severely active UC who have previously failed corticosteroids, AZA/6-MP, or TNFi. And that there is no single currently approved therapeutic option that offers both induction and maintenance efficacy, in TNFi failure patients.

A proportion of patients with moderately to severely active UC fail to respond to TNFi agents either initially or lose their initial response. For example, only approximately half of patients with moderately to severely active UC had a clinical response and less than 20% were in remission after adalimumab (Week 8)5 or golimumab (Week 6) induction. 6  Even after initially achieving a clinical response, 33%50% of patients subsequently lose their response. 8,9  Considering the outcome following 1-year treatment, approximately one-third of patients were still in clinical remission after 1 year of infliximab therapy in their pivotal trials. 7 In a real-word setting based on a Spanish IBD registry study of UC patients treated with adalimumab, 28% of patients did not have a clinical response at any time during the 1-year follow up, and 47% did not achieve clinical remission at any time during the first year of

Invented name: Xeljanz

International non-proprietary name: tofacitinib

Procedure no.: EMEA/H/C/004214/X/0005/G

<div style=\"page-break-after: always\"></div>

treatment. More than one-third of patients required dose escalation due to loss of response. In 16% of patients, secondary loss of response led to adalimumab discontinuation during follow up. 10

Patients who have failed TNFi, whether primary or secondary non-response, have limited treatment options given the limited effectiveness of other TNFi agents or vedolizumab in these patients. For this patient population, colectomy may be the only remaining option. It has been reported that 21% of subjects required colectomy after 1 year of adalimumab. The rate was significantly higher in TNFi exposed (26%) than naïve patients (10%), indicating patients who have previously received TNFi therapy may have more difficult-to-treat disease. 15 More than half of patients treated with TNFi experience treatment failure, either primary or secondary 8,9 .

All currently approved therapies for both induction and maintenance of moderately to severely active UC are administered either intravenously (3 infusions over 6 weeks initially) or subcutaneously (3-6 injections over 2 weeks initially). 19,20,21,22 The route of administration of these biologic therapies may be undesirable for many patients.

## 3. Assessment of the MAH's justification of significant clinical benefit

## 3.1. Demonstration of new therapeutic indication

The proposed indication for Xeljanz in this application is treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent' in comparison with existing therapies.

It is agreed that the proposed indication is considered a new indication for Xeljanz, as this indication is targeting a new disease target in comparison to the authorised indications.

## 3.2. Details of existing therapies

The MAH review of existing therapies is satisfactory and agreed upon.

## 3.3. Significant clinical benefit based on improved efficacy

There are no direct comparative studies of tofacitinib against approved biologics in patients with moderate to severely active UC. There are many challenges of indirect comparison of trials in ulcerative colitis, with the variability in subject selection, previous therapies, concomitant medications endpoint definitions and study methodology, thus only limited conclusions with regards to efficacy or safety of tofacitinib with comparison to existing therapies can be made. The indirect comparison with second line agents for UC is challenging. Taking these limitations into account it could be inferred from the presented literature that the efficacy of tofacitinib in the induction and maintenance of remission is at least similar to those currently approved.  The results for tofacitinib are comparable in induction and maintenance of remission, and compare favourably against approved biologics for clinical remission in patients with prior TNFi failure (particularly for the 10 mg BID dosing) and for corticosteroid-free

Invented name: Xeljanz International non-proprietary name: tofacitinib Procedure no.: EMEA/H/C/004214/X/0005/G

<div style=\"page-break-after: always\"></div>

remission. However, with prior TNFi failure patients the difference in maintenance of clinical remission from placebo was 35.2% in tofacitinib and 31.9% in vedolizumab patients, which does not imply 'exceptional benefit' compared to vedolizumab. Also, for steroid-free remission the difference from placebo was 18.8% for tofacitinib, 17.5% for vedolizumab and 16.9% for infliximab (7.6% for adalimumab; in 'sustained steroid-free remission' also adalimumab was similar to tofacitinib), barely representing a significant or exceptional clinical benefit.

Therefore the CHMP considers that the indirect comparisons submitted by the MAH do not demonstrate major differences in efficacy (or 'exceptional benefit') in the the claimed indication for XELJANZ compared to currently approved biologic agents. Significant clinical benefit over existing therapies based on improved efficacy has not been demonstrated.

## 3.4. Significant clinical benefit based on improved safety

The MAH has conducted an indirect comparison between the safety profile of tofacitinib and a claimsbased comparison cohort (Truven Marketscan database). The incidence rates of Herpes Zoster for tofacitinib was higher than that of TNFi agents, whereas the incidence rates of serious infection and Nonmelanoma Skin Cancer (NMSC) for tofacitinib were numerically lower than those of TNFi agents. There is no conclusive direct evidence that there is improved safety with Xeljanz in comparison to currently authorised products. However, the safety profile does appear to be similar between tofacitinib and TNFi agents from the presented literature indirect comparisons.

Having considered the data submitted by the MAH, the CHMP does not consider that the claimed indication for XELJANZ brings a significant clinical benefit over existing therapies based on improved safety compared to currently approved biologic agents.

## 3.5. Significant clinical benefit based on major contribution to patient care

Tofacitinib does have a novel mechanism of action and as such could be considered a treatment alternative to currently authorised products for ulcerative colitis, especially in those patients who have not responded to TNFi therapy.

In contrast to the authorised biologic agents, which each engage a single molecular target, tofacitinib has a distinct mechanistic action, inhibiting JAK-dependent cytokines, that have been implicated in UC disease pathogenesis and re-establish homeostasis of T-cell signalling, including signalling pathway components predictive of disease severity and likely to mediate TNFi resistance. Genetic association studies have implicated the JAK/STAT pathway in UC, including loci containing the receptors for IL-2, IL-15, IL-12 and IL-23; the shared P40 subunit for IL 12 and IL-23; IL-10; IL-2 and IL-21; IL-13; Interferonγ (IFNγ), Oncostatin M (OSM); STATs and suppressors of cytokine signalling. Connecting these genetic associations to pathogenesis, infiltrating T cells are activated by IL 7 and IL-15 released from damaged epithelial cells and IL-2 and IL-21 can activate T cells in an autocrine manner. Dendritic cells and macrophages produce IL-12 and IL-23 leading to the differentiation of T cells to Th1 cells which produce IFNγ and Th17 cells which produce IL-17a, IL-21 and IL-22.  Pre-clinical UC models and observations in humans suggest that the immune response may be skewed away from the TH2/IL-13 axis and toward increased TH1 or TH17 response in TNF non-responders.  Therefore, given the potential of the TH2/IL-13 axis to promote fibrosis, it may be best to dampen TH1, TH2, and TH17 responses in unison by JAK inhibition so as to re-establish homeostasis without skewing the T cell response in either pathogenic direction.   Tofacitinib can inhibit differentiation to TH1, TH2, and TH17

Invented name: Xeljanz

International non-proprietary name: tofacitinib

Procedure no.: EMEA/H/C/004214/X/0005/G

<div style=\"page-break-after: always\"></div>

subsets  and is efficacious in diseases where each of these subsets dominate (eg, TH1 in rheumatoid arthritis [RA], TH17 in psoriasis, and TH2 in atopic dermatitis).

Beyond the concept that it may be useful to target multiple cytokines, high levels of the JAKdependent cytokine OSM at baseline in two Phase 3 trials of infliximab and golimumab were predictive of disease severity and likely mediate resistance to anti-TNFs.  The OSM receptor is expressed on nonepithelial intestinal stromal cells and responds to OSM by producing IL-6, adhesion molecules and chemokines to attract neutrophils, monocytes, and T cells. Both OSM and IL-6 signalling are inhibited by tofacitinib and may explain the activity of tofacitinib in UC patients who have failed TNFi agents.

Moreover, as a small molecule inhibitor, tofacitinib is less susceptible to formation of anti-drug antibodies that may account for decreasing efficacy of biologics with time. This may also account for its activity in patients who have experienced failure to TNFi agents and the consistent plasma tofacitinib concentrations over time. Thus, on a mechanistic level there is biological plausibility for efficacy of tofacitinib, particularly in relation to prior TNFi resistance/failure, relating to its effects on signalling pathways implicated in disease pathogenesis.

The MAH has presented literature data regarding the response rates to TNFi therapy and indeed there are a significant number of patients who do fail to respond to this therapy and thus have limited treatment options; therefore, a therapy with a different mechanism of action may be considered a clinical benefit.

The evidence for clinical benefit of tofacitinib in relation to currently authorised agents is discussed above (under '3.3. Significant clinical benefit based on improved efficacy). Considering the limitations of comparisons across studies, and the more stringent definitions of response in the tofacitinib programme, the data for tofacitinib compare favourably against approved biologic therapies.

All currently approved therapies for moderately to severely active UC are administered either intravenously or subcutaneously, requiring repeated hospital admission and trained staff to administer and monitot the patients. The route of administration of these therapies and need for refrigeration for subcutaneous agents may be undesirable for many patients. As the bulk of disease burden occurs during the most productive years of a UC patient's life and patient preference is an important consideration for treatment decision, the current availability of only intravenously or subcutaneously administered therapies represents an important limitation in treating UC. Therefore, the oral method of administration of Xeljanz may offer an advantage to some patients with regards to putative convenience and does introduce a patient choice and as such could be considered a significant clinical benefit.

Data on compliance with oral therapy has been supplied by the MAH, reporting mean compliance of 99.0% (range 50.9-101.6%) and 99.3% (range 71.1-102.4%) in the two induction studies and compliance of 99.1% (range 90.2-100.8%) and 98.8% (range 76.9-106.9%) for the 5mg BID and 10mg BID dosing, respectively, in the maintenance study. The limitations of calculating compliance rates based upon patient records is acknowledged, although in this clinical trial setting the compliance rates are considered satisfactory. Compliance rates in the clinical trial setting were high, and the helpful day/night labelling of the product blister packs is considered helpful in reducing patient forgetfulness for this BID oral dosing product.

MAH has provided a detailed discussion on factors relating to adherence to medication in patients with chronic conditions, including in UC, and a good justification of how tofacitinib can overcome several of these factors. In chronic diseases, common barriers to adherence to therapy are related to patients' issues and beliefs.  The only significant barriers related to the medications are a high pill burden, beliefs about the medication and concerns about side effects. Tofacitinib offers a therapy with a low pill

<div style=\"page-break-after: always\"></div>

burden and good tolerability. In addition, the expected response to therapy and more serious side effects are well described.

Complexity of dosing regimens (large numbers of pills and/or beyond twice daily dosing) and/or the need for concomitant medications as well as side effects from these concomitant medications is associated with increased non-adherence.   Tofacitinib, as a medication proposed for treatment of UC for BID use and as an effective monotherapy allowing for the elimination of corticosteroids and nonuse of concomitant immunomodulators with their own associated unique side effects, may be able to address these factors contributing to poor adherence.

Another factor cited as contributing to non-adherence was lack of knowledge about or belief in the efficacy of the medication.  In moderately to severely ill patients, prompt onset of therapeutic benefit may help to reassure patients that the medication prescribed will provide meaningful therapeutic benefit.  Given tofacitinib's early onset of benefit for many patients, as demonstrated in the replicate induction studies by the first assessment of benefit by Week 2, it is likely that this rapid onset of meaningful benefit could encourage the large subset of patients who experience this rapid onset of benefit to adhere to their treatment regimen in order to accrue additional therapeutic benefit. Additionally, especially for those subjects who had prior failure to TNFi, the induction efficacy results showing that tofacitinib provides significant efficacy regardless of prior TNFi status might provide some confidence and reassurance to patients regarding tofacitinib's efficacy in this difficult to treat patient population.

An important finding from recent systematic reviews of adherence in treating immune-mediated inflammatory diseases including IBD in general is the central importance of psychological factors in patient adherence. Assessments of quality of life in patients with IBD have shown significant deficits, comparable to subjects with chronic kidney disease and cancer. The significant improvements provided by treatment with tofacitinib in both physical and emotional component measurements of quality of life by the SF-36 and IBDQ instruments, particularly with potential for rapid onset of clinical benefit discussed above, may mitigate the negative effect on treatment adherence noted for depression in patients with UC

Having considered the data submitted by the MAH, the CHMP considers that the claimed indication for XELJANZ brings a significant clinical benefit over existing therapies based on a major contribution to patient care compared to currently approved biologic agents.

## 4. Conclusion

With a novel mechanism of action compared to established products for moderate to severely active UC, and evidence of clinical efficacy in patients with prior failure on TNFi agents for whom few or no other medical options are available, together with a more convenient oral dosing presentation regarded to be of benefit to patients, it is considered that a significant clinical benefit is demonstrated on the following grounds:

3.5 - Significant clinical benefit based on major contribution to patient care.

| Existing therapies   | XELJANZ           | XELJANZ         | XELJANZ                            |
|----------------------|-------------------|-----------------|------------------------------------|
| Existing therapies   | Improved efficacy | Improved safety | Major contribution to patient care |
| Infliximab           | No                | No              | Yes                                |
| Adalimumab           | No                | No              | Yes                                |
| Golimumab            | No                | No              | Yes                                |
| Vedolizumab          | No                | No              | Yes                                |

Invented name: Xeljanz

International non-proprietary name: tofacitinib

Procedure no.: EMEA/H/C/004214/X/0005/G

<div style=\"page-break-after: always\"></div>

## 5. Recommendation

Taking into account the provisions of Article 14(11) of Regulation (EC) No 726/2004 and the 'Guidance on elements required to support the significant clinical benefit in comparison with existing therapies of a new therapeutic indication in order to benefit from an extended (11-year) marketing protection period', it is considered that XELJANZ in the new therapeutic indication brings a significant clinical benefit in comparison with existing therapies.

International non-proprietary name: tofacitinib

Procedure no.: EMEA/H/C/004214/X/0005/G

<div style=\"page-break-after: always\"></div>

## References

- 1 Torres J, Billioud V, Sachar DB, et al. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis 2012;18:1356-63.
- 2 Kornbluth A, Sachar DB. Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105:501-23.
- 3 Sandborn WJ. Azathioprine: state of the art in inflammatory bowel disease. Scand J Gastroenterol Suppl 1998;225:92-9.
- 4 Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369(8):699-710.
- 5 Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate to severe ulcerative colitis. Gastroenterology 2012;142(2):257-65.
- 6 Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146(1):85-95.
- 7 Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353(23):2462-76.
- 8 Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med 2013;369(8):754-62.
- 9 Olesen CM, Coskun M, Peyrin-Biroulet L, et al. Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. Pharmacol Ther 2016;159:110-9.
- 10 Taxonera C, Iglesias E, Mun ˜ oz F, et al. Adalimumab maintenance treatment in ulcerative colitis: Outcomes by prior anti-TNF use and efficacy of dose escalation. Dig Dis Sci 2017;62:481-90.
- 11 Hanauer SB. How will new and future therapies change our management of IBD? Northwestern University Feinberg School of Medicine. Advances in Inflammatory Bowel Diseases Scientific Meeting December 2015, p 27.
- 12 Essat M, Tappenden P, Ren S, et al. Vedolizumab for the treatment of adults with moderate to severe active ulcerative colitis: an evidence review group perspective of NICE single technology appraisal. Pharmacoeconomics 2016;34(3):245-57.
- 13 Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011;106(4):685-98.
- 14 Kopylov U, Ben Horin S, Seidman E. Therapeutic drug monitoring in inflammatory bowel disease. Ann Gastroenterol 2014;27(4):304-12.
- 15 Iborra M, Perez-Gisbert J, Bosca-Watts MM, et al. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naive and nonnaive patients. J Gastroenterol 2016:1-12.
- 16 Brandse JF, van den Brink GR, Wildenberg ME, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology 2015;149(2):350-5.
- 17 Ertz-Archambault N, Kosiorek H, Taylor GE, et al. Association of therapy for autoimmune disease with myelodysplastic syndromes and acute myeloid leukemia. JAMA Oncol. Published online 02 February 2017.

<div style=\"page-break-after: always\"></div>

doi:10.1001/jamaoncol.2016.6435.

18 Tarp S, Furst DE, Boers, M, et al. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. Rheumatology 2016;53:1-9.

19 Entyvio Prescribing Information. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2014. Reference ID: 350997.

20 Humira Prescribing Information. North Chicago, IL: AbbVie Inc.; 2016.

- 21 Simponi Prescribing Information. Horsham, PA: Janssen Biotech, Inc; 2014.
- 22 Remicade® Prescribing Information. Horsham, PA: Janssen Biotech, Inc; 2013.
- 23 The Committee for Medicinal Products for Human Use. Draft guideline on the development of new medicinal products for the treatment of ulcerative colitis. In: Committee for Medicinal Products for Human Use (CHMP). London: European Agency for the Evaluation of Medicinal Products; 8 Jan 2016. Report No:CHMP/EWP/18463/2006 Rev. 1. 2016:16 pages.

24 European Commission Guideline on Elements Required to Support the Significant Clinical Benefit in Comparison with Existing Therapies of a New Therapeutic Indication in Order to Benefit From an Extended (11 year) Marketing Protection Period. Nov 2007. Available:

http://ec.europa.eu/health/files/edralex/vol 2/c/guideline\\_14 11 2007\\_en.pdf. 10 Oct 2016.

25 Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60(6):780-7.

26 Humira Summary of Product Characteristics. AbbVie Bioresearch Center: Worcester, MA. Available: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicine090177e18c50602d \\Final\\Final On: 11-Jul-2017 13:36 (GMT)

27 Simponi Summary of Product Characteristics. Janssen Biologics B.V. Leiden, The Netherlands. Available: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicin es/000992/human\\_med\\_001053.jsp&amp;mid=WC0b01ac058001d124. 03 May 2017.

28 Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: Current management. J Crohns Colitis 2017;1-24.

29 Faubion WA, Loftus EV, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study.Gastroenterology 2001;121(2):255-60.

30 Hydrocortisone sodium succinate injection Prescribing Information. Lake Forest, IL: Hospira, Inc; 2011. RL-2526.

- 31 Medrol Prescribing Information. NY, NY: Pharmacia and Upjohn Company LLC; 2016. ID 618054084.
- 32 Imuran® Prescribing Information. San Diego, CA: Prometheus Laboratories Inc.; Reference ID 3448651. 2014.
- 33 Purinethol® Prescribing Information. Sellersville, PA: Gate Pharmaceuticals; 2011. Reference ID 2953022.

34 Gisbert JP, Linares PM, McNicholl AG, et al. Meta-analysis; the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther 2009;30:126-37.

<div style=\"page-break-after: always\"></div>

35 Axelrad JE, Roy A, Lawlor G, et al. Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective. World J Gastroenterol 2016;22(46):10103-17.

36 Timmer A, Patton PH, Chande N, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev2016;CD000478.

- 37 Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis 2017;1-39.

38 Shibolet O, Regushevskaya E, Brezis M, et al. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005;CD004277.

39 SANDIMMUN® Concentrate for Solution for Infusion 50 mg/mL Summary of Product Characteristics. Surrey, GU: Novartis Pharmaceuticals UK Ltd. Updated on 09 May 2016. Available: http://www.medicines.org.uk/emc/medicine/1317#CLINICAL\\_PRECAUTIONS. 11 Apr 2017.

40 Baumgart DC, Pintoffl JP, Sturm A, et al. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease: a long-term follow-up. Am J Gastroenterol 2006;101:1048-56.

- 41 Prograf 5mg/ml Concentrate for Solution for Infusion Summary of Product Characteristics. Surrey, KT: Astellas Pharma Ltd. Updated on 02 October 2015. Available https://www.medicines.org.uk/emc/medicine/17973. 11 Apr 2017.

42 Loftus CG, Egan LJ, Sandborn WJ, et al. Cyclosporine, tacrolimus, and mycophenolate mofetil in the treatment of inflammatory bowel disease. Gastroenterol Clin N Am 2004;33:141 -69.

43 Remicade® Summary of Product Characteristics. Janssen Biologics B.V., Leiden, The Netherlands. Available: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicin es/000240/human\\_med\\_001023.jsp&amp;mid=WC0b01ac058001d124. 03 May 2017.

44 Essat M, Tappenden P, Ren S, et al. Vedolizumab for the treatment of adults with moderate-tosevere active ulcerative colitis: an evidence review group perspective of NICE single technology appraisal. Pharmacoeconomics 2016;34(3):245-57.

45 Entyvio Summary of Product Characteristics. AbbVie Bioresearch Center: Worcester, MA. Available:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicin es/002782/human\\_med\\_001751.jsp&amp;mid=WC0b01ac058001d124. 03 May 2017.